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Abstract 
   Infection with hepatitis C virus (HCV) is cleared spontaneously in only 20% 
of cases with the majority of individuals developing a chronic infection.  This 
discrepancy in disease outcome is incompletely understood but current 
understanding of the immune response to HCV suggests that rapid induction of 
a broadly neutralising antibody (nAb) response leads to resolution of acute 
infection.  The majority of nAb identified target the envelope glycoproteins, 
particularly E2, and most appear to inhibit binding of E2 to the cellular 
receptor CD81.  Antibodies targeting other interactions, such as those with the 
receptor CLDN or the fusion determinant, are underrepresented in the 
repertoire of anti-HCV antibodies.  However, the antibody discovery process 
may have been biased by the nature of the assays used.  Therefore new assays 
are needed to enable the discovery and characterisation of antibodies in an 
unbiased manner.  To facilitate this, a novel insect cell display library was 
developed for mapping antibody-binding epitopes.  Cells expressing specific 
E2 mutants provided the necessary proof-of-principle that loss of antibody 
binding could be detected in this system before a library expressing randomly 
mutated E2 was developed.  Sorting experiments demonstrated that single cells 
could be isolated and enriched based on loss of antibody binding.  Secondly, a 
method for characterising the immunoglobulin (Ig) genes of HCV infected 
patients was developed; Ig genes were isolated from small numbers of B cells 
and the sequences analysed.  Finally, a patient cohort was studied with a view 
to investigating the evolution of the antibody response during early infection.  
The unreliable nature of the samples prevented such analysis; however a DNA 
fingerprinting method of testing the origin and relatedness of serum samples 
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was developed.  This will improve the reliability of future studies.  Together 
these methods provide a work model for the assessment of samples and the 
isolation and characterisation of antibodies. 
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1 General Introduction 
1.1 Natural History 
   Hepatitis C virus (HCV) was first identified as the cause of non-A, non-B 
hepatitis in the late 1980s (Choo et al., 1989; Kuo et al., 1989) and is currently 
estimated to infect 170 million people worldwide (Ascione et al., 2007) with 
up to 3 million new infections per year (Anon., 1999).  In 20-30% of 
infections, the virus is cleared spontaneously (Santantonio et al., 2008); 
however in the majority of cases the virus persists.  The reasons for this 
discrepancy in disease outcome are poorly understood but host genetic 
polymorphisms have been implicated following the discovery of a protective 
variant of the IL28B gene.  This gene encodes the type III interferon (IFN), 
IFN-ȜDQG WKHSUHVHQFHRID&DOOHOHFRUUHODWHVZLWKVSRQWDQHRXVUHVROXWLRQ
of infection (Thomas et al., 2009).  This variant has also been associated with 
treatment induced response to HCV (Ge et al., 2009).  In those who fail to clear 
the virus, chronic HCV infection can lead to cirrhosis of the liver, and in some 
cases hepatocellular carcinoma (HCC).  Cirrhosis develops in 20% of chronic 
infections (Anon., 1999) and approximately 500,000 cases of HCV-associated 
HCC occur each year (Ascione et al., 2007).  Chronic HCV infection is the 
leading cause of liver transplantation in developed countries (Shepard et al., 
2005) but as yet, there is no way to prevent reinfection of the newly grafted 
liver. 
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1.2 Transmission 
   HCV is transmitted primarily through exposure to contaminated blood or 
blood products, organ transplantations, the use of unsterilized medical 
equipment and needle-stick injury to healthcare workers.  In developed 
countries, the most common route of transmission is via intravenous drug use 
and the sharing of drug paraphernalia (Alter, 2007).  The role of sexual 
transmission in the spread of HCV is debatable.  There does not appear to be a 
significant risk of transmission between long-term, monogamous, heterosexual 
partners of HCV-positive individuals.  HCV infection risk increases with the 
number of sexual partners, although this may be confounded by increased use 
of injecting drugs in these groups.  The greatest association appears to be with 
human immunodeficiency virus (HIV)-coinfection (Tohme & Holmberg, 
2010).  Perinatal transmission can occur, although this is rare, and there is no 
association between breast-feeding and HCV transmission (Alter, 2007).  
 
1.3 Diversity and distribution of HCV 
   HCV can be classified on the basis of its genome sequence into genotypes 
and subtypes.  Six major genotypes of HCV have been well described 
(Simmonds et al., 2005); more recently a seventh genotype was identified and 
has been added to the phylogenetic tree of HCV diversity (Nakano et al., 
2012).  Genotypes differ by >30% at the nucleotide level.  HCV can be further 
categorised into different subtypes, showing 20-25% sequence divergence 
(Simmonds et al., 2005).  Further diversity is observed between viral variants 
circulating within a single host.  Due to the error-prone nature of the virus-
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encoded RNA-dependent RNA polymerase and the high replication rate of the 
virus (1012 virions per day) (Neumann et al., 1998), a  highly diverse 
population of viral variants is generated.  This has been described as a 
µTXDVLVSHFLHV¶(Martell et al., 1992), although the ability of HCV to form a true 
µTXDVLVSHFLHV¶LQQDWXUHKDVEHHQFDOOHGLQWRTXHVWLRQ(Holmes, 2010).   
   The global distribution of different HCV genotypes varies.  Genotypes 1 and 
3 are the most common genotypes in Northern Europe and the USA and are 
associated with intravenous drug use.  Genotype 2 is found in the 
Mediterranean and the Far East.  Genotype 4 is dominant in North Africa and 
the Middle East (Simmonds et al., 2005).  Genotype 5 is commonly found in 
South Africa whilst genotype 6 is prevalent in the Far East and Australia 
(Simmonds et al., 2005).  The prevalence of HCV varies greatly by geographic 
location, with prevalence estimated to be as low as 0.1% in the United 
Kingdom and Scandinavia.  In comparison, prevalence in Egypt is reported at 
15-20%  (Alter, 2007).    
 
1.4 Current treatment regime and prospects 
   The current standard of therapy for HCV infection is a combination of 
ribavirin plus pegylated IFN-Į  7KLV UHJLPH LV RQO\ HIIHFWLYH LQ -60% of 
cases however, and response to therapy varies between the different viral 
genotypes (genotypes 2 and 3 show better response rates than genotypes 1, 4, 5 
and 6).  Side effects are also common and can be severe leading to 
discontinuation of therapy (Poynard et al., 2003).  As knowledge of the virus 
lifecycle has increased, the search for HCV-specific, direct-acting antivirals 
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(DAAs) has intensified.  Two protease inhibitors (targeting the serine protease 
NS3) improve recovery rates when given in combination with ribavirin and 
IFN-Į  %RFHSUHYLU LQFUHDVHV VXVWDLQHG YLURORJLFDO UHVSRQVH 695 UDWHV LQ
genotype 1 infected patients from 38% to 75% (Kwo et al., 2010) compared to 
ribavirin and IFN-Į DORQH  7HODSUHYLU LQFUHDVHV 695 UDWHV LQ JHQRW\SH 
infected patients to 67%, compared with 41% of patients receiving standard 
therapy (McHutchison et al., 2009).  Telaprevir also improves SVR rates in 
patients who have previously failed standard therapy (McHutchison et al., 
2010).  However, adverse events associated with Boceprevir and Telaprevir 
have been reported.  They also show limited cross-genotype reactivity and a 
low barrier to resistance leading to the search for second-generation protease 
inhibitors with improved pharmacokinetics (Sarrazin et al., 2012).  The RNA-
dependent RNA polymerase NS5B has also been investigated as a target for 
antiviral therapy leading to the development of nucleoside and non-nucleoside 
analogue inhibitors.  Nucleoside analogues generally show cross-genotype 
activity, whereas the non-nucleoside inhibitors are more restricted and have a 
lower barrier to resistance mutations (Sarrazin et al., 2012).  Several drugs in 
both classes are currently under development and initial trials of the nucleoside 
analogue PSI-7977 in combination with ribavirin plus IFN-Į (Lalezari et al., 
2011) or with ribavirin only (Sarrazin et al., 2012) have shown promise. 
 
1.5 Genome organisation and protein function 
   HCV belongs to the Hepacivirus genus within the Flaviviridae family of 
viruses.  HCV is an enveloped viral particle possessing a single-stranded, 
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positive sense, RNA genome  (Lemon et al., 2007).  The genome is 9.6 kb in 
length and encodes a single polyprotein of 3000 amino acid residues, flanked at 
WKH ¶ DQG ¶ HQG E\ XQWUDQVODWHG UHJLRQV 875 (Lemon et al., 2007).  The 
¶875LVDKLJKO\VWUXFWXUHGUHJLRQFRQWDLQLQJWKHLQWHUQDOULERVRPHHQWU\Vite 
(IRES) required for polyprotein synthesis, as well as elements necessary for 
RNA replication (Tellinghuisen et al., 2007)7KH¶875LVDOVRHVVHQWLDOIRU
virus replication (Kolykhalov et al., 2000) and may enhance translation from 
the IRES in human liver cells and initiate negative-strand RNA synthesis 
(Tellinghuisen et al., 2007).  The polyprotein is cleaved co-translationally and 
post-translationally into 10 products by the cellular proteins, signal peptidase 
and signal peptide peptidase, as well as the viral proteases, products of the 
NS2-3 and NS3-4A proteins (Op De Beeck & Dubuisson, 2003; Penin et al., 
2004b) (Figure 1-1).  The polyprotein encodes three structural proteins; core, 
and the envelope glycoproteins E1 and E2; the viroporin p7 and six non-
structural proteins; NS2, NS3, NS4A, NS4B, NS5A and NS5B. 
 
1.5.1 Core 
   The core protein forms the viral nucleocapsid housing the RNA genome and 
is surrounded by a host-derived lipid envelope or membrane.  Core is cleaved 
from E1 by the action of signal peptidase, producing an immature 191 amino 
acid protein that undergoes further processing by the signal peptide peptidase 
to yield the mature protein (McLauchlan et al., 2002) predicted to be at least 
177 amino acids in length (Kopp et al., 2010).  The N-terminal domain (D1) of 
the mature core protein functions in protein oligomerisation and RNA binding 
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Figure 1-1. Schematic representation of the HCV polyprotein. The structural proteins, core, E1 and E2 and the viroporin p7 are 
cleaved from the polyprotein by host signal peptidase and signal peptide peptidase. Following translation of the polyprotein, the viral 
NS2-3 protease and the NS3-4A serine protease cleave the remaining non-structural proteins from the polyprotein. 
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(Boulant et al., 2005) whilst D2 targets the core protein to lipid droplets and 
plays an important role in viral particle assembly (Shavinskaya et al., 2007).   
 
1.5.2 E1 and E2 
   The envelope glycoproteins are produced by cellular signal peptidase 
cleavage of the polyprotein (Op De Beeck & Dubuisson, 2003) (Figure 1-1).  
E1 and E2 are highly glycosylated structures displayed on the surface of the 
viral particle that form non-covalent heterodimers (Dubuisson et al., 1994).  
The C-terminal transmembrane domains are thought to function in 
heterodimerisation and contain endoplasmic reticulum (ER) retention signals 
that may anchor the glycoproteins within the lipid membrane (Op De Beeck et 
al., 2001).  These non-covalent heterodimers have long been considered the 
functional form of the envelope glycoproteins.  Recent studies however, have 
shown that within the HCV cell culture (HCVcc) system, particles also possess 
envelope glycoproteins in larger covalent complexes stabilised by disulphide 
bridges (Vieyres et al., 2010).  Further study is needed to determine which of 
these represents the functional form of the glycoproteins. 
   E1 and E2 are highly glycosylated; their ectodomains are targeted to the ER 
lumen where they undergo N-linked and O-linked glycosylation (Op De Beeck 
et al., 2001; Op De Beeck & Dubuisson, 2003).  N-linked glycosylation is 
carried out by the enzyme oligosaccharyl transferase during protein synthesis.  
It catalyses the transfer of a Glc3Man9GlcNAc2 oligosaccharide from a lipid 
intermediate to an asparagine residue within the Asn-X-Thr/Ser consensus 
sequence (Goffard & Dubuisson, 2003).  This transfer takes place on the 
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lumenal face of the ER (Goffard & Dubuisson, 2003; Op De Beeck & 
Dubuisson, 2003) resulting in the exposure of the glycosylated glycoproteins 
on the surface of the virion.  E1 possesses six potential N-linked glycosylation 
sites, although not all are glycosylated.  E2 has 11 possible N-linked 
glycosylation sites (Goffard & Dubuisson, 2003; Op De Beeck et al., 2001) 
(Figure 1-2a), nine of which are conserved across genotypes (Helle et al., 
2007).  These glycans play an important role in the structure and function of 
the glycoproteins (Goffard et al., 2005) and some are essential for entry of 
HCVpp into target cells (Falkowska et al., 2007) suggesting a role for glycans 
in E2-receptor interactions.  Other glycans play a role in modulating 
immunogenicity; the removal of specific glycans enhances binding to CD81 
and increases sensitivity to neutralisation by sera and antibodies (Falkowska et 
al., 2007; Helle et al., 2007; Helle et al., 2010). 
   The role of E1 is poorly understood although it has been proposed to function 
as the fusion determinant, triggering fusion of the viral and cellular membranes 
during entry (Lavillette et al., 2007).  It has also been suggested that E1 
functions in virus entry by binding to apolipoprotein B (apoB) and apoE and 
promoting virus attachment to the low density lipoprotein receptor (LDLr) 
(Mazumdar et al., 2011).   
   The N-terminal ectodomain of E2 contains the entry determinants for 
infection of a host cell.  E2 comprises amino acids (aa) 384-748 of the HCV 
polyprotein, with the transmembrane domain located at aa 718-748.  The linear 
structure of the E2 ectodomain highlights three highly variable regions (Figure 
1-2b).  Hypervariable region 1 (HVR1), located at the N-terminus, is 26-28 
amino acids in length (depending on genotype).  This region, between aa 384-
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Figure 1-2. Structure of the envelope glycoprotein E2. a) Schematic 
representation of the linear structure of E2. Amino acid numbering of the N- 
and C-terminals and the transmembrane domain (TMD) is based on amino 
acid numbering of H77. Position and numbering of the N-linked glycans (ȥ) 
are shown, based on Falkowska et al., (2007). The hypervariable regions 
(HVR1, HVR2 and igVR) are highlighted in blue.  Red boxes denote the CD81 
binding sites (see text for details). Epitopes forming the antibody binding 
region of AR3 are shown in yellow.  Epitopes recognised by linear antibodies 
are shown as light green boxes. b) Model of the 3D structure of E2 as 
proposed by Krey et al., (2010). The three domains are shown: DI, containing 
the majority of CD81 binding sites, in red; DII, site of the putative fusion 
determinant, in yellow; and DIII in blue.   
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410, plays an important role in entry through its interaction with SR-BI 
(Bartosch et al., 2005; Bartosch et al., 2003c) as well as in antibody binding 
(Vieyres et al., 2011) and disease outcome (Farci et al., 2000).  HVR2 and the 
intergenotypic variable region (igVR), both downstream of HVR1, may play a 
role in heterodimerisation of E1E2 and virus infectivity (Albecka et al., 2011; 
McCaffrey et al., 2011).  Two additional hypervariable regions have been 
identified in genotype 3a isolates only but the role of these regions, HVR495 
(aa 495-501) and HVR575 (aa 575-578), in antibody binding and disease 
outcome has yet to be established (Humphreys et al., 2009).  Several putative 
sites for CD81 binding (see section 1.7.4), as well the majority of known 
antibody binding epitopes have also been mapped to E2. 
   A recently described 3D structural model (Krey et al., 2010) proposes that E2 
is a class II fusion protein, analogous to the envelope glycoproteins of the 
related viruses, alphavirus (E1) and flavivirus (E).  These proteins have a three 
domain architecture consisting of DI, DII and DIII (Figure 1-2b).  In HCV E2, 
DI contains most of the CD81 binding determinants.  The majority of glycans 
also cluster within this domain, consistent with a role of some glycans in 
modulating HCV entry (Falkowska et al., 2007; Goffard et al., 2005).  DI is 
preceded by an N-terminal extension containing HVRI.  DII contains the 
putative fusion peptide (aa 502-520) (Krey et al., 2010), contradicting studies 
that attribute the fusion determinant to E1 (Lavillette et al., 2007).  However, 
in class fusion II proteins, the protein analogous to HCV E1 functions as a 
chaperone, exposing the fusion loop buried within the prefusion form of the 
protein (Krey et al., 2010).  Further study will be needed to determine if E1 
does fulfil this role in HCV entry.  Domains DI and DIII of E2 are linked by 
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IgVR which can be extended to enable the necessary movement of DIII during 
membrane fusion.  DIII is followed by the stem region that contains a 
conserved heptad repeat (aa 675-699) involved in E1E2 heterodimerisation and 
entry of HCVpp (Drummer & Poumbourios, 2004).  A further segment at aa 
705-715 has been identified as essential for entry of HCVcc (Albecka et al., 
2011).  The stem connects to the transmembrane domain responsible for 
anchoring E2 to the viral membrane (Op De Beeck et al., 2001).  The 3D 
structure of E2 is partly determined by the position of 18 cysteine residues 
forming 9 putative disulphide bonds (Krey et al., 2010) all of which are 
essential for infectivity of HCVpp and HCVcc (McCaffrey et al., 2012). 
 
1.5.3 p7 
   There has been some debate over whether p7 is a structural or non-structural 
protein.  p7 is a 63 amino acid, integral membrane protein containing two 
transmembrane domains connected by a short cytoplasmic loop (Carrere-
Kremer et al., 2002).  It is located in the ER membrane where it forms an ion 
channel that can be blocked by amantadine (Griffin et al., 2003; Wozniak et 
al., 2010) and iminosugars (Pavlovic et al., 2003).  p7 is essential for 
infectivity in vivo (Sakai et al., 2003) and functions in the efficient assembly 
and release of viral particles (Steinmann et al., 2007) by de-acidifying 
intracellular vesicles, presumably to protect the immature, acid sensitive viral 
particles (Wozniak et al., 2010).  However, it remains to be seen whether p7 
possesses additional, ion channel-independent functions. 
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1.5.4 NS2 
   NS2 is a 23 kDa membrane protein that, in combination with the N-terminal 
portion of NS3, forms a protease required for cleavage of the polyprotein at the 
NS2-NS3 boundary (Grakoui et al., 1993b).  The N-terminus of NS2 contains 
the transmembrane domain (Santolini et al., 1995) with the cysteine protease 
activity residing in the C-terminal domain (Lorenz et al., 2006).  NS2 is 
essential for the production of infectious HCV particles (Jirasko et al., 2008; 
Jones et al., 2007) and is able to form a complex with E1, E2, NS3, and 
possibly also NS4, that presumably functions to bring structural and non-
structural proteins together for particle assembly (Stapleford & Lindenbach, 
2011). 
 
1.5.5 NS3 and NS3-4A 
   NS3 is a multifunctional protein containing both serine protease and 
NTPase/helicase activity.  The serine protease activity requires NS4A as a 
cofactor (Failla et al., 1994) and is responsible for cleaving the polyprotein at 
the NS3-NS4A, NS4A-NS4B, NS4B-NS5A and NS5A-NS5B boundaries 
(Grakoui et al., 1993a).  NS3-4A is also able to block innate antiviral 
responses, such as the RIG-I induced pathway of NF-ț% DQG ,)1 UHJXODWRU\
factor 3 (IRF3) activation, by cleaving the adaptor protein Cardif /MAVS (Li et 
al., 2005b; Meylan et al., 2005), thereby reducing production of type-I IFN.  It 
also interferes with the activation of IRF3 and NF-ț% YLD 7ROO-like receptor 
(TLR)-3 by cleaving the adaptor protein Trif (Li et al., 2005a).  NS3-4A may 
therefore contribute to the persistence of HCV infection.  This dual function 
makes NS3 a particularly promising target for antiviral therapies, as it raises 
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the possibility of simultaneously targeting viral replication and enhancing the 
immune response (Raney et al., 2010).  The NTPase (Suzich et al., 1993) and 
helicase activity (Tai et al., 1996) of NS3 unwinds double-stranded RNA and 
'1$LQD¶ WR¶GLUHFWLRQ LQD UHDFWLRQFRXSOHG WR WKHK\GURO\VLVRI173V
The precise function of this helicase activity is not completely understood, 
(Raney et al., 2010) although it is essential for viral replication (Lam & Frick, 
2006) and infectivity (Kolykhalov et al., 2000). 
 
1.5.6 NS4B 
   NS4B is a 27 kDa hydrophobic membrane protein (Yu et al., 2006).  The 
expression of NS4B results in the formation of a membranous web structure.  
All viral proteins are associated with this structure leading to the suggestion 
that the membranous web is the site of HCV replication within an infected cell 
(Egger et al., 2002).  Polymerisation and lipid modification, specifically 
palmitoylation, of NS4B is required for the protein-protein interactions 
involved in formation of the replication complex to occur (Yu et al., 2006).  
NS4B has also been postulated to play a role in the production of viral particles 
(Jones et al., 2009). 
 
1.5.7 NS5A 
   NS5A is a phosphoprotein that binds NS5B and modulates its RNA-
dependent RNA polymerase activity in vitro (Shirota et al., 2002).  The N-
WHUPLQDO Į-helical region anchors the protein within the ER membrane and 
provides a platform for formation of the replication complex (Penin et al., 
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2004a) $GMDFHQWWRWKHĮ-helix, domain I of NS5A is a zinc-binding domain 
that is essential for RNA replication, although its precise role is unclear 
(Tellinghuisen et al., 2004).  NS5A is also able to bind single-stranded RNA, 
suggesting a role in RNA replication via binding to U/G rich regions in the 
NTRs of the HCV genome (Huang et al., 2005).  NS5A exists in a basally 
phosphorylated (56 kDa) form and a hyperphosphorylated (58 kDa) form.  
Differential phosphorylation of NS5A modulates RNA replication (Appel et 
al., 2005), protein-protein interactions (Evans et al., 2004) and infectious 
particle production (Tellinghuisen et al., 2008) and may therefore function as a 
regulatory switch during virus replication.  NS5A may also modulate the IFN 
response to HCV by inhibiting PKR, a protein kinase that reduces mRNA 
translation, with important implications for treatment of the virus (Katze et al., 
2002). 
 
1.5.8 NS5B 
   NS5B is the RNA-dependent RNA polymerase and as such is indispensable 
for replication (Kolykhalov et al., 2000; Lohmann et al., 1999).  It is a tail-
anchored protein with the C-terminal 21 amino acids essential for correct 
insertion into the ER membrane (Moradpour et al., 2004).  Cooperative 
initiation and elongation of RNA requires the formation of NS5B oligomers 
(Wang et al., 2002) and NS5B interacts with other viral proteins to form the 
replication complex (Ishido et al., 1998; Shirota et al., 2002).  More recently an 
interaction between NS5B, p7 and NS2 has been postulated to function in virus 
particle production (Gouklani et al., 2012).  The essential role of NS5B in the 
HCV life-cycle has made it a target for antiviral therapies (see section 1.4). 
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1.6 Model systems to study HCV 
   A number of model systems have been developed to study the lifecycle and 
immune response to HCV.  As this thesis is focussed on elucidating the 
antibody response to HCV, the following section will focus on those systems 
that have enabled such studies of the antibody response as well studies of the 
cellular receptors and the envelope glycoproteins.  Although the subgenomic 
replicon system (Lohmann et al., 1999) is an important development that 
provides insight into the replication of viral RNA, it lacks the structural 
proteins, precluding any studies of viral assembly or structure, and therefore 
will not be discussed further. 
 
1.6.1 Chimpanzees as model organisms 
   Chimpanzees are the only species other than humans that are permissive for 
HCV infection.  Early studies of the antibody response showed that infection of 
chimpanzees could be prevented by in vitro neutralisation of HCV (Farci et al., 
1994) and infectivity in vivo was also neutralised by the administration of 
immune sera (Farci et al., 1996).  Furthermore, chimpanzees were capable of 
eliciting an HCV-specific neutralising antibody (nAb) response following 
immunisation with the envelope glycoproteins, a response that partially 
protected against experimental challenge with the virus (Choo et al., 1994).  
However, it has since been noted that the outcome of HCV infection in 
chimpanzees differs greatly from that in humans.  Chimpanzees tend to suffer a 
milder disease with a higher rate of viral clearance and are less likely to 
develop liver fibrosis or cirrhosis (Jo et al., 2011).  In terms of the immune 
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response, viral clearance in chimpanzees is associated with a strong cellular 
immune response (Barth et al., 2011; Grakoui et al., 2003; Shoukry et al., 
2003).  As will be discussed later, spontaneous resolution in humans is 
associated with strong nAb responses.  Therefore studies of chimpanzees may 
not give an accurate assessment of the role played by the immune response in 
clearance of HCV.  The ethical and financial constraints of chimpanzee studies 
also make it a difficult model to work with. 
 
1.6.2 Soluble E2 and neutralisation of binding assays 
   Recombinant, soluble, full-length or truncated forms of E2 were used to 
identify the first entry receptors involved in HCV entry.  However, the use of 
soluble E2 (sE2) may not represent the native form of the envelope 
glycoprotein.  Indeed a study of truncated sE2, mammalian expressed E1E2 
and VLPs (see section 1.6.3) has highlighted structural, and therefore antigenic, 
dissimilarities between the three forms of E2 (Owsianka et al., 2001).  
Following the discovery that E2 binds to the cellular receptor CD81 (Pileri et 
al., 1998), many early in vitro studies of the antibody response probed this 
particular interaction.  The neutralisation-of-binding (NOB) assay measures E2 
binding to Molt-4 cells in the presence of nAb (Flint et al., 1999a; Rosa et al., 
1996).  However, Molt-4 cells, a lymphoma cell line, express CD81 but none 
of the other HCV entry receptors.  Therefore studies using this assay would be 
limited to identifying antibodies targeting E2-CD81 interactions only.  
Subsequent studies comparing Molt-4 cells and Huh7 hepatocarcinoma cells 
have shown that these antibodies inhibit the binding of E2 to Molt-4 cells more 
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readily than to Huh7 cells (Heo et al., 2004) potentially overstating the 
neutralising capabilities of some antibodies. 
 
1.6.3 Virus-like particles 
   Virus-like particles (VLPs) can be generated by the expression of the HCV 
structural proteins (core-E1-E2) in a baculovirus-insect cell (Spodoptera 
frugiperda Sf9) expression system.  The resulting particles are structurally 
similar to virions isolated from HCV-infected humans and chimpanzees 
(Baumert et al., 1998) and react with HCV-specific immune sera (Baumert et 
al., 1999).  They are also immunogenic and able to elicit an anti-E2 antibody 
response in mice (Baumert et al., 1999).  However, these VLPs are not secreted 
from the insect cells but rather are retained within intracellular vesicles 
(Baumert et al., 1998) making the isolation of VLPs difficult. 
 
1.6.4 HCVpp 
   The HCV pseudoparticle (HCVpp) system uses HCV envelope glycoproteins 
displayed on the surface of retroviral or lentiviral core particles (Bartosch et 
al., 2003b) to mimic the attachment and entry steps of the HCV lifecycle.  
Infectivity of a human hepatoma cell line is assessed by measurement of a 
specific reporter incorporated into the pseudoparticle.  HCVpp have been used 
to characterise E1 and E2 (Flint et al., 2004) and to identify nAbs in human 
and chimpanzee sera (Bartosch et al., 2003a; Yu et al., 2004).  More recently, 
E1E2 isolated from patient sources has been displayed on the surface of the 
pseudoparticle (Fafi-Kremer et al., 2010; Tarr et al., 2011) and used to assess 
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the evolution of the antibody response in individual patients (Dowd et al., 
2009).  However, not all pseudoparticles bearing patient-derived E1E2 are 
functional (Dowd et al., 2009; Lavillette et al., 2005).  One study suggests that 
less than 50% of pseudoparticles bear E1E2 at the surface and that the number 
of E1E2 molecules on each particle is low (Bonnafous et al., 2010).  It is also 
important to note that, unlike serum derived particles, HCVpp are not 
associated with any lipoproteins (Burlone & Budkowska, 2009).  Lipoproteins 
are thought to play an important role in modulating entry and neutralisation of 
HCV; therefore the HCVpp system may not mimic accurately the in vivo 
situation.  Furthermore, glycoprotein maturation and assembly of HCVpp 
differs from that seen in the HCVcc system (see below); HCVpp are assembled 
in a post-Golgi compartment following transit of the glycoproteins through the 
cell secretory pathway independently of other particle components (Sandrin et 
al., 2005).  In contrast, HCVcc assemble in an ER-derived compartment 
(Miyanari et al., 2007).  These differences may lead to variations in 
morphology and indeed, differential glycosylation of E1E2 has been observed 
between HCVcc and HCVpp (Vieyres et al., 2010)  
 
1.6.5 HCVcc 
   For many years, studies of the HCV lifecycle were hampered by the failure 
of the virus to replicate in cell culture.  The discovery of a genotype 2a strain, 
JFH-1, capable of replicating in cell culture without accumulating adaptive 
mutations (Kato et al., 2001; Wakita et al., 2005) has greatly improved our 
knowledge of the virus.  This HCV cell culture (HCVcc) system generates 
infectious viral particles enabling studies of the entire virus lifecycle.  Much 
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effort has gone into developing chimeric infectious clones of this virus, in 
order to study viruses of different genotypes.  This involves replacing the 
structural proteins (core-E1-E2) plus p7 and NS2 of JFH-1 with the 
corresponding proteins from genotypes 1-7.  Although generation of these 
chimeras has been successful, they often have poor replication kinetics and 
acquire cell culture adaptive mutations (Gottwein et al., 2009; Pietschmann et 
al., 2006).  Cell culture adaptations have been reported to increase the 
sensitivity of some isolates to antibody neutralisation and to alter binding to 
entry receptors (Dhillon et al., 2010; Grove et al., 2008).  Therefore studies of 
virus neutralisation carried out in the HCVcc system must be interpreted 
carefully. 
 
1.6.6 Mouse models 
   Chimpanzees and humans are the only species naturally infected with HCV.  
Small animal models are available, however these are unable to support the 
complete replication cycle of HCV.  The uPA-SCID mouse model uses 
immunosuppressed chimeric mice transplanted with human hepatocytes.  This 
renders the mice susceptible to HCV infection (Lindenbach et al., 2006; 
Mercer et al., 2001), although their immunodeficiency precludes any study of 
the host adaptive immune response.  Despite this, these mice have been used to 
demonstrate the protective nature of passively transferred anti-HCV antibodies 
(Law et al., 2008; Vanwolleghem et al., 2008), anti-CD81 antibodies 
(Meuleman et al., 2008) and anti-SR-BI antibodies (Meuleman et al., 2012).  A 
genetically humanised mouse bearing the human HCV entry factors (CD81, 
SR-BI, CLDN-1 and OCLN) was recently developed that is able to support 
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HCV entry but does not permit viral replication.  Studies of the complete viral 
lifecycle are therefore not possible but these mice are immunocompetent and 
do produce antibody in response to vaccination.  Furthermore, this antibody 
response protects against subsequent viral challenge.  Passive transfer of E2-
specific and receptor-specific antibodies also protects against infection in these 
mice (Dorner et al., 2011; Giang et al., 2012).   
 
1.7 Cell entry and receptors 
   A number of receptors and co-receptors for HCV entry have been identified; 
however, not all of them bind directly to E2 and instead may be required for 
the formation of a co-receptor complex at the surface of hepatocytes that 
mediates HCV entry.  A schematic representation of the HCV entry pathway, 
as it is currently understood, is presented in Figure 1-3. 
 
1.7.1 Lectins 
   The lectins DC-SIGN (dendritic cell-specific intracellular adhesion molecule-
3-grabbing non-integrin) and L-SIGN (liver-specific SIGN) are type II 
membrane proteins belonging to the C-type lectin family.  DC-SIGN and L-
SIGN are able to bind sE2 and HCVpp via the mannose containing N-linked 
glycans (Lozach et al., 2004; Pohlmann et al., 2003).  DC-SIGN is expressed 
on dendritic cells and lymphocytes while L-SIGN is expressed on liver 
sinusoidal cells.  These cells are not thought to internalise the virus and there is 
HYLGHQFHWRVXJJHVWWKDWWKH\DFWDVµFDSWXUHUHFHSWRUV¶ZKLFKWUDQVPLWWKHYLUus 
to susceptible cells i.e. hepatocytes (Lozach et al., 2004). 
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1.7.2 Glycosaminoglycans 
   Glycosaminoglycans (GAGs) are cell surface polysaccharides found on most 
cell types and the GAG heparan sulphate (HS) is required by several viruses 
for attachment to the target cell (Barth et al., 2003).  HS binds to E2 with N-
terminal epitopes proposed as the sites of interaction (Barth et al., 2003; Barth 
et al., 2006).  E1 is also able to bind HS, although the affinity is much lower 
than for E2 (Barth et al., 2006).  E2-HS binding and HCVpp entry can be 
inhibited by patient-derived anti-E2 antibodies and HS analogues such as 
heparin (Barth et al., 2003; Barth et al., 2006).  GAGs function at an early step 
in virus attachment to the target cell, prior to the binding of co-receptors such 
as CD81 (Barth et al., 2006; Koutsoudakis et al., 2006). 
 
1.7.3 LDL receptor (LDLr) 
   HCV circulating in patient sera is heterogeneous, displaying a range of 
buoyant densities caused by association with different lipoproteins (Burlone & 
Budkowska, 2009).  Low-density particles containing apoB and apoE, termed 
lipoviral particles (LVPs), are the most infectious (Agnello et al., 1999; Andre 
et al., 2002; Bradley et al., 1991).  Lipoproteins appear to play a role in entry 
as LDLr mediates entry of HCV and other Flaviviridae family members via 
binding of low-density lipoprotein (LDL) or very-low-density lipoprotein 
(VLDL) but not high-density lipoprotein (HDL) (Agnello et al., 1999).  
Specifically, the apoB and apoE components of VLDL (or apoB within LDL) 
mediate attachment to LDLr (Andre et al., 2002) and the reaction is 
independent of E2 binding to LDLr (Wunschmann et al., 2000).  Therefore 
lipoprotein receptors, such as LDLr, could promote HCV entry indirectly, via 
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binding to lipoproteins associated with the virus particle rather than by binding 
to the envelope glycoproteins.  However a recent study suggests that LDLr is 
not involved in productive HCV entry but is essential for replication of the 
virus via its role in lipid metabolism (Albecka et al., 2012).  
  
1.7.4 CD81 
   CD81 is a member of the tetraspanin family of transmembrane proteins.  It is 
a ubiquitous protein which normally forms part of the T cell and B cell receptor 
complex.  It has four transmembrane domains, two small extracellular loops 
(SEL) and one large extracellular loop (LEL).  The N and C terminals are 
located intracellularly (Levy & Shoham, 2005).  CD81 was the first receptor 
identified as being critical for HCV entry (Pileri et al., 1998).  CD81 is able to 
bind sE2 via the LEL and this interaction is inhibited by anti-CD81 monoclonal 
antibodies (MAb) and soluble CD81 LEL, preventing infectivity of HCVpp 
and HCVcc (Bartosch et al., 2003b; Wakita et al., 2005).  Down-regulation of 
CD81 expression using small interfering RNA (siRNA) also reduces infectivity 
of serum-derived HCV (Molina et al., 2008).  Human hepatoma cell lines, such 
as HepG2, which do not naturally express CD81 are rendered permissive to 
HCV infectivity following ectopic expression of CD81 (Bartosch et al., 2003c; 
Lavillette et al., 2005).  CD81 has been proposed as a species-specific 
determinant of HCV infectivity (Ploss et al., 2009).  CD81 binding sites within 
E2 have been extensively studied and research indicates that they map to the 
regions aa 412-423 (Owsianka et al., 2001), aa 432-447 (Clayton et al., 2002), 
aa 528-535 (Owsianka et al., 2001) and aa 544-551 (Flint et al., 1999a).  
Additionally, specific residues W420, Y527, W529, G530 and D535 
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(Owsianka et al., 2006) and the motif 436GWLAGLFY443 (Drummer et al., 
2006) are critical for E2-CD81 binding (Figure 1-2a).   
 
1.7.5 SR-BI 
   Human scavenger receptor class B type I (SR-BI) is a glycoprotein found on 
the surface of several mammalian cells but is particularly abundant on liver 
cells (Burlone & Budkowska, 2009).  SR-BI binds to sE2, a process that 
requires HVR1 as binding is prevented by the deletion of HVR1 and in the 
presence of anti-HVR1 antibodies (Bartosch et al., 2003c; Scarselli et al., 
2002).  SR-BI is thought to function at a post-attachment step and at a similar 
point in the entry process as CD81 (Zeisel et al., 2007).  CD36, a scavenger 
receptor molecule which is very similar to SR-BI but found on endothelial cells 
and macrophages, does not bind sE2, indicating a potential role for SR-BI in 
determining viral tropism (Scarselli et al., 2002).  The main function of SR-BI 
is in lipid metabolism, specifically the selective uptake of cholesteryl ester 
from HDL (Connelly & Williams, 2003).  Serum HCV particles are often 
associated with lipoproteins, including LDL and VLDL (Andre et al., 2002), 
raising the possibility that association of lipoproteins with HCV could facilitate 
infection in an SR-BI-dependent process.  It has since been demonstrated that 
infectivity of HCVpp and HCVcc is enhanced by the addition of HDL, via 
interaction between SR-BI and HDL (Bartosch et al., 2005; Dreux et al., 2006; 
Voisset et al., 2005).  HCVpp infectivity is also enhanced by the 
apolipoprotein C1 (Meunier et al., 2005).  HDL-enhancement of infection 
requires HVR1, as infectivity of HCVpp lacking HVR1 cannot be enhanced by 
HDL (Bartosch et al., 2005).  A recent study suggests that the requirement for 
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HVR1 in infectivity varies between genotypes; HVR1 is essential for 
infectivity of genotypes 1a, 1b, 2b, 3a and 4a whereas genotypes 2a, 5a and 6a 
carrying a deletion of HVR1 remain infectious (Prentoe et al., 2011).  
Therefore regions of contact between E2 and SR-BI may exist outside of 
HVR1.  HCV binding to SR-BI is also mediated via apoB-containing VLDL 
and may provide an alternative SR-BI entry mechanism that does not require 
direct HVR1-SR-BI binding (Maillard et al., 2006), although precise details of 
the role of SR-BI in HCV entry remain to be determined. 
 
1.7.6 Claudin-1 
   Claudin-1 (CLDN-1) is a tight junction protein required for HCV entry 
(Evans et al., 2007).  It is a four transmembrane protein, with two extracellular 
loops (EL) and intracellular N- and C-terminals.  The entry determinants of 
CLDN-1 map to EL1 (Cukierman et al., 2009; Evans et al., 2007).  There is no 
evidence of direct contact between HCV and CLDN-1 (Evans et al., 2007; 
Krieger et al., 2010); however, CD81 and CLDN-1 co-localise within cultured 
cells and hepatocytes (Harris et al., 2008) and form a CD81-CLDN-1 co-
receptor complex necessary for HCV entry (Harris et al., 2010).  A recent 
study suggests that CD81-CLDN-1 endocytosis is enhanced by HCV to 
promote entry into hepatocytes (Farquhar et al., 2012).  The interaction 
between CD81 and CLDN-1 can be disrupted by anti-CLDN-1 antibodies 
thereby inhibiting HCV entry (Fofana et al., 2010; Krieger et al., 2010).  
Claudin-6 and claudin-9 can also function as co-receptors in the entry of 
HCVcc and HCVpp (Harris et al., 2010; Zheng et al., 2007).   
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1.7.7 Occludin 
   The tight-junction protein occludin (OCLN) is also an essential co-receptor 
for HCV entry (Ploss et al., 2009), functioning at a post-attachment step 
(Benedicto et al., 2008).  OCLN and E2 are thought to interact directly, as 
demonstrated by co-precipitation of the proteins (Benedicto et al., 2008; Liu et 
al., 2009).  OCLN is a four transmembrane protein possessing two ELs and the 
entry determinants have been mapped to EL2 (Liu et al., 2010).  OCLN, along 
with CD81, form the minimal species-specific determinants for HCV entry, as 
the mouse and other non-primate homologues of OCLN are refractory to HCV 
infectivity (Dorner et al., 2011; Michta et al., 2010; Ploss et al., 2009).  These 
species-specific determinants also map to EL2 (Michta et al., 2010; Ploss et al., 
2009). 
 
1.7.8 Additional entry factors 
   Recently three additional co-factors have been implicated in HCV entry.  
Epidermal growth factor receptor (EGFR) and ephrin receptor A2 (EphA2) 
were identified using a siRNA screen of cellular kinase networks.  These 
receptor tyrosine kinases regulate the formation of the CD81-CLDN-1 co-
receptor complex, and therefore act at a post-binding step as well as playing a 
role in fusion.  Reduced expression of EGFR and EphA2 reduces infectivity of 
both HCVcc and HCVpp.  Infectivity is also inhibited by the EGFR inhibitor, 
erlotinib, and the EphA2 inhibitor, dasatinib, as well as antibodies targeting 
both receptors.  Furthermore, erlotinib reduces infectivity in the uPA-SCID 
mouse model (Lupberger et al., 2011).   
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   Niemann-Pick C1-like 1 (NPC1L1) cholesterol absorption receptor is a 
transmembrane protein involved in cholesterol homeostasis.  Its role in HCV 
entry was recently demonstrated as siRNA silencing of NPC1L1 reduces 
HCVcc infectivity.  NPC1L1 acts prior to viral fusion and its activity is 
dependent on the level of cholesterol within the viral particle.  Entry is also 
blocked by an NPC1L1-specific antibody blocking virus binding to the first 
LEL of NPC1L1.  The NPC1L1 inhibitor, ezetimibe, reduces HCV infectivity 
in vitro and delays the development of HCV infection in vivo (Sainz et al., 
2012).   
 
1.7.9 Proposed mechanism of HCV entry into target cells 
   The exact role played by each cellular receptor or entry factor is still 
incompletely understood; however, the experimental evidence has made it 
possible to piece together an entry model (Figure 1-3). 
   The viral particles circulate as LVPs in the vascular system (Burlone & 
Budkowska, 2009).  The lectins, L-SIGN and DC-SIGN, are believed to act as 
µFDSWXUH UHFHSWRUV¶ FDSDEOH RI ELQGLQJ WKH YLUXV DQG WUDQVPLWWLQJ LW WR
permissive cells (Lozach et al., 2004).  Initial attachment to hepatocytes is 
mediated by LDLr binding to the lipoprotein components of LVPs (Andre et 
al., 2002) and GAG binding to the envelope glycoproteins (Barth et al., 2003) 
in a low affinity reaction which brings the virus into close proximity with the 
high affinity receptors CD81 and SR-BI at the cell surface.  It has been 
proposed that this triggers cytoskeletal rearrangements which enable 
translocation of the viral particle to sites containing CLDN-1 and OCLN 
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Figure 1-3. Mechanism of HCV entry into hepatocytes. (1) Viral 
particles circulate as LVPs. The lectins, L-SIGN and DC-SIGN, act as 
µFDSWXUH UHFHSWRUV¶ ELQGLQJ WKH YLUXV DQG WUDQVPLWWLQJ LW WR SHUPLVVLYH
cells. Initial attachment is mediated by LDLr and GAG binding in low 
affinity reactions which bring the virus into close proximity with high 
affinity receptors. (2) E1E2 binds CD81 and SR-BI at the cell surface 
triggering cytoskeletal rearrangements leading to translocation of the 
viral particle to sites containing CLDN-1 and OCLN. (3) The E2-CD81-
CLDN-1 co-receptor complex is formed leading to internalisation via 
clathrin-mediated endocytosis. (4) pH-dependent fusion of the viral 
envelope with endosomal plasma membranes releases the 
nucleocapsid into the cytoplasm. Figure is taken from Edwards et al., 
(2011). 
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(Brazzoli et al., 2008).  An E2-CD81-CLDN-1 co-receptor complex is formed 
and is necessary for entry to occur (Harris et al., 2010; Harris et al., 2008).  
The precise function of OCLN has not yet been determined but interaction of 
the virus with co-receptors leads to internalisation via clathrin-mediated 
endocytosis (Blanchard et al., 2006; Farquhar et al., 2012).  Trafficking via 
endosomes and pH-dependent fusion of the viral envelope with endosomal 
plasma membranes is thought to occur (Blanchard et al., 2006; Lavillette et al., 
2006; Tscherne et al., 2006), however, further study is needed to elucidate the 
precise mechanism and to identify the fusion determinant within the envelope 
glycoproteins. 
   The entry factors EGFR, EphA2 and NPC1L1 are not included on this 
diagram as they have only recently been described.  However, EGFR and 
EphA2 are thought to regulate formation of the CD81-CLDN-1 co-receptor 
complex (Lupberger et al., 2011).  The function of NPC1L1 is less clear 
although its cholesterol-dependent nature may indicate an indirect mode of 
action, whereby it removes virus-associated cholesterol to reveal glycoprotein 
binding sites or allow conformational changes necessary for binding (Sainz et 
al., 2012).   
 
1.8 The immune response to HCV 
1.8.1 The cellular immune response 
   The humoral immune response does not function alone and the role played 
by the cellular adaptive immune response has been well studied.  The 
importance of CD8+ T cells and CD4+ T cells has been demonstrated by 
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depletion studies carried out in chimpanzees.  Depletion of CD8+ T cells results 
in the persistence of HCV until CD8+ T cells recover (Shoukry et al., 2003) 
while depletion of CD4+ T cells causes persistent infection which becomes 
chronic due to the selection of mutations in MHC class I epitopes (Grakoui et 
al., 2003).   
   CD8+ (cytotoxic) T lymphocyte (CTL) responses are directed against 
epitopes spanning the HCV polyprotein, encompassing both structural and non-
structural proteins (Neumann-Haefelin et al., 2008).  In acute resolving 
infection, the CD8+ T cell response peaks within 4 to 10 weeks following 
exposure to the virus and is thought to contribute to liver pathology as the CTL 
response coincides temporally with the onset of liver disease (Lechner et al., 
2000).  CD8+ T cells also preferentially accumulate in the liver compared to the 
peripheral blood (Neumann-Haefelin et al., 2008; Spangenberg et al., 2005).  
&7/V SURGXFHG HDUO\ GXULQJ LQIHFWLRQ H[KLELW D µVWXQQHG¶ SKHQRW\SH DQG
produce low levels of IFN-Ȗ EXW WKHVH DUH ODWHU UHSODFHG E\ D PHPRU\
phenotype producing high levels of IFN-Ȗ  $ VWURQJ &'+ T cell response 
targeting multiple epitopes is generally associated with viral clearance (Chang 
et al., 2001; Lechner et al., 2000; Thimme et al., 2002); however, some studies 
have demonstrated virus persistence despite the presence of a multi-specific 
CD8+ T cell response (Cox et al., 2005).  Therefore the breadth of the CD8+ T 
cell response is not always a determinant of disease outcome.  A number of 
reasons have been suggested for this apparent immune failure.  Dysfunctional 
CD8+ T cell responses have been demonstrated in some patients with chronic 
infection.  These dysfunctions include impaired cytokine production (IFN-Ȗ
and tumour necrosis factor (TNF)-Į(Gruener et al., 2001; Spangenberg et al., 
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2005; Wedemeyer et al., 2002), reduced lytic activity due to low levels of 
perforin (Gruener et al., 2001) and low proliferative capacity (Wedemeyer et 
al., 2002).  Mutational escape by the virus may also occur and in fact most 
CD8+ T cells do not proliferate against the circulating antigen but rather a 
previous antigen which has been eliminated by viral escape mutations 
(Neumann-Haefelin et al., 2008).   
   Despite the ability of the liver to delete CD8+ T cells, virus-specific T cells 
may persist in the liver for many years and continue to contribute to disease 
pathology (Neumann-Haefelin et al., 2008; Spangenberg et al., 2005; 
Wedemeyer et al., 2002).  As suggested by depletion studies, CD8+ T cells 
may be insufficient to clear the virus without CD4+ T cell help (Grakoui et al., 
2003).  This hypothesis is supported by the findings that CD4+ Th1 cell 
responses are lower in chronically infected patients (Wedemeyer et al., 2002) 
and that resolving acute infection is usually characterised by a broad CD4+ T 
cell response which targets multiple epitopes (Schulze Zur Wiesch et al., 
2005).  An impaired CD4+ Th1 response during the acute phase is associated 
with the failure to mount an effective, memory CD8+ T cell response (Urbani et 
al., 2006).  Recently it has been suggested that a CD4+ T cell response 
develops in all acute HCV infections but that these CD4+ T cells fail to 
proliferate and rapidly decline in those patients who develop a persistent 
infection (Schulze Zur Wiesch et al., 2012).   
   The relative roles played by CD8+ and CD4+ T cells in resolution of infection 
need to be carefully considered for future vaccination strategies.  The 
importance of both CD4+ and CD8+ T cells in spontaneous resolution of HCV 
infection is well established although the precise mechanisms for failure are 
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still being deciphered.  It is also important to remember that CD4+ T helper 
cells are required to stimulate an effective memory B cell response (McHeyzer-
Williams et al., 2012); therefore a defective CD4+ T cell response may inhibit 
the development of the antibody response.  As such it may be necessary to 
simultaneously target both humoral and cellular arms of the immune response 
to ensure that any vaccine has a protective effect. 
 
1.8.2 The antibody response to HCV infection 
1.8.2.1 Evidence of a protective antibody response in HCV 
   Due to the asymptomatic nature of acute HCV infection it is difficult to 
identify patients in the early phase of disease.  This can make analysis of the 
role played by antibodies in spontaneous recovery problematic.  However, 
early evidence of a protective effect came from a retrospective study of patients 
receiving polyclonal immunoglobulin (Ig) against hepatitis B virus antigen 
(HBIG).  Prior to the introduction of screening for HCV infection, patients who 
received HBIG were less likely to develop HCV than those patients who 
received screened HBIG.  Subsequently, anti-HCV antibodies were found in 
HCV-negative patients receiving unscreened HBIG indicating that anti-HCV 
antibodies had been passively transferred from donor to recipient within the 
HBIG and that these antibodies were protective (Feray et al., 1998).  
Hypogammaglobulinaemic patients exhibit a rapid disease progression upon 
infection with HCV, suggesting that antibodies contribute to controlling 
chronic infection (Bjoro et al., 1994).  However, others report spontaneous 
resolution of acute HCV in hypogammaglobulinaemic patients, suggesting that 
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cellular immunity may clear infection in some cases (Razvi et al., 2001).  
Finally, HCV-positive patients with depleted B cell populations following 
rituximab therapy experience an increase in viral load which returns to normal 
after cessation of treatment (Ennishi et al., 2008), presumably as the B cell 
population recovers.  Therefore B cells and the antibody response may be 
involved in maintenance of a steady viral load during chronic infection.   
 
1.8.2.2 Neutralising antibody response in acute vs. chronic disease 
   Studies of the acute phase nAb response in patient cohorts suggest that nAb 
do play a critical role in disease outcome.  In a cohort infected with a single 
strain of HCV (genotype 1b strain AD78), studies using HCVpp bearing the 
autologous AD78-derived E1E2 demonstrated that rapid induction of nAb 
early during infection was associated with spontaneous recovery.  Patients who 
developed a chronic infection generated no antibodies or a very low titre 
antibody response in the early phase of the infection.  Antibodies isolated from 
spontaneous resolvers showed broader cross-neutralising activity than those 
with chronic infection.  In contrast, when the nAb response was assessed 
several years later, nAb were detectable at high titres in chronically infected 
patients, although these were unable to clear the virus.  Neutralising antibodies 
were largely undetectable at this stage in patients who had resolved infection 
(Pestka et al., 2007).  In a cohort of injecting drug users infected with different 
strains of HCV a similar pattern was observed.  Using patient-specific E1E2 
sequences from sequential time points to generate HCVpp, a high titre, 
autologous nAb response was observed early during infection in all individuals 
who spontaneously resolved the infection but was absent in those who 
 33 
 
developed a chronic infection (Dowd et al., 2009).  Despite these striking 
observations it remains to be established which viral epitopes are targeted by 
the acute phase antibody response, raising the possibility that the very early 
antibody response in these patients targets novel viral epitopes.  These findings 
also contrast with many studies carried out in chimpanzees which show poor 
induction of nAb in animals that spontaneously control the infection 
(Logvinoff et al., 2004; Meunier et al., 2005).  However, this may be due to 
observed differences in disease progression between chimpanzees and humans 
(discussed in section 1.6.1) which may make chimpanzees an unreliable model 
organism.   
   One of the best studied cases of HCV infection is that of patient H who 
became infected in 1977 after receiving a blood transfusion and developed a 
chronic infection.  This individual is the source of the 1a strain H77 which is 
used in most studies of HCV and forms the basis for several assays.  A study of 
the nAb response in patient H over a period of 26 years showed that the early 
antibody response was targeted toward HVR1 but was not maintained (von 
Hahn et al., 2007), consistent with the view that HVR1 acts as an 
immunological decoy (Ray et al., 1999).  The induction of a broadly nAb 
response targeting E1E2 was not observed until the chronic phase (Bartosch et 
al., 2005; von Hahn et al., 2007). 
 
1.8.2.3 Dynamics of the antibody response during infection 
   Over the years many studies of anti-HCV antibody responses have relied 
upon neutralisation of HCVpp bearing H77 E1E2 sequences as a marker of 
neutralising ability.  However several studies have shown that the nAb 
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response is dynamic and drives the evolution of viral envelope sequences 
(Dowd et al., 2009; Farci et al., 2000; von Hahn et al., 2007).  Both von Hahn 
et al., (2007) and Dowd et al., (2009) show that sequential serum samples are 
limited in their ability to neutralise the concurrently circulating viral strains but 
are able to efficiently neutralise virus strains from earlier time points.  
Therefore even within one individual, a single viral envelope sequence may not 
EH VXIILFLHQW WR µSXOO-RXW¶ DOO Q$E  ,QGHHG WKH XVH RI KHWHURORJRXV +-
HCVpp to measure nAb is less sensitive than the use of autologous HCVpp.  
This over-reliance upon H77 may explain why the nAb response appears to lag 
behind the cellular immune response and why it appears to develop so much 
later than in other viral infections (Dowd et al., 2009).  A recent study also 
shows that patient-derived E1E2 sequences are more resistant to neutralisation 
than H77 E1E2 which may have resulted in an over-estimation of the number 
and potency of nAb.  The frequency of patient sera with cross-neutralising 
activity was also lower than previously reported which was attributed to the 
limited number of viral genotypes against which many antibodies or sera have 
been tested (Tarr et al., 2011).  This highlights the importance of choosing an 
appropriate assay method to accurately assess the neutralising potential of a 
given antibody and possible shortcomings in the way broadly nAbs are defined. 
 
1.8.3 Specific viral targets of neutralising antibodies 
1.8.3.1 HVR1 binding sites within E2 
   HVR1 is a linear epitope located at aa 384-410 of E2 (Figure 1-2) that plays 
an important role in SR-BI binding (see section 1.7.5).  It is immunogenic and 
anti-HVR1 antibodies have been identified in vivo (Kato et al., 1994; Kato et 
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al., 1993; Weiner et al., 1992) although these antibodies tend to be strain 
specific (Bartosch et al., 2003a; Shimizu et al., 1996; Vieyres et al., 2011) and 
high concentrations are required for effective neutralisation (Bartosch et al., 
2003a).  Nevertheless, HVR1 plays an important role in disease outcome.   
   Antibodies binding to HVR1 are either neutralising or non-neutralising 
depending on the region of HVR1 to which they bind.  The HVR1-specific rat 
MAb 9/27 inhibits SR-BI binding to E2 and neutralises infectivity of HCVpp 
bearing genotype 1a-derived envelope glycoproteins (Bartosch et al., 2003a; 
Hsu et al., 2003).  The epitope bound by 9/27 maps to aa 396-407, within the 
C-terminal region of HVR1.  Other nAbs, such as the mouse MAb AP213 and 
the polyclonal sera R1020 and R140, also bind to the C-terminal region of 
HVR1 (Vieyres et al., 2011).  In contrast, antibodies binding to epitopes within 
the N-terminal region of HVR1 (aa 384-395) including rat MAbs 7/59, 6/16 
and 6/82a, are non-neutralising (Hsu et al., 2003).  Therefore, HVR1 possesses 
two immunogenic domains which differ in their ability to stimulate a nAb 
response. 
   
1.8.3.2 HVR1 as an immunological decoy 
   Infectivity of HCVpp and HCVcc is enhanced by HDL in an HVR1 and SR-
BI dependent manner (Bartosch et al., 2005; Voisset et al., 2005).  This 
interaction also inhibits neutralisation of HCVpp and HCVcc by antibodies 
binding to E2 regions outside of HVR1 (Bartosch et al., 2005; Dreux et al., 
2006).  HVR1 is also able to mask some nAb epitopes within E2 and deletion 
of HVR1 increases neutralisation by CD81 binding site-specific human MAbs 
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and patient sera (Bankwitz et al., 2010; Prentoe et al., 2011) presumably by 
exposing these CD81 binding sites.  Therefore HVR1 may protect viral entry 
determinants within E2 from neutralisation during the early stages of entry 
(Bankwitz et al., 2010).  Thus HVR1 appears to play multiple roles during 
HCV entry which are somewhat contradictory in nature.  This has led some to 
suggest that HVR1 functions as an immunological decoy.   
   Studies of viral evolution during the acute phase of infection suggest that 
resolved infection is associated with stable HVR1 sequences.  In contrast 
persistent infection is characterised by considerable sequence change within 
HVR1 (Farci et al., 2000; Ray et al., 1999).  The immunological decoy 
hypothesis posits that HVR1 stimulates a strong antibody response that is 
unable to clear the virus, but which instead drives mutational escape of the 
virus (Ray et al., 1999).  Viruses able to mutate rapidly within HVR1 will 
escape the nAb response and persist, whereas viruses with constrained 
evolution of HVR1 do not escape the antibody response and are cleared.  The 
HVR1-focussed acute phase antibody response of patient H and the emergence 
of escape mutations within HVR1 leading to chronic infection may reflect this 
situation occurring in vivo (von Hahn et al., 2007).  However, recently 
published work contradicts the hypothesis that stable HVR1 sequences 
correlate with viral clearance.  Liu et al., (2012) observed that HVR1 evolved 
rapidly in patients who spontaneously resolved infection in response to the 
induction of a strong HVR1-specific nAb response.  Sequence change within 
HVR1 was not observed in patients who progressed to chronic infection due to 
the lack of a nAb response driving HVR1 evolution (Liu et al., 2012).  The 
failure to identify the target of the antibody response in some spontaneous 
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resolvers (Dowd et al., 2009; Pestka et al., 2007) also suggests that other 
broadly neutralising epitopes may contribute to clearance of the virus. 
Therefore the ability to induce a strong nAb response targeting multiple 
epitopes, including HVR1, early during infection may be a more critical 
determinant of disease outcome. 
 
1.8.3.3 The CD81 binding region within E2 
   A number of CD81 binding sites have been identified within E2 (see section 
1.7.4).  Among these, residues W420, Y527, W529, G530 and D535 and the 
436GWLAGLFY443 motif are highly conserved across genotypes.  In the 3D 
structural model of E2, the CD81 binding sites are oriented in close proximity 
to each other within DI (Krey et al., 2010).  Antibodies targeting both linear 
and conformational epitopes have been isolated and anti-CD81 MAbs are the 
most numerous identified to date. 
   A linear epitope immediately downstream of HVR1, aa 412-423, is 
recognised by the broadly neutralising mouse MAb AP33 (Owsianka et al., 
2005) and the rat MAb 3/11 (Flint et al., 1999a)(Figure 1-2a), although 
residues critical for binding differ between the two MAbs leading to 
differences in neutralising potency (Tarr et al., 2006).  Although the epitope 
bound by both MAbs is linear, optimal binding is dependent on the overall 
conformation of the E2 glycoprotein (Tarr et al., 2006), showing the 
importance of using native E2 when studying antibodies.  AP33 shows broad 
neutralising activity against the major genotypes of HCV (Owsianka et al., 
2005) making this region of E2 an interesting target for vaccination.  However 
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antibodies targeting this region of E2 are found in <5% of individuals with 
resolved or chronic infection (Tarr et al., 2007) suggesting that this region is 
less immunogenic in humans than in rodents.  Two other antibodies targeting 
this region, HCV1 and 95-2, have been identified in transgenic mice bearing 
human Ig genes (Broering et al., 2009), further evidence that this domain is 
preferentially targeted by the murine immune response.  Murine MAbs 
recognising conformational epitopes have been identified (H35 and H48), 
however these show limited breadth of neutralisation (Cocquerel et al., 1998; 
Owsianka et al., 2006). 
   Many human MAbs targeting the CD81 binding site recognise 
conformational epitopes.  E2 has been divided into five antigenic regions (AR); 
AR1, AR2, AR3 (Law et al., 2008), AR4 and AR5 (Giang et al., 2012) with 
AR3 consisting of discontinuous epitopes aa 396-424, aa 436-447 and aa 523-
540 (Figure 1-2a).  A number of neutralising MAbs have been mapped to this 
region including 1:7 and A8 (Johansson et al., 2007b), AR3A, AR3B, AR3C 
and AR3D (Law et al., 2008), CBH5 and CBH2 (Hadlock et al., 2000; 
Owsianka et al., 2008), HC-1 (Keck et al., 2008a) as well as the Fab e137 
(Perotti et al., 2008) and Fab e20 (Mancini et al., 2009).  All of these 
antibodies are broadly neutralising and MAbs AR3A and AR3B protect against 
infection in vivo (Law et al., 2008).  In contrast antibodies binding to AR1 and 
AR2 are poorly neutralising (Law et al., 2008).  The human MAbs CBH4B, 
CBH4D and CBH4G, that bind a region distinct from the three described ARs, 
are also non-neutralising (Keck et al., 2004a).  Therefore AR3 may represent 
an immunogenic, neutralising determinant within E2, which encompasses the 
CD81 binding site (Law et al., 2008).  CD81 binding site-specific MAbs have 
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also been described that bind to the regions aa 410-446 (overlapping with 
residues forming AR3) and aa 611-617, indicating that DIII of E2 may also be 
involved in CD81 binding.  This group of MAbs, termed HC-84, were broadly 
neutralising and did not lead to neutralisation escape mutations (Keck et al., 
2012).   
   Antibodies recognising the CD81 binding site have been described that show 
no neutralisation or limited neutralisation.  The rat MAb 1/39 binds aa 432-
443, overlapping the CD81 binding site aa 432-447, but shows only limited 
neutralisation of HCVpp entry.  MAbs 9/75 and 2/64a both recognise the 
524APTYSWGA531 motif (overlapping aa 528-535) (Figure 1-2a), yet whereas 
2/64a shows intermediate neutralisation of entry, 9/75 is non-neutralising (Hsu 
et al., 2003).  Therefore the presence of antibodies targeting CD81 binding 
does not necessarily correlate with neutralisation of infection and subtle 
differences in antibody specificity may alter their neutralising potency. 
   Recently a novel antibody was described with inhibitory activity against both 
CD81 and SR-BI.  The broadly neutralising mouse MAb, H77.39, binds a 
region of E2 encompassing aa 384-520, with critical binding residues located at 
N415 and N417 (Sabo et al., 2011) and therefore overlapping the epitope 
bound by AP33 (Owsianka et al., 2005) and 3/11 (Flint et al., 1999a).  Its 
ability to inhibit CD81 binding to E2 is presumably mediated via binding to, 
and blocking, the CD81 binding site at aa 412-423.  However, it is not yet clear 
how it might also inhibit SR-BI, although its close proximity to HVR1 may 
cause steric inhibition of SR-BI binding to E2 (Sabo et al., 2011). 
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1.8.3.4 The fusion determinant and stem region 
   The fusion determinant of HCV entry, thought to reside within one of the 
envelope glycoproteins, has not yet been conclusively identified.  However, 
studies suggest that patient-derived antibodies can block virus entry by 
inhibiting the fusion process (Haberstroh et al., 2008; Kobayashi et al., 2006).  
More recently broadly neutralising antibodies targeting the region aa 496-515 
(which overlaps the putative fusion determinant at aa 502-520) have been 
described following vaccination of mice with recombinant E1E2 (Kachko et 
al., 2011) although their ability to block fusion specifically was not tested.  
Identifying the function of such antibodies could help to confirm the location 
of the fusion determinant and provide another target for antibody-based 
therapies, in a manner analogous to the inhibition of HIV-1 gp41 fusion 
(Karlsson Hedestam et al., 2008) and influenza virus haemagglutinin (HA) 
fusion (Sui et al., 2009) by nAbs. 
   Antibodies targeting other epitopes within E2 have also been described.  In 
contrast to AR3, which encompasses a CD81 binding site within E2, the newly 
described AR4 and AR5 encompass discontinuous epitopes within the E1E2 
complex.  Antibodies targeting these AR do not block E2 binding to CD81 yet 
are able to neutralise infectivity in vivo.  Binding of MAb AR4A maps to the 
membrane proximal external region (residue D698) within the stem region, 
indicating an additional target for the neutralising antibody response beyond 
those previously described (Giang et al., 2012).  
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1.8.3.5 Antibodies targeting E1 
   Antibodies targeting epitopes within E1 are rare in patient sera (Leroux-
Roels et al., 1996; Pestka et al., 2007).  This may be due to the immunological 
dominance of E2, the masking of E1 epitopes by E2 (Garrone et al., 2011) or 
glycan-shielding of immunogenic domains within E1 (Fournillier et al., 2001).  
More simply, it may be caused by technical difficulties in detecting anti-E1 
antibodies, as E1 misfolds unless it is co-translated with E2 (Dubuisson et al., 
1994).   
   Characterised E1-specific MAbs are limited in number.  The human MAb H-
111 binds the 192YEVRNVSGVYH211 epitope near the N-terminus of E1 from 
genotypes 1a, 1b, 2b and 3a but not genotypes 2a or 4a suggesting partial 
conservation of this epitope.  H-111 binding to VLPs can reduce entry into 
Molt-4 cells, albeit with a maximum 70% inhibition of entry (Keck et al., 
2004b).  The human MAbs IGH505 and IGH526 show broad inhibition of 
entry of HCVpp, as well as neutralising HCVcc infectivity.  Both antibodies 
map to a linear epitope within E1 encompassing aa 313-327 (Meunier et al., 
2008) showing that some regions of E1 are immunogenic and elicit a nAb 
response, although the frequency of such antibodies is low.   
   Several trials of E1 protein vaccine candidates have demonstrated that anti-
E1 antibody responses are induced (Garrone et al., 2011; Leroux-Roels et al., 
2004; Nevens et al., 2003), although the efficacy of the anti-E1 response is 
unclear.  In one study, viral load in chronically infected patients was not 
reduced although improved liver histology was reported (Nevens et al., 2003).  
A recent study of VLPs expressing E1, used in a prime-boost protocol with 
soluble E1, reported the induction of an E1-specific antibody response but this 
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was not neutralising.  Neutralisation was only observed when animals were 
also vaccinated with E1E2 (Garrone et al., 2011).  In contrast, induction of 
anti-E1 antibodies following immunisation with a recombinant form of E1 that 
was protective against challenge with a heterologous HCV has been reported.  
This was more effective than an E2-based vaccine (Verstrepen et al., 2011).   
   The role played by E1 in HCV entry is still unclear.  As yet it has not been 
shown to bind to the entry receptors, CD81, SR-BI, CLDN-1 or OCLN.  It has 
been proposed to function as the fusion determinant (Lavillette et al., 2007) 
although this is in disagreement with the proposed 3D model of E2 (Krey et al., 
2010).  It therefore remains to be seen which aspect of E1 structure and 
function might best be targeted in the search for nAbs. 
 
1.8.3.6 Other targets for the neutralising antibody response 
   To date, antibodies inhibiting E2 binding to CD81 and SR-BI have been the 
focus of research.  However the discovery of several additional receptors and 
entry factors has opened up new targets.  Although OCLN co-precipitates with 
E2 (Benedicto et al., 2008; Liu et al., 2009), no virus-specific antibodies 
targeting this interaction have been identified.  Anti-CLDN-1 antibodies have 
been demonstrated to inhibit the formation of the E2-CD81-CLDN-1 co-
receptor complex (Fofana et al., 2010; Krieger et al., 2010) and thereby reduce 
infectivity of HCVcc and HCVpp.  The usefulness of anti-receptor rather than 
anti-virus antibodies has also been demonstrated with antibodies targeting 
CD81 (Fafi-Kremer et al., 2010; Meuleman et al., 2008; Molina et al., 2008), 
SR-BI (Catanese et al., 2010; Meuleman et al., 2012) and, more recently, the 
 43 
 
newly described co-factors EGFR (Lupberger et al., 2011) and NPC1L1 (Sainz 
et al., 2012) which were able to block or inhibit viral entry.  Furthermore, 
combinations of anti-receptor antibodies had an additive effect on 
neutralisation of infectivity (Krieger et al., 2010) as did a combination of anti-
receptor plus anti-HCV antibodies (Fofana et al., 2010).  Targeting 
components of normal human cells may not be appropriate in healthy 
individuals; however anti-receptor antibodies may provide an important facet 
of future therapies to control the spread of HCV, particularly among transplant 
recipients. 
 
1.8.4 Virus mechanisms for evading antibody neutralisation 
   Neutralising antibodies can clear acute infection, yet broad nAb responses are 
commonly seen in chronically infected patients.  This implies that the virus 
must be able to subvert or evade the immune response in order to establish a 
persistent infection.  Several mechanisms have been described by which HCV 
may persist.   
 
1.8.4.1 Mutational escape 
   The HCV single-stranded RNA genome has a high mutation rate due to the 
error-prone nature of the RNA-dependent RNA polymerase and the rapid 
turnover of the virus (Neumann et al., 1998).  This results in a diverse 
population of viral variants within the host, with variable sensitivity to a given 
antibody.  In the presence of nAb, escape variants will have a selective 
advantage over neutralisation-sensitive variants and will rapidly become the 
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dominant strain.  This situation has been observed in vivo, where evolution of 
the envelope glycoproteins is driven by the nAb response (Dowd et al., 2009; 
Pestka et al., 2007; von Hahn et al., 2007).  In chronic infection, positively 
selected amino acids are found in E2 and are situated within or in close 
proximity to receptor binding sites and nAb epitopes (Brown et al., 2005; 
Brown et al., 2007) and a high number of selected sites within E2 is associated 
with rapid progression to persistent infection (Sheridan et al., 2004).  Therefore 
PXWDWLRQDOHVFDSHLVDNH\ZHDSRQLQ+&9¶VDELOLW\WRSHUVLVWGHVSLWHDVWURQJ
nAb response.   
 
1.8.4.2 Glycan shielding 
   The envelope glycoproteins of HCV are highly glycosylated structures and 
the 11 N-linked glycans of E2 play an important role in its structure, function 
and immunogenicity (see section 1.5.2).  Specific glycans at positions N1, N2, 
N4, N6 and N11 (Figure 1-2a) modulate HCVpp and HCVcc binding to CD81 
and removal of these glycans increases entry inhibition by the CD81-LEL 
(Falkowska et al., 2007; Helle et al., 2007; Helle et al., 2010).  Furthermore, 
removal of these glycans increases the sensitivity of HCVpp and HCVcc to 
neutralisation by patient sera and MAbs (Falkowska et al., 2007; Helle et al., 
2007; Helle et al., 2010).  This has led to the suggestion that HCV possesses a 
glycan shield, which protects certain epitopes from neutralisation.  The finding 
that some of these glycans also modulate CD81 binding shows that a fine 
balance has to be achieved by the virus, namely the protection of entry 
determinants from neutralisation without blocking their function.  Both HIV-1 
gp120 and influenza HA possess a glycan shield which affords the virus 
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protection from neutralisation without blocking entry.  However, these glycan 
shields are evolving, continually shifting the position as well the frequency of 
glycans on the exposed face of the glycoprotein (Abe et al., 2004; Wei et al., 
2003).  HCV does not exhibit such diversity in its glycosylation state.  Indeed, 
of the 11 potential N-linked glycosylation sites on E2, nine show conservation 
of >97% across the genotypes (Falkowska et al., 2007) with N7 absent from 
genotype 3 as well as most genotype 6 sequences and N5 missing in some 
subtypes (Helle et al., 2007).  The majority of the glycans in E2 do not undergo 
positive selection, with the exception of N5 in genotype 1, N6 in genotype 5 
and N9 in genotype 4 (Brown et al., 2007) and some glycans are critical for 
entry (Falkowska et al., 2007) or infectious particle production (Helle et al., 
2010).  Therefore HCV is not able to evolve the glycan shield in response to a 
changing nAb repertoire, but glycans may protect some entry determinants 
from neutralisation at key steps during entry. 
 
1.8.4.3 Cell-to-cell transmission 
   The mechanism by which cell-free HCV attaches to the target cell-surface 
and enters is gradually being deciphered (Figure 1-3 and section 1.7.9).  
However, it has recently been discovered that HCV is also capable of direct 
cell-to-cell transmission (Timpe et al., 2008).  This requires the entry receptors 
CD81, SR-BI, CLDN-1 and OCLN and occurs with all viral genotypes 
(Brimacombe et al., 2011).  Cell-to-cell transmission is largely resistant to E2-
specific antibody-mediated neutralisation (Timpe et al., 2008) although it is 
partially inhibited by the rat MAbs 9/27 and 11/20c which target the HVR1 
epitope, aa 396-407, and the CD81 binding sites, aa 412-423 and 436-447, 
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respectively (Brimacombe et al., 2011).  However, it is sensitive to anti-SR-BI 
antibody mediated neutralisation (Meuleman et al., 2012) suggesting an 
important role for SR-BI in this mechanism of viral spread.  Direct cell-to-cell 
transmission as a mechanism of immune evasion is characteristic of a number 
of other enveloped viruses, such as the herpesviruses, measles virus, and the 
retroviruses HIV-1, murine leukaemia virus and human T-cell lymphotrophic 
virus (Mothes et al., 2010).  Such direct cell-to-cell transmission may have 
implications in terms of antibody-based therapeutics.  Once the virus has 
entered hepatocytes, cell-to-cell transmission may contribute significantly to 
the establishment of a chronic infection.  Therefore only a relatively short 
window may exist for antibody neutralisation to prevent infection of the liver 
and this will be an important consideration when treating transplant recipients. 
 
1.8.4.4 Non-neutralising antibody interference 
   Neutralisation by antibodies may be further inhibited by the presence of non-
neutralising antibodies (non-nAb) circulating within patient sera, although this 
is an area of some disagreement.  It has been suggested that non-nAbs, binding 
distinct epitopes within E2, block antibody binding to neutralising epitopes 
(Zhang et al., 2007).  Two distinct epitopes have been identified within E2; 
epitope I (aa 412-419), reported to function as the neutralising epitope and 
epitope II (aa 434-446), reported to bind non-nAbs that block binding to 
epitope I (Zhang et al., 2007).  Furthermore, depletion of epitope II-specific 
antibodies enabled the detection of nAbs in sera that were previously deemed 
to be non-neutralising (Zhang et al., 2009).  This mechanism of antibody 
interference was proposed as a reason for the treatment failure of polyclonal Ig 
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preparations (Davis et al., 2005); however, this is in contrast to the protective 
effects of polyclonal Ig (HBIG) previously reported (Feray et al., 1998).  A 
recent study found that affinity-purified Igs and MAbs targeting epitope II 
neutralised HCVpp and HCVcc entry and there was no observed interference 
between epitope I and epitope II-specific antibodies (Tarr et al., 2012b).  
Broadly neutralising, conformation sensitive MAbs targeting epitope II have 
also been described (Keck et al., 2012).  Whilst this suggests that epitope II 
does not constitute a non-neutralising epitope per se, different MAbs bind 
different but overlapping epitopes within this region with varying potency.  
Therefore, it remains to be seen if individual antibodies are able to interfere 
with virus neutralisation or if different epitopes elicit a non-neutralising 
response. 
 
1.8.4.5 Lipid shielding 
   Lipoproteins form an important component of the HCV particle and play a 
key role in viral entry via binding to LDLr and SR-BI (as discussed in sections 
1.7.3 and 1.7.5).  Components of HDL, such as apoCI, can enhance the 
infectivity of HCVpp and HCVcc (Bartosch et al., 2005; Dreux et al., 2007; 
Meunier et al., 2005), reduce the sensitivity of HCVpp to nAbs (Dreux et al., 
2006) and enhance fusion between viral and cellular membranes (Dreux et al., 
2007).  This has led to the suggestion that lipid shielding protects the virus 
from neutralisation and facilitates infectivity, although the precise interactions 
occurring between the virus, lipoproteins, receptors and antibodies remains to 
be deciphered. 
 48 
 
1.8.5 Role of antibody effector functions in HCV clearance 
   In addition to mediating viral clearance by neutralisation of entry, antibodies 
carry out specific effector functions that control infection via non-neutralising 
mechanisms.  Antibody-dependent cellular cytotoxicity (ADCC) is the lysis of 
virus-infected target cells by macrophages, neutrophils and natural killer (NK) 
cells following binding to the Fc region of antibody molecules bound on the 
surface of the target cell.  This is mediated by Fc receptors (FcR) expressed by 
the effector cells (Eales, 2001).  Complement-dependent cytotoxicity (CDC) 
requires binding of the complement protein C1q to the Fc region of an antibody 
bound to a virus particle or virus-infected cell.  This triggers the classical 
complement cascade leading to the formation of a membrane attack complex 
(MAC) on infected cells causing lysis of the target (Tarr et al., 2012a).  ADCC 
is an important component of the immune response to HIV that may enhance 
the activity of nAbs or facilitate inhibition by otherwise non-nAbs (Chung et 
al., 2008) but its role in HCV infection is less well understood.  Acute- and 
chronic-phase sera can mediate ADCC via binding to E2 expressed on the 
surface of infected cells (Natterman et al., 2005).  Interestingly, in this study, 
chronic sera showed greater ADCC, compared to the acute phase sera, 
suggesting that ADCC does not necessarily clear the virus.  The broadly 
neutralising MAbs CBH2 and CBH5 as well as the non-neutralising MAb 
CBH4 possess CDC activity on target cells (Machida et al., 2008).   
   Mechanisms by which the virus evades these immune responses have been 
described.  HCV-induced hypermutation of Ig genes has been proposed as a 
potential mechanism to subvert CDC (Machida et al., 2008) although this 
would presumably also affect antibody-mediated neutralisation and ADCC.  
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7KH FRUH SURWHLQ RI +&9 SRVVHVVHV DQ )FȖ5-like domain, spanning aa 3-75, 
that can bind IgG molecules via their Fc region (Maillard et al., 2004).  
Therefore, core binding to the Fc region of antibodies would inhibit effector 
functions such as ADCC and CDC.  Recently, it has been suggested that HCV 
particles incorporate the host protein CD59 into their envelope.  CD59 is a 
regulator of complement activation that prevents formation of the MAC and 
thereby inhibits CDC of target cells or virus particles.  Indeed, inhibition of 
CD59 was found to increase lysis of cell culture and patient-derived virus 
particles (Amet et al., 2012).  It has also been reported that sub-neutralising 
concentrations of antibodies enhance infectivity through binding of virus-
antibody complexes to the FcRII receptor on hepatocytes (Meyer et al., 2011).  
A greater understanding of antibody-mediated effector functions and their 
contribution to HCV pathogenesis will inform the design of effective vaccines 
or therapeutics.  It will be particularly important to understand evasion tactics 
employed by the virus to ensure that treatment is ultimately successful.   
 
1.9 Neutralising antibodies in vaccines or therapeutics 
   There is currently no vaccine against HCV and preventing reinfection of a 
newly grafted liver is not yet possible.  Therefore identifying protective 
immune determinants that may be induced by a vaccine is an important goal 
for HCV researchers.  The correlation between strong T cell (Schulze Zur 
Wiesch et al., 2005; Thimme et al., 2002) and nAb responses (Dowd et al., 
2009; Pestka et al., 2007) and the spontaneous resolution of acute infection 
indicates that the immune system plays an important role in disease outcome.  
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The protection afforded by polyclonal immunoglubulins (Feray et al., 1998) 
and resistance to reinfection of IVDUs who spontaneously resolve primary 
infection (Osburn et al., 2010) support the notion that protection against HCV 
infection can be generated by vaccination.   
   Several trials with vaccine candidates have been carried out but have met 
with mixed results.  A formulation of HCV-enriched Ig (Civacir) reduced 
levels of alanine transaminase (ALT), a marker of liver injury, and caused a 
transient reduction in viral load but could not prevent reinfection of the liver in 
transplant recipients (Davis et al., 2005).  A neutralising, human anti-E2 MAb 
HCV-AbXTL68, reduced HCV RNA levels in patients undergoing liver 
transplantation but this was not maintained long term and therapeutically useful 
levels of serum antibody were not achieved (Schiano et al., 2006).  A 
recombinant form of E1E2 developed by Chiron Corp. has proven effective in 
chimpanzees, inducing a strong T cell and nAb response that completely 
protected against infection with the homologous virus strain and prevented 
chronic infection following experimental challenge with a heterologous virus 
(Houghton & Abrignani, 2005).  Preliminary studies of an adjuvanted form of 
the vaccine, HCV E1E2/MF59.C1, indicate that it is immunogenic, capable of 
inducing cellular and humoral immune responses in healthy individuals.  
Furthermore, few adverse events were reported suggesting that the safety 
profile of the vaccine is good (Frey et al., 2010).  Results of phase I clinical 
trials are awaiting publication.  A recombinant form of E1 trialled in patients 
suffering a chronic, genotype 1 infection was found to induce an E1-specific T 
cell and antibody response that reduced ALT levels and fibrosis but did not 
affect viral load (Nevens et al., 2003).  The authors suggest that E1-based 
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therapy may improve liver pathology; however a subsequent study found no 
improvement in liver histology despite the induction of cellular and humoral 
immunity (Wedemeyer et al., 2008). 
   Other vaccine candidates have focussed on inducing cellular immunity 
against the non-structural and/or core proteins of HCV.  These include a 
synthetic peptide vaccine containing conserved CD8+ and CD4+ T cell epitopes 
(IC41) from core, NS3 and NS4 that is able to induce a strong cellular immune 
response.  However, trials in chronically infected patients have shown mixed 
results in terms of reducing viral load (Torresi et al., 2011), highlighting the 
importance of choosing an appropriate dosing regimen in achieving a 
favourable outcome.  Another novel vaccine candidate expressing a core-NS3 
protein, termed GI-5005, induces a strong T cell response that reduces viral 
load and ALT levels (Torresi et al., 2011).  Furthermore, when combined with 
standard therapy (ribavirin plus IFN-Į *,-5005 improved early virological 
response rates and SVR rates compared to standard therapy alone (Jacobson et 
al., 2010).  DNA vaccines have also proven successful, specifically a codon-
optimised NS3/NS4A gene expressed from a cytomegalovirus (CMV) 
immediate early (IE) promoter (ChronVac-C).  In studies of genotype 1 
infected, treatment-naive patients, vaccination reduced viral load in 67% of 
recipients and was temporally associated with the induction of an HCV-
specific T cell response (Sallberg et al., 2009).  No adverse events were 
reported indicating that this vaccination approach is safe although further trials 
are ongoing.    
   Given the variable nature of HCV and its ability to evade or subvert both the 
humoral and cellular arms of the immune response, preventive or therapeutic 
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vaccines may need to target multiple viral components.  Targeting a single 
viral epitope is likely to lead to the development of escape mutations and 
therefore resistant strains.  The rational design of immunogens to be included 
in any vaccine is likely to require an approach similar to that used in the 
treatment of HIV ± simultaneous targeting of multiple viral proteins or 
epitopes.  Including host targets (e.g. entry receptors) as well as viral targets 
may broaden the scope and effectiveness of vaccination.  A recent study of the 
antibody response to HIV suggests that a combination of less potent MAbs, 
that individually do not neutralise infection, may be more representative of the 
in vivo situation and provide greater protection than a single MAb (Walker et 
al., 2011).  Such an approach would require the identification of multiple 
antibodies targeting distinct but overlapping targets. 
 
1.10  General aims  
   Since the discovery of HCV more than 20 years ago, considerable advances 
have been made in our understanding of this important pathogen.  Advances 
continue to be made in the search for antiviral therapies; however the current 
standard of therapy is poorly tolerated and unable to resolve all cases of the 
disease.  The burden of HCV-related liver transplantation and the inability to 
protect the newly grafted organ from reinfection has heightened the search for 
therapeutic or preventive vaccines.  Neutralising antibodies may provide an 
important component of new vaccines or therapies and improving our 
knowledge of such antibodies will aid in the design of immunogens. 
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   The majority of nAbs identified to date target CD81 binding sites within E2.  
However, this may be due to the early bias of experimental methods towards 
CD81-specific antibodies and it has become clear in recent years that a number 
of other factors are involved in HCV entry (see section 1.7).  The identity of 
the fusion determinant is also unclear (Krey et al., 2010; Lavillette et al., 2007) 
but it appears to elicit nAbs capable of blocking infection.  The 
immunogenicity of E1 has also been a subject of debate but anti-E1 antibodies 
have been reported (Keck et al., 2004b; Meunier et al., 2008) and may 
contribute to resolution of infection.  Any of these may feasibly provide 
additional targets for nAb and are deserving of thorough investigation.  
However, studying the full spectrum of the nAb response may be hampered by 
the assay systems commonly in use, many of which rely upon truncated 
versions of E2 or use single virus strains.  Ideally a method is needed that is not 
biased towards a specific epitope or receptor binding region within E2 and that 
faithfully represents the native form of the glycoprotein.  Furthermore, 
identifying nAb that are relevant in viral clearance in vivo has proven difficult.  
Broadly neutralising murine MAbs are limited to targeting the linear epitope aa 
412-423, an epitope that is poorly immunogenic in humans (Tarr et al., 2007), 
whereas broadly neutralising human MAbs target conformational epitopes.  
Therefore isolating human MAbs is more desirable at it holds the promise of 
providing broadly nAbs that contribute to virus control in a natural disease 
setting.  A suitable method for screening large numbers of patients for nAbs is 
needed, in order to isolate those that have a protective effect in vivo.  The 
overall aims at the outset were therefore to develop assay systems for the 
discovery and characterisation of anti-HCV antibodies.  Firstly cell-surface 
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display technology was used to develop an E2 library with which to map MAb-
binding residues.  Secondly, the Ig genes were PCR amplified and sequenced 
from the B cells of HCV-infected individuals and finally, a study of the 
antibody response in a cohort of HCV-infected patients was undertaken.  The 
aim of all three projects was to facilitate studies of nAb and to further our 
understanding of their role in disease outcome. 
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2 Design and development of an E2 cell-surface 
display library 
 
2.1 Introduction 
2.1.1 Approaches to peptide and protein mapping 
   To improve our understanding of the mechanisms of antibody neutralisation 
it is necessary to identify the location and structure of neutralising epitopes; 
that is, whether they are linear or conformational in nature.  This is turn can tell 
us the nature of the interaction that is blocked or inhibited by nAbs.  
Knowledge of the location of several nAb epitopes has already informed the 
generation of a 3D model of E2 (Krey et al., 2010).  A greater understanding 
could help to direct the design of immunogens, therapeutic antibodies or 
vaccine components and several approaches have been developed to decipher 
the nature of antibody-receptor interactions.   
   Peptide scanning has been used to identify a number of linear epitopes within 
E2.  This method uses MAb binding to a panel of overlapping peptides to 
determine the specific regions involved in antibody recognition (Broering et 
al., 2009; Clayton et al., 2002; Owsianka et al., 2001).  Linear epitopes have 
also been mapped using phage display libraries of random peptides (Tarr et al., 
2006; Vieyres et al., 2011; Zhang et al., 2007; Zhang et al., 2009).  These 
generally consist of a phage host displaying peptides of between 6-40 amino 
acids that undergo several rounds of affinity enrichment with a specific MAb 
or polyclonal serum.  After several rounds of biopanning the library is enriched 
for those peptides binding the target antibody.  The phages are propagated in a 
bacterial host forming plaques from which the DNA sequence of the selected 
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peptide can be amplified.  Alignment of these peptide sequences will identify 
the amino acids likely to be involved in antibody binding (Smith & Petrenko, 
1997).  The use of phage display may however, be limited by the use of 
bacteria, such as Escherichia coli, for propagation of the phage host.  
Prokaryotic cells do not possess an ER or Golgi apparatus and, as a result, are 
unable to carry out the complex glycosylation and folding of proteins observed 
in eukaryotic cells (Weerapana & Imperiali, 2006).  HCV E2 is a highly 
glycosylated structure containing up to 11 N-linked glycans that play an 
important role in its structure, function and immunogenicity (see section 1.5.2).  
Without complex glycosylation, the peptides expressed in a phage display 
library may not represent the native glycoprotein, and as such, may not be 
appropriate for mapping more complex epitopes.  However, phage display has 
been successfully used to produce mimotopes of conformation-sensitive 
antibody binding epitopes (Prezzi et al., 1996; Zwick et al., 2001), although 
such peptides often show little or no sequence homology to the native antigen 
(Larralde et al., 2007). 
   An alternative approach to mapping conformation-sensitive epitopes is the 
use of panels of glycoproteins containing single amino acid substitutions to 
probe antibody-receptor interactions.  Typically alanine scanning mutagenesis 
is used to interrogate antibody binding to a region of particular interest.  This 
method has been successfully used to map the epitopes bound by 
conformation-sensitive MAbs (Johansson et al., 2007b; Keck et al., 2008a; 
Law et al., 2008; Owsianka et al., 2008; Perotti et al., 2008) as well as linear 
epitopes (Tarr et al., 2006).  The majority of these studies however, have relied 
upon preliminary studies, including peptide phage display (Tarr et al., 2006), 
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NOB assays (Johansson et al., 2007b; Law et al., 2008; Owsianka et al., 2008) 
or antibody competition experiments (Keck et al., 2008a; Law et al., 2008; 
Perotti et al., 2008) to identify potential regions of interest for subsequent 
alanine scanning mutagenesis.  This reduces the size of the protein or peptide 
undergoing mutagenesis but does require some prior knowledge of the likely 
epitopes.  This approach may also miss some rare, genotype-specific variants 
involved in antibody recognition as it has tended to focus on regions of high 
conservation within E2 (Perotti et al., 2008).   
  More recently antibody-binding epitopes have been mapped by generation 
and sequence analysis of in vitro neutralisation escape mutants.  Both linear 
(Gal-Tanamy et al., 2008) and conformation-sensitive (Keck et al., 2011) 
epitopes have been mapped in this way.  This approach has been used to 
identify small variations in the specific residues involved in recognition by two 
different antibodies, namely CBH-2 and HC-11, that bind overlapping epitopes 
within E2 (Keck et al., 2011).  Generation of the escape mutants is however, a 
lengthy and labour-intensive process requiring repeat passage of HCVcc in 
non-neutralising concentrations of antibody.  In some cases no neutralisation 
escape mutants will be generated.  This is possible if all the antibody contact 
residues are essential for virus fitness, for example residues involved in CD81 
binding, making epitope mapping via this method impossible (Keck et al., 
2011).   
   The use of combinatorial polypeptide libraries has been widely used to map 
antibody- and ligand-binding epitopes within a variety of different proteins.  
Several different host organisms have been used for the generation of these 
display libraries, including bacteria, yeast, and insect cells.  A number of 
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bacterial outer membrane, cell envelope and adhesion proteins, from both 
Gram-negative and Gram-positive organisms, have been modified for the 
surface display of foreign proteins (Lee et al., 2003).  Bacteria can be 
propagated in large numbers, grow rapidly and are easily handled; however 
bacterial hosts are unable to support the expression of large proteins (Lee et al., 
2003), lack the foldases and chaperones necessary to process disulphide-
bonded proteins (Boder & Wittrup, 1997) and cannot glycosylate proteins 
fully,  making them unsuitable for the expression of the E2 glycoprotein.   
   Yeast cell display library systems have been developed in Saccharomyces 
cerevisiae, the most successful of which exploits the cell surface mating 
adhesins for the attachment of foreign proteins.  The protein folding and 
secretory machinery of S. cerevisiae is very similar to mammalian cells and a 
eukaryotic expression system has the advantage of processing proteins through the 
ER, unlike bacterial expression systems (Boder & Wittrup, 1997).  This system 
has been used to map antibody-binding epitopes within the envelope 
glycoproteins of the flaviviruses West Nile Virus (WNV) (Oliphant et al., 
2005) and dengue virus (DENV) (Sukupolvi-Petty et al., 2010; Sukupolvi-
Petty et al., 2007).  Its use has recently been reported in mapping studies of 
HCV E2 (Sabo et al., 2011).   
   An alternative eukaryotic expression system involves the use of insect cells.  
Typically this has employed expression of proteins on the surface of a 
baculovirus, such as the Autographa californica multiple nucleopolyhedrovirus 
(AcMNPV).  The protein of interest is attached to the AcMNPV major 
envelope protein gp64.  When the virus infects Spodoptera frugiperda (Sf9) 
cells, the gp64-fusion protein becomes localised to the surface of the insect 
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cells (Grabherr et al., 2001).  As a result, the protein of interest can be detected 
by flow cytometry such that a population of insect cells can be screened based 
on binding affinity for a test protein.  A variety of different proteins have been 
expressed in this system, including complex mammalian and viral proteins 
requiring extensive post-translational modification (Grabherr et al., 2001).  
These include the Japanese encephalitis virus E protein (Xu et al., 2011), 
influenza A virus HA (Yang et al., 2007) and HIV-1 gp120 (Toellner, 2002).  
Baculoviruses are able to incorporate large protein-coding sequences into their 
DNA and grow to high titres but the system is a single round infection cycle 
leading ultimately to the death of the host insect cell.  Therefore it is not 
possible to develop stable cell lines that can be repeatedly used, making this a 
labour-intensive process.  More recently a secreted protein expression system 
has been developed in the Drosophila melanogaster S2 insect cell line.  This 
has been successfully used to express a number of different proteins from both 
transiently and stably transfected cells including hepatitis B virus surface 
antigen (HBsAg) (Deml et al., 1999) and HIV gp120 (Culp et al., 1991).  More 
recently the HCV E2 glycoprotein expressed in      D. melanogaster S2 cells 
has been shown to be largely monomeric and correctly folded.  This approach 
also allows for the production of large amounts of protein (Krey et al., 2010).   
   Expression of correctly folded and glycosylated truncated versions of the E2 
ectodomain by transfection of the human embryonic kidney (HEK) 293 cell 
line (Flint et al., 1999b) and the Chinese hamster ovary (CHO) cell line (Heile 
et al., 2000) have been described.  Such mammalian-derived glycoprotein has 
been used in studies of protein structure and function.  However, due to the 
inherent difficulty culturing mammalian cells, their growth as monolayers 
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requiring direct cell-to-cell contact and the expense and technical challenge of 
scaling-up mammalian tissue culture, these cells would not be the ideal host for 
a protein display library.   
   The most important consideration when choosing a protein or peptide 
mapping method is for the protein to be correctly folded and displayed in its 
native form.  Although E1 and E2 assemble to form non-covalent heterodimers 
on the surface of the virion (Deleersnyder et al., 1997), E2 can be expressed 
alone in model systems (Michalak et al., 1997).  The majority of the protein 
generated is monomeric; however disulphide-linked aggregates also form that 
do not bind conformation-sensitive antibodies (Michalak et al., 1997) or 
cellular receptors (Flint et al., 2000; Heile et al., 2000).  The glycosylation 
state of E2 is also important as several N-linked glycans are critical for correct 
protein folding (Goffard et al., 2005).  Therefore presentation of the protein in 
its native form is essential if epitopes bound by naturally occurring antibodies 
are to be accurately mapped and potential targets for therapeutic antibodies 
identified.  As described, several approaches to epitope mapping are limited in 
their ability to express E2 in its native form.  The most promising host 
candidates for generation of an E2 protein display library are S. cerevisiae 
yeast cells and D. melanogaster S2 insect cells.  These will be discussed in 
more detail in the following sections.  
 
2.1.2 Principles of the yeast cell display system 
   The yeast cell display system was developed by Boder and Wittrup (1997) 
for the expression of mammalian proteins on the surface of S. cerevisiae 
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EBY100 cells.  This is achieved by exploiting the natural mating machinery of 
yeast cells.  S. cerevisiae exists as a diploid cell from which two haploid cells 
are generated during meiosis.  These haploid cells may be one of two mating 
types ± 0$7DRU0$7Į7ZRKDSORLGFHOOVRIRSSRVLWHPDWLQJW\SHFRPELQH
by conjugation to produce a diploid cell (Cross et al., 1988).  Cells of different 
mating type can be identified by the expression of either a-DJJOXWLQLQ RU Į-
agglutinin on the cell surface.  These agglutinins are induced in response to 
pheromones produced by cells of the opposite mating type and bring the cells 
into direct contact required for conjugation.  Therefore MATa cells express a-
DJJOXWLQLQ LQ UHVSRQVH WR WKH Į-IDFWRU SKHURPRQH SURGXFHG E\ 0$7Į FHOOV
ZKLOVW0$7ĮFHOOVH[SUHVVĮ-agglutinin in response to the a-factor produced by 
MATa cells (Fehrenbacher et al., 1978; Lipke & Kurjan, 1992).  The a-
agglutinin is composed of two subunits, a core subunit (Aga1p) and a binding 
subunit (Aga2p) (Figure 2-1a).  The core subunit is a 725 amino acid protein 
rich in serine and threonine residues and is the product of the AGA1 gene (Roy 
et al., 1991).  The binding subunit is a 69 amino acid protein encoded by the 
AGA2 gene (Cappellaro et al., 1991).  Both proteins are highly O-glycosylated 
but lack any N-linked glycosylation sites (Cappellaro et al., 1991; Roy et al., 
1991).  The core subunit is DWWDFKHGWRȕ-glucans within the yeast cell wall via 
its C-terminus in a reaction thought to involve binding of a glycosyl 
phosphatidyl inositol anchor (Lipke & Kurjan, 1992).  The binding subunit is 
attached to the core subunit via two disulphide bonds (Cappellaro et al., 1994).  
The binding site within a-agglutinin has been localised to the C-terminal region 
of Aga2p (Cappellaro et al., 1994; Shen et al., 2001). 
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Figure 2-1. Schematic representation of the yeast display system. 
(a) Display of the E2 glycoprotein on the yeast cell surface via 
attachment to the Aga2p protein.  Aga2p is attached via disulphide 
bonds to Aga1p which is anchored to the cell wall of S. cerevisiae. 
X, Xpress epitope; V5, V5 epitope; His, poly-histidine tag. (b) The 
pYD1 plasmid and AGA2 cassette (taken from pYD1 Yeast Display 
Vector Kit manual, cat. no. V835-01).  
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   The yeast cell display system is based upon fusion of a non-native protein to 
the C-terminus of the a-agglutinin binding subunit, Aga2p, resulting in 
expression and display of the protein on the cell surface (Figure 2-1a) (Boder 
& Wittrup, 1997).  The plasmid pYD1 (Invitrogen) (Figure 2-1b) is a 5.0 kb 
expression vector that contains the AGA2 gene derived from S. cerevisiae.  
The multiple-cloning site allows fusion of the gene-of-interest to the AGA2 
gene.  AGA2 expression is under the control of a galactose-inducible promoter, 
PGAL1, allowing for controlled expression of the protein of interest.  Aga1p 
subunit expression is also under the control of the PGAL1 promoter, stably 
integrated into the chromosome of the S. cerevisiae EBY100 strain (Boder & 
Wittrup, 1997).  The Aga1p and Aga2p-fusion gene products associate within 
the secretory pathway and are exported to the cell surface (Boder & Wittrup, 
1997).  The Xpress epitope, V5 epitope and poly-histidine tag within pYD1 
enable detection and purification of the cell surface expressed protein. 
 
2.1.3 Principles of the insect cell display system 
   The insect cell display system is based upon the Drosophila Expression 
System (DES) developed by Invitrogen.  This system uses the D. melanogaster 
S2 cell line, derived from a primary culture of late-stage (20-24 hour old) 
embryos (Schneider, 1972).  These cells are typically spherical in appearance 
and grow in suspension with a tendency to form clumps of between 10 and 20 
cells.  Spindle-shaped cells may form at high density (Schneider, 1972).  D. 
melanogaster S2 cells display characteristics similar to haemocytes, the insect 
equivalent of macrophages, including the ability to carry out phagocytosis 
(Luce-Fedrow et al., 2008).  Cells are easily cultured in serum-free media at 
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28°C without CO2 and will grow at room temperature (Cherbas & Cherbas, 
2000).   
   The DES utilises the plasmid pMT/BiP/V5-His (Invitrogen) to express 
secreted proteins in D. melanogaster S2 cells.  Protein expression is under the 
control of a metallothionein-inducible promoter, pMT (Angelichio et al., 1991; 
Bunch et al., 1988), and protein secretion is controlled by the BiP secretion 
signal (Figure 2-2).  Expression can be induced by the addition of the heavy 
metal ions copper, zinc or cadmium to the growth medium (Bunch et al., 
1988).  The BiP protein is an Ig-binding chaperone protein which targets 
proteins to the ER lumen and facilitates protein folding (Kirkpatrick et al., 
1995).  In this study a modified version of the plasmid pMT/BiP/V5-His was 
used.  The plasmid, termed pMT, has a modified multiple cloning site, lacks 
the V5 epitope and poly-histidine tag, and contains a Strep-tag (WSHPQFEK) 
for protein purification (Krey et al., 2010) (Figure 2-2).  This plasmid has been 
successfully used for expression of sE2 from D. melanogaster S2 cells (Krey et 
al., 2010).  By cloning the gene of interest in frame with the BiP secretion 
signal it is possible to generate large amounts of secreted protein. 
  The DES is designed for secreted protein expression.  Therefore it is 
necessary to adapt this system for cell surface display of proteins.  This can be 
achieved by the addition of a transmembrane domain to the E2 envelope 
glycoprotein.  The native E2 transmembrane domain contains ER retention 
signals which would prevent translocation of the protein to the cell surface 
(Cocquerel et al., 1998).  To overcome this problem, the native domain can be 
removed and replaced with the transmembrane and cytoplasmic domain of the 
influenza A virus HA.  The transmembrane and cytoplasmic domains are 27 
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and 10 amino acids respectively and are found within the HA2 subunit of the 
influenza HA (Armstrong et al., 2000).  This approach has been used to 
express a truncated version of E2 on the surface of mammalian cells.  The 
protein is recognised by conformation-dependent antibodies and binds CD81 
suggesting that it is representative of the native E2 glycoprotein (Flint et al., 
1999b). 
   Stable D. melanogaster S2 cell lines can be generated by cotransfection of 
the expression plasmid with the selection plasmid, pCoBlast.  The plasmid 
Figure 2-2. Schematic representation of the Drosophila expression 
plasmid, pMT. The expression cassette, containing the BiP secretion 
signal upstream of the cloning cassette, an enterokinase sequence and 
the Strep-Tag is under the control of a metallothionein promoter, pMT. 
The ampicillin resistance cassette, Amp is required for selection and the 
pUC origin is necessary for replication in E. coli. The SV40 late 
polyadenylation signal, SV40 pA, is necessary for transcription 
termination and polyadenylation of mRNA (Angelichio et al., 1991). 
Plasmid map is based on the pMT/BiP/V5-His Vector manual 
(Invitrogen, Paisley, UK) plus additional information provided by 
Thomas Krey (personal communication). 
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pCoBlast contains the blasticidin resistance gene, bsd, from Streptomyces 
griseus under the control of the Drosophila copia promoter (Anon., 2003).  
Copia elements are transposable elements with characteristics similar to some 
retroviral replication proteins which generate large amounts of transcript 
(Mount & Rubin, 1985).  Stable cell lines contain multi-copy inserts of the 
gene of interest forming arrays of 500-1000 copies arranged in a head-to-tail 
fashion.  The number of copies inserted can be varied by altering the ratio of 
expression vector to selection vector (Anon., 2003).  Stable cell lines can be 
maintained over long periods of time by growth in blasticidin-containing media 
and protein expression selectively induced by addition of copper sulphate.  An 
advantage of using D. melanogaster S2 cells is their rapid growth and ease of 
handling.  Cells grow exponentially between 5 x105 and 1 x107 cells/ml, with a 
doubling time of 24 hours.  The cells are generally stable over long culture 
periods and much less susceptible to gross changes in their morphology than 
mammalian cells (Cherbas & Cherbas, 2000).  Cultures of D. melanogaster S2 
cells can be easily scaled-up for increased protein production.  
 
2.2 Aims of the work presented in this chapter 
   The major aim of this work was to develop a cell-surface display library 
system for the expression of randomly mutated HCV E2 protein.  This library 
would then be used to map antibody-binding epitopes within E2 by flow 
cytometry analysis and sorting of loss-of-binding mutants.  To reach this stage 
it was necessary firstly to demonstrate expression and correct fold of E2 on the 
surface of the display library host.  A suitable random mutagenesis method was 
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chosen to generate the library.  The randomly mutated E2 library was then used 
to screen a control MAb against known loss-of-binding mutants to demonstrate 
proof-of-principle that antibody-binding residues could be mapped with this 
system.  The yeast strain, S. cerevisiae EBY100, and the insect cell line, D. 
melanogaster S2, were both tested as the host organism for library 
development. 
 
2.3 Materials and Methods 
2.3.1 Construction of a yeast display library in S. cerevisiae 
EBY100 
2.3.1.1 Polymerase chain reaction (PCR) amplification of E2 
   Primers were designed to generate three truncated versions of E2 from HCV 
strain H77.20 (genotype 1a) (Table 2-1); H77 E2650 (amino acids 384-650; 
primers H77c384_s EcoRI and H77c650_as XhoI), H77 E2661 (amino acids 
384-661; primers H77c384_s EcoRI and H77c661_as XhoI) and H77 E2715 
(amino acids 384-715; primers H77c384_s EcoRI and H77c715_as XhoI).  
Primers contained either EcoRI or XhoI restriction sites for directional cloning 
into the vector pYD1. 
   E2 was amplified from plasmid pCR3.1::H77.20 with appropriate primer 
pairs.  One microlitre of plasmid (diluted 1:1000 in Molecular Biology (MB) 
grade H20 (Sigma Aldrich, Gillingham, UK) to give a concentration of 
approximately 0.3-QJȝOwas used as template in a total reaction volume of 
25 µl containing 200 µM dNTPs (Fermentas St. Leon-Rot, Germany), 5 pM 
each primer and 0.25 units Phusion High-Fidelity DNA Polymerase 
(Finnzymes, Vantaa, Finland).  PCR amplification was performed in a 2-step 
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Table 2-1. Sequence of primers used in this chapter. Primers were synthesised by Eurofins MWG Operon, Germany. 
Restriction sites are underlined. EcoRI, GAATTC; XhoI, GAGCTC; BglII, AGATCT; BstBI, TTCGAA 
Target Function of primer Primer 
orientation 
Primer name 3ULPHUVHTXHQFH¶-¶ 
E2 (H77) PCR amplification Sense H77c384_s EcoRI GATCGAATTCGAAACCCACGTCACCGGG 
 PCR amplification Antisense H77c650_as XhoI AGCTGAGCTCTTCGCCCCGCGTCCAGTTG  
 PCR amplification Antisense H77c661_as XhoI AGCTGAGCTCCTCGGACCTGTCCCTGTCT 
 PCR amplification Antisense H77c715_as XhoI AGCTGAGCTCCTTAATGGCCCAGGACGC  
 PCR, fusion PCR, 
sequencing 
Sense H77c384_s BglII GATCAGATCTGAAACCCACGTCACCGGG 
 PCR amplification  Antisense H77_715_as CTTAATGGCCCAGGACGCGAT 
 Sequencing Internal S2_IF CGTATAGGCTTTGGCACTATC 
 Sequencing Internal S2_IR TGCCAGCAGTAGGGGCGTTCG 
E2 (UKN 
2B1.1) 
PCR amplification, 
fusion PCR 
Sense 2B1.1_384_s BglII GATCAGATCTGAGACTCATACCACCGGC 
 PCR amplification Antisense 2B1.1_715_as TTTTGTGATAGCCGGAGT 
HA TM 
domain 
PCR amplification 
(H77 compatible) 
Sense HA_H77_linker_s  GCGTCCTGGGCCATTAAGATTCTGGCGATCTACTCA 
 PCR amplification 
(2B1.1 compatible) 
Sense HA_2B1.1_linker_s ACTCCGGCTATCACAAAAATTCTGGCGATCTACTCA 
 PCR amplification, 
Fusion PCR 
Antisense HA_TM_as BstBI AGCTTTCGAAGATGCATATTCTGCACTG 
pYD1 Plasmid screening Sense pYD1_fwd AGTAACGTTTGTCAGTAATTGC 
 Plasmid screening Antisense pYD1_rev GTCGATTTTGTTACATCTACAC 
pMT Plasmid screening Sense MT_fwd CATCTCAGTGCAACTAAA 
 Plasmid screening Antisense BGH TAGAAGGCACAGTCGAGG 
pGEM-T 
Easy 
Plasmid screening Sense M13 fwd GTAAAACGACGGCCAGT 
 Plasmid screening Antisense M13 rev AACAGCTATGACCATG 
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cycling reaction consisting of 98°C for 30s, 35 cycles of 98°C for 10s and 
72°C for 30s, followed by 72°C for 60s.  PCR products were detected by 
agarose gel electrophoresis as described in 2.3.1.2. 
 
2.3.1.2 Agarose gel electrophoresis analysis of PCR products 
   Five microlitres of PCR product was mixed with 6x Loading Buffer (50% 
glycerol in H20, 0.002% bromophenol blue) and loaded onto a 2% agarose 
(Bioline, London, UK) gel made with 1x Tris Acetate-ethylene diamine 
tetraacetic acid (EDTA) buffer (Sigma Aldrich, Gillingham, UK) containing    
5 µl ethidium bromide solution (Fisher Scientific, Loughborough, UK).  PCR 
products were loaded alongside 5 µl of Generuler DNA ladder mix (Fermentas, 
St. Leon-Rot, Germany).  Samples were resolved by exposure to a potential 
difference of 95 V for 0.7 hours and visualised on a UV Transilluminator.  
Results were recorded photographically. 
 
2.3.1.3 Purification of PCR products 
   PCR positive samples were purified on a Qiaquick PCR Purification Kit 
(Qiagen, Crawley, UK) using a vacuum manifold according to the 
PDQXIDFWXUHU¶VLQVWUXFWLRQV%ULHIO\YROXPHVRI%XIIHU3%ZHUHDGGHGWR
volume of PCR product, mixed and loaded onto a QIAquick spin column.  The 
column was loaded onto a QIAvac 24 Plus vacuum manifold (Qiagen, 
Crawley, UK).  DNA was bound to the silica membrane by applying the 
vacuum and allowing the sample to pass through.  Sample was washed in     
750 µl Buffer PE under vacuum to remove any residual impurities or primers.  
DNA was eluted from the column in 50 µl Buffer EB by centrifuging at 17,900 
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x g for 1 minute.  DNA concentration was quantified using a Nanodrop 
ND1000 Spectrophotometer (Thermo Fisher Scientific, Loughborough, UK). 
 
2.3.1.4 Cloning of E2650, E2661 and E2715 into plasmid pYD1 
   Purified E2 PCR products and pYD1 (Invitrogen, Paisley, UK, a gift from 
Jialing Liu, UCSF, USA) were digested with 10 units EcoRI (New England 
Biolabs, Hitchin, UK) and 10 units XhoI (New England Biolabs, Hitchin, UK) 
in a 10 µl reaction for 1 hour at 37°C.  Restriction enzymes were inactivated by 
heating to 65°C for 20 minutes.  Parental plasmid was removed from the PCR-
generated E2 fragments by incubation with 10 units of DpnI (New England 
Biolabs, Hitchin, UK) in a 10 µl reaction for 3 hours at 37°C.  Enzyme was 
inactivated by heating to 80°C for 20 minutes.  
   Linearised plasmid was de-phosphorylated by incubation with 5 units of 
Antarctic phosphatase (New England Biolabs, Hitchin, UK) in a 10 µl reaction 
for 1 hour at 37°C.  Enzyme was inactivated by heating to 65°C for 20 minutes.  
   E2 fragments were ligated into linearised pYD1 bearing complementary ends 
at a 3:1 molar ratio of insert to vector in a 20 µl volume reaction containing 
1000-2000 cohesive end units of T4 DNA ligase (New England Biolabs, 
Hitchin, UK) supplemented with 2mM ATP (Fermentas, St. Leon-Rot, 
Germany).  The sample was incubated at room temperature for 1 hour or 
overnight at 4°C.  Ligation products were transformed into E. coli TOP10 cells 
as described in 2.3.1.7. 
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2.3.1.5 Cloning of E2650, E2661 and E2715 into plasmid pGEM-T Easy 
   PCR amplification with Phusion High-Fidelity DNA Polymerase 
(Finnzymes, Vantaa, Finland) results in blunt-ended PCR products.  In order to 
clone the purified E2 PCR products into pGEM-T Easy (Promega, 
Southampton, UK), which contains thymine (T) overhangs, it was necessary to 
add adenosine (A) overhangs to the PCR products.  Single A overhangs were 
added to E2 fragments by incubation with 0.1 µM dNTPs and 0.5 units HotStar 
Taq DNA Polymerase (Qiagen, Crawley, UK) at 94°C for 15 minutes followed 
by 72°C for 30 minutes.  E2 fragments were DpnI treated as described in 
2.3.1.4.  E2 fragments were ligated into pGEM-T Easy (Promega, 
Southampton, UK) at a 3:1 molar ratio of insert to vector in a 10 µl volume 
reaction containing 3 units T4 DNA ligase (Promega, Southampton, UK).  The 
sample was incubated at room temperature for 1 hour or overnight at 4°C.  
Ligation products were transformed into E. coli TOP10 cells as described in 
2.3.1.7. 
 
2.3.1.6 Subcloning of E2650, E2661 and E2715 into pYD1 
   E2 inserts were cut from pGEM-T Easy (Promega, Southampton, UK) by 
digestion with 10 units EcoRI (New England Biolabs, Hitchin, UK) and 10 
units XhoI (New England Biolabs, Hitchin, UK) in a 10 µl reaction overnight at 
37°C.  Samples were run on a 1% low-melting-point agarose (Promega, 
Southampton, UK) gel as described in 2.3.1.2 with exposure to a potential 
difference of 40 V for 0.7 hours.  Bands corresponding to the digested insert 
were excised from the gel and the DNA recovered by digestion with Agarase 
(Fermentas, St. Leon-Rot, Germany).  Briefly, agarose was melted by heating 
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at 70°C for 10 minutes followed by incubation at 42°C for 5 minutes.  Two 
units of agarase per 100 mg of agarose gel was added and incubated at 42°C 
for a further 30 minutes.  Ammonium acetate was added to a concentration of 
2.5 M, chilled on ice for 5 minutes and centrifuged at 9,300 x g for 10 minutes.  
Supernatant was transferred to a clean tube and 2 volumes of ethanol added.  
Samples were incubated at room temperature for 1 hour to precipitate DNA.  
DNA was pelleted by centrifugation at 9,300 x g for 15 minutes, supernatant 
removed and air-dried at room temperature.   
   Extracted and purified E2 fragments were cloned into pYD1 as described in 
2.3.1.4.  Plasmids were transformed into E. coli TOP10 cells as described in 
2.3.1.7. 
 
2.3.1.7 Transformation of plasmids into E. coli TOP10 cells 
   Fifty microlitres of competent E. coli TOP10 cells were incubated with 3 µl 
of ligation product or plasmid on ice for 20 minutes.  Cells were transformed 
by heat-shocking at 42°C for 40s and 125 µl SOC media (Sigma Aldrich, 
Gillingham, UK) was added.  Cells were incubated at 37°C for 1 hour with 
shaking at 250 rpm before plating onto LB (Sigma Aldrich, Gillingham, UK) 
agar plates containing 25 µg/ml ampicillin and incubated at 37°C overnight. 
 
2.3.1.8 PCR screening of transformant colonies 
   Single colonies were picked into a 12.5 µl reaction volume containing 2.5 
pM of each plasmid-specific primer, 2.5 mM dNTPs (Fermentas, St. Leon-Rot, 
Germany) and 0.3 units HotStar Taq DNA Polymerase (Qiagen, Crawley, UK).  
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Colonies were screened in a 3-step cycling reaction consisting of 95°C for 15 
minutes, 40 cycles of 94°C for 30s, 50°C for 30s and 72°C for 1 minute 30s 
followed by 72°C for 10 minutes.  PCR products were detected by agarose gel 
electrophoresis as described in 2.3.1.2.  Positive colonies containing the desired 
insert were inoculated into a 3 ml LB (Sigma Aldrich, Gillingham, UK) culture 
containing 25 µg/ml ampicillin and incubated at 37°C overnight. 
 
2.3.1.9 Plasmid extraction from cultures of E. coli TOP10 cells 
   Plasmid was extracted from overnight cultures using a Qiaprep Miniprep kit 
(Qiagen, Crawley, UKDQGYDFXXPPDQLIROGDFFRUGLQJWRWKHPDQXIDFWXUHU¶V
instructions.  Briefly, bacterial cells were pelleted by centrifugation at 6800 x g 
for 3 minutes and cells resuspended in 250 µl Buffer P1.  Cells were lysed by 
the addition of 250 µl Buffer P2 and inverted to mix.  The lysis reaction was 
neutralised by the addition of 350 µl of Buffer N3 and inverted to mix.  Cell 
debris was precipitated by centrifugation at 17,900 x g for 10 minutes and the 
supernatant transferred to a Qiaprep spin column.  The column was loaded onto 
a QIAvac 24 Plus vacuum manifold (Qiagen, Crawley, UK).  DNA was bound 
to the silica membrane by applying the vacuum and allowing the sample to 
pass through.  Sample was washed in 500 µl Buffer PB followed by a wash 
step with 750 µl Buffer PE under vacuum to remove any residual impurities or 
primers.  DNA was eluted from the column in 50 µl Buffer EB by centrifuging 
at 17,900 x g for 1 minute.  DNA concentration was quantified using a 
Nanodrop ND1000 Spectrophotometer (Thermo Fisher Scientific, 
Loughborough, UK).  Plasmid was sequenced with plasmid-specific primers as 
described in 2.3.1.10. 
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2.3.1.10 DNA sequencing by the dideoxy chain terminator method 
   DNA sequencing was carried out by the dideoxy chain terminator method 
(Sanger et al., 1977).  For PCR products 200-500 bp in size, 3-10 ng of DNA 
was sequenced.  For PCR products 500-1000 bp in size, 5-20 ng of DNA was 
sequenced.  For double-stranded plasmid, 100-200 ng was sequenced.  
Template was mixed with 0.5 µl BigDye Terminators V1.1 (Applied 
Biosystems, Paisley, UK) containing all dNTPs and fluorescently labelled 
ddNTPs, 3.5 µl BetterBuffer (Microzone, Haywards Heath, UK), and 3.2 pM 
of sequence-specific primer in a final volume of 10 µl MB H20 (Sigma 
Aldrich, Gillingham, UK).  Samples were amplified in a thermal cycling 
reaction of 25 cycles at 96°C for 30s, 50°C for 10 seconds and 60°C for 4 
minutes.  The single stranded DNA sequencing products were diluted with 10 
µl MB H20 (Sigma Aldrich, Gillingham, UK) and precipitated by addition of 
50 µl 100% ethanol, 2 µl sodium acetate and 2 µl 125 mM EDTA.  
Precipitation reactions were carried out in the dark for 1-24 hours.  Samples 
were centrifuged at 17,900 x g for 30 minutes, washed once with 70% ethanol 
and centrifuged at 17,900 x g for 15 minutes to pellet the DNA.  DNA pellets 
were air dried at 50°C for 10 minutes.  Pellets were resuspended and analysed 
on an ABI Prism 3130 Fluorescent DNA analyser (Perkin-Elmer, Cambridge, 
UK).  Sequencing reads were edited using Chromas 2.13 (Technelysium, 
Brisbane, Australia) and contiguous sequences were made from paired or 
grouped sequences using SeqMan II software (DNASTAR Inc., Madison, 
USA).  Phylogenetic analyses were carried out with MEGA 4 software 
(Tamura et al., 2007) with sequence alignment to reference sequences. 
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2.3.1.11 Transformation of plasmids into S. cerevisiae EBY100 
   Competent S. cerevisiae EBY100 cells (Invitrogen, Paisley, UK, a gift from 
Marlene Schweitzer, BOKU, Austria) were prepared according to the Pichia 
EasyComp kit (Invitrogen, Paisley, UK).  Briefly, an overnight culture of S. 
cerevisiae EBY100 in YPD broth (1% (w/v) yeast extract, 2% (w/v) peptone, 
2% (w/v) D-glucose) was diluted to an OD600 of 0.3 and grown at 30°C for 
approximately 4 hours to reach an OD600 of 0.6 to 1.0.  Cells were pelleted by 
centrifugation at 500 x g for 5 minutes and resuspended in 10 ml solution I.  
Cells were immediately pelleted as before and resuspended in 1 ml solution I.  
Aliquots of competent cells (50 µl) were transformed with 5 µl plasmid 
according to the Pichia EasyComp kit (Invitrogen, Paisley, UK).  Briefly, 1 ml 
solution II was added to the cell-DNA mix and incubated at 30°C for 1 hour 
with gentle mixing every 15 minutes.  Cells were transformed by heat-shock at 
42°C for 10 minutes and centrifuged at 3000 x g for 5 minutes.  Cells were 
resuspended in 1 ml solution III and centrifuged at 3000 x g for 5 minutes.  
Cells were resuspended in 100 µl solution III and plated onto minimal dextrose 
agar plates (0.67% (w/v) yeast nitrogen base (YNB), 2% (w/v) glucose) 
containing 0.1% (w/v) leucine and ampicillin (100 µg/ml).  Plates were 
incubated at 30°C for 72-96 hours until colonies appeared. 
 
2.3.2 Expression and characterisation of E2 proteins expressed in 
S. cerevisiae EBY100 
2.3.2.1 Induction of protein expression in S. cerevisiae EBY100 
   A single colony of S. cerevisiae EBY100 containing the plasmid of interest 
was inoculated into YNB-CAA glucose media (0.67% (w/v) YNB, 0.5% (w/v) 
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casamino acids, 2% (w/v) glucose) and grown at room temperature overnight 
with shaking to an OD600 of 2.0 to 5.0.  Cells were centrifuged at 5000 x g for 
10 minutes and resuspended in YNB-CAA galactose media (0.67% (w/v) 
YNB, 0.5% (w/v) casamino acids, 2% (w/v) galactose) to an OD600 of 0.5 to 
1.0.  Culture was incubated at room temperature for 48 hours in galactose-
containing media to allow sufficient protein expression. 
 
2.3.2.2 SDS-PAGE analysis of E2 protein 
   An aliquot of cells equivalent to 2 OD600 units was removed for analysis, 
centrifuged at 3000 x g for 5 minutes and washed once with 1x phosphate 
buffered saline (PBS).  Cells were resuspended in 100 µl PBS. 
   Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
analysis of E2-expressing cells was carried out on a 12% polyacrylamide gel 
(Laemmli, 1970).  The resolving gel was prepared by mixing 2.5 ml H2O, 3 ml 
30% acrylamide:bisacrylamide (37.5:1) (Severn Biotech Ltd., Kidderminster, 
UK), 1.9 ml 1.5 M Tris (pH 8.8), 37.5 µl 20% (w/v) SDS, 50 µl 30% (w/v) 
ammonium persulphate (APS) and 11.25 µl tetramethylethylene diamine 
(TEMED) (Sigma Aldrich, Gillingham, UK).  This was loaded onto a minislab 
gel apparatus (Atto Corporation, Tokyo, Japan) and allowed to set.  A 5% 
stacking gel consisting of 1.7 ml H2O, 415 µl 30% acrylamide:bisacrylamide 
(37.5:1) (Severn Biotech Ltd., Kidderminster, UK), 315 µl 1 M Tris (pH 6.8), 
12.5 µl 20% (w/v) SDS, 30% (w/v) APS and 5 µl TEMED (Sigma Aldrich, 
Gillingham, UK) was loaded onto the resolving gel and allowed to set.  Fifteen 
microlitres of cell or protein sample was mixed with an equal volume of 2x 
Laemmli reducing buffer (100 mM Tris-HCl, 20% (v/v) glycerol, 4% (w/v) 
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SDS, 0.2% (w/v) bromophenol blue, 2% (v/v) ɴ-mercaptoethanol) and boiled 
for 5 minutes.  Samples were resolved by electrophoresis at 150 V, 400 mA for 
approximately 90 minutes alongside Spectra Multicolour Broad Range Protein 
Ladder (Fermentas, St. Leon-Rot, Germany) in 1x running buffer (25 mM Tris, 
250 mM Glycine, 0.1 % (w/v) SDS, pH 8.3).  
 
2.3.2.3 Western blot analysis of SDS-PAGE separated samples 
   Following electrophoretic separation, samples were transferred to a Hybond 
ECL nitrocellulose membrane (GE Healthcare, Amersham, UK).  The 
polyacrylamide gel was placed on top of the nitrocellulose membrane and then 
sandwiched between eight layers of Whatman chromatography paper Grade 
No. 3MM (Fisher Scientific, Loughborough, UK) soaked in Transfer Buffer 
(38 mM glycine, 47 mM Tris, 0.04% (w/v) SDS, 20% (v/v) methanol, pH 8.3).  
Proteins were transferred onto the membrane in a Transblot SD semi-dry 
transfer cell (Biorad, Hemel Hempstead, UK) under a current of 1 mA/cm2 
membrane for 2 hours.  Successful transfer could be determined by 
visualisation of the molecular weight marker on the membrane.  Membrane 
was blocked overnight in blocking buffer (5% milk powder, 1x PBS, 0.05% 
Tween-20), washed three times in 1x PBS containing 0.05% Tween 20 (PBS-
T) and incubated with an appropriate primary antibody (diluted 1:200 in PBS-
T) for 1 hour on a rocker.  Washing was repeated and the membrane incubated 
for 1 hour with rabbit anti-mouse or rabbit anti-human IgG conjugated to 
horseradish peroxidase (HRP) (Dako, Ely, UK) (1:1000 in PBS-T).  Membrane 
was washed six times and soaked in 2 ml ECL Western blotting detection 
reagents (GE Healthcare, Amersham, UK) for 5 minutes.  Proteins present on 
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the membrane were visualised by chemiluminescent detection of the oxidation 
of luminol catalysed by HRP.  Kodak Biomax light film (Sigma Aldrich, 
Gillingham, UK) was exposed to the membrane for 2-10 minutes and signal 
detected by soaking the film sequentially in Kodak GBX developer (Sigma 
Aldrich, Gillingham, UK), Kodak GBX fixer (Sigma Aldrich, Gillingham, UK) 
and water.   
 
2.3.2.4 Flow cytometry analysis of EBY100 cells 
   Cells were counted on a haemocytometer and 1 x106 cells aliquoted into 12 
mm x 75 mm sterile culture tubes with lids (Simport, Beloeil, Canada).  Cells 
were washed once in 500 µl yeast wash buffer (1x PBS, 0.5% bovine serum 
albumin (BSA), 2 mM EDTA) by centrifuging at 350 x g for 5 minutes.  Ten 
microlitres of primary antibody, diluted to the desired concentration in yeast 
wash buffer, was added to the cells and incubated on ice for 1 hour.  Cells were 
washed twice in yeast wash buffer as before.  Ten microlitres of Alexafluor 
488-conjugated goat anti-mouse IgG (Invitrogen, Paisley, UK) (1:200 in yeast 
wash buffer) was added to the cells and incubated on ice, in the dark for 1 hour.  
Cells were washed twice in yeast wash buffer as before and resuspended in 500 
µl fixing buffer (isoton, 0.5% formaldehyde) and stored at 4°C until analysis 
on a Beckman Coulter FC500 Flow Cytometer (Beckman Coulter, High 
Wycombe, UK) with 50,000 events captured.  Results were analysed using 
WEASEL v3.0 for Windows (Walter and Eliza Hall Institute of Medical 
Research, Parkville, Australia) and presented as dot plots.  Wild-type EBY100 
cells were included as negative controls in all experiments and provided the 
baseline from which all values for percentage binding were calculated. 
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2.3.3 Construction of an insect cell display library in D. 
melanogaster S2 cells 
2.3.3.1 PCR amplification of E2 and influenza HA TM domain 
   E2 comprising amino acids 384-715 (E2715) was amplified from plasmid 
pCR3.1::H77.20 (H77, genotype 1a) with primer pairs H77c384_s BglII and 
H77_715_as and from pCR3.1::UKN2B1.1 (2B1.1, genotype 2b) with primer 
pairs 2B1.1_384_s BglII and 2B1.1_715_as (Table 2-1).  One microlitre of 
plasmid was used as template in a total reaction volume of 25 µl containing 
200 µM dNTPs (Fermentas, St. Leon-Rot, Germany), 5 pM each primer and 
0.25 units Phusion High-Fidelity DNA Polymerase (Finnzymes, Vantaa, 
Finland).  PCR amplification was performed in a 2-step cycling reaction 
consisting of 98°C for 30s, 35 cycles of 98°C for 10s and 72°C for 30s, 
followed by 72°C for 60s.  PCR products were detected by agarose gel 
electrophoresis as described in 2.3.1.2 and purified as described in 2.3.1.3. 
   A 111 nucleotide region of the transmembrane and cytoplasmic domain 
(amino acids 529-565) of influenza HA (H1) (HATM) was amplified from 
plasmid HA/A/PR/8/34 (a gift from Nicola Clementi, Universita µ9LWD-6DOXWH¶
San Raffaele, Milan) with primers HA_TM_as BstBI and either 
HA_H77_linker_s or HA_2B1.1_linker_s (Table 2-1).  Reaction mix was set 
up as described.  PCR amplification was performed in a 3-step reaction 
consisting of 98°C for 30s, 35 cycles of 98°C for 10s, 70°C for 30s and 72°C 
for 30s, followed by 72°C for 5 minutes.  PCR products were detected by 
agarose gel electrophoresis as described in 2.3.1.2 and purified as described in 
2.3.1.3. 
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2.3.3.2 Fusion PCR to generate E2715HATM 
   PCR products generated in 2.3.3.1 were combined in a Fusion PCR reaction 
(Figure 2-3).  H77 E2715 and HATM with an H77-compatible end were 
combined using primers H77c384_s BglII and HA_TM_as BstBI.  UKN2B1.1 
E2715 and HATM with an UKN2B1.1-compatible end were combined using 
primers 2B1.1_384_s BglII and HA_TM_as BstBI (Table 2-1).  An equal 
molar concentration of E2715 and HATM PCR products were used as template in 
a total reaction volume of 50 µl containing 200 µM dNTPs (Fermentas, St. 
Leon-Rot, Germany), 10 pM each primer and 0.5 units Phusion High-Fidelity 
DNA Polymerase (Finnzymes, Vantaa, Finland).  PCR amplification was 
performed in a 3-step reaction consisting of 98°C for 30s, 35 cycles of 98°C for 
10s, 70°C for 15s and 72°C for 30s, followed by 72°C for 5 minutes.  PCR 
Figure 2-3. Schematic representation of the Fusion PCR cloning 
strategy. E2715 (blue) was PCR amplified from pCR3.1::H77.20. The 
influenza haemagglutinin transmembrane (HATM) tag (red) was 
amplified from HA/A/PR/8/34. The forward primer, HA_TM_linker_s, 
FRQWDLQV D VHTXHQFHFRPSOHPHQWDU\ WR WKH ¶ HQGRI(715 (shown in 
blue) which forms an E2 tag within the HATM product. This enables the 
fusion of the HATM tag to E2715 producing the complete E2715HATM 
product. 
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products were detected by agarose gel electrophoresis as described in 2.3.1.2 
and purified as described in 2.3.1.3. 
 
2.3.3.3 Preparation of the Drosophila expression plasmid, pMT 
   The plasmid pT425, derived from plasmid pMT/BiP/V5-His (Invitrogen, 
Paisley, UK) (Figure 2-2), was kindly provided by Thomas Krey (Pasteur 
Institute, Paris).  The original plasmid insert was removed by restriction 
enzyme digestion of 4 µg plasmid with 10 units BglII (New England Biolabs, 
Hitchin, UK) and 20 units BstBI (New England Biolabs, Hitchin, UK) in a     
30 µl reaction volume containing NEB buffer 2 at 37°C overnight.  Digested 
plasmid was visualised on a 1% agarose gel prepared as described in 2.3.1.2.  
The band corresponding to the plasmid backbone without the insert was 
excised and purified using a Qiaquick Gel Extraction kit (Qiagen, Crawley, 
UK) according to the PDQXIDFWXUHU¶V instructions.  Briefly, the excised gel 
fragment was weighed, mixed with 3 volumes of buffer QG and heated to 50°C 
for 10 minutes to allow the agarose to dissolve.  The solution was loaded onto a 
Qiaquick column preloaded onto a QIAvac 24 Plus vacuum manifold (Qiagen, 
Crawley, UK) and DNA bound to the silica membrane by applying the vacuum 
and allowing the sample to pass through.  Sample was washed with 500 µl 
buffer QG to remove residual agarose followed by 750 µl buffer PE under 
vacuum to remove any residual impurities.  DNA was eluted from the column 
in 50 µl Buffer EB by centrifuging at 17,900 x g for 1 minute.  DNA 
concentration of the resulting plasmid, pMT, was quantified using a Nanodrop 
ND1000 Spectrophotometer (Thermo Fisher Scientific, Loughborough, UK). 
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2.3.3.4 Cloning of E2715HATM constructs into plasmid pMT 
   Approximately 1 µg of the constructs H77 E2715HATM and UKN2B1.1 
E2715HATM, generated in 2.3.3.2, were digested with 10 units BglII (New 
England Biolabs) and 20 units BstBI (New England Biolabs, Hitchin, UK) in a 
20 µl reaction volume containing NEB buffer 2 at 37°C overnight.  Digested 
products were column purified using a Qiaquick PCR Purification kit (Qiagen, 
Crawley, UK) as described in 2.3.1.3.  E2715HATM fragments were ligated into 
pMT containing compatible ends at a 3:1 molar ratio of insert to vector in a   
20 µl reaction volume containing 400 cohesive end units T4 DNA ligase (New 
England Biolabs, Hitchin, UK).  The reaction was incubated at 16°C for 1 hour 
and plasmids transformed into E. coli TOP10 competent cells as described in 
2.3.1.7.  Transformant colonies were screened with pMT-specific primers 
(Table 2-1) as described in 2.3.1.8.  Putative positive colonies were picked and 
grown, plasmid extracted as described in 2.3.1.9 and sequenced with pMT-
specific primers as described in 2.3.1.10 to confirm that E2715HATM was 
inserted into the plasmid and did not contain any mutations.  The resulting 
plasmids were designated pMT::E2715HATM (H77) and pMT::E2715HATM 
(UKN2B1.1) 
 
2.3.3.5 Site-directed mutagenesis 
   Site-directed mutagenesis was carried out on plasmid pMT::E2715HATM 
(H77) to reverse an asparagine residue at position 391 back to the wild-type 
serine residue (N391S) and to generate alanine substitutions at amino acids 530 
(G530A) and 535 (D535A).  These residues are known CD81 binding sites and  
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Table 2-2. Sequences of the site-directed mutagenesis primers. 
Target Orientation Primer 
name 
3ULPHUVHTXHQFH¶-¶ 
G530A Sense G530A_s CTACCTACAGCTGGGCTG
CAAATGATACGG 
G530A Antisense G530A_as CCGTATCATTTGCAGCCCA
GCTGTAGGTAG 
N391S Sense N391S_s GTCACCGGGGGAAGTGCC
GGCCGCAC 
N391S Antisense N391S_as GTGCGGCCGGCACTTCCC
CCGGTGAC 
D535A Sense D535A_s GGTGCAAATGATACGGCT
GTCTTCGTCCTTAAC 
D535A Antisense D535A_as GTTAAGGACGAAGACAGC
CGTATCATTTGCACC 
All primers were synthesised commercially by Eurofins MWG Operon, 
Germany. 
 
form part of the epitope recognised by the antibodies AR3A, A:8 and 1:7 
(Johansson et al., 2007b; Law et al., 2008).  Mutagenesis primers were 
designed using PrimerX (http://bioinformatics.org/primerx/cgi-bin/DNA_1.cgi) 
(Table 2-2).  Mutagenesis was carried out on 50 ng of plasmid in a total 
reaction volume of 50 µl containing 125 ng each plasmid, 200 µM dNTPs 
(Fermentas, St. Leon-Rot, Germany), 3% dimethyl sulphoxide (DMSO) and 
0.5 units Phusion High-Fidelity DNA Polymerase (Finnzymes, Vantaa, 
Finland).  Thermal cycling consisting of 98°C for 2 minutes and 30 cycles of 
98°C for 10s, 55°C for 15s and 72°C for 5 minutes was performed.  Parental 
plasmid was removed by overnight digestion with 20 units DpnI (New England 
Biolabs, Hitchin, UK) at 37°C.  Plasmid was transformed into E. coli TOP10 
competent cells as described in 2.3.1.7 and colonies screened with pMT-
specific primers as described in 2.3.1.8.  Putative positive colonies were grown 
and the plasmid extracted as described in 2.3.1.9 and sequenced with pMT-
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specific primers as described in 2.3.1.10 to confirm the presence of the desired 
mutations. 
 
2.3.3.6 Random mutagenesis of pMT::E2715HATM 
   Random mutations within the E2715HATM region of pMT::E2715HATM (H77) 
were generated using the Genemorph II EZClone Domain Mutagenesis Kit 
(Agilent Technologies, Stockport, UK DFFRUGLQJ WR WKH PDQXIDFWXUHU¶V
instructions.  In the first step, a megaprimer was generated from 
pMT::E2715HATM (H77).  To obtain a medium mutation rate, 300 ng of 
pMT::E2715HATM (H77) plasmid was used as template in a total reaction 
volume of 50 µl containing 125 ng/µl insert specific primers (Table 2-1), 200 
µM dNTPs and 2.5 units Mutazyme II DNA Polymerase (Agilent 
Technologies, Stockport, UK).  Amplification was carried out with cycling at 
95°C for 5 minutes, 30 cycles of 95°C for 30s, 58°C for 30s, and 72°C for       
1 minute, followed by 72°C for 10 minutes.  The Megaprime reaction product 
was purified using a Qiaquick PCR Purification Kit (Qiagen, Crawley, UK) as 
described in 2.3.1.3.  The megaprimer was subsequently used to prime 
amplification of pMT::E2715HATM (H77) in the EZClone reaction.  Two 
hundred and fifty nanograms of megaprimer was used to prime amplification 
from 50 ng of the template plasmid in a total reaction volume of 50 µl 
containing 3 µl EZClone soluWLRQ DQG  ȝO (=&ORQH HQ]\PH PL[ (Agilent 
Technologies, Stockport, UK).  Amplification was carried out with cycling at 
95°C for 1 minute, 25 cycles of 95°C for 50s, 60°C for 50s and 68°C for 9 
minutes and 30s.  Parental plasmid was removed by digestion with 10 units 
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DpnI (Agilent Technologies, Stockport, UK) for 2 hours at 37°C prior to 
transformation into XL10-Gold Ultracompetent cells.   
 
2.3.3.7 Transformation of plasmids into XL10-Gold Ultracompetent 
cells 
 
   Plasmid was transformed into XL10-Gold Ultracompetent cells (Agilent 
Technologies, Stockport, UK DFFRUGLQJ WR WKH PDQXIDFWXUHU¶V LQVWUXFWLRQV
%ULHIO\  O ȕ-mercaptoethanol mix (Agilent Technologies, Stockport, UK) 
was added to 45 µl XL10-Gold cells and incubated on ice for 10 minutes with 
gentle swirling every 2 minutes.  To this, 1.5 µl plasmid was added and 
incubated on ice for a further 10 minutes.  Cells were heat-shocked at 42°C for 
30s and incubated on ice for 2 minutes.  Five hundred microlitres of NZY+ 
broth (1% (w/v) casein hydrolysate, 0.5% (w/v) yeast extract, 0.5% (w/v) 
NaCl, 12.5 mM MgCl2, 12.5 mM MgSO4, 20 mM glucose) preheated to 42°C 
was added and cells incubated at 37°C for 1 hour with shaking at 250 rpm 
before plating onto LB (Sigma Aldrich, Gillingham, UK) agar plates 
containing 25 µg/ml ampicillin and incubated at 37°C overnight.  Colonies 
were screened with pMT-specific primers (Table 2-1) as described in 2.3.1.8.  
Putative positive colonies were picked and grown, plasmid extracted as 
described in 2.3.1.9 and sequenced with pMT-specific primers as described in 
2.3.1.10 to assess mutation frequency.  The Programme for Estimating 
Diversity in Error-prone PCR libraries (PEDEL-AA) (Patrick et al., 2003) 
(accessed at http://guinevere.otago.ac.nz/aef/STATS/index.html) was used to 
determine the size of the library required.  The resulting plasmid pool was 
designated pMT::H77 library. 
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2.3.3.8 Stable transfection of D. melanogaster S2 cells 
   D. melanogaster S2 cells were stably transfected by co-transfection of the 
pMT plasmid, containing the gene of interest, and the plasmid pCoBlast 
(Invitrogen, Paisley, UK), containing the blasticidin resistance gene, at a 20:1 
ratio of expression plasmid to selection plasmid.  Cells were seeded at a density 
of 5 x 106 cells/well in a 6-well tissue culture plate for suspension cells 
(Sarstedt, Leicester, UK) in a total volume of 2.5 ml Insect Xpress media 
(Lonza, Slough, UK).  After 24 hours growth at 28°C, 2 µg pMT and 0.1 µg 
pCoBlast were mixed with 6 µl FuGene 6 transfection reagent (Roche, Burgess 
Hill, UK), incubated at room temperature for 20 minutes and added dropwise 
to the cells.  Cells were incubated at 28°C for a further 48 hours and stable 
transfectants selected by the addition of Blasticidin S (25 µg/ml) (Invivogen, 
Nottingham, UK).  Every 2 to 5 days media was removed by centrifuging cells 
at 100 x g for 5 minutes and replaced with fresh Insect Xpress media (Lonza, 
Slough, UK) containing 25 µg/ml Blasticidin S (Invivogen, Nottingham, UK) 
to maintain selection pressure.  Clumps of cells became visible after 20 to 25 
days of selection indicating that stable transfection was successful.  These 
cultures were expanded into larger volumes and maintained in T25 or T75 
tissue culture flasks for suspension cells (Sarstedt, Leicester, UK).  Cells were 
grown in Insect Xpress media (Lonza, Slough, UK) containing 25 µg/ml 
Blasticidin S (Invivogen, Nottingham, UK) to maintain stable transfection of 
the gene of interest. 
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2.3.4 Expression and characterisation of E2 proteins expressed in 
D. melanogaster S2 cells 
2.3.4.1 Induction of protein expression in D. melanogaster S2 cells 
   Cells were seeded at a density of 2 x 106 cells/ml in a 6-well tissue culture 
plate for suspension cells (Sarstedt, Leicester, UK) containing 3 ml Insect 
Xpress media (Lonza, Slough, UK).  After 24 hours growth at 28°C protein 
expression was induced by addition of 700 µM copper sulphate (CuSO4).  Cells 
were grown for a further 5 days at 28°C before protein was assayed. 
 
2.3.4.2 Preparation of D. melanogaster S2 cells for SDS-PAGE 
   Cells were counted and aliquots containing 1 x 106 cells washed once in PBS 
by centrifuging at 100 x g for 5 minutes.  For analysis of whole cells, pellets 
were resuspended in 200 µl PBS.  For analysis of cell lysates, pellets were 
resuspended in 200 µl lysis buffer (150 mM NaCl, 1% Igepal CA-630 (Sigma 
Aldrich, Gillingham, UK), 50 mM Tris pH 7.4, 1 mM EDTA, 37 ng/ml 
iodoacetamide), incubated at 37°C for 10 minutes, vortexed briefly and 
centrifuged as above to pellet cell debris.  SDS-PAGE was carried out as 
described in 2.3.2.2 followed by Western blot analysis of protein samples as 
described in 2.3.2.3. 
 
2.3.4.3 Galanthus nivalis agglutinin (GNA)-capture ELISA analysis 
of protein expressed in D. melanogaster S2 cells 
 
   A Maxisorp 96-well plate (Nunc) (Fisher Scientific, Loughborough, UK) was 
coated with 50µl of GNA (5 µg/ml in 50 mM carbonate/bicarbonate buffer (pH 
9.8)) overnight at 4°C in a humidity chamber.  Non-specific binding sites were 
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blocked with 300 µl blocking buffer (5% milk powder, 1x PBS, 0.05% Tween-
20) for 2 hours at room temperature.  Wells were washed once in PBS-T.  D. 
melanogaster S2 cell lysates (prepared as described in 2.3.4.2) were diluted 1:5 
in PBS and 50 µl coated onto wells for 2 hours at room temperature alongside 
the positive control (sE2650 from a genotype 1a (H77) isolate expressed in HEK 
293T cells).  Wells were washed three times in PBS-T.  Bound cell lysates 
were detected by the addition of 50 µl of primary antibody (5 µg/ml diluted in 
PBS-T) and incubated at room temperature for 1 hour.  Wells were washed 
three times in PBS-T.  Bound primary antibody was detected by the addition of 
50 µl of alkaline phosphatase (AP)-conjugated secondary antibody (goat anti-
mouse or goat anti-human IgG) (Sigma Aldrich, Gillingham, UK) (1:1000 in 
PBS) and incubated at room temperature for 1 hour.  Wells were washed three 
times in PBS-T and bound antibody identified by the addition of 100 µl p-
Nitrophenyl Phosphate (pNPP) (Fisher Scientific, Loughborough, UK).  Plates 
were incubated in the dark for approximately 30 minutes to allow a yellow 
colour to develop indicating a positive reaction.  Absorbance at 405 nm was 
determined using a Fluorostar Optima plate reader (BMG Labtech, Aylesbury, 
UK).  All samples were run in triplicate and the results analysed using 
Graphpad Prism 4.03 for Windows (Graphpad Software, San Diego, USA).  
Error bars were calculated as the standard deviation of the replicates and the 
results presented as percentage of positive control.  Significance of differences 
was determined using a one-ZD\$129$ZLWK7XNH\¶VPXOWLSOHFRPSDULVRQ
test.  Values of P <0.05 were deemed significant. 
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2.3.4.4 Flow cytometry analysis of D. melanogaster S2 cells ± cell 
surface staining 
 
   Cells were counted and resuspended at 1 x 106 cells/ml in Insect Xpress 
media (Lonza, Slough, UK) in 12 mm x 75 mm sterile culture tubes with lids 
(Simport, Beloeil, Canada).  Cells were washed once in 500 µl media by 
centrifuging at 300 x g for 5 minutes.   
   Cells were stained with a single MAb.  Cells were incubated with 10 µl of 
primary antibody, diluted to the desired concentration in media, on ice for 1 
hour.  Cells were washed twice in media as before.  Bound MAb was detected 
by the addition of 10 µl of an Alexafluor 488-conjugated secondary antibody 
(goat anti-mouse or goat anti-human IgG) (Invitrogen, Paisley, UK) (1:200 in 
Insect Xpress media (Lonza, Slough, UK)) and incubated on ice, in the dark for 
1 hour.  Cells were washed twice in media as before and resuspended in 500 µl 
media.  For flow cytometry analysis without sorting, samples were run 
immediately on a Beckman Coulter FC500 Flow Cytometer (Beckman Coulter, 
High Wycombe, UK) with 50,000 events captured.  Results were analysed 
using WEASEL v3.0 for Windows (Walter and Eliza Hall Institute of Medical 
Research, Parkville, Australia) and presented as histograms or dot plots.  Wild-
type S2 cells were included as negative controls in all experiments and 
provided the baseline from which all values for percentage binding were 
calculated. 
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2.3.4.5 Flow cytometry analysis of D. melanogaster S2 cells ± 
intracellular staining 
 
   Cells were counted and resuspended at 1 x 106 cells/ml in Insect Xpress 
media (Lonza, Slough, UK) in 12 mm x 75 mm sterile culture tubes with lids 
(Simport, Beloeil, Canada).  Cells were washed once in 500 µl media by 
centrifuging at 300 x g for 5 minutes.  Cells were fixed by incubating in 1 ml 
Insect Xpress media containing 4% formaldehyde at room temperature for 5 
minutes.  Cells were washed once in 1 ml of media as before.  Cells were 
washed twice in 1 ml permeabilisation buffer (Insect Xpress media, 0.4 mg/ml 
saponin, 50 mM glucose) by centrifuging at 300 x g for 5 minutes.  Cells were 
stained with 10 µl of primary antibody, diluted to the desired concentration in 
media, and incubated on ice for 1 hour.  Cells were washed twice in 
permeabilisation buffer as before.  Bound MAb was detected by the addition of 
10 µl of an Alexafluor 488-conjugated secondary antibody (goat anti-mouse or 
goat anti-human IgG) (Invitrogen, Paisley, UK) (1:200 in Insect Xpress media 
(Lonza, Slough, UK)) and incubated on ice, in the dark for 1 hour.  Cells were 
washed once in permeabilisation buffer as before, resuspended in 500 µl fixing 
solution (Insect Xpress media, 0.5% formaldehyde) and stored at 4°C until 
analysis.  Samples were run on a Beckman Coulter FC500 Flow Cytometer 
(Beckman Coulter, High Wycombe, UK) and analysed as described in section 
2.3.4.4. 
2.3.4.6 Fluorescence-activated cell sorting of D. melanogaster S2 
cells 
 
   For sorting, D. melanogaster S2 cells were stained with a pool of MAbs that 
had been directly labelled with either the Alexafluor-488 fluorophore or the 
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Alexafluor-647 fluorophore using a Monoclonal Antibody Labelling Kit 
(Invitrogen, Paisley, UK).  Cells were simultaneously stained with a single 
Alexafluor 488-conjugated MAb, AR3A, (AR3A-A488) and a pool of 
Alexafluor 647-conjugated MAbs, AR2A (AR2A-A647) and H53 (H53-A647) 
 ȝO WRWDO YROXPH  $QWLERGLHV ZHUH XVHG DW D FRQFHQWUDWLRQ RI 1 ȝJPO 
each, diluted in Insect Xpress media (Lonza, Slough, UK).  
   Cells were counted and resuspended at 1 x 106 cells/ml in Insect Xpress 
media (Lonza, Slough, UK) containing Penicillin-Streptomycin (1:100) 
(Invitrogen, Paisley, UK) in 12 mm x 75 mm sterile culture tubes with lids 
(Simport, Beloeil, Canada).  Cells were washed once in 500 µl media 
containing Penicillin-Streptomycin by centrifuging at 300 x g for 5 minutes. 
   Cells were mixed with the pooled MAb mixture and incubated on ice, in the 
dark for 2 hours.  Cells were washed twice as before and resuspended in 500 µl 
media containing Penicillin-Streptomycin.  Samples were analysed and sorted 
immediately on a Beckman Coulter MoFlo Cell sorter (Beckman Coulter, High 
Wycombe, UK).  All cells within the sample were analysed.  Sorting data was 
analysed as described in section 2.3.4.4. 
 
2.3.4.6.1 Bulk sorting and expansion of D. melanogaster S2 cells 
   $FFRUGLQJ WR WKH PDQXIDFWXUHU¶V SURWRFRO D. melanogaster S2 cells do not 
grow well when seeded at a density below 5 x 105 cells/ml (RUFHOOVȝO).  It 
is also reported that the cells grow better when passaged into conditioned 
media.  Therefore cells were sorted in bulk into a 96-well flat-bottom plate for 
suspension cells (Sarstedt, Leicester, UK) containing 10ȝORImixed fresh and 
conditioned Insect Xpress media (Lonza, Slough, UK) containing Penicillin-
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Streptomycin (1:100) (Invitrogen, Paisley, UK).  Due to the low density of 
cells sorted, wild-type D. melanogaster S2 cells were seeded at a density of 
500 cells/µl into each well prior to sorting.  This provided a sufficient density 
of cells onto which stained cells could be sorted, allowing the sorted population 
to survive and grow.  All cells within a tube were run through the Beckman 
Coulter MoFlo Cell sorter and as many cells falling within the population of 
interest were sorted into a single well.  Cells were incubated at 28°C and the 
media replenished every other day to maintain a constant volume.  When the 
population reached a sufficient density the cells were expanded into larger 
growth vessels (48-well, 24-well, 6-well tissue culture plates (Sarstedt, 
Leicester, UK)).  After approximately 3 weeks the cultures had been expanded 
into a 6-well tissue culture plate.  Penicillin-Streptomycin was removed from 
the growth media at this stage.  Blasticidin S (25 µg/ml) (Invivogen, 
Nottingham, UK) was re-introduced to the growth media to remove the wild-
type cells and select only for the sorted cells of interest.  After a further 2 
weeks selection, the cells were re-sorted as described in section 2.3.4.6. 
 
2.3.4.6.2 Sorting D. melanogaster S2 cells into 96-well PCR plate 
   For a more direct analysis of the library, single cells were sorted into a 96-
well PCR plate containing 10 µl 1x Tris-buffered saline (TBS) per well. 
 
2.3.5 PCR amplification from single D. melanogaster S2 cells 
   Following sorting into a 96-well PCR plate, samples were heated to 95°C for 
15 minutes to lyse the cells.  Amplification of the H77 E2715HATM DNA 
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contained within each cell was carried out in a nested PCR reaction with 
primers MT_fwd and BGH in the first round, and primers H77c384_s BglII 
and HA_TM_as BstBI in the second round (Table 2-1).  For the first round,  
2.5 pM each primer, 200 µM dNTPs (Fermentas St. Leon-Rot, Germany) and 1 
unit LongAmp Taq DNA Polymerase (New England Biolabs, Hitchin, UK) 
was added to each well to a total volume of 15 µl.  Amplification was 
performed in a 3-step cycling reaction consisting of 94°C for 30s, 45 cycles of 
94° for 30s, 50°C for 30s and 65°C for 1 minute 15s, followed by 65°C for 10 
minutes.  One microlitre of first round product was used as template in the 
second round reaction with the following cycling parameters; 94°C for 30s, 45 
cycles of 94° for 30s, 64°C for 30s and 65°C for 1 minute 15s, followed by 
65°C for 10 minute.  Products were visualised by agarose gel electrophoresis as 
described in 2.3.1.2.  Positive samples were column purified as described in 
2.3.1.3 and sequenced with primers H77c384_s BglII, HA_TM_as BstBI, 
S2_IF and S2_IR (Table 2-1) as described in 2.3.1.10. 
 
2.4 Results 
2.4.1 Development of a yeast display library in S. cerevisiae 
EBY100 
2.4.1.1 Cloning E2 into pYD1 
   To generate an E2 cell-surface display library in the yeast S. cerevisiae 
EBY100, three truncated versions of the E2 glycoprotein were PCR amplified 
from the genotype 1a strain H77 (Figure 2-4).  All constructs began at the first 
amino acid residue of E2 (E384) and were truncated at residue E650 (E2650), 
E661 (E2661) or K715 (E2715).  E2661 is a soluble form of E2 which is widely 
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used and has been shown to express well in different culture systems 
(Cocquerel et al., 2006; Flint et al., 1999b).   
However, according to the recently described model of E2 (Krey et al., 2010), 
this WUXQFDWLRQ UHVXOWV LQD µVSDUH¶F\VWHLQH UHVLGXHZKLFK LVXQDEOH WR IRUPD
disulfide bond.  This may result in an unstable or incorrectly folded protein.  
7UXQFDWLRQDWUHVLGXH(UHPRYHVWKHµVSDUH¶F\VWHLQHDQGWKHUHIRUHVKRXOG
overcome any problems associated with incorrect folding.  E2715 lacks only the 
transmembrane domain (the C-terminal 31 amino acids) and therefore 
represents the entire ectodomain (Cocquerel et al., 1998).  This version of E2 is 
expressed well and folds correctly in D. melanogaster S2 cells (Krey et al., 
2010).   
   Attempts were made to clone E2 PCR products directly into pYD1 (Figure 2-
1b) by restriction enzyme cloning.  This proved unsuccessful however, despite 
several attempts.  The decision was then made to clone E2 products into 
pGEM-T Easy (Promega, Southampton, UK) by TA-cloning and subclone E2 
Figure 2-4. Generation of E2 with truncated ectodomains. PCR 
amplification products E2650, E2661 and E2715. were analysed by 
agarose gel electrophoresis. + denotes PCR products, - denotes 
negative control. Position of DNA marker (M) is shown in base pairs. 
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into pYD1 by restriction enzyme cloning.  Colonies were obtained containing 
the desired fragment (Figure 2-5) and sequencing of the inserts within these 
plasmids showed that E2715 had been inserted into pYD1.  However, the 
presence of an additional EcoRI restriction site within pGEM-T Easy prevented 
E2715 being cut correctly from pGEM-T Easy.  This resulted in the insertion of 
a 14 bp fragment of pGEM-T Easy into pYD1 downstream of E2715 and led to 
the introduction of a stop codon (Figure 2-6 a,c).  Alignment of this sequence 
to a pYD1::E2 sequence generated in silico showed that three additional amino 
acids were present at the end of E2715 followed by the stop codon.  The E2715 
was cloned in-frame with Aga2p allowing expression of the fusion protein, 
however the reading frame of the plasmid was altered knocking out the V5 
epitope and the poly-histidine tag (Figure 2-6d).  Despite attempting several 
different cloning strategies, this plasmid, termed pYD1::E2715(stop), was the best 
construct generated. 
 
Figure 2-5. Cloning of E2650 and E2715 constructs into pGEM-T Easy. 
Colonies were screened by PCR. Bands at approximately 1200 bp 
represent putative positive colonies containing the desired insert. Bands 
at approximately 400 bp represent undigested vector. Neg. denotes 
negative control. Position of DNA marker (M) is shown in base pairs. 
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2.4.1.2 Expression of E2 on the surface of S. cerevisiae EBY100 
cells 
 
   To test the utility of the yeast display system for expression of HCV E2, 
plasmid pYD1::E2715(stop) was transformed into S. cerevisiae EBY100 and 
expression of the protein was characterised.  S. cerevisiae has a tendency to 
hyper-glycosylate proteins by the addition of extra mannose residues to the 
Glc3Man9GlcNAc2 oligosaccharide (Conde et al., 2004) which can result in 
mis-folding of the protein.  To ascertain if this was the case, expression of 
pYD1::E2715(stop) was tested by Western blot analysis using an anti-Xpress 
primary antibody (1:2500) (Invitrogen, Paisley, UK) specific to the Xpress 
Figure 2-6. Sequence analysis of pYD1::E2 plasmids. (a) Section of 
pYD1 (blue) containing E2715 (red) and a fragment of pGEM-T Easy 
(green). Restriction sites are shown in black. E2715 containing XhoI 
UHVWULFWLRQVLWHDWWKH¶HQGZDVFORQHGLQWRS*(0-T Easy and excised 
by digestion with EcoRI and XhoI. However, due to the close proximity 
of an EcoRI site to the TA cloning site (b) there is preferential cleavage 
of this EcoRI site. (c) This results in an EcoRI ended product which 
contains a 14 bp fragment of pGEM-T Easy (green) attached to E2715 
(red). This is subsequently cloned into pYD1 which has been linearised 
by a single cut with EcoRI. This results in the introduction of a stop 
codon (underlined) downstream of E2715. (d) Amino acid sequence of 
the pYD1::E2715(stop) aligned to an in silico derived pYD1::E2715 
sequence. E2 is shown in red, the pGEM-T Easy derived sequence is 
shown in green. The V5 epitope and poly-histidine tag are shown in 
blue. 
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Figure 2-7. E2715(stop) protein 
expression in S. cerevisiae EBY100 
cells. After 48 hours induction, an 
aliquot of whole cells equivalent to 2 
OD600 units was analysed by Western 
blot under reducing conditions using 
Anti-Xpress antibody. Untransformed 
EBY100 cells served as a negative 
control. Cells transformed with the 
pYD1 plasmid alone or pYD1::HCFC1 
served as positive controls for Xpress 
protein expression. Percentage protein 
expression, relative to HCFC1, is listed 
below. Position of molecular weight 
marker is shown in kDa. 
epitope within pYD1 (Figure 2-1a).  Protein expression after 48 hours of 
induction was tested alongside expression of the Aga2p protein alone (from 
plasmid pYD1), the human host cell factor C1, HCFC1 (from plasmid 
pYD1::HCFC1) (a gift from Jialing Liu, UCSF) and untransformed EBY100 
cells.  Expression of E2715(stop) in S. cerevisiae EBY100 cells was observed 
(Figure 2-7) and the protein did not appear to be hyper-glycosylated, indicated 
by a single, discrete band.   
The size of the protein, approximately 90 kDa, was larger than would be 
expected for E2, which is typically observed at 72 kDa.   This was due to the 
presence of the Aga2p protein in the fusion product.  The levels of E2715(stop) 
expression were lower than those seen for the Aga2p protein alone and 
HCFC1.  Aga2p expression was 28.6% of HCFC1 expression, whilst E2715 
expression was only 4%.  The expected size of HCFC1 is 150 kDa, however 
the large smear on this Western blot suggests that the protein is hyper-
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glycosylated in this system.  This may unduly impact the relative levels of 
protein expression.  When Aga2p and E2715(stop) expression are compared, 
E2715(stop) was expression was 14% of Aga2p expression.  Increasing the 
duration of protein induction to 72 hours did not increase expression levels 
(Figure 2-8) as demonstrated by Western blot analysis of His-Tag expression in 
pYD1-transfected S. cerevisiae EBY100 cells using PentaHis biotin (1:200) 
(Qiagen, Crawley, UK) and streptavidin-HRP (1:1000).  
 
   Having confirmed that E2715(stop) expressed in S. cerevisiae EBY100 cells was 
not hyper-glycosylated, it was necessary to confirm that protein was expressed 
on the cell surface and to test if the protein was correctly folded.  This was 
achieved by flow cytometric analysis of cell surface expressed proteins with 
anti-Xpress antibody (Invitrogen, Paisley, UK) (400 µg/ml) or with the E2-
specific antibodies AP33 (400 µg/ml), recognising a linear epitope (Owsianka 
Figure 2-8. Expression of His-tagged 
protein from pYD1 in S. cerevisiae 
EBY100 over a 72 hour period. An aliquot 
of whole cells equivalent to 2 OD600 units 
was analysed at each time point by 
Western blot under reducing conditions 
with PentaHis Biotin and streptavidin-
HRP. Percentage protein expression is 
listed below. Position of molecular weight 
marker shown in kDa. 
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et al., 2005), and H53 (400 µg/ml), recognising a conformation-dependent 
epitope (Cocquerel et al., 1998).  Anti-Xpress staining of cells confirmed that 
Aga2p and E2715(stop) were expressed on the cell surface.  Aga2p was expressed 
at slightly higher levels than E2715(stop), (Figure 2-9) however the expression of 
E2715 was better than that observed by Western blotting.  
 
Figure 2-9. Aga2p protein expression on the surface of S. cerevisiae 
EBY100 cells. Cells transformed with pYD1 alone or pYD1::E2715(stop) 
were induced for 72 hours and protein expression in 1 x 106 cells 
measured by flow cytometry with a MAb specific to the Xpress epitope. 
Cells stained with Į-Xpress are enclosed by a region and the 
percentage of cells stained is indicated on the right-hand side of the 
dot-plot. The no antibody control provided a baseline for specific 
antibody binding. 
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Cell staining with AP33 and H53 demonstrated that cell-surface E2 was 
present on cells expressing plasmid pYD1::E2715(stop) (Figure 2-10a).  This was 
specific to E2715(stop)-expressing cells as only a small amount of background 
staining of cells expressing plasmid pYD1 could be seen.  Similarly, 
untransformed EBY100 cells did not bind AP33 or H53.  The level of H53 
binding to E2715(stop)-expressing cells was similar to the level of AP33 binding 
(16.61% vs. 22.74%) (Figure 2-10a), suggesting that the E2715(stop) construct 
was correctly folded on the cell surface.  However, levels of cell-surface 
staining with E2-specific MAbs were much lower than staining with anti-
Xpress (approx. 20% (Figure 2-10a) vs. approx. 50%. (Figure 2-9).  The 
fluorescence intensity values for surface expressed E2 are also low (Figure 2-
10b) with values of 12.7 and 9.8 for AP33 binding and H53 binding 
respectively.  This is compared to values of 7.1 and 8.1 respectively for the 
pYD1-expressing control. This suggests that the E2715(stop) protein specifically 
is poorly expressed on the surface of S. cerevisiae EBY100 cells.  This may be 
due to the presence of the additional pGEM-T Easy fragment and the stop 
codon downstream of E2 (Figure 2-6).  It is difficult to predict the impact that 
this might have on protein expression and fold but it would appear to be 
detrimental.  In the absence of a suitable E2 construct expressed in                  
S. cerevisiae EBY100 cells and the difficulties encountered with cloning, the 
decision was made to develop an alternative display library, using the             
D. melanogaster S2 system. 
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Figure 2-10. E2715(stop) protein expression on the surface of S. cerevisiae 
EBY100 cells. See overpage for full figure legend. 
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2.4.2 Development of an insect cell display library in D. 
melanogaster S2 cells 
2.4.2.1 Generation of HA-tagged E2 and cloning into pMT 
   To adapt the DES secreted protein expression system for surface display of 
proteins, the E2 ectodomain alone (amino acids 384-715) was PCR amplified 
from the genotype 1a strain H77 and the genotype 2b strain UKN2B1.1 (Figure 
2-11).  This resulted in the removal of the native transmembrane domain 
containing the ER-retention signals which would prevent trafficking of the 
protein to the cell surface (Cocquerel et al., 1998).  This truncation also 
removed the endogenous signal sequences from E2 allowing protein 
translocation to be controlled by the BiP secretion signal within the pMT 
plasmid.  This E2 truncation has previously been successfully expressed in     
D. melanogaster S2 cells (Krey et al., 2010).  The influenza A virus HA 
transmembrane and cytoplasmic domain, HATM, was PCR amplified from the 
subtype H1 strain A/PR/8/34 (Figure 2-11).  The purified PCR products were 
subsequently combined in a fusion PCR reaction (Figure 2-3) to generate the 
products H77 E2715HATM (Figure 2-11) and UKN2B1.1 E2715HATM.  The 
fusion PCR primers were designed to introduce the restriction sites BglII and 
Figure 2-10. E2715(stop) protein expression on the surface of S. cerevisiae 
EBY100 cells. Untransformed cells and cells transformed with pYD1 
alone or pYD1::E2715(stop) were induced for 72 hours and protein 
expression in 1 x 106 cells measured by flow cytometry using the E2-
specific MAbs AP33 (left panel) and H53 (right panel). a) Cells binding 
the specific MAb are enclosed within a region and the percentage of cells 
staining is indicated on the right. Binding was MAb-specific as mock-
stained cells did not fluoresce (not shown). b) Histograms of pYD1-
expressing cells (black) and E2715(stop)-expressing cells (red) staining with 
AP33 and H53.  Mean fluorescence intensity (FI) was calculated using 
Weasel v3.0 software and given in arbitrary units. Vertical line denotes 
antibody binding and the percentage of E2715(stop)-expressing cells 
staining positive is shown to the right hand side. 
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Bst%, DW WKH ¶ DQG ¶ HQGV UHVSHFWLYHO\ of the PCR products.  Restriction 
enzyme cloning was used to clone H77 E2715HATM and UKN2B1.1 E2715HATM 
into the plasmid pMT bearing compatible ends.  The resulting plasmids were 
designated pMT::E2715HATM (H77) and pMT::E2715HATM (UKN2B1.1). 
 
2.4.2.2 Generation of mutant plasmids 
   Sequencing of the plasmid pMT::E2715HATM (H77) showed that an erroneous 
substitution of S391N had been introduced during the PCR amplification step.  
Therefore site-directed mutagenesis was carried out in order to restore the 
wild-type sequence and successful mutagenesis was confirmed by sequencing 
(Figure 2-12).  The plasmid pMT::E2715HATM (H77) was also mutated to 
introduce alanine substitutions at residues known to be critical in the binding of 
specific MAbs to E2.  These residues, glycine at position 530 and aspartate at 
Figure 2-11. Generation of PCR products for Insect cell expression. 
E2715 and HATM PCR products are shown in columns 6 and 7.  
Replicates for the Fusion PCR product E2715HATM are shown in 
columns 2-4. Neg. denotes negative control. Position of DNA marker 
(M) is shown in base pairs. 
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Figure 2-12. Generation of the pMT::E2715HATM mutants 
D535A and G530A. Sequence chromatograms show (a) 
replacement of  asparagine (N) at residue 391 with serine (S) 
by mutation of AAT to AGT, restoring the wild-type E2 (H77) 
sequence; (b) replacement of glycine (G) by alanine (A) at 
residue 530 by mutation of GGT to GCT. (c) and replacement 
of aspartate (D) by alanine (A) at residue 535 by mutation of 
GAT to GCT. Nucleotide substitutions are denoted by a black 
arrow.  
 
 105 
 
position 535, are involved in the binding of Fab e137 (Perotti et al., 2008), as 
well as the MAbs AR3A, AR3B and AR3C (Law et al., 2008), 1:7 and A8 
(Allander et al., 2000; Johansson et al., 2007b) and CBH-5 (Hadlock et al., 
2000; Owsianka et al., 2008).  Alanine was introduced at these sites as a search 
of the Los Alamos HCV sequence database shows that it does not occur 
naturally at residue 530 or 535.  It is also one of the simplest amino acids with 
respect to molecular structure and does not directly impact protein function.  
Thus its impact on overall protein fold should be minimal.  Substitution of 
G530 and D535 with alanine was confirmed by sequencing (Figure 2-12) and 
the resulting plasmids were designated pMT::E2715G530A and 
pMT::E2715D535A. 
   The introduction of random mutations within E2 was achieved using the 
Genemorph II EZClone Domain Mutagenesis Kit (Agilent Technologies, 
Stockport, UK).  This utilises an error-prone PCR method to amplify the 
E2715HATM region.  This first round product ZDVWKHQXVHGDVDµPHJDSULPHU¶
to prime amplification of the pMT::E2715HATM (H77) plasmid in a second 
reaction.  The resulting plasmid should contain mutations only in the 
E2715HATM gene and should not be mutated within other functional regions of 
the plasmid.  It may however, contain mutations within the transmembrane 
domain (HATM) which could prevent trafficking of the protein to the cell 
surface or its anchoring within the cell membrane.  However the frequency of 
such mutations should not be so great as to significantly reduce the function of 
the library.   
   It was important to generate a library containing, on average, one amino acid 
substitution per sequence, without introducing deleterious mutations.  It was 
 106 
 
also important to ensure that the library generated was large enough to be 
representative of all possible mutations within the E2 ectodomain.  The 
mutation rate achieved with the Genemorph II EZClone Domain Mutagenesis 
Kit can be altered by adjusting the concentration of template used.  Test 
mutagenesis reactions were carried out with either 300 ng or 500 ng template 
DNA and several colonies were sequenced.  PEDEL-AA online software was 
used to assess the mutation rate and size of library required (Table 2-3).   
 
Table 2-3. Statistics for determining the size of the E2 display library 
Property 
  
Input DNA (ng) 300 500 
Total libary size 1 x 104 1 x 104 
No. of variants with no in-frame deletions or stop 
codons 
8701 9478 
Mean no. of amino acid substitutions per variant 1.721 0.5267 
Unmutated sequences (% of library) (Poisson 
estimate) 
15.57 55.97 
No. of distinct full-length proteins in the library 
(Poisson estimate) 
5645 1974 
No. of variants that differ from the parent by a 
single amino acid (Poisson estimate)* 
1182 1041 
Data generated with the Programme for Estimating Diversity in Error-prone 
PCR libraries (PEDEL-AA). *E2 is 331 amino acids 
 
This indicated that 300 ng of input DNA was optimal for the generation of a 
randomly mutated library.  With a library size of 1 x 104 cells, each protein 
should contain an average of 1.7 amino substitutions resulting in 1182 variants 
that differ from the parent by a single amino acid, based on a Poisson 
distribution.  Given that E2715 is 332 amino acids long (E2715HATM is 369 
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amino acids), this library should be representative of all single amino acid 
mutations within E2.  PEDEL-AA analysis also indicated that the majority of 
sequences (8,701 out of 10,000) would not contain stop codons or in-frame 
deletions.  Following transformation of mutated plasmids into E. coli XL10 
cells, as described in 2.3.3.7, approximately 12,000 colonies were picked and 
pooled into a single LB culture.  This is greater than the 1 x 104 cells required.  
The resulting pooled plasmid was designated pMT::H77 library. 
 
2.4.2.3 Expression of E2 on the surface of D. melanogaster S2 cells 
   D. melanogaster S2 cells were co-transfected with a pMT plasmid containing 
the protein of interest and pCoBlast to generate stable cell lines.  Expression of 
the various E2 constructs in the different cell lines was initially confirmed by 
Western blot analysis of cell lysates using MAb AP33 which recognises a 
linear epitope within E2 and does not require the residues G530 and D535 for 
binding (Owsianka et al., 2005; Tarr et al., 2006).  All constructs were 
expressed in D. melanogaster S2 cells (Figure 2-13).  To confirm localisation 
of E2 to the cell surface, flow cytometry analysis was carried out on surface 
stained and intracellularly stained cells expressing E2715.  Cell staining with 
AP33 ( ȝJPO) showed that E2715 was expressed on the cell surface; 
however, intracellular staining of permeabilised cells indicated that not all 
protein was trafficked to the cell surface (Figure 2-14).  The level of AP33 
binding was only slightly lower for the intracellular staining than the cell 
surface staining (53.50% compared to 63.43%).  This may be due to E2715 
protein which is in the process of being transported to the cell surface by the 
protein secretion machinery but which is momentarily retained within the ER. 
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   To confirm that all proteins were expressed on the cell surface and in the 
correct fold or conformation, cells expressing E2715HATM, E2715G530A and 
E2715D535A were analysed by flow cytometry with the MAbs AP33 and H53.  
All stable cell lines expressing E2 could be stained with AP33 and H53 
showing that the cell-surface expressed E2 is correctly folded (Figure 2-15).  
Similar levels of AP33 and H53 binding were observed for each construct 
(62.41% vs. 58.26% E2715HATM, 47.04% vs. 46.27% E2715G530A, 44.86% vs. 
38.38% E2715D535A) demonstrating that the majority of expressed E2 was in 
its native conformation.  (Cells staining at the top of the dot plot were not 
included in the analysis due to high side-scatter values indicating that these are 
probably dead cells).  The slightly lower levels of H53 binding to E2715HATM 
and E2715D535A compared to AP33 binding may be due to the presence of a 
small amount of incorrectly folded protein.  Flow cytometry analysis with 
AP33 and H53 was repeated a number of times and expression levels of around 
50-60% E2715HATM and around 40-45% E2715D535A was typically seen.  This 
may be due to the transfection of some cells with the resistance plasmid 
Figure 2-13. E2715 expression 
in D. melanogaster S2 cells. 
Cell lysate from 1 x 106 cells 
was analysed by Western blot 
under reducing conditions with 
the E2-specific MAb AP33. 
Wild-type S2 cells served as a 
negative control. sE2661 
served as positive control for 
protein expression. Position of 
the molecular weight marker is 
shown in kDa. 
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pCoBlast only.  This would result in blasticidin-resistant cells that are unable to 
express E2 protein. 
 
2.4.2.4 Binding of specific MAbs to antibody-binding site mutants 
of E2 
 
   To provide proof-of-principle that the Insect cell display library could be 
used to map antibody-binding residues, alanine substitutions were introduced 
into E2715HATM at known antibody-binding residues (see section 2.4.2.2).  
Having confirmed expression and correct fold of the wild-type and mutant E2 
Figure 2-14. Cell surface and intracellular expression of E2715 in D. 
melanogaster S2 cells. Cells were induced to express protein for 120 
hours and protein expression in 1 x 106 cells measured by flow 
cytometry. Cells were either surface stained (left-hand column) or 
intracellularly stained (middle column) with the E2-specific MAb AP33 
(10 ȝg/ml). Wild-type cells (top row) were compared to cells expressing 
E2715HATM. Cells binding the specific MAb are enclosed within a region. 
Percentage of cells staining with the desired MAb are show in the 
bottom right-hand corner. A mock staining control was included (right-
hand column). 
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Figure 2-15. Expression of different E2 constructs on the surface of D. 
melanogaster S2 cells. Cells were induced to express protein for 120 
hours and  protein expression in 1 x 106 cells measured by staining with 
the linear-dependent MAb AP33 (left-hand column) or the conformation-
dependent MAb H53 (middle column). Cells binding the specific MAb 
are enclosed within a region. Percentage of cells staining with the 
desired MAb are show in the bottom right-hand corner of the dot-plot. A 
mock staining control was included (right-hand column).   
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proteins, protein expression was tested with a panel of MAbs whose binding 
characteristics are well described.  The ability of the MAbs to bind the different 
protein constructs was tested by ELISA (Figure 2-16) and flow cytometry 
(Figure 2-17).  AP33, which recognises a linear epitope within E2 (Owsianka 
et al., 2005; Tarr et al., 2006), was able to bind to all three protein constructs 
expressed in D. melanogaster S2 cells (Figure 2-16 and 2-17).  The increased 
binding of AP33 to E2715G530A and E2715D535A relative to E2715HATM 
(Figure 2-16) was consistently seen (and found to be significant) and may be 
due to an increased exposure of the AP33 epitope caused by the introduction of 
alanine substitutions at residues 530 and 535.  Binding of H53 to all protein 
constructs (Figure 2-16 and 2-17) confirmed previous observations that the 
surface-expressed proteins are correctly folded.  According to the flow 
cytometry data there was a slight reduction in H53 binding to E2715D535A 
compared to E2715HATM (mean FI= 159.6 vs. 105.4)(Figure 2-17).   
Figure 2-16. MAb reactivity to different E2 constructs expressed in D. 
melanogaster S2 cells. GNA-capture ELISA of cell lysates from 1 x 106 
cells was performed with a panel of MAbs recognising linear and 
conformation-dependent epitopes. Results are given as percentage 
binding relative to a genotype 1a, sE2650 protein control. Error bars were 
calculated from the standard deviation of three assay replicates. One 
ZD\ $129$ ZDV SHUIRUPHG ZLWK 7XNH\¶V PXOWLSOH FRPSDULVRQ WHVW
Significant differences, P <0.05 are shown; * P = 0.01-0.05, ** P = 
0.001-0.01, *** P= <0.001. 
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This may indicate a role for D535 in the epitope bound by H53 although this 
has not been reported previously.  Alternatively, this may have been caused by 
the experimental set up whereby the same number of cells are counted and 
stained but not all cells will express protein, leading to different levels of 
antibody binding.  AR2A recognises a discontinuous epitope within E2 that 
does not include the amino acid residues G530 and D535 (Law et al., 2008) 
and should therefore bind to all protein constructs.  As expected, binding of 
AR2A to all proteins was observed (Figure 2-16 and 2-17) providing further 
evidence that the proteins were correctly folded.  MAbs 1:7 and AR3A 
recognise a conformation-sensitive epitope which includes residues G530 and 
D535 (Johansson et al., 2007b; Law et al., 2008).  Previous studies have shown 
Figure 2-17. MAb binding to D. melanogaster S2 cells expressing 
different E2 constructs. Cells were induced to express protein for 120 
hours and 1 x 106 cells stained individually with MAbs AP33, AR2A, 
H53, AR3A or 1:7. Each histogram shows binding of a specific MAb to 
wild-type S2 cells (black), E2715HATM (red), E2715G530A (yellow) and 
E2715D535A (green) expressing cells. Mean FI was calculated for each 
histogram using Weasel v3.0 software and is given in arbitrary units. 
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that amino acid substitution at these sites severely impairs or abolishes 
antibody binding to E2 (Johansson et al., 2007b; Law et al., 2008).  As 
predicted there was a reduction in AR3A and 1:7 binding to E2715G530A and 
E2715D535A relative to binding to E2715HATM (Figure 2-16 and 2-17).  The 
ELISA data showed 22.3% AR3A binding to E2715HATM (relative to the 
positive control), reduced to 2.5% binding to E2715G530A and 7.4% binding to 
E2715D535A.  Using a one-way ANOVA, both differences were significant    
(P <0.05) (Figure 2-16).  MAb 1:7 binding to E2715HATM was 26.8% of that 
observed for the positive control.  This was reduced to 5.78% for E2715G530A 
and was completely abolished for E2715D535A (less than 0%).  Both of these 
observations were found to be significant (P <0.05) (Figure 2-16).  The D535A 
mutation reduced binding of 1:7 to E2 to a greater extent than the G530A 
mutation.  This is in agreement with the observations made by Johansson et al. 
(2007).  Although 1:7 binding to E2715D535A was completely abolished 
according to the ELISA data (Figure 2-16), flow cytometric analysis indicated 
some residual binding to the D535A mutant protein (Figure 2-17) (E2715D535A 
mean FI = 48.7 vs S2 cells mean FI = 37.7).  This may have been caused by the 
different protein preparations used, with cell-surface expressed protein 
maintaining some residual binding activity not seen in the cell lysates.  The use 
of cell lysates in the ELISA may also explain the fluctuating patterns of MAb 
binding to different protein preparations.  If different cell lysates contained 
different numbers of protein-expressing cells, the relative amounts of protein 
would have varied.  Unfortunately the protein content of each preparation was 
not quantified; however it is important to note that the same patterns of 
antibody binding were observed across at least three repeat experiments using 
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different cell lysate preparations.  According to the flow cytometry analysis of 
surface expressed protein, binding of AR3A to the mutant constructs 
E2715G530A and E2715D535A was abolished.  The fluorescence intensity 
values of 53.5 and 53.3 respectively were similar to the values obtained for 
wild-type E2715HATM (Figure 2-17).  However, this data does also highlight 
that AR3A binding to the wild-type protein was poor, with fluorescent intensity 
values lower than for any other MAb.  This may have been due to inefficient 
detection of the fluorescently-labelled MAb preparation that was used and 
indeed similar results were observed throughout.  This is discussed further in 
section 2.5.  However, taken together this data provided the necessary proof-of-
principle that cell-surface display of E2 on D. melanogaster S2 cells can be 
used to map antibody-binding residues within the glycoprotein. 
 
2.4.2.5 Generation of an E2 random-mutation display library in     
D. melanogaster S2 cells 
 
   A randomly mutated pMT::H77 library plasmid pool was isolated from E. 
coli XL10 cells and subsequently used to transfect D. melanogaster S2 cells.  
The resulting transfectants were termed the H77 library.  Stable transfection 
and expression of the E2 library was confirmed by Western blot analysis with 
AP33 (Figure 2-13).  Expression of E2 on the cell surface of the random 
mutant library and correct fold of the protein was determined by flow 
cytometry using the MAbs AP33, AR3A, AR2A and H53 (1ȝJPO (Figure 
2-18).  AP33 binding demonstrated that protein was expressed at the cell 
surface.  AP33 and H53 bound the library-expressing cells at a similar level 
(34.94% vs. 35.28%) suggesting that the cells expressed correctly folded E2.  
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Figure 2-18. Expression of a randomly mutated E2715 (H77) library on the surface of D. melanogaster S2 cells. Cells 
were induced to express protein for 120 hours and protein expression in 1 x 106 cells measured by staining individual 
cell aliquots with MAbs AP33, AR3A-A488, H53 or AR2A-A647. Cells binding the specific MAb are enclosed by a 
region and the percentage of cells given above. Wild-type S2 cells were included as the negative control (top panel). 
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However, the amount of protein expressed by the H77-library expressing cells 
appears to be lower than levels of E2715HATM expression (34.94% vs. 62.41%, 
Figure 2-18 and 2-15).  This may be due to the transfection process which 
relies upon co-transfection of pMT and pCoBlast and may result in cells 
transfected with pCoBlast alone.  Binding of AR2A and AR3A was observed 
but at a lower level than AP33 or H53 binding.  This may be due to a lower 
affinity of the MAbs for surface-expressed E2.  Alternatively, the process to 
directly label the MAbs may have been inefficient.  This could result in 
unlabelled MAb binding to the cells that cannot be detected, thereby reducing 
the fluorescent detection of these cells.  However, this provided enough 
evidence that the H77 library is able to express correctly folded E2 and can 
bind to DOOµWHVW¶0$EV 
   Protein expression was subsequently tested on both E2715HATM-expressing 
cells and the H77 library-expressing cells using the directly labelled MAbs 
AR3A-A488 and pooled AR2A-A647 plus H53-A647 (Figure 2-19).  All 
MAbs bound to the cell confirming the presence of surface expressed protein.  
The combined level of H53 plus AR2A binding to H77 library-expressing cells 
(20.7%) was lower than the level of binding observed previously with 
individual antibodies (35.28%, H53; 23.19%, AR2A, Figure 2-18).  Again, this 
may be due to the presence of inefficiently labelled MAb that cannot be 
detected.  Some non-specific labelling of H53 was also observed suggesting 
that un-conjugated fluorescent dye was present in this antibody preparation.  
Reducing the number of washes during the staining protocol did not improve 
MAb binding, nor did increasing the concentration of antibody used.   
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2.4.2.6 Maintaining the effective size of the randomly mutated H77 
library 
 
   To ensure that the diversity of the library was maintained following 
transfection into D. melanogaster S2 cells, stably transfected cells were 
screened and sequenced.  The diversity of the plasmid contained within the 
E.coli XL10 cells was also assessed by sequencing after resurrection of the 
glycerol stock.  The results suggested that the frequency of mutation and the 
number of distinct sequences within the library were similar to those reported 
in Table 2-3.  Therefore, storage and resurrection of the plasmid pool and 
Figure 2-19. Binding of pooled directly labelled MAbs to the surface of 
D. melanogaster S2 cells expressing E2715HATM or the H77 library. 
Cells were induced for 120 hours and protein expression in 1 x 106 cells 
measured by flow cytometry. Binding of AR3A-A488 alone is shown in 
the top row. Binding of pooled H53-A647 and AR2A-A647 are shown in 
the bottom row. The percentage of cells staining with each antibody is 
give in the bottom right-hand quadrant. Wild-type S2 cells were included 
as negative control (left-hand column) and provided the baseline for 
gating positive cells. Cells were gated on forward scatter vs. side 
scatter. 
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transfection into insect cells did not appear to alter the diversity of E2715 within 
the H77 library.   
   In order to maintain the diversity of the library, it was important to consider 
transfection efficiency and protein expression levels.  Transfection of             
D. melanogaster S2 cells with a green fluorescence protein (GFP)-containing 
plasmid indicated that transfection efficiency was approximately 25% (Figure 
2-20).  Transfection was carried out on 5 x 106 cells; therefore between 7.5 x 
105 and 1.25 x106 cells should be transfected with the pMT plasmid.  This 
provides an excess of cells for transfection of a library size of 1 x 104.   
The transfection protocol uses 2 µg plasmid, or 3.95 x 1011 copies of plasmid 
(Staroscik, 2004); therefore each plasmid variant should be represented 
multiple times over.  Finally, it was important to consider levels of protein 
expression within the library.  Based on AP33 and H53 binding to the H77 
Figure 2-20. Efficiency of plasmid transfection into D. melanogaster S2 
cells. A pMT::GFP plasmid containing green fluorescence protein was 
transfected into 5 x 106 cells. GFP was measured in the fluorescein 
isothiocyanate (FITC) channel of a Beckman Coulter FC500 Flow 
Cytometer with 50,000 events captured. Fluorescence in untransfected, 
wild-type cells was used to assess background staining. The 
percentage of cells that do not fluoresce (falling within R1) is given in 
each dot plot. Approximately 25% of transfected cells fluoresce. 
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library, approximately 35% of cells expressed protein (Figure 2-18).  Provided 
therefore that a minimum of 3 x 104 cells were labelled and analysed, 104 cells 
would be recovered, sufficient to theoretically cover the entire library, if each 
amino acid is mutated once.  All protein analysis was carried out on 1 x 106 
cells to provide the greatest possibility of including all variant protein 
constructs contained within the library.  Considering that the effective library 
size (i.e. sequences that do not contain any stop codons or in-frame deletions) 
is 8701 (Table2-3), it was felt that sufficient cell numbers were transfected and 
analysed to allow for assessment of the total library. 
   
2.4.2.7 Sorting of loss-of-binding mutants expressed on                
D. melanogaster S2 cells 
 
   The use of D. melanogaster S2 cell-expressed E2 as a means of mapping 
antibody-binding residues was tested in an artificially mixed population of cells 
and in the H77 library.  The artificially mixed population consisted of 
E2715HATM-expressing cells and E2715D535A-expressing cells mixed at a 1:1, 
10:1 or 100:1 ratio.  Initial staining analysis was carried out to determine the 
parameters for gating and sorting in order to collect the cells of interest.  
Analysis of mixed cells at a 1:1 ratio with AR3A showed cells staining in the 
bottom right-hand quadrant of the dot-plot, while AR2A and H53 stained cells 
appeared in the top left-hand quadrant (Figure 2-21).  When the cells were 
stained with all MAbs simultaneously a small population was seen in the top 
left-hand quadrant.  This corresponds to those cells which were able to bind the 
conformation-sensitive MAbs, AR2A and H53, but which failed to bind the 
test MAb, AR3A.  This was therefore deemed to be the population of interest 
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Figure 2-21. Identification of a population of interest within a culture of D. melanogaster S2 cells. An artificially mixed population 
of cells as well as the H77 library were stained with combinations of directly labelled MAbs. Antibody binding was measured in 1 
x106 cells after 120 hours of protein expression. Wild-type S2 cells were included as negative control (left-hand panel) and 
provided the baseline for gating positive cells. Bottom left-hand quadrant; percentage of cells that do not bind antibody. Bottom 
right-hand quadrant; percentage of cells staining with AR3A-A488 only. Top left-hand quadrant; percentage of cells binding 
AR2A-A647 and H53-A647 only. Top right-hand quadrant; percentage of cells binding all MAbs. Cells were gated on forward 
scatter vs. side scatter. 
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for future sorting experiments and is more easily seen when designated as a 
region (Figure 2-21).  The same population of cells in the top left-hand 
quadrant was also seen when H77 library-expressing cells were tested with 
pooled MAbs (Figure 2-21).  Repeat analysis of the H77 library-expressing 
cells produced similar results, with the population of interest ranging between 
1.00% and 2.50% of the total cell population (Figure 2-22a). 
   Mixed populations of cells at a 1:1, 10:1 or 100:1 ratio were tested to see if 
the population of cells gated in the top left-hand quadrant decreased as the 
number of E2715D535A cells decreased.  As expected, there was a decrease in 
the percentage of cells staining positive for H53 and AR2A but negative for 
AR3A as the ratio of E2715D535A cells decreased (Figure 2-22b).  Data from 
two separate experiments showed a similar trend with cells mixed at a 1:1 ratio 
producing the largest population of gated cells.  Fewer cells were observed in 
the region of interest for cells mixed at a 10:1 ratio with even fewer cells 
observed for cells at a ratio of 100:1 (Figure 2- 22b).  Despite this overall 
trend, the percentage reduction in cells within the region of interest did not 
precisely correlate with the ratio of cells in the artificially mixed population.  In 
Figure 2-22b (top row), the population of interest in the 1:1 mixed culture 
accounts for 2.87% of the total.  The population of interest in the 10:1 mixed 
culture is 0.25% of the total.  This 10-fold reduction correlates well with a 10-
fold reduction in the number of E2715D535A cells; however the population of 
interest in the 100:1 mixed culture accounts for 0.20% of the total.  This is very 
similar to the percentage of cells observed in the 10:1 mixed culture and is also 
approximately 10-fold lower than the percentage of cells observed in the 1:1 
mixed culture.  This could be caused by non-specific staining of cells leading 
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Figure 2-22. Measuring the size of a population of interest within a culture of D. melanogaster S2 cells. Cells were stained with 
pooled directly labelled MAbs. Antibody binding was measured in 1 x106 cells after 120 hours of protein expression. Population of 
interest (AR2A/H53 positive and AR3A negative) is highlighted by a region and percentage of cells in each region given in the top 
left-hand corner. Cells were gated on forward scatter vs. side scatter. (a) H77 library-expressing cells. Panels correspond to two 
separate experiments. (b) Artificially mixed populations of E2715HATM-expressing cells and E2715D535A-expressing cells at 1:1, 10:1 
or 100:1 ratio. Each row corresponds to two separate experiments. 
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to false positives, thereby increasing the number of cells within the population 
of interest.  Indeed the position of the gate in Figure 2-21 (panel 1) shows 
0.52% of wild-type S2 cells staining in the top-left hand quadrant.  This value 
may fluctuate meaning that cells from a 100:1 culture staining in this quadrant 
are likely to be composed largely of false positive cells.  It is also important to 
bear in the mind the different expression levels observed between E2715HATM 
and E2715D535A expressing cells; therefore a mixed culture based on cell 
number will not correlate precisely with the amount of protein present.  As 
approximately 40-45% of E2715D535A cells expressed protein (Figure 2-15), at 
a ratio of 100:1, very few E2715D535A-expressing cells would be stained and 
sorted into the population of interest.  A similar pattern was observed in Figure 
2-22b (bottom row), with an overall trend towards a decreasing population of 
interest but discrepancies between the precise figures.  The 10:1 mixed culture 
has a population of interest of 1.00%, a reduction of approximately one third 
compared to the 1:1 mixed population (3.44%).  The 100:1 mixed culture has a 
population of interest of 0.75%, approximately 4.5-fold lower than the 
population observed for the 1:1 mixed culture.  Again these discrepancies are 
probably caused by non-specific antibody binding leading to false positives 
within the region of interest and ambiguities in the actual amount of protein 
present.  This data does still provide evidence that D. melanogaster S2 cells 
expressing E2 on their cell surface can be selected and sorted on the basis of 
antibody binding. 
   Once the population of interest had been identified, the cells were sorted in 
bulk into 96-well tissue culture plates for continued culture and expansion, or 
individually into 96-well PCR plates for PCR and sequence analysis. 
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2.4.2.8 Expansion of sorted cells 
   D. melanogaster S2 cells do not grow well when seeded at a density below 5 
x 105 cells/ml (or 500 cells/µl).  This presents a problem when sorting small 
populations of cells as the loss-of-binding mutant may represent only a tiny 
fraction of the total library population.  The volume of media into which cells 
are seeded is also limited by the rate at which the media evaporates in the 
incubator.  Expanding very small numbers of cells is difficult and early 
experiments were hampered by the low number of cells that were sorted and 
the inability to keep them alive thereafter.  It was therefore necessary to bulk 
sort all cells into a 96-well plate containing 500 cells/µl of wild-type              
D. melanogaster S2 cells to provide a sufficient cell density for the cells to 
survive and grow.  With this method it was possible to keep sorted cultures of 
cells alive for several weeks and expand them into larger culture vessels.  
There were however, issues with contamination, despite the use of Penicillin-
Streptomycin in the wash buffer and culture media, and several cultures were 
lost in the early days post-sorting.  Plate-based culturing and microscopic 
analysis of the bacterial contaminant indicated a Pseudomonas spp. which may 
have been introduced in the sheath fluid contained within the flow cytometer.  
The sheath fluid was subsequently autoclaved prior to use which largely solved 
the problem, however observation of strict aseptic technique was essential to 
ensure survival of the cultures.  The sorted cultures were also very sensitive to 
seeding at a low density and the addition of too much media, even after several 
days¶ growth.  Only one culture of sorted cells was maintained long enough for 
re-sorting to be attempted.  This was from an artificially mixed population of 
cells seeded at a 100:1 ratio (E2715HATM:E2715D535A) from which the 
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population of interest had been sorted (Figure 2-22b).  These cells were 
cultured with wild-type D. melanogaster S2 cells for 3 weeks and expanded 
prior to selection with Blasticidin S (25 µg/ml) for 2 weeks.  Repeat sorting 
showed that a higher percentage of cells were now staining within the 
population of interest, 1.30% vs. 0.20% (Figure 2-23), an increase of 650%, 
suggesting that the E2715D535A-expressing cells had been enriched within the 
total population.  Initial experiments had indicated that cells sorted from a 
100:1 ratio mixed culture were likely to contain a large number of false 
positives (Figure 2-22).  However, the ability to isolate a larger population of 
interest following expansion and re-sorting of cells demonstrates the 
importance of such iterative enrichment.   
Figure 2-23. Enrichment of a population of interest within a culture of D. 
melanogaster S2 cells by repeat sorting. An artificially mixed population 
of E2715HATM-expressing cells and E2715D535A-expressing cells were 
sorted for loss-of-binding to MAb AR3A (left-hand plot). The selected 
population was grown for 3 weeks and selected for a further 2 weeks. 
Cells were re-sorted for loss-of-binding to MAb AR3A (right-hand plot). 
Cells were stained with a pool of directly labelled MAbs. In both rounds 
of sorting, antibody binding was measured in 1 x106 cells after 120 
hours of protein expression. Population of interest is highlighted by a 
region and percentage of cells in each region given in the top left-hand 
corner. Cells were gated on forward scatter vs. side scatter. 
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Although this data does not represent large numbers of cells, it does indicate 
the potential value of such an approach, particularly if cells undergo several 
rounds of enrichment.  The staining patterns of the two cultures were slightly 
different; the sorted and enriched population stained less brightly (Figure 2-23) 
with higher forward scatter and side scatter values (data not shown), indicating 
that this culture was less healthy than the initial culture.  This may be caused 
by the presence of wild-type D. melanogaster S2 cells within the culture 
which, in the presence of blasticidin, would be dead or dying.  Prolonged 
exposure to the selective agent should remove all wild-type cells and continued 
culturing of the selected cells should result in a healthier population.   
 
2.4.2.9 Sequence analysis of sorted single S2 cells 
   Single cells were sorted from the H77 library and from mixed cultures of 
E2715HATM-expressing cells and E2715D535A-expressing cells at a 1:1 ratio.  
Cells were sorted into 96-well PCR plates and screened (Figure 2-24).  
Recovery rates of the E2715 PCR product ranged from 42% to 70%.  Recovery 
rates less than 100% may be due to failure of the flow cytometer to accurately 
deposit a single cell into each well, resulting in some empty wells.  It is also 
possible that random mutagenesis of the H77 library generated mutations 
within the primer binding sites preventing amplification of E2715.  It is also 
possible for cells to become transfected with the resistance plasmid pCoBlast 
only, resulting in blasticidin-resistant cells which do not express protein.  
These cells may be stained as false positives and deposited into the plate; 
however subsequent PCR analysis would fail to amplify E2715. 
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   PCR positive samples were sequenced to determine which mutations within 
E2715 might be responsible for the loss of antibody binding.  Any sequences 
that appeared to be derived from more than one template were discounted from 
the analysis.  As expected, 100% of samples (out of 10 samples sequenced) 
sorted from the artificially mixed population contained the D535A mutation.  
This mutation is known to abrogate AR3A binding; therefore within an 
artificial population containing wild-type E2715 and mutant E2715D535A only, 
cells no longer able to bind AR3A would be expected to contain the D535A 
mutation.  This provided further proof-of-principle that the insect cell display 
library could be used to map antibody-binding residues.  
   A total of 48 sequences isolated from the H77 library were analysed.  Table 
2-4 lists the mutations recorded and their frequency.  Most mutations appear 
only once; however, two mutations appear at high frequency within the 
samples tested.  These are L399I (81.6% of sequences) and C644R (85.7% of 
sequences).  Neither of these residues is critical for AR3A binding, according 
to previous analysis; however, L399 does fall within the first region forming 
the discontinuous epitope AR3 (AR3A spans aa396-424, aa436-447 and aa523-
540) (Law et al., 2008).  In previous studies this residue was not subject to 
Figure 2-24. Screening single D. melanogaster S2 cells for the 
presence of E2715. Representative agarose gel electrophoresis results 
showing products at approximately 1.1 kb. +, positive control (plasmid 
pMT::E2715HATM). -, negative control (no template). 
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Table 2-4. Mutations isolated from the H77 display library sorted for 
loss of reactivity to AR3A. Frequency is shown in parenthesis. 
Mutation Frequency (%) 
T396Q 1 (2.0) 
L399I 40 (81.6) 
W420R 1 (2.0) 
N423K 1 (2.0) 
C429R 1 (2.0) 
S473G 1 (2.0) 
Y489C 1 (2.0) 
G565A 1 (2.0) 
I571T 1 (2.0) 
G572R 1 (2.0) 
R596W 1 (2.0) 
C644R 42 (85.7) 
P664S 1 (2.0) 
S668T 1 (2.0) 
H691L 1 (2.0) 
D698V 1 (2.0) 
Y701F 1 (2.0) 
 
 
Y720F 1 (2.0) 
Y720H 1 (2.0) 
S725C 1 (2.0) 
alanine-scanning mutagenesis (Law et al., 2008) and it will be necessary to test 
its role in AR3A binding by carrying out antibody binding studies with E2 
containing isoleucine at position 399.  Isoleucine and leucine both contain 
aliphatic side chains and are hydrophobic in nature.  Such a conservative 
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mutation would not be expected to cause massive changes in the overall protein 
fold but may be sufficient to alter the affinity of the MAb for its epitope.  In all 
sequences containing isoleucine at position 399, mutation was due to a single 
point mutation from C to A (at nucleotide 46).  Isoleucine is a naturally 
occurring variant at residue 399 in some genotype 2a, 3, 4 and 6 sequences, 
according to the Los Alamos HCV sequence database.  The high frequency of 
this mutation within isolated sequences may be indicative of a crucial role in 
AR3A binding, although it may also be due to over-representation of this 
mutation within the library.  If this mutation were introduced early during the 
PXWDJHQHVLV SURFHVV LW PD\ KDYH EHFRPH µIL[HG¶ ZLWKLQ WKH OLEUDU\ and its 
importance in AR3A binding to E2 may be overstated. 
   The residue C644 does not lie within the AR3 discontinuous epitope nor is it 
involved with AR3A or CD81 binding.  It does however form a disulphide 
bond with the cysteine residue at position 607 (corresponding to the eighth 
disulphide bond), according to the recently described E2 structure (Krey et al., 
2010).  Introduction of arginine at position 644 would abolish the disulphide 
bond and, as such, this mutation would be expected to alter the overall fold of 
the protein.  However, staining by the conformation sensitive MAbs AR2A and 
H53 (Figure 2-22a) indicated that this protein was correctly folded.  A recent 
study by McCaffrey et al., (2012) showed that although H53 reactivity was 
abolished by replacement of C644 with an alanine residue in the context of 
HCVpp, in sE2661 H53 binding was maintained, albeit reduced (to 25-75% of 
wild type).  In both cases this mutation prevented E2 binding to CD81-LEL 
(McCaffrey et al., 2012).  This mutation may therefore influence CD81, and 
consquently also AR3A binding, by altering the overall presentation of the 
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discontinuous CD81 and AR3 epitope.  This would need to be further 
investigated by testing AR3A binding to E2 containing arginine at position 
644.  The lower levels of conformational antibody binding to the cysteine 
mutant in the study by McCaffrey et al., may be caused the use of an alanine 
replacement.  Alanine is a smaller amino acid than the arginine residue 
observed in our mutants and may result in larger conformational changes to the 
protein.  This study also tested the combined binding of two conformation-
sensitive MAbs targeting different epitopes.  It is also worth noting that all 
sequences containing the C644R mutation (except one) also contain one 
additional mutation within the first AR3 epitope, (Table 2-5) raising the 
possibility that this mutation does not function directly in AR3A binding and is 
simply over-represented in the library. 
Table 2-5. Combinations of mutations in isolated library sequences 
Mutated residues within sequenced E2715HATM Frequency (%) 
L399I, C644R 36 (73.5) 
I571T, S668T 1 (2.0) 
T396Q, C644R 1 (2.0) 
L399I, G565A, C644R 1 (2.0) 
L399I, C644R, P664S 1 (2.0) 
L399I, G572R, C644R 1 (2.0) 
L399I, C644R, L720H 1 (2.0) 
W420R, N423K, C429R S473G, Y489C 1 (2.0) 
H691L, D698V, Y701F, Y720F, T722S, S725C 1 (2.0) 
 
 
C644R 1 (2.0) 
R596W 1 (2.0) 
No mutations 3 (6.1) 
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   The mutations T396Q, W420R and N423K are located within the AR3 
discontinuous epitope (Law et al., 2008) and may therefore reduce the affinity 
of AR3A binding.  These mutations only appear once each within the isolated 
sequences.  The mutations W420R and N423K appear within the same 
sequence (Table 2-5) and it is possible that they have an additive effect on 
AR3A binding.  Mutations within AR3 would be expected to be recovered at a 
higher frequency as they should have the greatest impact on AR3A binding.  
The low frequency of such mutations may be due to the relatively small 
number of sequences that were analysed.  The mutation at N423 is unusual as it 
knocks out the second N-linked glycan of E2.  Binding of AR2A and H53 
indicated that this protein was correctly folded (Figure 2-22a), an observation 
supported by previous studies showing that E2 lacking the N-linked glycan at 
position 423 is immunoprecipitated by H53 (Goffard et al., 2005).  This 
mutation was reported to reduce binding of AR3A to E2, albeit at an 
intermediate level (Law et al., 2008).  It is therefore not surprising that this 
mutation should have been isolated and demonstrates the utility of this method 
in identifying residues involved, indirectly at least, in MAb binding. 
   Residues T396 and L399 both fall within HVR1.  Although this encompasses 
part of AR3, these residues have not been directly implicated in the binding of 
AR3A to E2 (Law et al., 2008).  The position of these residues in HVR1 and 
their possible role in AR3A binding is potentially interesting.  MAb AR3A has 
been demonstrated to interfere with CD81 binding to E2 (Law et al., 2008), 
whereas HVR1 has been implicated in binding to SR-BI (Bartosch et al., 
2003c; Scarselli et al., 2002).  It is tempting to speculate that AR3A binding to 
these residues may interfere with HVR1-SR-BI interactions.  However, further 
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studies would be needed to test if AR3A really could play a role in inhibiting 
SR-BI binding to E2. 
   The cysteine at residue 429 forms a disulphide bond with the cysteine residue 
at position 552, corresponding to the first disulphide bond (Krey et al., 2010).  
Replacement of this cysteine with arginine would abolish the disulphide bond.  
The study by McCaffrey et al. (2012) found that mutation of C429 to alanine 
reduced H53 binding to E2 in the context of HCVpp but had no effect on 
binding to sE2611.  This discrepancy may have been caused by the different 
forms of E2 tested.  In both contexts, the C429A mutation abolished binding to 
CD81-LEL (McCaffrey et al., 2012).  This is consistent with the location of 
disulphide 1 within DI of E2, which also contains the majority of CD81 
binding determinants (Krey et al., 2010).  This cysteine residue falls between 
two discontinuous epitopes forming AR3 and within a known CD81 binding 
region.  Therefore it may alter the whole antigenic region preventing or 
reducing both AR3A and CD81 binding. 
   The remaining E2 mutations (S473G, Y489C, G565A, I571T, G572R, 
R596W, P664S, S668T, H691L, D698V and Y701F) have not been extensively 
studied in the context of AR3A binding.  They do not fall within antigenic 
region 3, as identified by antibody competition studies (Law et al., 2008), nor 
are they involved in CD81 binding (Clayton et al., 2002; Drummer et al., 2006; 
Flint et al., 1999a; Owsianka et al., 2001; Owsianka et al., 2006).  Indeed 
residues P664, S668, H691, D698 and Y701 lie within a region of E2 that is 
often excluded from studies relying upon truncated sE2661.  As such they 
present an intriguing set of residues for further investigation.  The majority of 
the substitutions within E2 are non-conservative and as such would be 
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expected to alter the structure of the protein, thereby reducing AR3A binding.  
A cluster of mutations around residues 565 to 571 may indicate the position of 
another region involved in AR3A binding and could be of interest for further 
study. 
   The mutations Y720F, Y720H and S725C occur within the HATM tag.  
Mutations within the tag are possible due to the nature of the random 
mutagenesis method.  These mutations may alter anchoring of E2715 within the 
cell membrane and reduce levels of expression at the cell surface; however any 
cells carrying deleterious mutations would most likely be removed from further 
analysis as they fail to generate surface expressed protein.  Such mutations 
should not interfere directly with the ability of AR3A to bind E2715, and all 
sequences containing mutations within the HA tag were found to contain other 
mutations within E2715 responsible for loss of binding (Table 2-5). 
   Table 2-5 shows the appearance of multiple mutations within the isolated 
sequences.  The majority of sequences contained one or two mutations and 
none of the 49 sequences contained a stop codon or in-frame deletion.  This is 
in line with the statistical assessment of the library size and diversity (Table 2-
3) which was designed to reduce the frequency of such mutations.  Only three 
sequences were found to contain no mutations.  These were clearly among the 
false positive staining cells and again highlight the importance of iterative 
enrichment of a population of interest.  Six sequences were found to contain 
three or more mutations.  Sequences containing large numbers of mutations are 
not desirable for mapping studies as the process of identifying the important 
mutations becomes more difficult.  It is likely that only one of the mutations 
within each of these sequences is responsible for loss-of-binding but each 
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residue would need to be investigated individually.  However, the presence of 
mutations W420R, N423K and C429R in the same sequence is potentially 
interesting.  The close proximity of these residues suggests they form part of 
the AR3A epitope and have an additive effect on AR3A binding; indeed W420 
and N423 have already been postulated to form part of AR3 (Law et al., 2008).  
Similarly the presence of H691L, D698V and Y701F in the same sequence 
may indicate the presence of a novel epitope involved in AR3A binding.  
 
2.4.2.10 Failure of the UKN2B1.1 library 
   Initially it was hoped that a randomly mutated display library could be 
generated in a genotype 2b E2715 as well as genotype 1a.  To this end, the 
pMT::E2715HATM (UKN2B1.1) plasmid was successfully generated and stably 
transfected into D. melanogaster S2 cells.  Western blot analysis of protein 
expression with AP33 suggested that protein was produced in the E2715HATM 
(UKN2B1.1) transfected cells (Figure 2-25a).  However subsequent flow 
cytometry analysis of intracellular and cell-surface protein expression indicated 
that protein was not expressed as expected.  AR3A bound only around 1% of 
E2715HATM (UKN2B1.1) expressing cells regardless of whether staining was at 
the cell surface or intracellular (Figure 2-25b) suggesting that the protein was 
incorrectly folded.  To exclude the possibility that protein was not translocated 
to the cell surface, the sequence of the HATM domain within the E2715HATM 
(UKN2B1.1) construct was checked and contained no mutations that might 
have reduced or abrogated cell-surface expression of E2.  There might however 
have been mutations within the BiP secretion signal contained within pMT, 
reducing the ability of the cell to translocate protein to the ER.  BiP targets 
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Figure 2-25. Expression of UKN2B1.1 E2715HATM in D. melanogaster S2 cells. a) Cell lysate from 1 x 106 cells was analysed by 
Western blot under reducing conditions using MAb AP33. Wild-type S2 cells served as negative control. sE2661 served as positive 
control. Molecular weight marker is shown in kDa. b) Cell-surface and intracellular protein expression after 120 hours in 1 x 106 cells 
measured by flow cytometry. Cells were intracellularly (left-hand column) or surface stained (right-hand column) with MAb AR3A. 
Wild-type cells (bottom row) are shown for baseline binding levels. Percentage of cells binding AR3A is shown. 
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proteins to the ER lumen and facilitates protein folding (Kirkpatrick et al., 
1995); therefore any reduction in BiP function may result in incorrectly folded 
protein.  This could explain how protein was produced and detected by AP33 
binding a linear epitope, as demonstrated by Western blot analysis, but could 
not be detected on or within the cell by the conformation-dependent MAb, 
AR3A.  Sequencing of the BiP secretion signal would be needed to confirm 
this hypothesis.  Alternatively, mutation of BiP could result in poor protein 
expression. However, due to time constraints it was not possible to repeat the 
flow cytometry with a MAb binding to a linear epitope, such as AP33, that may 
have resolved the issue of poor expression or incorrect folding.   
 
2.5 Discussion 
   Initially this project was designed with the Yeast display library system in 
mind.  It was intended that S. cerevisiae EBY100 cells would be used as the 
host for an E2 random mutant library.  This system was originally developed 
for the expression of antibody single chain Fv (scFv) fragments via the cell 
surface mating machinery of yeast (Boder & Wittrup, 1997).  It was found 
however, that only low levels of E2 expression could be obtained from            
S. cerevisiae EBY100 cells.  Expression levels, as assessed by Western blot, 
were considerably lower than either of the two controls (Figure 2-7).  
Hyperglycosylation of proteins is a common problem with yeast-expressed 
proteins; however Western blot analysis of the E2715(stop) protein indicated that 
it was not hyperglycosylated.  S. cerevisiae is capable of elongating the core 
oligosaccharide molecule, GlcNAc2-Man8, by the addition of up to 200 
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mannose residues, a phenomenon that occurs in the Golgi apparatus and is 
postulated to protect yeast glycoproteins excreted into the extracellular 
environment (Conde et al., 2004).  However, hyperglycosylation of E2 could 
result in incorrect folding of the protein (Goffard et al., 2005) and alter its 
immunogenicity (Falkowska et al., 2007).  The presence of a single band 
between 72 and 95 kDa (corresponding to E2715(stop) with the Aga2p fusion 
protein) and the absence of a large protein smear (Figure 2-7) would suggest 
that monomeric E2 is expressed at the cell surface.  E2715(stop) also appeared to 
be correctly folded as it bound the conformation-sensitive MAb H53 at a 
similar level to the MAb AP33, which recognises a linear epitope (Figure 2-
10).  Expression of the Aga2p protein from S. cerevisiae EBY100 cells was not 
enhanced by increasing the duration of protein induction (Figure 2-8) 
suggesting that the optimal conditions for expression were employed.  It is 
interesting to note that flow cytometry analysis of E2715(stop)-expressing cells 
with the anti-Xpress antibody showed much higher levels of surface staining 
(49.5%) than staining with the MAbs AP33 or H53 (16.6-22.7%) (compare 
Figure 2-9 and 2-10).  This demonstrates that protein was efficiently expressed 
in the cells but suggests a problem with E2 expression specifically.  The E2 
construct expressed in these cells contained a stop codon immediately 
downstream of the E2 glycoprotein (Figure 2-6).  Whilst this abolished the V5 
epitope and the poly-histidine tag preventing detection or purification via these 
tags, it should not affect the coding region of the Aga2p fusion protein or E2.  
Therefore, it was not expected that expression of E2 would be altered.  It is 
possible however that the addition of ~20 bp derived from pGEM-T Easy 
and/or the introduction of a stop codon altered the ability of the cells to process 
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and fold E2, thereby reducing its expression at the cell surface.  Western blot 
analysis of cell lysates to identify intracellular protein aggregates or 
intracellular staining for flow cytometry may have proved informative in this 
regard.  $OWHUQDWLYHO\ WKH0$7ĮWUDQVFULSWLRQ WHUPLQDWLRQUHJLRQ UHVSRQVLEOH
for polyadenylation of mRNA, may have been altered.  If this were the case 
however, it would be expected to reduce expression of all protein, not just the 
E2715(stop) region of the fusion protein. 
   The Yeast display library system has been successfully used to express and 
characterise antibody binding to the envelope glycoproteins of WNV (Oliphant 
et al., 2005) and DENV (Sukupolvi-Petty et al., 2010; Sukupolvi-Petty et al., 
2007).  The envelope proteins (E) of these viruses are well studied and their 
crystal structures have been determined.  Both the WNV and DENV E proteins 
are class II fusion proteins, with a three domain architecture (DI, DII and DIII) 
(Modis et al., 2003; Nybakken et al., 2006), analogous to the structure 
proposed for E2 (Krey et al., 2010).  The DENV E ectodomain (117 or 292 
amino acids) used in mapping studies was smaller than the HCV E2715 
ectodomain (332 amino acids) used in our library.  The larger WNV E 
ectodomain (415 amino acids) was successfully expressed in yeast cells; 
however the WNV E protein is less highly glycosylated, containing only one 
N-linked glycan (Nybakken et al., 2006).  The DENV E is also less highly 
glycosylated, containing just two N-linked glycans (Modis et al., 2003), 
compared to the 11 potential N-linked glycans within HCV E2 (Goffard et al., 
2005).  The DENV and WNV E proteins each contain just six disulphide bonds 
(Modis et al., 2003; Nybakken et al., 2006), whereas E2 contains nine (Krey et 
al., 2010).  This smaller size and reduced complexity of the E proteins may 
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facilitate their expression within the yeast cells.  More recently the Yeast 
display system has been successfully adapted for expression of the HCV E2 
protein (Sabo et al., 2011).  This was achieved using a more truncated version 
of the H77 E2 ectodomain, E2660, resulting in the removal of one disulphide 
bond.  A smaller E2 construct may therefore be necessary for successful 
expression within yeast cells.  This does however limit the scope of any 
mapping carried out with such a library.  The main advantage of such systems 
is the ability to interrogate the whole protein simultaneously and to map 
antibody-binding epitopes in any part of the protein without prior knowledge of 
potential binding sites.  By removing the C-terminal 56 amino acids, any 
antibodies binding to this region could not be mapped. 
   This experiment does highlight the importance of checking the quality of any 
protein construct used in mapping studies.  Although the data showed that 
E2715(stop) expressed at the cell surface was largely correctly folded (Figure 2-
10), the overall levels of expression were poor.  Use of poorly or incorrectly 
folded protein could result in the mistaken identification of loss-of-binding 
mutants.  The recent paper by Sabo et al. (2011) did not check the fold of 
yeast-expressed E2 using a conformation-sensitive MAb such as H53.  An 
oligoclonal pool of MAbs was used to test for cell-surface expression of E2; 
however this does not guarantee that the expressed protein is correctly folded, 
particularly as the pool of MAbs used was derived from mouse hybridomas and 
was largely uncharacterised.  As discussed in Edwards et al. (2012), most 
neutralising mouse MAbs target linear epitopes within E2 restricting their use 
as determinants of protein fold.  The E2 construct used by Sabo et al. was 
truncated at residue 660 which abolishes the final disulphide bond within E2 
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and, according to the recent E2 model (Krey et al., 2010) OHDYHV D µVSDUH¶
cysteine residue unable to bind with its partner residue.  This may make this 
construct particularly vulnerable to mis-folding.  Correct fold of the yeast-
expressed E2 would need to be confirmed before the system could be widely 
adopted for mapping studies.   
   In attempting to develop a Yeast display library, the limiting factor was 
found to be the cloning method.  Several variations of the cloning method were 
attempted including the use of different restriction sites, amplification of E2715 
from different strains or even different genotypes of HCV and the use of 
subcloning from an intermediate vector.  Despite this, cloning continued to be 
problematic and ultimately resulted in the generation of a sub-standard 
construct, pYD1::E2715(stop).  Poor cloning efficiency is likely to limit the size 
of the library generated and therefore the decision was taken to abandon this 
display library and instead to focus on the development of an insect cell display 
library. 
   D. melanogaster S2 cells have been used to express a number of different 
proteins such as Igs (Johansson et al., 2007a; Kirkpatrick et al., 1995) and viral 
glycoproteins (Ivey-Hoyle & Rosenberg, 1990) including the HCV E2 
ectodomain from different viral genotypes (Krey et al., 2010).  Therefore the 
decision was made to generate a display library comprising amino acids 384-
715 of E2, enabling us to study the entire ectodomain.  E2715 was successfully 
amplified from the H77 (genotype 1a) strain and UKN2B1.1 (genotype 2b) 
strain of HCV and adapted to cell surface display by fusion to the HA 
transmembrane region.  Generation of an E2715HATM (UKN2B1.1) construct 
was not successful (Figure 2-25).  Despite detecting protein by Western blot 
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with AP33, flow cytometry using AR3A could not detect cell-surface or 
intracellular E2.  This suggested that E2715HATM (UKN2B1.1) was incorrectly 
folded although it is feasible that mutation to the BiP secretion signal within 
the plasmid may have reduced protein expression; however due to time 
constraints this could not be further investigated.  In contrast, expression of the 
E2715HATM (H77) construct showed that the protein was expressed on the 
surface of D. melanogaster S2 cells and was correctly folded (Figure 2-14 and 
2-15).  The level of E2715HATM expression in the D. melanogaster S2 cells was 
considerably higher than that observed in the S. cerevisiae EBY100 cells.  
When comparing AP33 binding, only 16.61% of S. cerevisiae EBY100 cells 
expressing E2715(stop) stained positive, whereas 62.41% of D. melanogaster S2 
cells expressing E2715HATM (H77) stained positive (Figure 2-10 vs. 2-15).  
This strongly indicated that insect cell expression would provide a better 
platform in which to develop a display library.  To test the utility of the system 
for mapping antibody epitopes, a reverse genetics approach was adopted 
whereby known antibody-binding residues were replaced with alanine and the 
resulting mutants subjected to antibody binding studies.  The mutated residues, 
G530A and D535A, are critical for binding of MAb AR3A to E2 (Law et al., 
2008).  As expected E2715HATM carrying these mutations were no longer able 
to bind AR3A (Figure 2-16 and 2-17) demonstrating that antibody epitopes 
could be mapped by isolating and identifying loss-of-binding mutants.  
Crucially for mapping studies, E2715HATM (H77) expressed in D. melanogaster 
S2 cells was correctly folded, as demonstrated by the binding of the 
conformation-sensitive MAb H53 to all protein constructs (Figure 2-15).   
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   The random mutant library was generated in the E2715HATM (H77) 
background and termed the H77 library.  The EZClone random mutagenesis 
method did have the potential to introduce mutations into the HATM tag, and 
indeed sequencing analysis showed this to be the case (Table 2-4).  It was not 
considered to be too detrimental to the overall function of the library, however, 
due to the small size of the tag (37 amino acids) relative to the E2 ectodomain 
(332 amino acids).  Any mutations within the HATM tag that knocked out cell 
surface attachment or affected the fold of E2 would be unable to bind the 
pooled conformation-sensitive MAbs and would simply be removed from any 
further analysis.  Three mutations within the HATM tag were found in 
sequences sorted from the H77 library; Y720F, Y720H and Y725H (Table 2-
4).  These mutations were all found in sequences containing additional 
mutations within the E2 ectodomain (Table 2-5) which could account for the 
loss-of-binding phenotype. 
   The H77 library was not expressed in the D. melanogaster S2 cells as 
strongly as the E2715HATM (H77) construct.  AP33 binding to both cell types 
showed 62.41% of E2715HATM (H77)-expressing cells staining positive 
compared to just 34.94% of H77 library-expressing cells (Figure 2-15 and 2-
18).  This may be due to differences in the transfection efficiency when 
generating stable cell lines.  This co-transfection method results in arrays of 
E2715HATM of between 500 and 1000 repeats inserted into the Drosophila 
genome (Anon., 2003).  The exact number of repeats is difficult to control and 
therefore levels of protein expression may vary.  The nature of the co-
transfection method may also result in cells becoming transfected with 
pCoBlast only.  These cells are blasticidin resistant but do not express the 
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protein of interest and therefore have a growth advantage over those cells 
expressing E2.  A greater proportion of pCoBlast-only cells may have been 
generated during the H77 library transfection resulting in a higher number of 
cells unable to express E2.  This phenomenon has been highlighted previously 
within the Drosophila expression system and may be overcome with the use of 
a single plasmid containing both the selection marker and the gene of interest.  
Such a plasmid utilising puromycin resistance has been generated and 
transfection with this single plasmid results in similar levels of protein 
expression as co-transfection with two separate plasmids (Iwaki & Castellino, 
2008).  Slightly reduced antibody binding to the H77 library would also be 
expected due to the presence of mutations within the antibody-binding epitope.  
Despite the lower levels of E2 expression, it is important to note that the level 
of AP33 and H53 binding to the H77 library was similar (Figure 2-18) 
suggesting that the expressed protein was correctly folded. 
   The ability to isolate a population of interest based on antibody binding was 
tested with the H77 library and an artificially mixed population of cells 
expressing wild-type and mutant (D535A) proteins.  The population of interest 
was characterised as staining positive for the pooled MAbs (H53 and AR2A) 
but negative for the test MAb (AR3A) and was positioned in the top left-hand 
quadrant of the dot-plot (Figure 2-21).  As expected, the percentage of cells 
falling within this region decreased as the number of E2715D535A mutant cells 
decreased (Figure 2-22b).  This reduction did not correlate precisely with the 
changing ratio of wild-type to mutant cells, possibly due to false-positive 
staining of some cells.  The overall trend however was encouraging and 
strongly suggested that a minor population of cells could be sorted on the basis 
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of antibody binding.  Sorting of the H77 library-expressing cells (and the 
artificially mixed populations) resulted in only a small percentage of cells in 
the region of interest (Figure 2-22a).  This was disappointing but may be 
improved by small alterations to the experimental protocol.  Firstly the MAbs 
used were directly labelled with Alexa fluorophore conjugates.  Comparison of 
H77 library staining with unlabelled and labelled H53 suggests that MAb 
labelling is <100% (Figure 2-18 vs. 2-19), resulting in false negatives as cells 
expressing protein bind unlabelled H53 but do not fluoresce.  The labelling 
process is sensitive to antibody concentration and requires the use of very pure 
MAb.  Labelling may be improved by using a MAb preparation at a higher 
concentration or labelling the same preparation twice to increase the chance of 
each MAb molecule carrying at least one fluorescent dye molecule.  Improving 
the labelling of these antibodies could increase the percentage of cells stained 
and thereby greatly enhance the sensitivity of the assay to isolate loss-of-
binding mutants.  Secondly, it is clear that stable transfection of                      
D. melanogaster S2 cells does not result in 100% protein expression.  The 
percentage of cells expressing protein ranges from ~35% for the H77 library to 
~60% for E2715HATM (H77).  Therefore there will always be a considerable 
percentage of cells which cannot be used for antibody mapping, but which may 
have a selective growth advantage.  It would therefore be extremely 
advantageous to enrich these stable cell lines for cells which do express E2.  
This could be done prior to mapping studies by conventional fluorescence 
activated cell sorting using single MAb staining or by a column-based 
enrichment method, such as that used by Sabo et al. (2010) to enrich yeast 
cells.  For example, cells could be labelled with a pool of human MAbs (i.e. 
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AR2A, 1:7) and mixed with Anti-IgG microbeads (human) (Miltenyi Biotech, 
Bisley, UK) before passing through a magnetic column.  Cells expressing E2 
would be enriched on the column as the remaining, unlabelled cells pass 
through.  By using a pool of conformation sensitive MAbs the population could 
also be enriched for cells expressing correctly folded E2 only.  Alternatively, 
introduction of a GFP gene into the pMT plasmid would enable cells 
transfected with pMT, and therefore the gene of interest, to be easily identified.  
Cells expressing GFP could be sorted by flow cytometry prior to mapping to 
enrich for E2-expressing cells.  Alternatively, cells could be sorted based on 
GFP expression and antibody binding simultaneously.  Due to time constraints 
and difficulties keeping sorted cells alive, it was not possible to do large scale 
enrichment of E2-expressing cells.  However, the results of preliminary 
experiments (Figure 2-23) suggest that enrichment for a specific population of 
cells is possible.  Such an enrichment step could greatly improve the library as 
removing large numbers of non-expressing cells and mis-folded protein would 
make mapping quicker, easier and reduce the amount of reagents, particularly 
antibody, required.  It was also observed that populations of cells binding 
antibody did not form a distinct group from non-antibody binders (Figure 2-
22); all dot plots contained a continuous populations of cells.  This is probably 
due to individual cells expressing different amounts of protein on the cell 
surface, possibly due to differences in the size of the repeat arrays inserted into 
the Drosophila genome.  It has also been postulated that the position of the 
repeats within the host cell chromosome may be crucial, as DNA can be 
integrated at more or less transcriptionally active sites.  Alternatively, the 
percentage of repeats that are transcriptionally active may vary due to 
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rearrangement of the DNA during chromosomal integration (Deml et al., 
1999).  As a result a range of antibody binding profiles, from very low to high, 
may be observed for cells expressing the same protein.  This situation is 
complicated further by the presence of cells transfected with the pCoBlast 
selection plasmid only.  Pre-enrichment of the cultures for protein expression 
would generate more distinct populations as non-expressers and very low 
expressers are removed.   
   One of the biggest problems encountered during the development of the 
insect cell display library was the maintenance and expansion of sorted cells.  
D. melanogaster S2 cells are very sensitive to growth at low densities and will 
not survive below a density of 5 x 105 cells per ml.  Initially it was hoped that 
by sorting cells into a small volume of media, the cells would be within the 
density threshold for survival.  Unfortunately due to the low percentage of cells 
falling within the region of interest, the cells could not be maintained.  This 
might be overcome by staining a larger number of cells.  All experiments were 
carried out with staining and sorting of 1 x 106 cells with approximately 2% of 
H77 library-expressing cells staining within the population of interest (Figure 
2-22a), resulting in a sorted population of around 20,000 cells (200 cells/µl).  
This number could be increased by sorting a larger number of cells and 
ultimately, with large enough numbers of cells, it may be possible to remove 
the feeder culture.  This would require a minimum of 50,000 cells to be sorted 
into a culture vessel containing 100 µl media.  Achieving such numbers would 
be greatly facilitated by pre-enrichment of the H77 library for cells expressing 
protein. 
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   Maintaining the sorted cultures was also hampered by bacterial 
contamination.  D. melanogaster S2 cells are described as being macrophage-
like (Luce-Fedrow et al., 2008) and therefore able to remove contaminants 
from their culture medium.  Unfortunately due to the high degree of handling 
necessary to stain, sort and expand the cells, contamination was common.  It 
was necessary to include Penicillin-Streptomycin in all wash buffers and the 
post-sorting culture media.  Penicillin-Streptomycin was not detrimental to the 
growth of D. melanogaster S2 cells and could be removed from the culture 
media after a few weeks.  All tissue culture handling was carried out in a Class 
II safety cabinet and the Beckman Coulter MoFlo Cell sorter was also housed 
within a Class II safety cabinet.  Sterilisation of the sheath fluid by autoclaving 
and cleaning of the cell sorter with bleach and ethanol prior to sorting were all 
found to reduce the likelihood of contamination.  Despite this, several sorted 
cultures were lost due to bacterial contamination. 
   An alternative to bulk sorting and enrichment for loss-of-binding mutants 
involves direct sequencing of the sorted cells.  Thanks to advances in flow 
cytometry technology, it is possible to rapidly and accurately sort large 
numbers of cells into culture plates or PCR plates, even down to a single cell 
per well.  This overcomes the problem of cell culture contamination or 
maintenance of cells at low density and allows potential antibody-binding 
residues to be identified more quickly.  It may also facilitate the isolation of 
rare variants which are only present at a low number within the library.  The 
rate of E2 amplification from single cells was between 42% and 70%.  This 
may be, in part, due to the failure of the cell sorter to deposit a single cell into 
each well.  This could be checked by the inclusion of primers to a 
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housekeeping gene during the PCR steps.  Typically the human hypoxanthine 
ribosyl transferase (HPRT) gene is used as a control for the presence of 
template in PCR amplifications.  In D. melanogaster S2 cells the ribosomal 
protein 49 (rp49) is commonly used (Luce-Fedrow et al., 2008).  Failure to 
amplify rp49 could be used to detect any empty wells from which E2 would 
not be recovered.  Low PCR recovery may also be caused by cells that do not 
contain pMT or have not been accurately stained with the MAb pool.  This 
could be improved by pre-enrichment of the H77 library and improved MAb 
labelling, as described above.  As expected, all cells sorted from an artificially 
mixed population on the basis of lost AR3A reactivity, contained the alanine 
substitution at D535.  Subsequent analysis of the H77 library sorted on the 
basis of lost AR3A reactivity identified a range of substitutions that may be 
involved in AR3A binding.  Of these, T396Q, L399I, W420R and N423K lie 
within the first discontinuous epitope forming AR3 and C429R falls between 
the first and second discontinuous epitopes (Law et al., 2008).  Although these 
residues have not previously been shown to play a direct role in AR3A binding, 
they lie within the region of E2 recognised by the AR3 group of MAbs.  
Residues W420 and N423 are found within the CD81 binding site at amino 
acids 412-423 (Owsianka et al., 2001), consistent with the known function of 
AR3A as an inhibitor of CD81 binding (Law et al., 2008).  Alanine 
replacement of residues 420 and 423 suggested that they were not involved 
directly in AR3A binding (Law et al., 2008); however the introduction of 
larger, charged amino acid residues (arginine and lysine respectively) may 
cause a localised conformational change that could explain the observed loss of 
binding.  It is also interesting to note that N423 is an N-linked glycosylation 
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site (Helle et al., 2007).  Removal of this glycan has been shown to reduce 
infectivity in the HCVpp system (Goffard et al., 2005); however in the HCVcc 
assay system, its removal does not affect infectivity but does enhance 
neutralisation by polyclonal antibodies and the MAb 3/11 (Helle et al., 2010).  
MAb 3/11 recognises a linear epitope (Flint et al., 1999a) which is exposed by 
removal of the glycan at residue 423.  Therefore removal of this glycan might 
be predicted to enhance antibody binding; however, binding of conformation 
sensitive MAbs, such as AR3A, is more dependent on the fold of the protein 
which does not appear to be affected by this glycan knock-out (Figure 2-22a) 
(Goffard et al., 2005).  
   Two of the mutations result in the replacement of a cysteine residue; C429R 
and C644R.  This would knock out the first and eighth disulphide bond 
respectively (Krey et al., 2010).  This is perhaps surprising given the 
importance of the disulphide bonds in maintaining protein fold.  However E2 
truncations up to residue 661 have been expressed and shown to bind H53 
(Flint et al., 1999a) demonstrating that the removal of glycans and even the 
JHQHUDWLRQ RI D µVSDUH¶ F\VWHLQH GRHV QRW universally generate mis-folded 
protein but rather a heterogeneous mix of correctly and incorrectly folded E2.   
   The L399I mutation and the C644R mutation appear at high frequency 
(>80%) within the recovered sequences.  This may be due to over-
representation of these sequences within the library, resulting in their recovery 
at higher than expected frequencies regardless of antibody binding.  This may 
occur if the library is not as diverse as predicted.  Attempts were made to 
assess the diversity of the library and steps were made to ensure that diversity 
was maintained.  This was based on the assumption that at all points the 
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maximum number of variants would be generated and, more importantly, 
maintained.  There are however, several points at which diversity might have 
been reduced, if, for example, transfection efficiency was unusually low or 
resurrection of the glycerol stock was insufficient to represent the full library.  
This may explain why mutations at G530 and D535 were not isolated during 
H77 library screening.  It was predicted that these variants would appear 
strongly in AR3A loss-of-binding mutants as they are known to be critical for 
AR3A binding (Figure 2-16 and 2-17) (Law et al., 2008).  It is also possible 
however, that these residues were mutated to amino acids other than alanine 
that do not have such a strong impact on AR3A binding.  The size of the 
library was calculated based on mutation of each amino acid at least once; 
however, a library expressing multiple different amino acids at each residue 
would give greater mapping capabilities as not all amino acid substitutions will 
impact antibody binding to the same extent.  For example, a conservative 
mutation of alanine to valine might not change the shape of an epitope as much 
as a non-conservative mutation to aspartate, resulting in variable antibody 
binding to epitopes containing aspartate and valine respectively.  Therefore a 
library containing the largest number of variants at a single residue might pick 
out rare sequences with reduced antibody binding.  However, a larger library 
would be needed to accommodate such variation within the E2 ectodomain, 
although it was encouraging to note the isolation of sequences containing two 
different mutations at the same residue, Y720F and Y720H (Table 2-4).  
Library statistics are listed in Table 2-3.  Input DNA of 300 ng was chosen as 
this would give 1182 variants differing from the parent by a single amino acid.  
This is theoretically sufficient to allow for amino acid substitution at each 
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position of the 331 residue protein.  However, the statistics also suggest that 
the library will contain 1790 distinct amino acid substitutions that are present 
in at least one sequence.  This is not sufficient to allow for substitution to every 
amino acid at each residue.  Recalculations using PEDEL-AA indicate that a 
larger library of 107, plus an increased mean mutation frequency from 5 to 16 
nucleotide substitutions per daughter sequence would be needed to produce a 
library containing 6312 distinct amino acid substitutions that are present in at 
least one sequence.  Theoretically this should provide sufficient coverage for 
every possible substitution to occur at each residue, if 331 residues are mutated 
from their original amino acid to each of the 19 possible alternatives.  
However, this is the upper limit of mutations achievable using the Genemorph 
II EZClone Domain Mutagenesis Kit.  Increasing the mutation frequency 
reduces the number of sequences containing a single substitution, making 
identification of individual residues involved in antibody binding more time 
consuming, and increases the number of sequences containing in-frame 
deletions and stop codons.  It may not be possible to achieve all amino acid 
substitutions at a given residue due to the complexity of the codon mutation 
that is required (i.e. mutating a single nucleotide vs substituting all nucleotides 
within the codon).  PEDEL-AA uses a generic Poisson model of sequence 
mutation that assumes that all substitutions are equally likely (Firth & Patrick, 
2005) however polymerases favour some mutations over others.  The 
Genemorph II EZClone Domain Mutagenesis Kit is designed to produce 
substitutions in an unbiased manner; nonetheless, some substitutions may occur 
more frequently than others.  Equally, some substitutions may abrogate protein 
processing and as such may not be tolerated.  Therefore a fine balance is 
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required in terms of the mutation frequency, such that sufficient diversity is 
achieved whilst maintaining the effective size of the library. 
   Finally it is worth considering that the degeneracy of the genetic code may 
result in some amino acids appearing more frequently than others.  Codon 
usage bias, the unequal use of codons encoding the same amino acid, is a trait 
shared by Drosophila species (Powell & Moriyama, 1997; Vicario et al., 
2007).  In D. melanogaster the trend is towards C/G-ending codons (Vicario et 
al., 2007) and the most common codons correlate well with the levels of 
isoaccepting tRNAs (Powell & Moriyama, 1997).  Such bias may result in the 
reduced expression of proteins containing suboptimal codons, further skewing 
the apparent diversity of the library.  This could be overcome by optimising 
codon usage for expression in D. melanogaster S2 cells, a technique that has 
been used to improve scFv antibody production (Gilmartin et al., 2012) and 
was also used in the generation of the 3D model of E2 (Thomas Krey, personal 
communication).  This may also improve expression levels of the other 
E2715HATM constructs.  Codon optimised proteins should be synthesised more 
rapidly within the cell leading to higher overall expression levels.  Lack of 
codon optimisation may help to explain why a maximum of ~60% of cells 
from any cell line were able to express protein.   
   The majority of recovered single cells expressing E2 contained only one or 
two mutations (Table 2-5).  Ideally most sequences should contain a single 
mutation as this facilitates the process of identifying the critical residues.  
Interrogating the role played by a specific residue can be achieved through 
reverse genetics and mapping studies with the MAb of interest.  However, this 
process becomes more complicated and more time-consuming as the number of 
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residues increases.  Therefore the recovery of E2 containing more than two 
mutations was disappointing, although these were the minority (12%) of 
sequences.  The presence of one or two mutations in 81% of sequences was 
encouraging and suggested that the mutation frequency was appropriate for this 
library. 
   The preliminary data suggested the involvement of some unexpected residues 
in AR3A binding to E2.  Most of the residues identified do not fall within 
regions of E2 previously shown to be involved in AR3A binding.  The 
potential identification of previously unrecognised residues highlights one of 
the advantages of using a library expressing full-length E2.  The whole protein 
can be interrogated simultaneously and no prior knowledge of potential 
antibody-binding epitopes is necessary.  A recent study of the CBH-2 epitope 
initially identified residues G530 and D535 that are also involved in CD81-E2 
binding, as critical for antibody binding.  However, further alanine mutagenesis 
of regions not involved in CD81 binding highlighted the importance of 
residues L640, A642 and A643 (Keck et al., 2008b).  The use of a display 
library encompassing the whole E2 glycoprotein would abrogate the need for 
lengthy alanine-scanning mutagenesis experiments, which are reliant upon 
prior knowledge of possible epitopes, and speed up the process of epitope 
identification.  It will be interesting to see if reverse genetics studies of these 
residues confirm their role in AR3A binding.  Collectively this data provides 
strong evidence that an E2 random mutant display library expressed in D. 
melanogaster S2 insect cells can be used to map antibody residues.  A number 
of steps could be taken to improve the library and ultimately facilitate the use 
of this library in high-throughput screening of antibody-binding epitopes. 
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3 Isolation and characterisation of monoclonal 
antibodies isolated from HCV-infected patients  
 
3.1 Introduction 
3.1.1 Antibody isotypes and function 
   Antibodies or Igs are globular glycoproteins produced by B cells in response 
to a particular antigen.  Five classes, or isotypes, of antibody are found in 
humans; IgA, IgD, IgE IgM and IgG.  Each antibody isotype has different 
properties with respect to size and function.  IgA is predominantly associated 
with mucosal immunity and can account for up to 50% of the Ig found at 
mucosal membranes and in secretions.  IgE is associated with the allergic 
immune response and hypersensitivity and accounts for <0.01% of serum Igs.  
IgD is also found at very low levels in the serum (<0.5%) and is thought to act 
primarily as a signalling receptor on the surface of B cells.  IgM is the main 
antibody produced during the primary immune response.  Monomeric IgM is 
expressed on the surface of B cells and secreted as a multimer, typically a 
pentamer.  Although usually of low affinity, the pentameric nature of IgM 
results in high avidity binding to antigen (Schroeder & Cavacini, 2010). 
   IgG is the most abundant, accounting for ~75% of circulating, serum Igs and 
has the longest serum half-life.  It exists as four subclasses, IgG1, IgG2, IgG3 
and IgG4.  IgG1 is the most abundant and, with the exception of IgG4, all 
subclasses are able to carry out complement fixation and opsonise targets 
(Schroeder & Cavacini, 2010).  The different subclasses also differ in their 
ability to bind cognate receptors via the Ig Fc domain (see section 3.1.2 and 
Figure 3-17KHVHUHFHSWRUVWHUPHG)FȖ5DUHH[SUHVVHGRQPRVWOHXNRF\WHV
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Figure 3-1. Schematic representation of an immunoglobulin 
molecule. a) The molecule is composed of two heavy chains and 
two light chains, linked by disulphide bonds (s-s). The constant 
domains are shown in green and the variable domains shown in 
blue. CH2 and CH3 make up the fragment crystallisable (Fc) 
region. The variable domains (VL and VH) plus CL and CH1 make 
up the antigen-binding fragment (Fab). The Fc portion and the Fab 
region are connected by a flexible hinge region. The framework 
regions (FR) and complementarity determining regions (CDR) 
within  Fab are shown. See text for references. b) PCR primer 
annealing sites within the Ig molecule. The cDNA encoding the 
heavy and kappa chains of the Fab fragment (red circle = heavy) is 
the target of the Ig-specific primers. First round sense primer 
anneals to the leader sequence, the antisense primer to the 
constant domain. Second round primers anneal internal to the first 
round primers. cDNA is shown broken down into its separate gene 
components encoded by the germline genes (listed in Figure 3-2).  
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DQGFDQEHGLYLGHG LQWR WKUHH W\SHV)FȖ5,)FȖ5,, DQG)FȖ5,,, (Jiang et al., 
2011).  IgG1 and IgG3 are able to bind all three receptors, IgG4 ELQGV)FȖ5,,
DQG )FȖ5,,, RQO\ DQG ,J*2 ELQGV WR )FȖ5,, (Schroeder & Cavacini, 2010).  
This has implications for the ability of the antibody to mediate effector 
functions, such as ADCC, and is an important consideration for therapeutic 
antibody or vaccine design (Jiang et al., 2011).   
 
3.1.2 Structure of the IgG molecule 
   IgG exists as a monomer composed of four polypeptide chains; two light 
chains and two heavy chains linked by disulphide bonds (Figure 3-1) 
(Tonegawa, 1983).  The type of heavy chain determines the antibody class; 
WKHUHIRUH ,J*KDVDȖ-type chain, IgM has a µ-W\SHFKDLQ ,J$KDVDQĮ-type 
FKDLQ ,J' KDV D į-W\SH FKDLQ DQG ,J( KDV DQ İ-type chain.  The light chain 
within an Ig PROHFXOHFDQEHHLWKHUDNDSSDț-W\SHRUDODPEGDȜ-type chain 
(Eales, 2001).  Each heavy chain contains three constant domains (CH1, CH2 
and CH3) and one variable (VH) domain (Figure 3-1).  The light chain contains 
a single constant domain (CL) and a single variable (VL) domain.  The CH2 
and CH3 domains form the fragment crystallisable (Fc) portion of the Ig, 
which biQGV)FȖ5DQGPHGLDWHVWKHDQWLERG\HIIHFWRUIXQFWLRQV7KHYDULDEOH
domain of the heavy and light chain, plus CL and CH1, forms the Fab 
fragment, responsible for antigen-binding.  The Fab and Fc portions of the Ig 
molecule are separated by a hinge region that enables slight movement of the 
Fab region, relative to the Fc region, and facilitates antigen binding (Figure 3-
1) (Eales, 2001; Schroeder & Cavacini, 2010).  The variable domains may also 
be referred to as the Fv fragment and are further divided into four framework 
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regions (FR) and three complementarity determining regions (CDR) (Figure 3-
1).  The CDRs are regions of hypervariability that contribute to the specificity 
of the antibody for its antigen and enhance the affinity of the interaction 
(Tonegawa, 1983). 
 
3.1.3 Generation of antibody diversity 
3.1.3.1 Recombination of germline genes 
   Ig light and heavy chains are encoded by germline genes that undergo 
recombination and somatic hypermutation to produce the great diversity of 
antibodies generated by a healthy human over their lifetime.  The heavy chain 
locus is located on chromosome 14q32.33 and encodes 39 functional variable 
(VH) genes that are divided into 7 families (Matsuda et al., 1998).  Located 
downstream of the VH genes are 27 D (or diversity) genes and six J (or 
junction) genes (Matsuda et al., 1998; Schroeder & Cavacini, 2010) (Figure 3-
2a).  The constant (C) genes, encoding each of the Ig isotypes, are located 
downstream of the JH genes.  During heavy chain recombination, DH and JH 
genes are the first to recombine, followed by recombination with a single VH 
gene to form the complete VDJ segment that comprises the variable heavy 
(VH) domain (Tonegawa, 1983).  The VH gene encodes CDR1 and CDR2 and 
the amino terminus of CDR3, with the remainder of CDR3 encoded by the DH 
and JH genes.  Combinatorial diversity generated by rearrangement of VDJ 
genes is estimated at 3.8 x104 combinations of genes (Schroeder & Cavacini, 
2010).   
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Figure 3-2. Schematic representation of the immunoglobulin gene loci. a) The heavy chain locus contains V, D and J genes that 
undergo VDJ recombination to form the functional variable domain. Initially recombination with the Cȝ gene generates IgM. During 
B cell maturation, class switch recombination with any of the remaining C genes results in the formation of different isotypes. b) The 
kappa chain locus contains V and J genes that recombine to form the variable domain. This undergoes recombination with the 
single Cț gene to form a functional light chain. C) The lambda chain locus contains VȜ genes that recombine with any of four JȜ 
genes, each associated with its own CȜ gene. See text for references. 
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   In contrast to the VH domain, the kappa variable domain is composed of V 
and J genes only.  The kappa chain locus is located on chromosome 2p11.2 and 
HQFRGHVDQHVWLPDWHGIXQFWLRQDO9țJHQHVGLYLGed into 6 families, plus five 
-ț JHQHV (Barbie & Lefranc, 1998) (Figure 3-2b  7KH 9ț DQG -ț JHQHV
recombine to form the complete VJ segment comprising the variable region, 
SULRUWRUHFRPELQDWLRQZLWKWKHVLQJOH&țJHQH(Tonegawa, 1983).  The lambda 
variable domain is also composed of V and J genes only.  The lambda chain 
locus is located on chromosome 22q11.2 (Kawasaki et al., 1997) and encodes 
IXQFWLRQDO9ȜJHQHVGLYLGHGLQWR1 families (Pallares et al., 1998) plus four 
-Ȝ JHQHV HDFK RI ZKLFK LV DVVRFLDWHG ZLWK LWV RZQ &Ȝ JHQH (Schroeder & 
Cavacini, 2010) (Figure 3-2c).  Genetic recombination takes place such that the 
-Ȝ-&ȜJHQHVUHFRPELQHZLWKD9ȜJHQH(Tonegawa, 1983).  In both kappa and 
lambda variable domains, CDR1 and CDR2 are encoded by the V gene whilst 
CDR3 is encoded by both the V and J genes (Schroeder & Cavacini, 2010).  
Approximately 175 kappa gene combinations and 120 lambda gene 
combinations can be generated by recombination of the germline sequences. 
   VDJ or VJ recombination is highly controlled to ensure that genes recombine 
in the correct order and that the same genes do not recombine with themselves.  
In heavy chain genes D-J recombination occurs first, followed by V-DJ 
recombination.  The process is controlled by recombination signal sequences 
(RSS) located at the recombination sites between genes.  These RSSs are non-
coding DNA sequences consisting of a conserved heptamer sequence, a spacer 
sequence of either 12 or 23-bp, and finally a conserved nonamer sequence.  An 
566LVIRXQGDWWKH¶HQGRIDOO9JHQHVDQGDWWKH¶HQGDOO-JHQHV'JHQHV
are flaQNHGDWWKH¶DQG¶HQGE\DQ566,QKHDY\FKDLQJHQHVWKH9DQG-
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genes have a 23-bp spacer-containing RSS whereas D genes are flanked by a 
12-ESVSDFHU,QOLJKWFKDLQJHQHVWKH9țJHQHVFRQWDLQD-ESVSDFHUDQG-ț
genes contain a 23-bp spacer; 9ȜJHQHV FRQWDLQD-ESVSDFHUDQG-ȜJHQHV
contain a 12-bp spacer.  Functional recombinations occur only between a 
sequence flanked by a 12-bp spacer and another sequence flanked by a 23-bp 
spacer.  Therefore, non-functional rearrangements between V-V genes or J-J 
genes are prevented by this so-FDOOHG µ UXOH¶ (Dudley et al., 2005; 
Tonegawa, 1983).  Recombination is initiated by binding of the recombination-
activating gene (RAG)-1 and RAG-2 to a 12-bp RSS, followed by binding to a 
23-bp RSS, bringing the two different gene segments into close contact in a 
synaptic complex.  RAG-1 and RAG-2 induce DNA single-strand breaks that 
result in the formation of a hairpin loop at the end of each coding gene 
segment.  The hairpin loops are resolved by further single-strand nicks carried 
out by the non-homologous end joining (NHEJ) proteins, Artemis and DNA-
PKcs.  This resXOWVLQD¶'1$RYHUKDQJWKDWFDQEHPRGLILHGE\WKHDFWLRQRI
exonucleases, DNA polymerases or terminal deoxynucleotidyl transferase 
(TdT) to add or remove germline nucleotides (Dudley et al., 2005).  This 
introduces mutations into CDR3 and leads to great variation in its length.  The 
introduction of N nucleotides by the action of TdT is thought to increase the 
diversity of the VH domain to around 107 different sequences (Tiller et al., 
2008).  A variety of host NHEJ proteins finally repair the DNA breaks 
generating the complete variable region (Dudley et al., 2005).   
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3.1.3.2 Somatic hypermutation and class switch recombination 
   Additional genetic diversity is introduced through the process of somatic 
hypermutation (SHM) of the variable domain upon exposure to antigen.  SHM 
introduces mutations at rate of 10-3 mutations per base pair per cell division via 
the activity of activation-induced cytidine deaminase (AID) (Schroeder & 
Cavacini, 2010).  AID deaminates cytidine residues within single stranded 
DNA resulting in the conversion of cytidine to uracil.  This uracil may be 
removed by the activity of uracil-DNA glycosylase resulting in an abasic site 
that is replaced by any nucleotide via the base excision repair mechanism.  
Alternatively the mismatch repair machinery may introduce additional 
mutations proximal to the initial C-U mutation.  SHM is restricted to the 
variable region and the constant domain is protected from mutation to ensure 
antibody function is maintained (reviewed in (Odegard & Schatz, 2006).  SHM 
takes place in B cell germinal centres and can involve several rounds of clonal 
expansion, exposure to antigen presented on follicular dendritic cells and 
selection of high-affinity variants (McHeyzer-Williams et al., 2012).  B cell 
germinal centres are also the site of class-switch recombination (CSR), the 
process by which affinity-matured, antigen-specific variable regions recombine 
ZLWKWKHFRQVWDQWUHJLRQJHQHV&Ȗ&ĮDQG&İWRSURGXFHGLIIHUHQWDQWLERG\
isotypes (Figure 3-2a).  Immature B cells initially express IgM (and also 
possibly IgD) but may undergo CSR during development to produce the 
different Ig isotypes.  This process also requires the action of AID at specific 
switch signals located between the constant region genes (Dudley et al., 2005).  
Maturation of the B cell response in germinal centres results in the production 
of long-lived plasma cells secreting high-affinity antibody as well the 
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production of long-lived, high-affinity memory B cells.  Germinal centres also 
play a crucial role in the removal of self-reactive B cells and non-functional Igs 
(McHeyzer-Williams et al., 2012).  IgG+ memory B cells are thought to reside 
close to germinal centres and upon re-exposure to antigen, take up and present 
antigen to CD4+ T helper cells via MHC class II.  Antigen-specific memory T 
helper cell interactions are required for clonal expansion and differentiation of 
memory B cells into plasma cells (Aiba et al., 2010), the precise mechanisms 
of which are poorly understood but may involve upregulation of cytokine 
signals (McHeyzer-Williams et al., 2012).   
   As a result of the recombination of germline genes, the addition or removal 
of germline nucleotides and SHM of the variable domain, as well as the 
recombination of heavy chains with either kappa or lambda-type chains, it has 
been estimated that the antibody repertoire may exceed 1016 different Igs 
(Schroeder & Cavacini, 2010). 
  
3.1.4 Methods to isolate monoclonal antibodies 
   The use of polyclonal Igs for prophylactic and therapeutic purposes was 
developed at the start of the 20th century and has proven effective in the 
treatment or prevention of respiratory bacterial infections, tetanus, hepatitis B 
virus and rabies virus (Keller & Stiehm, 2000).  However, the widespread use 
of poly-Igs has been hampered by limited availability, batch variability and the 
infection risk associated with the use of human blood products.  MAbs 
represent a more consistent and safer option but to date only one MAb therapy 
has been developed for use against an infectious disease, for the treatment of 
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respiratory syncytial virus infection (Johnson et al., 1997).  Nonetheless, 
several methods have been established to develop MAb therapies against a 
variety of different targets, the limitations of which will be discussed below. 
 
3.1.4.1 Murine antibodies 
   Hybridoma technology was one of the earliest methods developed for MAb 
production.  The technique fuses splenocytes from an immunised mouse donor 
with myeloma cells to generate a continuous cell line secreting antibody of a 
defined specificity (Kohler & Milstein, 1975).  The first stage in the generation 
of hybridomas is the immunisation of mice, which may require repeat boosting 
in order to stimulate a strong immune response.  B cells are then removed from 
the spleen and fused with a myeloma cell line.  This is followed by several 
weeks of selection with hypoxanthine, aminopterin and thymidine (HAT) 
which selectively removes unfused myeloma cells.  Fused hybridomas will 
grow in the presence of HAT although some loss may occur as unstable 
hybridomas regress.  Successful hybridomas must then be carefully selected for 
antibody specificity to eliminate non-specific hybridomas and in some cases it 
is necessary to re-clone hybridomas that have formed by fusion of more than 
one B cell to the myeloma cell line (Nelson et al., 2000).  As such, the process 
of generating hybridomas is time consuming and can be technically 
challenging with low fusion rates resulting in few successful hybridomas.  
Many murine MAbs are immunogenic when administered to patients making 
them inappropriate for use as therapeutics (Hwang & Foote, 2005).  They also 
show reduced effector function in humans due to differences in the Fc region 
(Li et al., 2006).  This has led to the humanisation of murine antibodies by the 
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insertion of murine CDRs into a human antibody scaffold (Jones et al., 1986) 
or by generation of a chimeric MAb containing a murine Fab region and a 
human Fc region (Boulianne et al., 1984; Morrison et al., 1984).  Both 
approaches reduce the immunogenicity of the MAb (Hwang & Foote, 2005) 
and have been successfully used to generate a number of effective antibody 
therapies in clinical use today (reviewed in (Jiang et al., 2011).  Such 
engineering can however, be time-consuming.  Transgenic mice bearing human 
germline Ig genes have been developed, although early methods were unable to 
recapitulate the entire human VDJ gene diversity (Green et al., 1994; Lonberg 
et al., 1994).  The use of chromosomal transfer techniques has enabled the 
introducWLRQ RI WKH FRPSOHWH ,J+ DQG ,Jț JHQH ORFL LQWR PLFH ODFNLQJ
endogenous Ig JHQHVKRZHYHUORZOHYHOVRI,J$SURGXFWLRQDQGXQVWDEOH,Jț
locus transfer were reported (Tomizuka et al., 2000).  Those human antibodies 
generated in transgenic mice do have low immunogenicity (Lonberg, 2005); 
however production of specific MAbs following immunisation still requires 
hybridoma generation, which is both time-consuming and challenging.  It is 
also important to consider that, despite the presence oIKXPDQ,J+DQG,JțORFL
the process of B cell development and maturation takes place in a murine 
genetic background.  This may alter the spectrum of antibodies derived from 
transgenic mice compared to humans (Lonberg, 2005).  Chimeric and 
humanised MAbs will also retain antigen-binding specificities from mice.  The 
antibody response in mice is unlikely to represent the complexity of the human 
immune response and therefore methods which directly interrogate human 
antibody responses to natural infection are likely to be more informative than 
vaccine induced antibody responses in experimental animals.  Indeed within 
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the field of HCV research it has been noted that mice are limited in their ability 
to generate conformation-dependent antibodies against the HCV envelope 
glycoprotein.  Conformation-dependent antibodies tend to show greater cross-
neutralising activity and therefore present a better therapeutic target (reviewed 
in(Edwards et al., 2012); however, murine anti-HCV MAbs identified to-date 
predominantly recognise linear epitopes (Clayton et al., 2002; Owsianka et al., 
2001; Owsianka et al., 2005; Tarr et al., 2006). 
 
3.1.4.2 Human antibodies 
   Phage display is widely used for the expression of protein and peptide 
fragments in E. coli (see section 2.1.1).  Typically in antibody display, the VH 
and VL genes are joined by a flexible glycine-serine linker resulting in 
expression of a scFv on the surface of a filamentous phage (McCafferty et al., 
1990).  Alternatively Fab fragments may be displayed by anchoring the heavy 
chain to the phage coat protein and secreting the light chain into the periplasm, 
where the two chains assemble to form the Fab fragment (Hoogenboom et al., 
1991).  ScFvs are more commonly used as they are easier to assemble and less 
likely to be degraded than Fab fragments (Bradbury & Marks, 2004).  
Antibody display technologies are generally considered to be an improvement 
over hybridoma technologies as more antibody specificities can be identified 
from a single immune donor.  The enrichment process may also facilitate the 
isolation of rare antibodies (Hoogenboom, 2005).  Phage display can be used 
for the generation of recombinant libraries from immune donors, non-immune 
donors and synthetic fragments.  Recombinant antibody libraries derived from 
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neutralising anti-HCV antibodies, some of which show broad neutralising 
activity (Allander et al., 2000; Giang et al., 2012; Johansson et al., 2007b; Law 
et al., 2008; Perotti et al., 2008).  Theoretically, non-immune libraries can be 
used to identify antibodies binding to any antigen (Carmen & Jermutus, 2002).  
Non-immune or synthetic libraries undergo in vitro affinity maturation via PCR 
mutagenesis of the CDRs or growth in mutator strains of E. coli.  However, 
this can be a time-consuming process requiring iterative rounds of enrichment 
and selection.  Alternatively targeted mutations can be introduced into regions 
known to enhance affinity, although this may require some prior knowledge of 
the immune response to the antigen (Hoogenboom, 2005).  Recombinant 
libraries expressing scFv fragments on the surface of S. cervisiae cells (Boder 
& Wittrup, 1997) using flow cytometric sorting of high-affinity binders, rather 
than biopanning on an immobilised antigen, are also available.  Yeast display 
combined with PCR mutagenesis and in vitro recombination has been used for 
the maturation of antibodies to extremely high affinity (48 fM) (Boder et al., 
2000), possibly due to the removal of expression biases associated with 
expression of mammalian genes in prokaryotic cells.  The affinity of the 
broadly neutralising anti-HCV antibody HC-1 was successfully enhanced by 
enrichment of scFv mutants displayed on yeast cells (Wang et al., 2011) and a 
number of therapeutic antibodies have been developed using the recombinant 
antibody technologies described above (Hoogenboom, 2005).   
   As discussed previously, hybridomas producing murine antibodies may not 
accurately mimic the human immune response and can be immunogenic in a 
therapeutic setting.  Recently, human-murine heterohybridomas, generated by 
the fusion of human splenocytes to modified murine myeloma cell lines 
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(Dessain et al., 2004) or human myeloma cell lines suitable for the generation 
of entirely human hybridomas (Karpas et al., 2001) have been developed.  
These methods are able to generate stable hybridomas (Dessain et al., 2004; 
Karpas et al., 2001) and the secreted antibodies are likely to be less 
immunogenic than murine MAbs.  However, the frequency of hybridoma 
generation is still low (Karpas et al., 2001) and obtaining human splenocytes 
for fusion can be difficult, although hybridoma generation by fusion of 
peripheral blood mononuclear cells (PBMCs) has been reported (Li et al., 
2006).  Neutralising anti-HCV MAbs have been isolated from PBMCs using 
modified hybridoma technology (Hadlock et al., 2000).  Antibody producing B 
cell lines have also been generated by immortalisation of lymphocytes with 
Epstein-Barr virus (EBV).  EBV immortalisation preserves the characteristics 
of the original cell including surface and secreted Ig, enabling the production 
of antigen-specific MAb (Steinitz et al., 1977).  Recently the technique has 
been improved by the addition of the polyclonal activator, CpG 2006, a single-
stranded DNA oligonucleotide that activates B cells via interaction with TLR-
9.  This increased the rate of memory B cell immortalisation from 1-2% to 30-
100%, and was successfully used to isolate nAbs against the SARS coronavirus 
(Traggiai et al., 2004).  EBV immortalisation is however a technically 
challenging process with others reporting immortalisation rates of only 40% 
(Pinna et al., 2009). 
   Recently methods have been developed to activate memory B cells in vitro 
and characterise the antibodies produced by a single B cell clone.  Memory B 
cells can be activated in vitro by antigen-independent mechanisms requiring T 
helper cell stimulation and cytokine production (Lanzavecchia, 1983; 
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Lanzavecchia et al., 1983).  Memory B cells express a number of TLRs on 
their surface including TLR-2, -6, -7, -9 and -10 (Lanzavecchia et al., 2006).  
When stimulated by TLR agonists, including CpG (Bernasconi et al., 2002) 
and R848 (Pinna et al., 2009), B cells proliferate and differentiate into antibody 
secreting cells (ASCs).  Class-switched memory B cells can also be stimulated 
by interleukin (IL)-2 (Pinna et al., 2009) and IL-15 (Lanzavecchia et al., 2006).  
This activation is antigen-independent and does not require direct T-cell 
interactions.  The polyclonal activation of memory B cells is required for 
plasma cell homeostasis and maintenance of serum antibody levels 
(Lanzavecchia et al., 2006).  More recently, highly proliferating, Ig-secreting B 
cells have been generated by transduction of germinal centre-specific proteins 
into memory B cells, followed by stimulation with CD40L and IL-21.  This 
resulted in long-lived antibody producing cells that were able to undergo SHM 
in vitro (Kwakkenbos et al., 2010).  This may enable continued affinity 
maturation, generating improved MAbs without the need for targeted affinity 
engineering.  Studying the memory B cell pool following polyclonal activation 
abrogates the need for specific antigen boosting, facilitating the identification 
of antibodies produced against many different antigens.  The short-lived nature 
of most ASCs (10-40 days) (Lanzavecchia et al., 2006) makes identification of 
B cell specificities problematic, particularly for those diseases that are difficult 
to diagnose during acute infection, such as HCV.  Memory B cells provide a 
record of all previous antigenic expRVXUH RYHU D SDWLHQW¶V OLIHWLPH therefore 
interrogating the memory B cell pool can shed light on the antibody response 
to past infections as well as chronic infections.   
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   Single memory B cell isolation has been greatly facilitated by developments 
in flow cytometry technology.  Following isolation, single B cells are 
stimulated to differentiate into ASCs producing large amounts of antibody and 
therefore mRNA transcript.  The antibodies can then be identified directly by 
reverse transcription and amplification of the rearranged Ig genes (Wang & 
Stollar, 2000; Wardemann et al., 2003).  Reverse transcription is typically 
carried out in the same vessel as used for culturing the B cells.  This reduces 
the potential for cross-contamination or loss of RNA.  Reverse transcription 
can be carried out with class-specific primers or universal primers binding to 
the constant region to isolate any antibody isotype.  Amplification of the Ig 
genes is achieved by nested PCR.  In the first round, the forward primers bind 
WKH,J+,JțRU,JȜOHDGHUVHTXHQFHDQGWKHUHYHUVHSULPHUELQGVWKHFRQVWDQW
region.  In the second round, primers binding within the variable region 
increase the specificity of the amplified sequences (Figure 3-1b) (Koelsch et 
al., 2007; Tiller et al., 2008; Wang & Stollar, 2000; Wardemann et al., 2003).  
Amplification of Ig genes directly from patient B cells has been used for the 
isolation of high-affinity and broadly reactive nAbs against influenza A virus 
M2 protein (Grandea et al., 2010) and HA (Corti et al., 2011); isolation of 
high-affinity, neutralising anti-gp120 HIV antibodies (Scheid et al., 2009; 
Scheid et al., 2011; Wu et al., 2011); characterisation of the specific antibody 
response to HIV gp41 (Pietzsch et al., 2010), and to study the antibody 
response to the seasonal influenza vaccine (Wrammert et al., 2008).  The 
simultaneous amplification of heavy and light chain genes from a single B cell 
culture overcomes the need for in vitro recombination and cloning of multiple 
sequences, thus avoiding unproductive gene recombination.  By looking at 
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memory B cell populations, it is possible to interrogate naturally occurring 
human antibody responses, including past exposure to a variety of antigens, 
without the need for antigen boost.  The method is not limited by the number of 
B cells that can be isolated and rare or infrequent B cells can be identified 
(Corti et al., 2011).  The time taken from single B cell culture to heavy and 
light chain amplification is shorter than that required for hybridoma production 
(Nelson et al., 2000) and reported antibody recovery rates are good (Scheid et 
al., 2009; Scheid et al., 2011; Wrammert et al., 2008).  The small sample 
volumes required both for cell culture and RT-PCR amplification make the 
process particularly amenable to a high-throughput platform.  This technique 
can identify different antibodies belonging to a single B cell clone, 
characterised as having high sequence identity, especially within CDR3 and 
shared V and J genes, in both the light and heavy chains (Scheid et al., 2011).  
This can be very informative in the search for high affinity variants of naturally 
occurring antibodies that may correlate with favourable disease outcome.  A 
number of vectors are available for expression cloning of the isolated genes, 
including mammalian expression vectors (Metheringham et al., 2009; Tiller et 
al., 2008) and insect cell expression vectors (Johansson et al., 2007a).  By 
introducing restriction sites within the PCR amplification primers it is possible 
to clone Ig gene products directly into an expression vector, enabling the 
production of large amounts of MAb.  Subsequent phenotypic studies, such as 
neutralisation, cross-reactivity and epitope binding can be easily correlated to 
the genotype of the antibody, providing a greater understanding of the antibody 
response to important pathogens.   
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3.2 Aims of the work presented in this chapter 
   Isolation and amplification of the Ig variable (VH and VL) chains from the B 
cells of HCV-infected individuals represents a powerful technique for studying 
antibody responses.  Several different approaches to B cell isolation and 
stimulation are available, as well as several primer sets for Ig gene transcript 
amplification.  This study was intended to explore the currently available 
methods and to develop a protocol for amplification of VH and VL gene 
transcripts from patients with good nAb responses.  All preliminary 
experiments were carried out on samples collected during the chronic phase of 
disease.  The work to isolate IgG+ memory B cells and stimulate their 
differentiation into ASCs under culture conditions was undertaken by Richard 
Urbanowicz and is covered briefly.  Recovering mRNA from B cell cultures, 
complementary DNA (cDNA) synthesis and PCR amplification of variable 
regions was undertaken as part of this PhD thesis and the troubleshooting of 
this method is covered in greater detail.  One of the original aims of this work 
was to clone paired VH and VL chains into an appropriate vector for the 
expression and characterisation of the antibody.  Ultimately this was not 
achieved, but the progress made towards this goal and the problems 
encountered are discussed. 
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3.3 Materials and methods 
3.3.1 Isolation and culturing of B cells 
   The protocols described in section 3.3.1 were developed by Dr. Richard 
Urbanowicz.  All work to isolate B cells from patient samples and culture them 
for antibody production was carried out by Dr. Richard Urbanowicz. 
 
3.3.1.1 Sample collection 
   Patients were identified through The Trent HCV Cohort.  The Nottingham 
Local Research Ethics Committee approved the study protocol and written 
informed consent was obtained from the participants before entering the study. 
 
3.3.1.2 Preparation of PBMCs from whole blood 
   Approximately 10 ml blood was diluted 2:1 in warm RPMI 1640 media 
(Invitrogen, Paisley, UK) (supplemented with 10% foetal bovine serum (FBS-
GOLD)).  Diluted blood was gently layered onto 10 ml warm Histopaque 
(Sigma Aldrich, Gillingham, UK) and centrifuged at 800 x g for 22 minutes.  
This separated the blood into four layers; (i) a bottom layer containing red 
blood cells, (ii) a clear layer of Histopaque, (iii) a thin white layer containing 
PBMCs and (iv) a top layer of serum.  PBMCs were removed using a 2 ml 
Pastette, taking care to remove as little Histopaque as possible and to avoid 
contamination of PBMCs with serum.  PBMCs were transferred to a 50 ml 
centrifuge tube and topped up to 50 ml with media.  Cells were washed by 
centrifugation at 300 x g for 10 minutes.  Supernatant was removed and cells 
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resuspended in 5 ml media.  A cell count was performed on 10 µl PBMC 
preparation using a haemocytometer.  The PBMC preparation was topped up to 
50 ml with media and washed by centrifugation at 300 x g for 5 minutes prior 
to removal of the supernatant. 
 
3.3.1.3 Separation of IgG+ memory B cells from total PBMCs  
   IgG+ memory B cell isolation was carried out using a MACS IgG+ Memory 
B Cell Isolation Kit (Miltenyi Biotech, Bisley, UK) according to the 
PDQXIDFWXUHU¶V LQVWUXFWLRQV  %ULHIO\ 3%0&V ZHUH UHVXVSHQGHG LQ  O
MACS buffer (PBS, pH 7.2; 0.5% BSA; 2 mM EDTA) plus 100 µl MACS 
Memory B cell Biotin-Antibody Cocktail microbeads (containing antibodies to 
CD2, CD14, CD16, CD36, CD43 and CD235a) per 108 cells.  Samples were 
mixed well and incubated at 4°C for 10 minutes.  A further 300 µl MACS 
buffer was added per 108 cells followed by 200 µl MACS Anti-biotin 
microbeads per 108 cells.  Samples were mixed well and incubated at 4°C for 
15 minutes.  Cells were washed by adding 10 ml MACS buffer and 
centrifuging at 300 x g for 10 minutes.  Supernatant was aspirated completely 
and the pellet resuspended in 1 ml MACS buffer. 
   An LD column was prepared by placing it in a MACS separator and washing 
with 2 ml MACS buffer.  The cell suspension was applied to the column and 
washed twice with 1 ml MACS buffer.  The flow through containing the total 
B cell fraction was collected.  (The LD column containing non-B cells, i.e. T 
cells, monocytes, dendritic cells, platelets etc., was removed from the separator 
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and the B cell negative fraction eluted into a separate tube for generation of 
macrophage feeder cells (see section 3.3.1.4)). 
   The total B cell fraction was mixed with 7 ml MACS buffer and centrifuged 
at 300 x g for 10 minutes.  Supernatant was aspirated completely and the pellet 
resuspended in 50 µl MACS buffer plus 50 µl MACS Anti-IgG microbeads per 
108 cells.  The sample was mixed well and incubated at 4°C for 15 minutes.  
Labelled cells were washed in 10 ml MACS buffer with centrifuging at 300 x g 
for 10 minutes.  Supernatant was aspirated completely and the pellet 
resuspended in 500 µl MACS buffer.  An MS column was prepared by placing 
it in a MACS separator and washing with 500 µl MACS buffer.  The cell 
suspension was applied to the column and washed 3 times with 500 µl MACS 
buffer.  The MS column was removed from the MACS separator and placed 
over a sterile collection tube.  IgG+ memory B cells were eluted from the 
column in 1 ml MACS buffer.  IgG+ memory B cells were counted using a 
haemocytometer, centrifuged at 300 x g for 10 minutes and resuspended at the 
desired concentration for culturing (see section 3.3.1.5). 
 
3.3.1.4 Generation of macrophage feeder cell cultures 
   The B cell negative fraction isolated in section 3.3.1.3 was resuspended to a 
total volume of 20 ml in RPMI 1640 media supplemented with 10% FBS-
GOLD and 50 ng/ml granulocyte-macrophage colony-stimulating factor (GM-
CSF) (R&D Systems, Abingdon, UK).  Cells were placed in a Corning T75 
tissue culture flask (Fisher Scientific, Loughborough, UK) and incubated at 
37°C with 5% CO2 for 5-7 days.  Supernatant was removed and the adherent 
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macrophages washed once in cold PBS.  Macrophages were removed from the 
plastic by addition of 5 ml warm cell dissociation buffer (Gibco) (Invitrogen, 
Paisley, UK) and incubated at 37°C for 5-10 minutes.  Macrophages were 
dislodged by gentle tapping and counted using a haemocytometer.  Cells were 
resuspended in 5 ml media in a sterile polystyrene tube wrapped in Parafilm M 
(Alpha Laboratories, Eastleigh, UK).  Macrophage cells were lightly irradiated 
(12Gy) using a caesium-137 source and plated at 2500 cells per well in a 384-
well flat-bottom tissue culture microplate (BD Biosciences, Oxford, UK). 
 
3.3.1.5 Culturing IgG+ memory B cells for production of antibody 
   IgG+ memory B cells were seeded onto macrophage feeder cells at 1.3, 10 or 
100 cells per well in 100 µl total volume of RPMI 1640 media supplemented 
with 10% FBS-GOLD, R848 (2.5 µg/ml) (Source BioScience, Nottingham, 
UK) and IL-2 (1000 units/ml) (R&D Systems, Abingdon, UK).  Cells were 
deposited using a Precision Microplate Pipetting System (BioTek UK, Potton, 
UK).  Cultures were incubated at 37°C with 5% CO2 for 10 days. 
 
3.3.1.6 Screening cell culture supernatants for antibody production  
3.3.1.6.1 GNA-capture ELISA 
   A Maxisorp 96-well plate (Nunc) (Fisher Scientific, Loughborough, UK) was 
coated, blocked and washed as described in section 2.3.4.3.  Cell lysate from 
HEK 293T cells transfected to express E1E2 (H77 genotype 1a) was diluted 
1:5 in 1x PBS and 50 µl coated onto each well for 1 hour at room temperature.  
Alternatively for detection of total Igs, anti-human IgG was coated onto the 
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wells.  Wells were washed three times in PBS-T.  Thirty microlitres of B cell 
supernatant was added and incubated at room temperature for 2 hours.  Wells 
were washed three times in PBS-T.  Bound Ig was detected by the addition of 
50 µl AP-conjugated secondary antibody (goat anti-human IgG) (Sigma 
Aldrich, Gillingham, UK) (1:2000 in PBS) and incubated at room temperature 
for 1 hour.  Wells were washed three times in PBS-T and IgG-containing 
supernatants identified by the addition of 100 µl pNPP (Fisher Scientific, 
Loughborough, UK).  Absorbance at 405 nm was determined using a 
Fluorostar Optima plate reader (BMG Labtech, Aylesbury, UK).   
 
3.3.1.6.2 Peptide capture immunoassay 
   Biotinylated peptides were synthesized using Synphase PA Lanterns 
(Mimotopes, Melbourne, Australia), using a C-terminal biocytin residue 
separated from the epitope sequence by a Gly-Ser-Gly spacer sequence.  
Peptide purity was assessed by MALDI-TOF spectrometry.  Peptides were 
initially dissolved in DMSO then PBS to a final concentration of 1 mg/ml.  The 
peptides corresponded to amino acids 412-423 (QLINTNGSWHIN; Peptide I) 
and 434-446 (NTGWLAGLFYQHK; Peptide II) of the HCV H77c polyprotein 
(Tarr et al., 2012b). 
   Neutravidin (Pierce, Cramlington, UK) was coated on to a Maxisorp 96-well 
plate (Nunc) (Fisher Scientific, Loughborough, UK) at 5 µg/ml in 50 mM 
carbonate/bicarbonate buffer (pH9.8) overnight at 4°C in a humidity chamber.  
Unbound neutravidin was removed by washing with PBS-T, and non-specific 
binding sites blocked using PBS-T containing 3% bovine serum albumin (PBS-
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TB).  Peptide solutions (1 µg/ml in PBS-T) were incubated at room 
temperature for 1 hour.  Unbound peptide was removed by washing with PBS-
TB and 30 µl of B-cell supernatant bound to the capture peptide for 2 hours at 
room temperature.  Unbound supernatants were removed by washing three 
times with PBS-T.  Bound Ig was detected by the addition of 50 µl AP-
conjugated anti-human IgG antibody (Sigma Aldrich, Gillingham, UK), diluted 
1:2000 in Tris-buffered saline-0.05% Tween 20 solution (TBS-T).  Unbound 
antibody was removed by washing with TBS-T and IgG-containing 
supernatants identified by the addition of 100 µl pNPP (Sigma Aldrich, 
Gillingham, UK).  Absorbance at 405 nm was determined using a Fluorostar 
Optima plate reader (BMG Labtech, Aylesbury, UK).   
 
3.3.2 Isolation and amplification of IgG genes from B cells 
3.3.2.1 Extraction of RNA from B cell samples 
   B cell supernatants testing positive for the GNA-capture ELISA and both 
peptide capture immunoassays (peptide I and peptide II) were selected for 
isolation and analysis of the IgG genes expressed.  The cells, along with the 
remaining supernatant (approximately 40 µl), were transferred to a 0.7 ml 
Eppendorf.  The sample was washed twice in 500 µl B cell wash buffer (1x 
PBS, 0.7 units/µl RNAse OUT (Invitrogen, Paisley, UK)) with centrifugation 
at 300 x g for 5 minutes.  Residual wash buffer was carefully removed by 
pipetting.  Cells were lysed with 10 µl B cell lysis buffer (10 units RNAse 
OUT (Invitrogen, Paisley, UK), 2.5 µl 5x Thermoscript RT buffer (Invitrogen, 
Paisley, UK), 0.625 µl 0.1 M dithiothreitol (DTT) (Invitrogen, Paisley, UK), 
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0.03125 µl Igepal CA-630 (Sigma Aldrich, Gillingham, UK), made up to 10 µl 
with diethyl pyrocarbonate (DEPC)-treated H2O (Invitrogen, Paisley, UK)).  
Samples were transferred to 0.2 ml PCR tubes and immediately snap frozen on 
dry ice and stored at -80°C.  This B cell lysis method is adapted from Wu et al. 
(Wu et al., 2010). 
 
3.3.2.2 IgG-specific cDNA synthesis from RNA samples 
   RNA samples were thawed slowly on ice.  To each sample 75 ng random 
hexamers (Invitrogen, Paisley, UK), 10 mM dNTPs (Invitrogen, Paisley, UK) 
and 7.5 units Thermoscript reverse transcriptase (RT) (Invitrogen, Paisley, UK) 
was added.  Samples were incubated on a thermal cycler at 25°C for 10 
minutes to allow random hexamer annealing.  cDNA synthesis was carried out 
at 50°C for 1 hour followed by 55° for 1 hour.  The reaction was terminated by 
heating to 85°C for 5 minutes.   
 
3.3.2.3 IgG variable (V) region amplification by nested PCR 
   IgG V regions were amplified from cDNA using a nested PCR protocol with 
primer sets specific for the heavy and light chains.  Two different primer sets 
were used in this analysis. 
 
3.3.2.3.1 PCR amplification using primer set A 
   Primer set A was taken from Wang and Stollar (Wang & Stollar, 2000).  
Primer names and sequences are listed in Table 3-1 and 3-2.  Gamma chain-
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Restriction sites are underlined.  NotI, GCGGCCGC; XbaI, TCTAGA. All primers were synthesised commercially by Eurofins MWG 
Operon, Germany. 
Table 3-1. Primer set A, heavy chain primers. 
Target 1st or 2nd 
round 
Primer 
orientation 
Primer name 3ULPHUVHTXHQFH¶-¶ 
+HDY\FKDLQȖ 1st  Sense VHL-1 TCACCATGGACTGCACCTGGA 
 1st  Sense VHL-2 CCATGGACACACTTTGCTCCAC 
 1st Sense VHL-3 TCACCATGGAGTTTGGGCTGAGC 
 1st Sense VHL-4 AGAACATGAAACACCTGTGGTTCTT 
 1st Sense VHL-5 ATGGGGTCAACCGCCATCCT 
 1st Sense VHL-6 ACAATGTCTGTCTCCTTCCTCAT 
 1st  Antisense &Ȗ,, GCCAGGGGGAAGACCGATG 
+HDY\FKDLQȖ 2nd Sense VH-1 TTGCGGCCGCCAGGTGCAGCTGGTGCAGTC 
 2nd Sense VH-2 TTGCGGCCGCCAGATCACCTTGAAGGAGTC 
 2nd   Sense VH-3 TTGCGGCCGCGAGGTGCAGCTGGTGGAGTC 
 2nd  Sense VH-4 TTGCGGCCGCCAGGTGCAGCTGCAGGAGTC 
 2nd  Sense VH-5 TTGCGGCCGCGAGGTGCAGCTGGTGCAGTC 
 2nd  Sense VH-6 TTGCGGCCGCCAGGTACAGCTGCAGCAGTC 
 2nd Antisense &Ȗ,,, AGGTCTAGAGACCGATGGGCCCTTGGTGGA 
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Restriction sites are underlined.  BglII, AGATCT; NcoI, CCATGG. All primers were synthesised commercially by Eurofins MWG 
Operon, Germany. 
Table 3-2. Primer set A, light chain primers. 
Target 1st or 2nd 
round 
Primer 
orientation 
Primer name 3ULPHUVHTXHQFH¶-¶ 
/LJKWFKDLQț 1st  Sense 9ț/-1 GCTCAGCTCCTGGGGCTCCTG 
 1st  Sense 9ț/-2 CTGGGGCTGCTAATGCTCTGG 
 1st Sense 9ț/-3 TTCCTCCTGCTACTCTGGCTC 
 1st Sense 9ț/-4 CAGACCCAGGTCTTCATTTCT 
 1st  Antisense &Ȗ,, GCCAGGGGGAAGACCGATG 
/LJKWFKDLQȜ 1st Sense 9Ȝ/-1 CCTCTCCTCCTCACCCTCCT 
 1st Sense 9Ȝ/-2 CTCCTCACTCAGGGCACA 
 1st  Sense 9Ȝ/-3 ATGGCCTGGATCCCTCTCC 
 1st  Antisense &Ȝ,, AGCTCCTCAGAGGAGGGCGG 
/LJKWFKDLQț 2nd Sense 9ț-1 CATAAGATCTCGACATCCAGATGACCCAGT 
 2nd Sense 9ț-2 CACCAGATCTCGATATTGTGATGACCCAG 
 2nd   Sense 9ț-3 CACCAGATCTCGAAATTGTGTTGACGCAGTCT 
 2nd  Sense 9ț-4 CACCAGATCTCGACATCGTGATGACCCAGT 
 2nd  Antisense &ț,,, TATTCCATGGAAGATGAAGACAGATGGTGC 
/LJKWFKDLQȜ 2nd  Sense 9Ȝ-1 TATTAGATCTCCAGTCTGTGCTGACTCAGC 
 2nd Sense 9Ȝ-2 TATTAGATCTCCAGTCTGCCCTGACTCAGC 
 2nd  Sense 9Ȝ-3 CACCAGATCTCTCCTATGAGCTGACTCAGC 
 2nd  Antisense &Ȝ,,, CATTCCATGGGGGAACAGAGTGACCG 
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VSHFLILF SULPHUV ZHUH XVHG WR VHOHFW IRU ,JȖ-type heavy chains only.  Both 
kappa and lambda-type light chains were amplified in a single reaction with 
light-chain specific primers.  IgG VH and VL was amplified from 2.5 µl cDNA 
in a total reaction volume of 15 µl containing 1.5 units LongAmp Taq DNA 
polymerase (New England Biolabs, Hitchin, UK), 200 µM dNTPs (Fermentas 
St. Leon-Rot, Germany) 3% DMSO (Finnzymes, Vantaa, Finland) and 5 pM 
each primer.  PCR amplification was performed in a 3-step reaction consisting 
of 94°C for 30s, 45 cycles of 94°C for 45s, 50°C for 45s and 65°C for 1 
minute, followed by 65°C for 10 minutes.  The second round PCR was carried 
out as described using 2.5 µl first round product as template with 55 cycles of 
amplification.  PCR products were detected by agarose gel electrophoresis as 
described in 2.3.1.2 and purified as described in section 2.3.1.3.  Purified PCR 
products were sequenced with the antisense primer specific to the chain type as 
described in 2.3.1.10. 
 
3.3.2.3.2 PCR amplification using primer set B 
   Primer set B was generated by combining primers described in Wardemann 
et al. (Wardemann et al., 2003), Koelsch et al. (Koelsch et al., 2007) and Tiller 
et al. (Tiller et al., 2008).  Primer names and sequences are listed in Table 3-3, 
3-4 and 3-5.  Gamma chain-VSHFLILFSULPHUVZHUHXVHG WR VHOHFW IRU ,JȖ-type 
heavy chains only.  Kappa-type light chains were amplified independently of 
lambda-type light chains in separate reactions with either kappa chain or 
lambda chain-VSHFLILFSULPHUV  ,J9+9țDQG9ȜWUDQVFULSWVZHUHDPSOLILHG
from 1.75 µl cDNA in a total reaction volume of 15 µl containing 1.5 units 
LongAmp Taq DNA polymerase (New England Biolabs, Hitchin, UK), 200 
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Table 3-3. Primer set B, heavy chain primers. 
Restriction sites are underlined.  AgeI, ACCGGT; SalI, GTCGAC.Primers were synthesised by Eurofins MWG Operon, Germany. 
Target 1st or 2nd 
round 
Primer 
orientation 
Primer name 3ULPHUVHTXHQFH¶-¶ 
IgH 1st  Sense 5' L-VH1 ACAGGTGCCCACTCCCAGGTGCAG 
 1st  Sense ¶/-VH3 AAGGTGTCCAGTGTGARGTGCAG 
 1st Sense 5' L-VH4/6 CCCAGATGGGTCCTGTCCCAGGTGCAG 
 1st Sense 5' L-VH5 CAAGGAGTCTGTTCCGAGGTGCAG 
 1st Antisense &ȖH[Wernal TCTTGTCCACCTTGGTGTTGC 
 1st Antisense &Ȗ&+ GGAAGGTGTGCACGCCGCTGGTC 
IgH 2nd Sense ¶AgeI VH1/5 CTGCAACCGGTGTACATTCCGAGGTGCAGCTGGTGCAG 
 2nd Sense ¶AgeI VH3 CTGCAACCGGTGTACATTCTGAGGTGCAGCTGGTGGAG 
 2nd   Sense ¶AgeI VH4 CTGCAACCGGTGTACATTCCCAGGTGCAGCTGCAGGAG 
 2nd  Sense ¶AgeI VH3-23 CTGCAACCGGTGTACATTCTGAGGTGCAGCTGTTGGAG 
 2nd  Sense ¶AgeI VH4-34 CTGCAACCGGTGTACATTCCCAGGTGCAGCTACAGCAGTG 
 2nd  Sense ¶AgeI VH1 CTGCAACCGGTGTACATTCCCAGGTGCAGCTGGTGCAG 
 2nd  Sense ¶AgeI VH1-18 CTGCAACCGGTGTACATTCCCAGGTTCAGCTGGTGCAG 
 2nd Sense ¶AgeI VH1-24 CTGCAACCGGTGTACATTCCCAGGTCCAGCTGGTACAG 
 2nd Sense ¶AgeI VH3-33 CTGCAACCGGTGTACATTCTCAGGTGCAGCTGGTGGAG 
 2nd Sense ¶AgeI VH3-9 CTGCAACCGGTGTACATTCTGAAGTGCAGCTGGTGGAG 
 2nd  Sense ¶AgeI VH4-39 CTGCAACCGGTGTACATTCCCAGCTGCAGCTGCAGGAG 
 2nd Sense ¶AgeI VH6-1 CTGCAACCGGTGTACATTCCCAGGTACAGCTGCAGCAG 
 2nd Antisense IgG internal       GTTCGGGGAAGTAGTCCTTGAC 
 2nd Antisense ¶SalI JH1/2 TGCGAAGTCGACGCCTGAGGAGACGGTGACCAG 
 2nd Antisense ¶SalI JH3 TGCGAAGTCGACGCTGAAGAGACGGTGACCATTG 
 2nd Antisense ¶SalI JH4/5 TGCGAAGTCGACGCTGAGGAGACGTGACCAG 
 2nd Antisense ¶ SalI JH6 TGCGAAGTCGACGCTGAGGAGACGGTGACCGTG 
 2nd Antisense &ȖQHVWHG AGGTGCTCTTGGAGGAGGGT 
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Table 3-4. Primer set B, kappa chain primers. 
Target 1st or 2nd 
round 
Primer 
orientation 
Primer name 3ULPHUVHTXHQFH¶-¶ 
,Jț 1st  Sense 5' L-9ț ATGAGGSTCCCYGCTCAGCTGCTGG 
 1st  Sense ¶/-9ț CTCTTCCTCCTGCTACTCTGGCTCCCAG 
 1st Sense 5' L-9ț ATTTCTCTGTTGCTCTGGATCTCTG 
 1st Antisense ¶&ț GTTTCTCGTAGTCTGCTTTGCTCA 
,Jț 2nd  Sense ¶3DQ9ț ATGACCCAGWCTCCABYCWCCCTG 
 2nd  Antisense ¶&ț  GTGCTGTCCTTGCTGTCCTGCTC 
,Jț Specific Sense 5' AgeI 9ț-5 CTGCAACCGGTGTACATTCTGACATCCAGATGACCCAGTC 
 Specific Sense 5' AgeI 9ț-9 TTGTGCTGCAACCGGTGTACATTCAGACATCCAGTTGACCCAGTCT 
 Specific Sense 5' AgeI 9ț'-43 CTGCAACCGGTGTACATTGTGCCATCCGGATGACCCAGTC 
 Specific Sense 5' AgeI 9ț-24 CTGCAACCGGTGTACATGGGGATATTGTGATGACCCAGAC 
 Specific Sense 5' AgeI 9ț-28 CTGCAACCGGTGTACATGGGGATATTGTGATGACTCAGTC 
 Specific Sense 5' AgeI 9ț-11 TTGTGCTGCAACCGGTGTACATTCAGAAATTC 
 Specific Sense 5' AgeI 9ț-15 CTGCAACCGGTGTACATTCAGAAATAGTGATGACGCAGTC 
 Specific Sense 5' AgeI 9ț-20 TTGTGCTGCAACCGGTGTACATTCAGAAATTGTGTTGACGCAGTCT 
 Specific Sense 5' AgeI 9ț-1 CTGCAACCGGTGTACATTCGGACATCGTGATGACCCAGTC 
 Specific Sense ¶AgeI 9ț-30 CTGCAACCGGTGTACATGGGGATGTTGTGATGACTCAGTC 
 Specific Antisense 3' Bsi:,-ț GCCACCGTACGTTTGATYTCCACCTTGGTC 
 Specific Antisense 3' Bsi:,-ț GCCACCGTACGTTTGATATCCACTTTGGTC 
 Specific Antisense 3' Bsi:,-ț GCCACCGTACGTTTAATCTCCAGTCGTGTC 
 
Restriction sites are underlined. AgeI, ACCGGT; BsiWI, CGTACG. Primers were synthesised by Eurofins MWG Operon, Germany. 
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Table 3-5. Primer set B, lambda chain primers. 
Target 1st or 2nd 
round 
Primer 
orientation 
Primer name 3ULPHUVHTXHQFH¶-¶ 
IgȜ 1st  Sense 5' L-9Ȝ GGTCCTGGGCCCAGTCTGTGCTG 
 1st  Sense ¶/-9Ȝ GGTCCTGGGCCCAGTCTGCCCTG 
 1st Sense 5' L-9Ȝ GCTCTGTGACCTCCTATGAGCTG 
 1st Sense ¶/-9Ȝ GGTCTCTCTCSCAGCYTGTGCTG 
 1st Sense ¶/-9Ȝ GTTCTTGGGCCAATTTTATGCTG 
 1st Sense ¶/-9Ȝ GGTCCAATTCYCAGGCTGTGGTG 
 1st  Sense ¶/-9Ȝ GAGTGGATTCTCAGACTGTGGTG 
 1st  Antisense ¶&Ȝ CACCAGTGTGGCCTTGTTGGCTTG 
IgȜ 2nd Sense ¶Age,9Ȝ CTGCTACCGGTTCCTGGGCCCAGTCTGTGCTGACKCAG 
 2nd Sense ¶Age,9Ȝ CTGCTACCGGTTCCTGGGCCCAGTCTGCCCTGACTCAG 
 2nd   Sense ¶Age,9Ȝ CTGCTACCGGTTCTGTGACCTCCTATGAGCTGACWCAG 
 2nd  Sense ¶Age,9Ȝ CTGCTACCGGTTCTCTCTCSCAGCYTGTGCTGACTCA 
 2nd  Sense ¶Age,9Ȝ CTGCTACCGGTTCTTGGGCCAATTTTATGCTGACTCAG 
 2nd  Sense ¶Age,9Ȝ CTGCTACCGGTTCCAATTCYCAGRCTGTGGTGACYCAG 
 2nd  Sense Ab sense GCTTCGTTAGAACGCGGCTAC 
 2nd Antisense ¶;KR,&Ȝ CTCCTCACTCGAGGGYGGGAACAGAGTG 
 
Restriction sites are underlined. AgeI, ACCGGT; XhoI, CTCGAG. Primers were synthesised by Eurofins MWG Operon, Germany. 
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µM dNTPs (Fermentas St. Leon-Rot, Germany) 3% DMSO (Finnzymes, 
9DQWDD)LQODQG DQGS0HDFKSULPHU  ,J9+DQG9țSURGXFWVZHUH PCR 
amplified in a 3-step reaction consisting of 94°C for 30s, 50 cycles of 94°C for 
30s, 57°C for 30s and 65°C for 55s, followed by 65°C for 10 minutes.  ,J9Ȝ
products were PCR amplified in a 3-step reaction consisting of 94°C for 30s, 
50 cycles of 94°C for 30s, 60°C for 30s and 65°C for 55s, followed by 65°C 
for 10 minutes.  The second round PCR was carried out as described using 1.75 
µl first round product as template with extension at 65°C for 45s. 
   6HFRQG URXQG DPSOLILFDWLRQ RI 9ț JHQHV ZDV LQLWLDOO\ FDUULHG RXt with the 
XQLYHUVDOSULPHUSDLU¶3DQ9țDQG¶&ț)ROORZLQJVHTXHQFHDQDO\VLVRI
WKHILUVW9ț3&5SURGXFWWRLGHQWLI\WKHJHQHIDPLO\VSHFLILFDPSOLILFDWLRQRI
9țZDVFDUULHGRXWZLWKWKHDSSURSULDWHSULPHUSDLUVSHFLILFSULPHUVDUHOLVWHG
in Table 3-4).  The reaction was carried out as described above.  PCR products 
were detected by agarose gel electrophoresis as described in section 2.3.1.2 and 
purified as described in section 2.3.1.3.  Purified PCR products were sequenced 
with the antisense primer or primers specific to the chain-type, as described in 
2.3.1.10. 
 
3.3.2.4 Cloning IgG VH and VL PCR products into pGEM-T Easy 
   Purified PCR products were ligated into pGEM-T Easy (Promega, 
Southampton, UK) at a 3:1 molar ratio of insert to vector in a 10 µl reaction 
containing 3 units T4 DNA ligase (Promega, Southampton, UK).  The sample 
was incubated at room temperature for 1 hour or overnight at 4°C.  Ligation 
products were transformed in E. coli TOP10 cells as described in 2.3.1.7 with 
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plating onto LB agar plates containing 25 µg/ml ampicillin (for pGEM-T Easy) 
or 35 µg/ml zeocin (for pDCORIG).  After overnight incubation colonies were 
screened as described in section 2.3.1.8.  Positive colonies containing the 
desired insert were inoculated into a 3 ml LB (Sigma Aldrich, Gillingham, UK) 
culture containing 25 µg/ml ampicillin (for pGEM-T Easy) or 35 µg/ml zeocin 
(for pDCORIG) and incubated at 37°C overnight.  Plasmid was extracted from 
overnight colonies as described in section 2.3.1.9 and sequenced with plasmid-
specific primers (Table 3-6) as described in 2.3.1.10. 
 
3.3.3 Characterisation of IgG variable regions 
3.3.3.1 Generation of contiguous sequences 
   Sequencing reads were edited using Chromas 2.13 software (Technelysium, 
Brisbane, Australia) and contiguous sequences were made using SeqMan II 
software (DNASTAR Inc., Madison, USA).  Sequences were converted into 
FASTA format for alignment using MEGA 4 software (Tamura et al., 2007). 
 
3.3.3.2 Analysis of VH and VL domains using the Immunogenetics 
database 
 
   The Immunogenetics (IMGT®) database (Lefranc, 2012) was accessed 
online to characterise the isolated VH and VL domain sequences.  The 
IMGT/V-QUEST (Brochet et al., 2008) sequence alignment software was used 
to align the isolated sequences to known Ig genes deposited in the database.  
Highest percentage identity matches to germline sequences for the V, J and D 
region are given for heavy chain sequences, or to the V and J region for light 
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Table 3-6. Additional primers used for adaptation of PCR products, sequencing and site-directed mutagenesis. 
Target Function of primer Primer 
orientation 
Primer name 3ULPHUVHTXHQFH¶-¶ 
pDCORIG 
huIgG1 
Site-directed 
mutagenesis 
Sense pDC_AgeI_s GTAGCAACAGCTACCGGTGTCCACTCCC 
 Site-directed 
mutagenesis 
Sense pDC_AgeI_KO CTACTTCCCCGAGCCGGTGACGGTG 
 PCR, sequencing Sense pDC_H_s CTCACTATAGGGAGACCCAAGCTTACC 
 PCR, sequencing  Antisense pDC_H_as AAGGGCGAATTCGCCCTTTAGA 
 PCR, sequencing  Sense pDC_k_s TAGCTTGGTACCGAGCTCGGATC 
 PCR, sequencing  Antisense pDC_k_as TCTAGATGCATGCTCGAGTCAACA 
Ig variable chain 
genes 
Expression re-
amplifcation 
Sense  VH_IgExp_s GATCACCGGTGTCCACTCCGAGGTGCAGCTGGTG 
 Expression re-
amplification  
Antisense VH_IgExp_as GATCTGTACACTCCGAMATYSWGATGACC 
 Expression re-
amplification 
Sense țBOHDGHU GATCGGATCCACCATGGGATGGAGCTGTATCAT 
CCTCTTCTTGGTAGCAACAGCTACCGGAGTCCA 
CTCCGAMATYSWGATGACCCAGWCT 
 Expression re-
amplification 
Antisense VK_IgExp_as GATCCGTACGTTTGATCTCCACCTT 
pGEM-T Easy PCR, sequencing Sense M13f GTAAAACGACGGCCAGT 
 PCR, sequencing Antisense M13r AACAGCTATGACCATG 
 
Restriction sites are underlined. AgeI, ACCGGT; AfeI, AGCGCT; BamHI, GGATCC; BsiWI, CGTACG.  Leader sequence within 
țBOHDGHULVKLJKOLJKWHGLQEROG3ULPHUVZHUHV\QWKHVLVHGE\(XURILQV0:*2SHURQ*HUPDQ\ 
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chain sequences.  Length and amino acid sequence of FRs and CDRs can be 
obtained and the amino acid sequence of CDR3 for all isolated genes is given.  
CDR3 is defined as the region from FR3 up to the conserved tryptophan-
glycine (WG) motif in VH domains, or the conserved phenylalanine-glycine 
(FG) motif in VL domains (Lefranc, 2011b).  Information regarding gene 
functionality is also given; productive denotes those gene rearrangements that 
contain no stop codons, have an in-frame junction and no defects in the genetic 
regulatory elements.  Unproductive rearrangements may result from stop 
codons, frameshift mutations, out-of-frame junctions or defects in the 
regulatory elements (Lefranc, 2011c).  In the results section, VH refers to the 
variable heavy region cDNA, encompassing rearranged VH, DH and JH 
germline genes.  VL refers to the variable light region cDNA, encompassing 
UHDUUDQJHGJHUPOLQH9țDQG-țRU9ȜDQG-ȜJHQHV,QWKHFDVHRISULPHUVHW
B, those PCR products generated with kappa-chain specific primers are 
referred to as Vk.  Gene rearrangements are annotated according to the IMGT 
nomenclature whereby IGHV denotes the group i.e. Ig heavy chain variable; 
IGHV1 specifies the subgroup and contains all genes sharing 75% or greater 
sequence homology; IGHV1-2 identifies the particular gene and IGHV1-2*01 
denotes the allelic variant from which the Ig is derived (Lefranc, 2011a).   
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3.3.4 Expression of whole IgG in mammalian cells 
3.3.4.1 Adaptation of the expression plasmid pDCORIG huIgG1 by 
site-directed mutagenesis 
 
   The expression plasmid pDCORIG huIgG1 was kindly provided by Lindy 
Durrant (Scancell Ltd, Nottingham, UK) (Figure 3-3).  Prior to cloning the VH 
and Vk domains, it was necessary to introduce appropriate restriction sites into 
the plasmid.  The restriction site AgeI was introduced into the heavy chain 
leader sequence and the AgeI site present in the heavy chain constant region 
was knocked-out (Figure 3-4a).  Site-directed mutagenesis was carried out on 
all sites simultaneously using the QuikChange Multi Site-directed Mutagenesis 
kit (Agilent Technologies, Stockport, UK).  Site-specific mutagenesis primers 
were designed using PrimerX (http://bioinformatics.org/primerx/cgi-
bin/DNA_1.cgi) (Table 3-6).  One hundred nanograms of plasmid was used as 
Figure 3-3. Plasmid map of the Ig expression vector, pDCORIG huIgG1 
(Scancell Ltd, Nottingham, UK). The light variable and heavy variable 
regions are shown in light blue. These were replaced by VH and Vț 
sequences isolated from patient B cells.  Expression cassettes are 
under the control of a cytomegalovirus immediate early (CMV IE) 
promoter that directs expression of the variable and constant region 
genes. The BGH polyadenylation (polyA) signal ensures correct 
processing of the mRNA transcripts. Zeocin, under the control of the 
SV40 promoter and polyA signals allows for selection of transfectants in 
both bacterial and mammalian cells. ColE1 enables replication of the 
plasmid in E. coli. Figure adapted from Metheringham et al., (2009). 
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Figure 3-4. Strategy to modify the vector and PCR products for Ig gene cloning. See overpage for full figure legend. 
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template in a total reaction volume of 25 µl containing 50 ng of each primer1 
µl dNTP mix, 2.5 units QuikChange Multi Enzyme mix and 3% QuikSolution.  
Mutagenesis was performed in a 3-step cycling reaction consisting of 95°C for 
2 minutes, 30 cycles of 95°C for 20s, 55°C for 30s and 65°C for 3 minutes, 
followed by 65°C for 5 minutes.  Parental plasmid was removed by the 
addition of 10 units DpnI and incubation at 37°C for 1 hour.  Plasmid was 
transformed into TOP10 cells as described in 2.3.1.7.  Selected colonies were 
picked and grown in 3 ml LB culture (Sigma Aldrich, Gillingham, UK) 
containing 35 µg/ml zeocin and incubated at 37°C overnight.  Plasmid was 
extracted as described in 2.3.1.9 and sequenced with heavy cassette-specific 
primers, pDC_H_s and pDC_H_as, (Table 3-6) as described in 2.3.1.10 to 
confirm the presence of the desired mutations. 
 
3.3.4.2 Re-amplification of IgG gene products with universal 
primers 
 
   Universal primers were designed to introduce the restriction sites AgeI and 
Afe,DWWKH¶DQG¶HQGUHVSHFWLYHO\RIDQ\9+3&5SURGXFWFigure 3-4b).  A 
Figure 3-4. Strategy to modify the vector and PCR products for Ig 
gene cloning. (a) The AgeI restriction site was introduced into the VH 
domain by site directed mutagenesis of A to T (blue text). An AgeI 
restriction site was removed from the CH domain by mutation of A to G 
(blue text). The light chain cassette was unmodified. (b) The PCR 
products generated as described in sections 3.3.2.3.1 and 3.3.2.3.2 did 
not contain compatible restriction sequences.  Therefore, Vț PCR 
products were reamplified with a sense primer containing the Ig leader 
sequence (dark blue) and the restriction site BamHI. The antisense 
primer contained BsiWI. VH PCR products were reamplified with a 
sense primer containing AgeI and an antisense primer containing AfeI. 
This allowed restriction enzyme cloning of the adapted PCR products 
into the vector. Vector map and sequence information was provided by 
Lindy Durrant (Scancell Ltd, Nottingham, UK). 
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universal primer was designed to introduce the restriction site Bsi:,DWWKH¶
end of any Vk product.  Another primer was designed to introduce the Ig leader 
sequence as well as Bam+,DWWKH¶HQGRIDQ\9NSURGXFWFigure 3-4b).  The 
Ig leader sequence was taken from plasmid pDCORIG huIgG1.  Primers are 
listed in Table 3-6.  Two microlitres of VH or Vk PCR product was used as 
template in a total reaction volume of 20 µl containing 1 unit LongAmp Taq 
DNA Polymerase (New England Biolabs, Hitchin, UK), 200 µM dNTPs 
(Fermentas St. Leon-Rot, Germany), 4 pM each primer (VH_IgExp_s and 
VH_IgExp_as for amplification of VH products; k_leader and Vk_IgExp_as 
IRU DPSOLILFDWLRQ RI 9ț SURGXFWV DQG 3% DMSO (Finnzymes, Vantaa, 
Finland).  PCR amplification was performed in a 2-step reaction consisting of 
94°C for 30s, 40 cycles of 94°C for 45s and 65°C for 50s, followed by 65°C 
for 10 minutes.  PCR products were detected by agarose gel electrophoresis as 
described in 2.3.1.2 and purified as described in 2.3.1.3.  Products were cloned 
into pGEM-T Easy (Promega, Southampton, UK) as described in 3.3.2.4 and 
transformed into E. coli TOP10 cells as described in 2.3.1.7. 
 
3.3.4.3 Cloning VH genes into pDCORIG huIgG1 
   Purified VH PCR products (containing appropriate restriction sites) and 
pDCORIG huIgG1 plasmid were digested with 10 units AgeI (New England 
Biolabs, Hitchin, UK) and 10 units AfeI (New England Biolabs, Hitchin, UK) 
in a 20 µl reaction volume for 1 hour at 37°C.  Restriction enzymes were 
inactivated by heating to 65°C for 20 minutes.  Plasmid digestion was 
confirmed by agarose gel electrophoresis as described in 2.3.1.2 and the 
plasmid column purified as described in 2.3.1.3.  VH was ligated into 
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pDCORIG huIgG1 containing compatible ends at a 3:1 molar ratio of insert to 
vector in a 20 µl reaction volume containing 400 cohesive end units T4 DNA 
ligase (New England Biolabs, Hitchin, UK).  Reaction was incubated at 16°C 
for 1 hour and plasmids transformed into E. coli TOP10 cells as described in 
2.3.1.7.  Colonies were screened, as described in section 2.3.1.8, with heavy 
cassette-specific primers, pDC_H_s and pDC_H_as, (Table 3-6) to confirm the 
presence of a full-length VH region.  PCR products were detected by agarose 
gel electrophoresis as described in 2.3.1.2 and putative positive colonies were 
inoculated into a 3 ml LB culture (Sigma Aldrich, Gillingham, UK) containing 
35 µg/ml zeocin and incubated at 37°C overnight.  Plasmid was extracted as 
described in 2.3.1.9 and sequenced as described in 2.3.1.10 with heavy 
cassette-specific primers to confirm the introduction of a novel VH region. 
 
3.3.4.4 Cloning Vț genes into pDCORIG huIgG1 
   Modified Vk products and plasmid pDCORIG huIgG1 containing a novel VH 
region were digested with 10 units BamHI (New England Biolabs, Hitchin, 
UK) in a 20 µl reaction volume for 1 hour at 37°C prior to the addition of 10 
units BsiWI (New England Biolabs, Hitchin, UK) and incubation for 1 hour at 
55°C.  Plasmid digestion was confirmed by agarose gel electrophoresis as 
described in 2.3.1.2.  All digested products were column purified as described 
in 2.3.1.3.  Vk was ligated into pDCORIG huIgG1 containing compatible ends 
as described in 3.3.4.3.  Transformation, screening, growth and plasmid 
extraction from putative positive colonies and detection of a novel Vk region 
was carried as described in 3.3.4.3 using kappa specific primers (pDC_k_s and 
pDC_k_as) (Table 3-6). 
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3.4 Results 
3.4.1 Stimulation of B cell cultures to produce IgG 
   Initial experiments were carried out with cultures of B cells seeded at either 
10 or 100 cells per well.  These cultures were stimulated for either 5 days or 10 
days with R848, a TLR7 and TLR8 agonist, and IL-2, a B cell growth factor 
(Pinna et al., 2009).  The IgG-specific mRNA was detected by cDNA synthesis 
and PCR amplification.  Both VH and VL gene transcripts could be detected by 
amplification with primer set A (Figure 3-5 and 3-6) but not with primer set B 
(data not shown).   
Figure 3-5. Amplification of IgG light chain variable domains.  Primer 
set A was used to amplify VL from cultures of 10 or 100 B cells isolated 
from two HCV-positive patients, RH or RJ.  Positive reactions contain 
products at ~400 bp. B, B cell negative controls; F, macrophage feeder 
cell negative controls; P, cDNA negative control. Position of DNA 
marker, M, is shown in base pairs.   
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VH and VL domains were detected in 5-day old cultures (data not shown) as 
well as in 10-day old cultures (Figure 3-5 and 3-6).  The age of the culture did 
not impact the number of IgG-PCR positive wells recovered; 74.0% of cultures 
tested positive for VL and 84.4% tested positive for VH after 5 days, whereas 
73.6% of cultures tested positive for VL and 79.0% of cultures tested positive 
for VH after 10 days.  This is comparable to the 70% PCR recovery levels 
(range 30-80%) reported previously for this primer set (Wang & Stollar, 2000).  
However, the number of cells seeded per well did influence the recovery of VH 
and VL transcripts.  After 10 days incubation, 93.6% of cultures containing 
100 B cells tested positive for VH compared to only 63.6% of cultures 
Figure 3-6. Amplification of IgG heavy chain variable domains. Primer 
set A was used to amplify VH from cultures of 10 or 100 B cells 
isolated from two HCV-positive patients, RH or RJ.  Positive reactions 
contain products at ~400 bp. B, B cell negative controls; F, 
macrophage feeder cell negative controls; P, cDNA negative control. 
Position of DNA marker, M, is shown in base pairs.   
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containing 10 B cells (Figure 3-5).  Similarly 91.5% of cultures containing 100 
B cells tested positive for VL compared to only 54.5% of cultures containing 
10 B cells (Figure 3-6).  This was expected as not all B cells within the culture 
will produce IgG.  Therefore, there is a greater chance of generating IgG-PCR 
negative cultures when fewer B cells are seeded.  These cultures were 
generated from B cells isolated from two separate patients, RH and RJ.  After 
10 days culture, there was very little difference between the patients in terms of 
IgG production, as quantified by recovery of PCR products; for 100 B cells, 
91.6% of RJ-derived cultures tested positive compared to 93.4% of RH-derived 
cultures; for 10 B cells, 59.5% of RJ-derived cultures tested positive compared 
to 60.8% of RH-derived cultures.  These experiments also showed that the PCR 
products recovered were specific to the IgG VH and VL domains, as cultures 
lacking B cells tested negative.  Macrophage feeder cell-negative control wells 
also did not contain IgG PCR products (Figure 3-5 and 3-6).  The feeder cells 
provide additional cytokines that support the proliferation of the IgG+ memory 
B cells (Pinna et al., 2009), without which the B cells are not able to produce 
antibody.  This confirmed that the PCR products were specific to IgG VH and 
VL transcripts expressed in B cells. 
   Having confirmed that both VH and VL transcripts could be isolated from 
cultured B cells with at least one primer set, it was necessary to identify those 
cultures that might be producing HCV-specific Igs.  Reactivity of the cell-
culture supernatants to HCV E1E2 (genotype 1a) was tested using GNA-
capture ELISA.  Only 4.1% of 5-day old cultures and 9.8% of 10-day old 
cultures were HCV E1E2-reactive.  This demonstrated that the majority of IgG 
produced under these culture conditions was not HCV-specific.  The B cell 
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isolation method distinguishes IgG+ memory B cells from other B cell isotypes 
(IgM, IgA etc); however, antigen specificity of the IgG response can only be 
tested after antibody production has been stimulated for several days.  
Evaluation of subsequent B cell cultures confirmed these initial findings; 20-
30% of cultures containing a single cell tested positive by ELISA for IgG 
production, of which 2-12% was HCV E1E2 (genotype 1a)-specific.  For 
cultures containing 10 B cells, 37-50% of wells tested positive for IgG 
production of which, 3-11% was HCV E1E2 (genotype 1a)-specific.  The 
values were obtained from multiple experiments with 3 different donors and 
suggest that the B cell stimulation method did not activate all the B cells, a 
phenomenon that has been reported in the literature (Pinna et al., 2009).  The 
level of IgG antibody production from single cell cultures was approximately 
100 ng/ml (range 74-170 ng/ml) (Figure 3-7) which appears to be lower than 
the production levels of 200 ng/culture (per cell) reported previously (Pinna et 
al., 2009).  These results prompted us to alter the way in which the cultures 
were analysed, with assessment of IgG production and HCV E1E2 reactivity 
preceding VH and VL isolation in all subsequent experiments.  It was felt that 
this would reduce the overall workload by avoiding cDNA synthesis and PCR 
amplification from cultures which were of no further interest.   
 
3.4.2 Cloning and characterisation of IgG transcripts from 
patients RH and RJ 
 
   Culture wells containing HCV E1E2-specific IgG were matched to those 
containing VH and VL PCR products.  Of thirteen wells testing positive for 
HCV-specific Igs, 10 were PCR positive for both the VH and VL domain, two 
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wells were PCR positive for VH but negative for VL and one well was 
negative for both PCR products.  This may have been caused by insufficient 
cDNA synthesis which can occur if the cultures become contaminated with 
RNAse leading to degradation of the IgG-specific mRNA.  However, as IgG 
transcripts were successfully amplified from the majority of cultures it seems 
unlikely that RNAse contamination would have affected a single sample.  It is 
more likely that the cell pellet was lost during the RNA extraction protocol due 
to a handling error.  Alternatively, mutation within the primer binding sites 
may have caused the amplification to fail, a problem that has been reported 
previously (Scheid et al., 2011).  This would also explain amplification of VH 
Figure 3-7. IgG production in B cell cultures. Cultures of 1, 10 or 50 
cells were plated onto irradiated macrophage feeder cells and 
stimulated with IL-2 and R848 for 10 days. IgG secreted into the culture 
supernatant was measured by ELISA. Data was generated and the 
graph produced in GraphPad Prism 4.03 for Windows (Graphpad 
Software, San Diego, USA) by Richard Urbanowicz. Data is 
representative of results for B cell cultures generated from three 
separate patients. 
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but not VL in two of the samples.  VH and VL PCR products were purified 
from all samples that tested positive for both transcripts and were also HCV 
E1E2 reactive.  The PCR products were then cloned into the vector pGEM-T 
Easy (Promega, Southampton, UK).  Multiple colonies containing the VH and 
VL inserts from different samples were screened.  Most colonies were found to 
contain the product of interest.  To ascertain the level of variation between 
sequences isolated from cultures of either 10 or 100 B cells, several colonies 
were sequenced across the VH or VL domain.  Sequences were then analysed 
using the IMGT® database (Lefranc, 2012) to determine the VDJ (for the 
heavy chain) or VJ (for the light chain) gene rearrangement forming the 
variable domain.  Table 3-7 and 3-8 show the results for several sequenced 
clones from patient RJ.  Sequence names correspond to the culture well from 
which the genes were isolated.  Sequences labelled 10.6, 12.2 and 23.2 were 
derived from cultures of 10 B cells.  Sequences labelled 19.2, 19.6 and 21.6 
were all derived from cultures of 100 B cells.  A single culture well from 
patient RH tested positive for HCV E1E2-reactive IgG production as well the 
VH and VL domains, however all sequences generated contained unproductive 
gene rearrangements.  As expected for cultures containing more than one B 
cell, there was diversity in the sequences isolated from a single culture well; 
however, some culture wells were more diverse than others.  For example 
sequences isolated from well 12.2 were derived from different VH-genes 
(IGHV4-31*03 and IGHV3-53*01) and DH-genes (IGHD4-4*01 and IGHD5-
12*01) with further differences observed between allelic variants (IGHV4-
31*03 and IGHV4-31*04), clearly showing the presence of more than one 
mRNA template.  Sequences isolated from well 10.6 showed much less 
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Table 3-7. Heavy chain sequences isolated from patient RJ. 
Sequence 
name 
V-GENE and allele Identity 
(%) 
J-GENE and allele Identity (%) D-GENE and allele CDR3 (amino acids) 
10.6_H1 IGHV1-69*01 88.19 IGHJ6*02 77.42 IGHD3-10*01 GVYYGSTYGVDV 
10.6_H2 IGHV1-69*01 88.54 IGHJ6*02 79.03 IGHD3-10*01 GVYYGSTYGVDV 
10.6_H3 IGHV1-69*01 88.89 IGHJ6*02 79.03 IGHD3-10*01 GVYYGSTYGVDV 
12.2_H2 IGHV4-31*04 91.75 IGHJ4*02 93.75 IGHD4-4*01 AREGTLQNFDY 
12.2_H3 IGHV3-53*01 96.14 IGHJ4*02 79.17 IGHD5-12*01 ARDLYGGPGS 
12.2_H5 IGHV4-31*03 94.50 IGHJ4*02 95.83 IGHD4-4*01 AREGTLQNFDY 
19.2_H1 IGHV3-11*01 94.44 IGHJ4*02 85.42 IGHD3-22*01 ARDSDSSGPSDY 
19.2_H2 IGHV3-11*01 94.44 IGHJ4*02 85.42 IGHD3-22*01 ARDSDSSGPSDY 
19.2_H3 IGHV3-15*01 97.28 IGHJ4*02 95.83 IGHD3-10*01 TTEGSYFDY 
19.2_H4 IGHV3-11*01 94.10 IGHJ4*02 85.42 IGHD3-22*01 ARGSDSSGPSDY 
19.2_H5 IGHV3-30*03 or IGHV3-30*18 
or IGHV3-30*19 
93.06 IGHJ4*02 75.00 IGHD3-22*01 TKDSGYYDSAGYPGEY 
19.6_H1 IGHV3-30*01 95.83 IGHJ5*02 94.12 IGHD4-23*01 ASTAEDYGDSWFDP 
19.6_H2 IGHV5-51*01 95.83 IGHJ3*02 90.00 IGHD2-2*02 AGPGYCSSTRCSNTFDM 
19.6_H3 IGHV3-30*01 95.83 IGHJ5*02 94.12 IGHD4-23*01 ASTTEDYGDSWFDP 
19.6_H4 IGHV4-b*01 93.06 IGHJ3*02 94.00 IGHD2-2*01 ARALYCSSPRCIWGKNDAFDI 
19.6_H5 IGHV5-51*01 94.44 IGHJ3*02 92.00 IGHD2-2*02 AGPGYCSSTRCSNTFDM 
21.6_H1 IGHV4-31*01 or IGHV4-31*03 94.16 IGHJ2*01 98.11 IGHD4-23*01 ARHRRSSWYFDL 
21.6_H2 IGHV4-31*01 or IGHV4-31*03 94.85 IGHJ2*01 98.11 IGHD4-23*01 ARHRRSSWYFDL 
21.6_H4 IGHV4-31*01 or IGHV4-31*03 95.19 IGHJ2*01 98.11 IGHD4-23*01 ARHRRSSWYFDL 
23.2_H1 IGHV1-18*01 96.88 IGHJ6*03 88.71 IGHD2-15*01 ARAVEGAVAAINYYFYMDV 
23.2_H2 IGHV1-18*01 97.92 IGHJ6*03 88.71 IGHD2-15*01 ARAVEGAVAAINYYFYMDV 
23.2_H5 IGHV1-18*01 96.88 IGHJ6*03 88.71 IGHD2-15*01 ARAVEGAVAAINYYFYMDV 
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Table 3-8. Light chain sequences isolated from patient RJ. 
diversity with all sequences matching the IGHV1-69*01, IGHJ6*02 and 
IGHD3-10*01 genes.  However, percentage identity to the germline gene 
varied between the isolated sequences, suggesting that more than one cDNA 
template was present.  Sequence variation could be induced during PCR 
amplification, although the amount of diversity observed is unlikely to be 
caused by experimental error alone.  Amino acid alignment showed variation 
between the sequences at residue 1 (Q-E), residue 6 (Q-E), residue 44 (Q-L), 
residue 99 (T-A) and residue 126 (I-V) (Figure 3-8).  Although not identical, 
these sequences were possibly clonal in origin, derived from a common B cell 
ancestor that had undergone SHM. 
   These sequences were also aligned to the closest germline sequence IGHV1-
69*01 (Figure 3-8).  CDRs are highlighted as these are the sites of greatest 
divergence from the germline sequence.  Only alignment to the germline VH 
genes is shown here, including the VH-encoded N-terminus of CDR3.  The 
remainder of CDR3 is encoded by the D (heavy chain only) and J genes.  
CDR3 shows the greatest length polymorphism and sequence diversity as a 
result of VDJ gene recombination, N-nucleotide addition and SHM.  Mutations 
Sequence 
name 
V-GENE and allele Identity (%) J-GENE and allele Identity (%) CDR3 (amino acids) 
10.6_L1 IGKV1-5*03 91.40 IGKJ1*01 92.11 QHYSDSSGT 
10.6_L3 IGKV1-5*03 91.40 IGKJ1*01 89.47 QHYSDSSGT 
12.2_L3 IGKV3-20*01 96.81 No rearrangement found, no junction identified 
19.2_L1 IGKV1-39*01 or IGKV1D-39*01 95.34 IGKJ3*01 97.37 QQSYSTPFT 
19.6_L2 IGKV3-20*01 97.87 IGKJ1*01 92.11 QQYGSSPGT 
19.6_L4 IGKV3-20*01 97.87 IGKJ1*01 92.11 QQYGSSPGT 
21.6_L1 IGKV1-39*01 or IGKV1D-39*01 94.98 IGKJ1*01 100.00 QQANSFPRT 
21.6_L2 IGKV1-39*01 or IGKV1D-39*01 96.06 IGKJ3*01 96.97 QQSYTIL 
21.6_L3 IGKV1-39*01 or IGKV1D-39*01 96.06 IGKJ3*01 96.97 QQSYTIL 
23.2_L4 IGKV1-39*01 or IGKV1D-39*01 92.11 IGKJ1*01 97.22 QQSYSTLRT 
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Figure 3-8. Sequence alignment of cloned VH domains and the closest germline relative. VH domain sequences were 
derived from a 5 day culture of 10 B cells isolated from patient RJ. The diversity between the isolates and the germline 
gene is a result of affinity maturation. The diversity between each isolate may suggest the presence of more than one 
cell in the initial culture. FRs are shown and CDRs are highlighted in blue. Dots denote amino acid sequence identity, 
dashes denote missing amino acids.  The C-terminus of CDR3 and FR4 are provided by the J and D gene 
rearrangements. Residues are numbered according to the IMGT numbering system (Lefranc, 2011b). The conserved 
cysteine at 104 and conserved tryptophan at 118 are also numbered. 
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within the CDRs are likely to be those responsible for enhanced binding to the 
antigen, following affinity maturation; however a large number of mutations 
were also present in the FRs of these sequences.  FRs are responsible for 
maintaining structural integrity of the IgG molecule and are less likely to 
tolerate mutations, yet a cluster of mutations within FR3 (residues 84-90) 
(Figure 3-8) differing from the germline gene was observed.  Antibodies have 
been described that not only tolerate substitutions and insertions within FRs, 
but also show improved affinity due to these FR mutations (Krause et al., 
2011).  However, other studies show that substitutions within FRs have little or 
no impact on antibody binding (Toran et al., 2001).  The FR3 mutations in 10.6 
are conservative mutations and as such would not be expected to alter the 
structure of the IgG significantly but it remains to be seen if they improve 
binding affinity.  The overall sequence identity remains high at >88% and all 
other sequences show germline sequence identity values >91% (Table 3-7). 
   Diversity was also seen between the light chains, all of which were found to 
be kappa class chains (Table 3-8).  The light chains derived from sample 10.6 
however, were very similar, containing identical IGKV germline genes 
(IGKV1-5*03) and CDR3.  However, each isolated sequence matched the 
IGKJ1*01 gene with different percentage identity and alignment highlighted a 
single amino acid difference at residue 78 (A-V mutation between clone 
10.6_L1 and 10.6_L3)(Figure 3-9).  Although these transcripts were derived 
from cultures containing 10 B cells, it is possible that fewer cells were actually 
seeded, or functional.  The small amount of diversity observed between 
sequences may have been caused by PCR induced mutations during the 
amplification and cloning process.  It may therefore be possible to isolate the 
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Figure 3-9. Sequence alignment of cloned VL domains and the closest germline relative. VL domain 
sequences were derived from a 5 day culture of 10 B cells isolated from patient RJ. The diversity between the 
isolates and the germline gene is a result of affinity maturation. FRs are shown and CDRs are highlighted in 
blue. Dots denote amino acid sequence identity, dashes denote missing amino acids. The C-terminus of 
CDR3 and FR4 are provided by the J and D gene rearrangements. Residues are numbered according to the 
IMGT numbering system (Lefranc, 2011b). The conserved cysteine at 104 and conserved phenylalanine at 
118 are also numbered. 
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different VH and VL domains from cultures such as these and produce 
antibody from the paired chains.  Other transcripts were also found to share 
common genes and have high levels of sequence identity e.g. transcripts 
derived from 21.6 and 23.3 (Table 3-7 and 3-8).  However, pairing heavy and 
light chains would be problematic for sequences such as 21.6_L1 and 21.6_L2 
that have diffeUHQW -ț-genes and CDR3 sequences (Table 3-8).  Correctly 
pairing heavy and light chains to produce a functional antibody would be even 
more problematic for transcripts derived from different germline genes e.g. 
19.6.  These sequences were isolated from a culture containing 100 B cells.  
Theoretically there could be 100 different heavy chains and 100 different light 
chains, resulting in 10,000 possible combinations of heavy and light chains.  
Generating and testing the functionality of all possible antibodies would be an 
extremely time-consuming and labour intensive process.  Incorrect pairing of 
chains would result in many of the antibodies being non-functional and the 
cloning steps required may introduce mutations which abrogate or reduce 
antibody binding or affinity.  Therefore it would be greatly advantageous to 
isolate VH and VL domains from single cell cultures to avoid the problem of 
matching heavy and light chains. 
 
3.4.3 Cloning and characterisation of IgG genes from patient SK 
   In order to obtain cultures of single B cells, fluorescence activated cell 
sorting was attempted using a Beckman Coulter MoFlo Cell sorter (Beckman 
Coulter, High Wycombe, UK) to isolate CD19+, CD27+ and IgG+ memory B 
cells from the PBMCs of patient SK.  Unfortunately, this proved unsuccessful 
as the sorting was not very efficient and the cells did not produce measurable 
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amounts of IgG.  This was believed to be caused by the failure of the B cells to 
expand.  Therefore, cultures were seeded at approximately 1.3 per well using 
an automated system that deposits a specific volume of cell suspension into 
each well.  Cultures receiving an average input of 1.3 cells were stimulated for 
10 days.  HCV-specific IgG-producing wells were identified by ELISA with 
E1E2 (genotype 1a) and peptide capture immunoassay to peptide I and peptide 
II.  Peptide I corresponds to the E2 region encompassing amino acids 412-423; 
peptide II corresponds to the E2 region encompassing amino acids 434-446.  
Although rare in natural infection, antibodies to these epitopes are neutralising 
and it has recently been shown that antibodies against peptide II can augment 
neutralisation by antibodies targeting peptide I (Tarr et al., 2012b).  Those 
wells testing positive for HCV-reactive IgG and either peptide I or peptide II 
reactivity were selected for isolation and characterisation of the VH and VL 
domains.  Eleven wells out of 384 (2.8%) produced HCV-specific IgG with 
reactivity to peptide I or II.  Both primer set A (data not shown) and primer set 
B (Figure 3-10) were able to amplify VH and VL transcripts from these 
cultures.  Of eleven HCV-specific IgG-positive samples, seven tested positive 
for the VH domain and all eleven samples tested positive for the VL domain.  
Primer set B includes kappa-chain and lambda-chain specific primer sets for 
amplification of the different chain types in separate PCR reactions.  
Surprisingly, kappa-specific and lambda-specific PCR products were obtained 
from all eleven samples.  Individual B cells produce antibody containing either 
kappa or lambda-type light chains and mechanisms exist to exclude the 
expression of both (Dudley et al., 2005).  The observation of both chain types 
was therefore suggestive of more than one B cell in each culture.  These 
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cultures were prepared by depositing B cells, diluted to a specific 
concentration, into a 384-well plate such that each well contained on average 
1.3 cells.  In reality this would result in a majority of wells containing one B 
cell but with the potential for a range of cell numbers, with some empty wells 
and others containing multiple B cells.  It is possible that the wells selected for 
VH and VL analysis were those containing more than one cell that were able to 
produce sufficient IgG.  The B cell culture protocol may have failed to 
stimulate the production of IgG from single B cells and the low recovery of 
ELISA/peptide immunoassay positive wells seems to support this hypothesis.  
The discrepancy between VL recovery (11/11 samples) and VH recovery (7/11 
samples) is probably due to mutation of the primer binding site preventing PCR 
amplification of highly mutated genes.   
   The VH and VL PCR products isolated from these samples were cloned into 
the vector pGEM-T Easy and representative colonies from each sample were 
sequenced to identify their corresponding germline gene (Table 3-9 and 3-10).  
With the exception of B11, diversity of the VH domain between the sequenced 
isolates was limited.  Transcripts from samples J8, K18 and M24 were derived 
Figure 3-10. Amplification of IgG variable chain domains from B cell 
cultures.  Primer set B was used to amplify VH, Vț and VȜ from putative 
single cell cultures isolated from patient SK and cultured for 10 days to 
produce IgG.  Positive reactions containing products at 400-500 bp are 
highlighted with *. RNA ±ve, RNA negative controls; cDNA ±ve, cDNA 
negative controls. Position of DNA marker, M, is shown in base pairs. 
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Table 3-9. Heavy chain sequences isolated from patient SK. 
Sequence 
name 
V-GENE and allele Identity 
(%) 
J-GENE and allele Identity (%) D-GENE and allele CDR3 (amino acids) 
B11_H2 IGHV3-48*03 91.32 IGHJ4*02 93.75 IGHD2-2*01 ARERPAEPYCFDY 
B11_H6 IGHV3-23*01 94.44 IGHJ3*02 90.00 IGHD3-22*01 AKDYYYDSGAYSGPGAFNI 
C20_H6 IGHV4-39*07 94.50 IGHJ3*02 88.00 IGHD6-19*01 ARDVRYCYSNGCYRNTFDT 
J8_H2 Unproductive IgH rearrangement (stop codons) 
J8_H3 IGHV3-7*01 or IGHV3-7*03 91.32 IGHJ5*02 94.12 IGHD3-10*01 ARGFIAQLVRGYINNWFDP 
J8_H6 IGHV3-7*01 or IGHV3-7*03 89.93 IGHJ5*02 92.16 IGHD3-10*01 ARGFIAQLVRGYINNWFDP 
K18_H3 IGHV1-2*02 87.50 IGHJ4*02 85.42 IGHD2-2*01 ARKYCTSVYCDLRFFDS 
K18_H4 IGHV1-2*02 91.67 IGHJ4*02 85.42 IGHD2-2*01 ARKYCTSVYCDLRFFDS 
M24_H1 IGHV373*02     92.52 No rearrangement found, no junction identified  
M24_H2 IGHV3-73*02 93.20 IGHJ6*02 or IGHJ6*03 74.19 IGHD4-17*01 SRPPYGDTKADV 
 
Table 3-10. Light chain sequences isolated from patient SK. 
Sequence 
name 
V-GENE and allele Identity 
(%) 
J-GENE and allele Identity (%) CDR3 (amino acids) 
B11_K3 IGKV1-NL1*01 90.04 IGKJ2*01 or IGKJ2*02 86.84 QQYYSTPPVT 
B11_K5 IGKV1-NL1*01 90.04 IGKJ2*01 or IGKJ2*02 86.84 QQYYSTPPVT 
C20_L5 IGKV3-20*01 91.13 IGKJ4*01 100 QQYAGSLT 
J8_K1 IGKV1-39*01 or IGKV1D-39*01 97.04 IGKJ4*01 91.67 QQSYSTLA 
J8_K3 No rearrangement found (stop codons) 
J8_L1 IGKV3-20*01 97.16 IGKJ4*01 94.74 QQYGNSPSLT 
J8_L2 IGKV1-12*01 or IGKV1-12*02 92.83 IGKJ3*01 94.74 QQSNSFPFT 
K18 L4 IGKV1-9*01 95.34 IGKJ2*01 91.89 QQLDTYPNA 
K18 L5 IGKV3-11*01 98.57 IGKJ2*01 or IGKJ2*02 91.43 QQRSNWPPS 
M24_K1 IGKV1-39*01 95.57 IGKJ4*01 100 QQSYSTPLT 
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from the same germline gene and allele for VH, DH and JH genes, with little 
diversity between sequences.  Only one sequence was isolated from sample 
C20 precluding any analysis of clonal variation.  However, upon closer 
analysis of the sequence alignments, differences between J8_H3 and J8_H6 
were observed at the amino acid level (E6Q and S86P) (Figure 3-11).  It is 
possible that these differences were due to PCR-induced errors or mutations 
introduced during cloning; however it is also likely that these represent 
descendants of a single B cell that have undergone affinity maturation and are 
not derived from single B cell cultures.  The presence of very different 
sequences derived from sample B11 was further indication that samples 
contained more than one B cell.  Sample B11_H2 was derived from the 
rearranged germline genes IGHV3-48*03, IGHJ4*02 and IGHD2-2*01 
whereas B11_H6 was derived from IGHV3-23*01, IGHJ3*02 and IGHD3-
22*01. 
   Interestingly when the analysis was extended to the VL products, all were 
found to contain kappa chain transcripts.  No PCR products corresponding to 
lambda germline genes were observed.  However, differing germline gene 
rearrangements between sequences was observed, providing further evidence 
of B cell cultures containing more than one cell.  In contrast to the situation 
with the VH transcripts, VL sequences from sample B11 were derived from a 
single germline gene rearrangement of IGKV1-NL1*01 and IGKJ2*01 (or 
*02) (Table 3-10).  Sequence changes were observed between B11_K5 and 
B11_K3 (A9F, V49A, C104W), (Figure 3-12) possibly due to affinity 
maturation of cells derived from the same B cell clone, or they may have been 
caused by PCR induced errors.  The mutation from cysteine to tryptophan at 
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Figure 3-11. Sequence alignment of cloned VH domains derived from a 10 day culture of B cells isolated from patient SK. 
Cells were seeded at a density of 1.3 cells per well, to give a majority of wells containing a single cell. The diversity 
between isolated sequences and the germline gene is a result of affinity maturation. The diversity between each isolate 
may suggest the presence of more than one cell in the initial culture. FRs are shown and CDRs are highlighted in blue. 
Dots denote amino acid sequence identity, dashes denote missing amino acids. The C-terminus of CDR3 and FR4 are 
provided by the J and D gene rearrangements. Residues are numbered according to the IMGT numbering system (Lefranc, 
2011b). The conserved cysteine at 104 and conserved tryptophan at 118 are also numbered. 
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Figure 3-12. Sequence alignment of cloned Vț domains derived from a 10 day culture of B cells isolated from 
patient SK. Cells were seeded at a density of 1.3 cells per well, to give a majority of wells containing a single 
cell. The diversity between isolated sequences and the germline gene is a result of affinity maturation. The 
diversity between each isolate indicates the presence of more than one cell in the initial culture. FRs are shown 
and CDRs are highlighted in blue. Dots denote amino acid sequence identity, dashes denote missing amino 
acids. The C-terminus of CDR3 and FR4 are provided by the J and D gene rearrangements. Residues are 
numbered according to the IMGT numbering system (Lefranc, 2011b). The conserved cysteine at 104 and 
conserved phenylalanine at 118 also are numbered. 
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residue 104 in B11_K3 was particularly interesting.  C104 is one of two 
conserved cysteine residues in the VL domain, along with C23, that form an 
intra-chain disulfide bond responsible for stabilising the protein fold (Lefranc, 
2011d).  Although this IGK gene rearrangement was productive, loss of C104 
may result in an unstable antibody with reduced function; however this could 
only be assessed by analysis of the expressed protein, which was beyond the 
scope of this work.  This cysteine residue was present in all other sequences 
analysed.  Other conserved features such as a conserved cysteine at residue 23, 
a conserved tryptophan at residue 41 and the conserved motif F/W-G-X-G at 
position 118-121 (Lefranc, 2011b) were also conserved amongst all sequences.  
   Sequenced transcripts from sample J8 and K18 had different VL domain 
germline gene rearrangements (Table 3-10) and were clearly not derived from 
a single B cell.  Therefore none of the samples from which VH and VL had 
been successfully isolated appeared to be derived from a single B cell culture.  
This observation was supported by direct sequence analysis of PCR products, 
prior to cloning.  Sequence chromatograms from several samples were found to 
contain mixed peaks (Figure 3-13), indicative of mixed template.  The results 
described led us to believe that the cultures did not contain single B cells and, 
as such, cloning of paired light and heavy chain genes into an expression vector 
could be problematic.  However, in order to develop the protocol and with the 
aim of producing antibody, cloning of these sequences into the expression 
vector was attempted. 
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Figure 3-13. Sequence chromatogram of Vț PCR product.  The Vț domain isolated from patient SK, sample J8, was sequenced 
directly following PCR amplification without cloning. Mixed peaks, indicative of multiple products within the sequencing reaction 
mix, were identified in the chromatogram and are highlighted by grey arrows. 
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3.4.4 Modification of the expression vector  
   The expression plasmid pDCORIG huIgG1 was developed by Lindy Durrant 
and colleagues at Scancell Ltd. for the generation of human IgG1 antibody 
containing T cell mimotopes in place of the CDRs (Metheringham et al., 
2009).  This vector has been used as a DNA vaccine for the induction of high 
avidity, anti-tumour CD8+ T cell responses (Pudney et al., 2010).  pDCORIG 
huIgG1 (Figure 3-3) contains a heavy chain cassette, consisting of a murine 
variable region and a human IgG1 constant region, under the control of the 
CMV IE promoter.  The light chain cassette contains a murine variable region 
and a human kappa chain constant region, under the control of a separate CMV 
IE promoter.  pDCORIG huIgG1 contains restriction sites flanking each of the 
CDRs, for replacement with T cell mimotopes, as well as restriction sites at the 
¶ DQG¶HQGRIWKHYDULDEOHGRPDLQVHQDEOLQJUHSODFHPHQWRIWKHHQtire VH 
and VL domain.  Due to incompatibilities between the expression vector and 
the primer sets used for PCR amplification, it was not possible to directly clone 
VH and VL PCR products into pDCORIG huIgG1.  The VH PCR products 
generated by primer set B contained an Age,UHVWULFWLRQVLWHDWWKH¶HQGDQGLW
was thought appropriate to use this site for cloning into pDCORIG.  Therefore, 
AgeI was introduced by site-direct mutagenesis into the heavy variable region 
of plasmid pDCORIG (Figure 3-4a).  The PCR primer sets used did not 
amplify the leader sequence of the VH domain, therefore AgeI was introduced 
DW WKH ¶ WHUPLQXV RI WKH QDWLYH OHDGHU VHTXHQFH ZLWKLQ WKH YHFWRU  $Q
additional AgeI site in the constant heavy domain was also knocked out via 
site-directed mutagenesis. 
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3.4.5 Adaptation of VH and VL PCR products for expression 
vector cloning 
 
   VH and Vk PCR products generated with different primer sets contained 
GLIIHUHQW UHVWULFWLRQ VLWHV DW WKH ¶ DQG ¶ HQG  3ULPHU VHW $ JHQHUDWHG 9+
domains with NotI/XbaI ends and Vk domains with BglII/NcoI ends (Table 3-1 
and 3-2).  Primer set B generated VH domains with AgeI/SalI ends (Table 3-3) 
and Vk with AgeI/BsiWI ends (Table 3-4).  The chosen expression vector, 
pDCORIG, utilised AgeI/AfeI restriction cloning for the VH domain and 
BamHI/BsiWI cloning for the Vk domain.  Due to these incompatibilities, it 
was necessary to re-amplify the VH and VL products isolated with different 
primer sets, prior to expression vector cloning.  Universal primers were 
designed to re-amplify VH and introduce AgeI/AfeI restriction sites where 
necessary.  Universal primers were also designed to introduce BamHI/BsiWI 
into those Vk products lacking the restriction sites (Figure 3-4b and Table 3-6).  
The sense primer for re-amplification of the kappa chain products also 
contained a 60 nucleotide sequence corresponding to the Ig leader sequence.  
Primers were designed such that the PCR products could be cloned into the 
expression vector without interrupting the reading frame.  PCR products 
amplified from patient SK were modified by re-amplification with the 
appropriate primer pairs.  VH from samples B11, C20 and K18 were 
successfully re-amplified (Figure 3-14a).  Vk re-amplification to introduce the 
leader sequence was successfully completed for samples B11, C20, M24 and 
E7 (Figure 3-14b).  Re-amplification was attempted on PCR products rather 
than individual plasmids to maintain any potential diversity between 
sequences.  Sequence analysis of the re-amplified products showed the 
 216 
 
presence of mixed peaks in the chromatogram suggesting that any diversity in 
the original product had been maintained.   
 
3.4.6 Cloning of VH and Vk gene products into the expression 
vector 
 
   Paired heavy and light chain PCR products had been successfully isolated 
and adapted for expression vector cloning from two samples, B11 and C20, 
both derived from patient SK.  These products were cloned by restriction digest 
into the modified pDCORIG huIgG1 expression vector beginning with VH 
cloning.  VH from sample B11 was successfully inserted into the vector, 
generating plasmid pDCORIG::B11h2.  Sequencing of the insert confirmed the 
introduction of a novel VH domain with identity to the IGHV3-23*04 germline 
gene.  This matched one of the sequences originally isolated from sample B11, 
B11_H6 (Table 3-9), showing that the VH domain is maintained throughout 
Figure 3-14. Generation of adapted IgG variable chain PCR products. 
(a) Heavy chains were re-amplified to introduce restriction sites AgeI 
and Afe, DW WKH ¶ DQG ¶ HQGV UHVSHFtively. (b) Light chains were re-
amplified to introduce the Ig leader sequence plus the restriction site 
Bam+,DWWKH¶HQG6XFFHVVIXOO\UH-amplified products form a band at 
350-400 bp. DNA -, no template control. Position of DNA marker, M, is 
shown in base pairs. 
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PCR amplification, adaptation and expression vector cloning.  It was then 
hoped that Vk from sample B11 could be cloned into pDCORIG::B11h2 to 
generate a vector with paired heavy and light chains capable of producing 
antibody.  Unfortunately, despite several attempts, no vector containing the 
B11 Vk domain was obtained.  Vk from sample C20 was successfully inserted 
into pDCORIG demonstrating that the cloning protocol worked.  This plasmid 
pDCORIG::C20k4, was sequenced and found to contain a novel and functional 
Vk domain corresponding to the germline gene IGKV1-12*01.  This did not 
correlate with the sequence originally identified in C20 (Table 3-10).  
However, the original sequence was derived from primer set A, whereas 
subsequent analyses were carried out on the Vk PCR product amplified with 
primer set B.  It is possible that these primer sets preferentially amplify 
different genes.  It is also important to remember that the products were 
obtained from cultures probably containing more than one B cell.  Only a 
single sequence from sample C20 was isolated during the initial analysis and 
this may not have been sufficient to cover the full diversity of sequences within 
the sample.  Due to time constraints it was not possible to continue with the 
expression vector cloning and, as such, no vector containing VH and Vk 
domains for antibody expression were generated; however, using the protocol 
described it should be possible to achieve this with sufficient time. 
 
3.5 Discussion 
   Methods for isolating antigen-specific IgG+ memory B cells from infected or 
recovered individuals can provide important insights into the natural immune 
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response to infection or vaccination.  In order to apply these techniques to 
studies of HCV, PBMCs were isolated from patients suffering a chronic HCV 
infection but who were known to generate a strong antibody response.  IgG+ 
memory B cells were isolated as they provide a record of past exposure to 
antigen and are able to proliferate upon stimulation leading to the production of 
ASCs producing high affinity antibody (McHeyzer-Williams et al., 2012).  
Using a memory B cell stimulation method described by Pinna et al. (2009), 
approximately 30% of single B cell cultures were found to proliferate and 
produce IgG; however this is only slightly lower than that reported in the 
literature where 37% of single B cell cultures were activated.  Reduced 
proliferation and expansion is an intrinsic property of some B cells as they 
enter the memory B cell pool (Pinna et al., 2009) and therefore it may not be 
possible to recover antibody from all cultured cells.  Previous studies cultured 
IgG+ memory B cells for 10 days to allow cell proliferation and antibody 
production (Pinna et al., 2009).  We compared B cells cultured for 5 days or 10 
days and found no difference between the number of cultures testing positive 
for IgG production.  It was however, noted that stimulating cultures for longer 
than 10 days reduced the ability to recover IgG-specific cDNA; of eleven 
cultures producing HCV-specific IgG, all were PCR negative for the VH and 
VL domains (data not shown).  This may have been due to exhaustion of the B 
cells, such that IgG was still present within the culture medium and detectable 
by ELISA, but the B cell was no longer secreting IgG and therefore not 
expressing IgG-specific mRNA.   
   Analysis of the IgG producing B cell cultures from patient SK (Table 3-9 and 
3-10; Figure 3-11 to 3-13) showed that single B cells were not present in these 
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cultures.  This raised the possiblity that the method did not stimulate IgG 
production from single B cell cultures and that the only IgG-producing cultures 
yielding detectable IgG were those containing more than one B cell.  Seeding 
more than one B cell is possible with the automated distribution method used 
but should result in the majority of wells containing a single cell.  The low 
recovery rates (2.8% wells were IgG positive) coupled with the presence of 
more than one template in the wells from which cDNA was recovered would 
seem to suggest sub-optimal stimulation of these single cell cultures.  
Additional factors have been tested for their ability to stimulate memory B 
cells, but have met with limited success (Pinna et al., 2009).  Although CD40L 
was found to reduce IgG production from memory B cells (Pinna et al., 2009), 
when combined with IL-21, CD40L was able to stimulate memory B cells 
expressing B cell lymphoma proteins (Kwakkenbos et al., 2010).  Therefore 
there may be alternative stimulants that could be used to improve the 
stimulation of single B cell cultures.  An alternative explanation is that the 
ELISA was not sensitive enough to detect the IgG produced by a single cell.  
However, the detection range for single cell cultures was 74-170 ng/ml IgG 
(Figure 3-7), within the range of IgG production observed in single cell 
cultures by Pinna et al., (2009).  It was estimated that the lower limit of 
detection for the ELISA was 5 ng/ml IgG (R. Urbanowicz, personal 
communication) and therefore, it is likely that this assay was sufficiently 
sensitive to detect the IgG produced by single cells.  It seems more likely that 
there was a failure to sufficiently stimulate the single cells in these cultures.  
   Of the IgG-secreting B cell cultures recovered, only a small percentage were 
HCV E1E2-specific.  This resulted in the needless culturing of B cells that 
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would ultimately be discarded.  Recent studies have used a pre-culture 
selection method to isolate HIV gp140-specific (Scheid et al., 2009) or gp120-
specific IgG+ memory B cells (Scheid et al., 2011; Wu et al., 2011).  It is 
feasible that a similar pre-enrichment step using HCV E1E2 selection prior to 
culturing could reduce the number of non-specific cultures recovered.  For 
patient RJ, only 10 samples (10.7%) tested positive for HCV-specific IgG 
production and IgG-specific mRNA, while only 1 sample (1.0%) from patient 
RH tested positive.  This is despite culturing multiple B cells in each culture 
well and probably represents differences in the antibody specificity and quality 
of memory B cell production between patients.  For patient SK, VH and VL 
domains were recovered from seven HCV-reactive IgG positive samples out of 
384 B cell cultures (1.8%).  Even if recombinant antibody were generated from 
all these positive samples, the rate of antibody recovery is low.  This is not 
uncommon; indeed Scheid et al. (2011) recently reported the recovery of 576 
antibodies from a starting population of 1.5 x105 IgG+ memory B cells cultured 
as single cells, a recovery rate of approximately 0.38%.  
   When considering the success of the PCR amplification protocol, both 
methods were capable of recovering VH and VL-specific products.  In the 
initial analysis of samples derived from patients RJ and RH, IgG specific 
cDNA was amplified with primer set A only.  However, in later experiments, 
including those with samples from patient SK, both primer sets were able to 
amplify VH and VL.  The initial failure of primer set B may be due to the use 
of HotStar Taq DNA polymerase in the PCR reaction.  This enzyme was used 
in the published literature (Tiller et al., 2008; Wardemann et al., 2003).  
However, following the failure of the original protocol, LongAmp Taq was 
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substituted for HotStar Taq to correspond with the protocol employed for 
primer set A.  LongAmp Taq DNA polymerase may be more sensitive and 
therefore better able to amplify from the low copy number cDNA present in the 
sample.  LongAmp Taq was therefore used in all subsequent experiments.  
Primer set A has a reported PCR recovery rate of 30-80% (Wang & Stollar, 
2000); primer set B is slightly lower at 30-60% recovery rate (Tiller et al., 
2008).  Recovery rates from cultures of 10 or 100 B cells using primer set A 
correlate well with those reported previously.  Recovery rates using primer set 
B are more difficult to assess as only those cells known to be producing HCV-
specific IgG were screened.  Recovery of VL (9țRU9ȜZDVFigure 3-
10).  Recovery of VH was 63.6% (7/11) (Figure 3-10), similar to the upper end 
of reported recovery rates.  This analysis is confounded however, by the 
presence of more than one B cell in most of these cultures and, in particular, 
WKHILQGLQJWKDW9țDQG9ȜFould be amplified from the same culture.  Tiller et 
al. (2008) also report the amplification oI ,JțDQG ,JȜ IURPDVLQJOHZHOOEXW
with a frequency of only 5%.  Approximately half contained functionally 
rearranged light chains from both alleles (Tiller et al., 2008; Wardemann et al., 
2003).  Although it is therefore possible that some of the wells containing both 
9țDQG9ȜFRQWDLQHGRQO\DVLQJOH%FHOOWKHKLJKQXPEHURIµGRXEOHSRVLWLYH¶
wells makes it extremely unlikely that this was the case.  It is also worth 
considering the possibility that primer sets were mixed up, contaminated or 
inadvertently combined.  Primer set B is, in fact, a combination of primers 
taken from three separate papers (Koelsch et al., 2007; Tiller et al., 2008; 
Wardemann et al., 2003).  In an attempt to improve the recovery of VH and VL 
domains from a variety of different germline genes, some non-specific binding 
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may have occurred.  However, this does not escape the fact that some, if not 
all, of the samples obtained from patient SK contained more than one B cell, as 
evidenced by the recovery of transcripts with differing germline gene 
rearrangements (Table 3-9 and 3-10) and the detection of mixed template in the 
sequence chromatogram (Figure 3-13). 
   The failure of some wells to test positive for IgG VH and VL PCR products 
may be due to the presence of primer site mutations.  Improved recovery of 
highly mutated VH and VL genes has been reported with a primer set that uses 
sense primers located further upstream within the leader region (Scheid et al., 
2011).  Neither primer set provides complete coverage of all possible germline 
genes and alleles.  Overall primer set B (Table 3-3 to 3-5) provides greater 
coverage than primer set A (Table 3-1 and 3-2), as it includes primers to a 
greater variety of alleles, SDUWLFXODUO\IRUWKH9ȜFKDLQVDOWKRXJKSULPHUVHW%
does not contain IGHV2 gene-specific primers.  However, a recent study found 
that IGHV2 was not used in the B cell repertoire of patients suffering from 
acute resolving or chronic HCV (Racanelli et al., 2011).  It is interesting to 
note that none of the VH domains isolated from patient RJ with primer set A 
belonged to the IGHV2 gene family (Table 3-7).  Therefore the lack of 
IGHV2-specific primers in set B may not be detrimental; however one cannot 
exclude the possibility that failure to amplify VH and/or VL chains from all 
samples was due to a lack of the appropriate gene or allele-specific primer.  
7KLVSUREOHPPD\EHRYHUFRPHE\WKHXVHRI¶UDSLGDPSOLILFDWLRQRIF'1$
HQGV ¶ 5$&(  7KLV PHWKRG DPSOLILHV XQNQRZQ P51$V E\ DGGLQJ D
guanine (G) tail to all single-stranded cDNA which is then replicated by the 
use of an oligo-dC adaptor (Ozawa et al., 2006)¶5$&(ZDVDttempted but 
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was unsuccessful at recovering IgG-specific PCR products.  Failure of this 
method was probably caused by the length of the oligo-dC adaptor (65 
nucleotides) and its high melting temperature, making optimisation of the 
annealing step problematic.   
   An alternative explanation for reaction failure may be RNAse contamination 
of the samples.  Great care was taken to exclude RNAses from the work 
environment and RNAse inhibitors were used in the B cell lysis buffer, in 
accordance with published protocols (Tiller et al., 2008; Wardemann et al., 
2003).  However, one experiment was lost due to RNAse contamination of the 
FBS.  This prompted us to use certified RNAse- and DNAse-free FBS for all B 
cell cultures and to introduce a wash step prior to lysis.  The B cell wash buffer 
also contained RNAse inhibitors.  These amendments were sufficient to 
overcome RNAse-induced culture losses and highlight the importance of 
maintaining an RNAse free environment at all stages of B cell handling and 
mRNA isolation.  
   The initial stages of method development were carried out on cultures of 
either 10 or 100 B cells.  Although it was possible to isolate IgG-specific PCR 
products from these cultures, it was felt that cloning paired light and heavy 
chain variable domains from such samples would be problematic.  Increasing 
the number of B cells in a culture increases the number of possible heavy and 
light chain combinations required to make a productive antibody.  In order to 
generate all possible combinations it is necessary to carry out a large amount of 
cloning.  This can be a time-consuming process when one considers that from a 
culture containing only 10 B cells, there are theoretically 100 different 
combinations of heavy and light chains.  The cloning process may result in the 
 224 
 
generation of random reassortments containing novel combining sites that 
ultimately prove to be unproductive when expressed as whole antibody.  It is 
also important to consider that every time an amplicon is subjected to PCR and 
cloning or sub-cloning, the chance of introducing artificial errors is increased.  
These errors may be mistaken for affinity matured antibody binding sites.  
LongAmp Taq was used in all amplification steps described and, due to its 
higher fidelity compared to HotStar Taq, should introduce fewer PCR-induced 
mutations.  However, in some of the sequences analysed it is possible that 
differences were caused by PCR mutation.  Direct sequencing analysis of the 
cDNA isolated from a single cell is the most accurate way to assess the level of 
affinity maturation.  The use of cDNA isolated from cultures containing 
multiple B cells may also give a misleading picture of the abundance of certain 
antibody specificities if individual B cells express variable levels of IgG 
mRNA (Wang & Stollar, 2000).  Therefore single B cell cultures present an 
ideal system in which to interrogate the antibody response to a given pathogen.  
Unfortunately, in our hands it has not yet been possible to obtain IgG-
producing B cell cultures that we are confident contain a single B cell. 
   Despite only obtaining VH and VL domains from cultures that contained 
more than one B cell, attempts were made to clone these products into an 
expression vector.  The two different primer sets used and the expression 
vector, pDCORIG huIgG1, were all obtained from different sources and, as a 
result, there were incompatibilities in the restriction sites used.  Therefore, it 
was necessary to adapt some of the PCR products and the expression vector 
prior to cloning.  Figure 3-4 shows the modifications that were made.  The 
restriction sites AgeI and AfeI were chosen for cloning of the VH domains.  VH 
 225 
 
domains amplified with primer set B contained Age,DWWKH¶HQGTable 3-3) 
and therefore this adaption was not required.  However, it was necessary to 
replace the Sal,VLWHDWWKH¶HQGZLWKAfeI.  VH domains amplified with primer 
set A required adaptation to replace NotI and Xba, DW WKH ¶ DQG ¶ HQG
respectively (Table 3-1).  Due to the presence of an Age,VLWHDWWKH¶HQGRIDOO
VL domains amplified with primer set B, it was necessary to clone the heavy 
chain first to avoid cutting pDCORIG huIgG1 more than once.  The restriction 
sites BamHI and BsiWI were chosen for clonLQJ RI WKH 9/ GRPDLQV  9ț
domains amplified with primer set B contained Bsi:,DWWKH¶HQGTable 3-4) 
and therefore this adaptation was not required.  VL products amplified with 
primer set A contained Nco, DW WKH ¶ HQG (Table 3-2).  Therefore it was 
necessary to adapt these products prior to cloning.  Attempts were made to 
adapt the expression vector such that a new restriction site was introduced into 
WKHNDSSDFKDLQFDVVHWWHDWWKH¶HQGRIWKHOHDGHUVHTXHQFHWKXVPDLQWDLQLQJ
the leader sequence needed for expression of the antibody.  However, this 
proved unsuccessful and the decision was taken to further modify the kappa-
type light chain PCR products by the introduction of the leader sequence at the 
¶ HQG (Figure 3-4b).  The leader sequence was taken from the expression 
vector and contained a BamHI site for direct restriction cloning into the vector.  
Although cORQLQJDGDSWHG9+DQG9/9țFKDLQVLQWRS'&25,*KX,J*1 was 
successful, no single vector containing paired heavy and light chains was 
obtained and this method has a number of drawbacks which would need to be 
rectified to improve the efficiency and accuracy of antibody cloning and 
expression.  The additional adaptation steps were time consuming and greatly 
increase the likelihood of introducing PCR-induced errors into the VH and VL 
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sequences which may reduce the affinity of the resulting antibody.  To 
overcome this problem the restriction sites within the primers could simply be 
altered to match those within the vector and the PCR products could be cloned 
directly into pDCORIG huIgG1&ORQLQJRIWKH9țGRPDLQLQWRWKHH[SUHVVLRQ
vector was complicated by the need to introduce the leader sequence into the 
PCR product itself.  It had been hoped that the restriction site BsrGI could be 
introduced into the kappa chain leader sequence by altering the nucleotide 
sequence (from AGTCCA to TGTACA), without disrupting the amino acid 
sequence.  Unfortunately this would have resulted in the introduction of 
another AgeI site.  Therefore kappa chain PCR products were re-amplified to 
include the leader sequence and cloning was carried out with the original 
BamHI and BsiWI sites contained within the vector.  However, such re-
amplifications were not always successful, the process was time-consuming 
and may introduce PCR-induced errors.  Using a method akin to that used for 
cloning of the heavy chain variable domain would be preferable to avoid 
additional PCR steps.  pDCORIG huIgG1 was designed as a vector for the 
production of mouse/human chimeric antibodies engineered to contain T cell 
mimotopes (Metheringham et al., 2009) (Figure 3-3) and as a result contains a 
murine leader sequence.  It is therefore important to consider the compatibility 
of the mouse leader sequence for translation of the human variable domain 
protein.  Comparison of the murine sequence within pDCORIG huIgG1 to 
human variable domain leader sequences deposited in Genbank shows only 
33% nucleotide sequence similarity.  This could reduce production of a fully 
human IgG1 from this vector and may require replacement of the leader 
sequences.  However, this would require the vector to be more significantly 
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redesigned, something which was beyond the scope and the time frame of this 
project.  Alternatively the primer sets, which do not currently allow for 
amplification of the leader sequence, could be modified.  The primer set 
described by Scheid et al. (2011), for improved amplification of mutated genes, 
uses primers located within the leader sequence for both rounds of 
amplification.  Therefore it should be possible to design primer sets capable of 
amplifying the variable domain including its leader sequence, if necessary.   
   Attempts at cloning into the expression vector were only partially successful, 
as paired heavy and light chains from a single culture could not be introduced 
into the same vector.  It was also noted that the recovery of colonies containing 
the gene of interest was very low.  In each case, approximately 20 colonies 
ZHUH VFUHHQHG IRU WKH KXPDQ ,J* 9+ RU 9ț LQVHUW \HW RQO\ D VLQJOH FRORQ\
was identified containing the gene of interest.  All other colonies contained the 
original murine variable domain.  The cloning protocol would need to be more 
efficient if clonal diversity is to be maintained and assessed and if different 
light and heavy chain pairings are to be generated.  Although this could be 
considered a flaw of the cloning method, it may not be a significant issue if 
single B cell cultures can be obtained and combining functional heavy and light 
chains from multiple sequences is no longer necessary.  However, failure to 
replace the original murine variable domain is still an issue.  Due to the 
inefficient recovery of DNA from gel extracted vector backbone, the vector 
was column purified following restriction digest.  This would not remove the 
original murine variable domain and it appears that this was preferentially re-
inserted into the vector rather than the human variable domain.  Due to the 
similar size of the murine and human fragments, their ligation into the vector 
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would be a stochastic event.  However, it may be possible to replace the murine 
variable domain with a stuffer fragment of around 10 bp in length.  A small 
fragment would be more efficiently removed by column purification, 
increasing the likelihood of inserting the human variable domain during the 
subsequent ligation step.  A plasmid stock containing such stuffer fragments 
could be used to increase the efficiency of the cloning protocol.  In order to 
improve the speed and accuracy with which Ig variable domains can be cloned 
from patient B cells and expressed in mammalian cells, several modifications 
to the primer sets and the expression vector are necessary.  These would greatly 
streamline the process and reduce the potential for introducing errors into the 
Ig gene sequences.   
   The expression vector pDCORIG huIgG1 was chosen as it allows expression 
of a complete IgG1 molecule from a mammalian cell culture system.  IgG was 
isolated from patient B cells, rather than IgM, as it is more useful from a 
therapeutic point-of-view.  IgM generally has low affinity for its antigen but 
due to its pentameric nature, has high avidity.  IgM is produced first in 
response to a pathogen and needs to respond quickly to a variety of antigens.  
As a result it can be more polyreactive (Schroeder & Cavacini, 2010).  
Therefore it may bind strongly to the target antigen but does not represent the 
most affinity matured Ig.  In contrast, IgG is produced later during infection by 
reFRPELQDWLRQRI&ȖZLWKDIILQLW\PDWXUHG9H genes.  The IgG1 subclass is the 
most abundant subclass in the serum (Schroeder & Cavacini, 2010) and is able 
WRELQG DOO WKUHH)FȖ5 W\SHV WULJJHULQJHIIHFWRU IXQFWLRQV VXFKDV$'&&DQG
CDC (Jiang et al., 2011).  The role played by Fc-mediated effector functions in 
HCV infection is poorly understood.  Both acute and chronic phase sera can 
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mediate ADCC via binding to E2 expressed on the surface of infected cells 
(Natterman et al., 2005) and several E2-specific MAbs can induce CDC of E2-
expressing cells (Machida et al., 2008).  Mechanisms to evade the antiviral 
effects of ADCC and CDC have also been reported (Machida et al., 2008; 
Maillard et al., 2004).  Therefore expressing antibodies as IgG1 molecules may 
provide an opportunity to investigate the Fc-mediated effector functions of 
anti-HCV antibodies.  However, in some cases effector functions are not 
desirable and in these situations antibodies expressed as IgG4 molecules are 
used due to theLU ORZHU DIILQLW\ IRU )FȖ5, DQG)FȖ5,, DQG ODFNRIELQGLQJ WR
)FȖ5,,,(Jiang et al., 2011).  The expression vector is also available with IgG4 
constant domains (Lindy Durrant, personal communication) for the generation 
of antibodies with reduced effector functions.  The production of whole Ig, 
rather than Fab fragments or scFv, more accurately replicates the in vivo 
structure and function of the antibody.  ScFv may not bind antigen with the 
same affinity as the whole IgG molecule, which also has a longer half-life in 
serum and is able to mediate effector functions via the Fc region.  The use of 
mammalian cells for antibody production would also ensure that the Ig 
molecules are correctly glycosylated.  Glycans have been implicated in correct 
folding and stabilisation of recombinant Igs (Liu et al., 2006) as well as in 
ELQGLQJ WR )FȖ5V UHYLHZHG LQ (Jiang et al., 2011).  The vector pDCORIG 
contains both the heavy and light chain expression cassettes; therefore 
transfection of only a single plasmid is required for successful expression.  
This is in contrast to other protocols that use separate plasmids for the 
expression of heavy and light chains (Scheid et al., 2011; Tiller et al., 2008; 
Wardemann et al., 2003).  Co-transfection of multiple plasmids may generate 
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transfectants containing only a single plasmid and therefore expressing only 
one Ig chain.  Stable transfection of pDCORIG into mammalian cells can be 
selected by the addition of zeocin (Metheringham et al., 2009).  Therefore this 
system should, in the future, provide a suitable system for the continued 
production of large amounts of whole Ig of known specificity. 
   Although the VH and VL domains isolated were not from single B cells, is it 
possible to make any observations or draw any conclusions from the data?  Out 
of 31 functional VH sequences isolated, 14 (45%) were from the IGHV3 gene 
family.  The remainder were from the IGHV1, IGHV4 and IGHV5 gene 
families (Table 3-7 and 3-9).  This pattern of IGHV gene usage was similar to 
that observed in a study of chronically infected patients (Racanelli et al., 2011), 
although IGHV4 was more abundant in this study (22% vs. <10% in Racanelli 
et al.).  IGHV2 gene usage was not found in either study nor was the use of 
IGHJ1 genes in memory B cells of chronically infected patients.  In fact, the 
use of IGHJ1*01 was found to be significantly associated with spontaneous 
resolution of HCV infection (Racanelli et al., 2011) so it is unsurprising that it 
was not found in either of the chronically infected patients studied here.  The 
IGHD2-2*01 gene and allele was also found more frequently by Racanelli et 
al. in chronically infected patients compared to spontaneous resolvers, an 
association that they found to be significant.  It is perhaps interesting to note 
that IGHD2-2*01 was used in 13% of the transcripts isolated in this study 
(Table 3-7 and 3-9). 
   Several studies of antibody responses to HIV and influenza have been carried 
out with this method.  Most of these studies report that antibodies binding to a 
defined antigenic epitope are derived from a very few related germline gene 
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sequences that undergo extensive affinity maturation via SHM (Grandea et al., 
2010; Scheid et al., 2009; Scheid et al., 2011).  Applying this method to the 
study of HCV could greatly improve our knowledge of the most highly 
conserved and immunogenic domains in vivo.  The method can be adapted to 
isolate antibodies targeting any part of E2, and could be used to identify 
antibodies binding to E1.  As such, it may help to expose novel antibody-
binding epitopes that have yet to be identified.  Interrogation of the total 
antibody response may also help to elucidate the importance of the total 
antibody pool in reducing viral spread.  Indeed, Scheid et al. (2009) found that 
no single antibody targeting HIV gp140 was able to neutralise virus infectivity.  
However, a combination of several antibodies displayed neutralising activity 
similar to serum neutralisation levels.  They postulate that rather than a single 
MAb, the total antibody pool may be responsible for reducing virus spread.  
Therefore studying the total antibody repertoire may represent the in vivo 
situation more accurately and provide a more rational approach to vaccine 
design.  Overcoming the problems encountered during the development of this 
method could be critical to further our understanding of the role played by 
nAbs in the outcome of HCV infection. 
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4 Analysis of acute phase serum samples from a 
cohort of patients in Egypt 
 
4.1 Introduction 
4.1.1 Natural history of HCV infection in Egypt 
   It is estimated that approximately 2% of the world population is chronically 
infected with HCV.  There is however wide geographic variation in levels of 
infection with less than 1% of the population in Northern Europe infected with 
HCV compared to 15-20% of the population in Egypt (Alter, 2007).  The high 
prevalence of HCV in Egypt is largely due to widespread anti-schistosomal 
treatment programmes established in the 1920s to reduce the burden of 
Schistosoma spp. infection in Egypt.  These treatment programmes consisted of 
a series of intravenous injections with tartar emetic (potassium antimony 
tartrate) and continued until the 1980s when the advent of oral therapies for the 
treatment of schistosomiasis rendered this approach obsolete.  On average 
between 6 and 9 anti-schistosomal injections were administered per patient in a 
treatment regimen carried out over several weeks.  Large numbers of patients 
were treated simultaneously regardless of age or treatment stage.  Reusable 
injection equipment was often used and observations at the time suggest that 
sterilisation procedures were either omitted or insufficient to fully sterilise 
equipment (Frank et al., 2000).  This resulted in large numbers of people 
becoming infected with HCV over many years leading to the high prevalence 
of HCV seen in Egypt today.  Infection patterns today correlate with age with a 
significant bias towards individuals aged 20 years and above (Frank et al., 
2000).  Genotype 4 is the most common genotype circulating within the 
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Egyptian population today (Dusheiko et al., 1994; Frank et al., 2000; Ramia & 
Eid-Fares, 2006), consistent with the theory of a local epidemic derived from a 
common transmission source (Pybus et al., 2003; Tanaka et al., 2004) i.e. 
antischistosomal treatment programmes.  Thus the Egyptian population 
provides an interesting study population.  Due to the large pool of HCV-
positive individuals, new infections, particularly of healthcare workers, are 
common and provide a good opportunity to identify acutely infected patients.  
Healthcare workers who obtain a needle-stick injury and close contacts of 
known HCV-positive individuals are followed closely facilitating the collection 
of patient samples during the early stages of infection.   
   The majority of studies into HCV infection and treatment have focussed on 
genotype 1 and, to a lesser extent, genotypes 2 and 3 as these genotypes 
predominate in Europe and North America (Simmonds, 2004); genotype 4 has 
been less well studied.  However, the current standard therapy (ribavirin and 
peglyated IFN-ĮKDVRQO\OLPLWHGHIILFDF\DJDLQVWJHQRW\SHUHVSRQVHUDWHV
are estimated at around 48% (Poynard et al., 2003).  Therefore studies of 
genotype 4 infections are important to increase our understanding of the 
disease and to aid in the development of better therapies. 
 
4.1.2 Role of the antibody response during the acute phase of 
infection 
 
   Much remains unknown about the antibody response to HCV during the 
acute phase of infection.  This is partly due to the difficulty of identifying 
patients during the acute phase when the disease is largely asymptomatic 
(Alter, 2007).  However, as discussed in section 1.8.2.2, studies of the acute 
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phase indicate that resolution of infection is associated with an antibody 
response which is both high titre and broadly neutralising.  Two recent studies 
demonstrated that spontaneous resolvers exhibit a high titre nAb response 
during the acute phase which declines slowly over several years.  Low titre or 
absent nAb responses were seen in patients with chronic HCV infection during 
the acute phase of the infection followed by an increase in nAb titres during the 
chronic stage of infection (Dowd et al., 2009; Pestka et al., 2007).  Studies 
have also shown that nAb drives envelope sequence evolution leading to the 
development of escape variants which may allow viraemia to persist.  This 
selective pressure continues throughout chronic infection leading to the 
development of a diverse viral population within the host (Dowd et al., 2009; 
von Hahn et al., 2007).   
 
4.1.3 Characteristics of the antibody response and viral 
sequences during acute infection 
 
   Following infection with HCV, antibody is detectable in the serum within 7 
to 8 weeks (Pawlotsky, 1999) although it may take up to 3 months to develop.  
The antibodies produced may target both structural and non-structural viral 
proteins (Thimme et al., 2008); however only those targeting E1 and E2 have 
neutralising activity (reviewed in (Edwards et al., 2012).  Studies have shown 
that antibodies may persist for several years after the initial infection in patients 
with a chronic infection and in those who resolve the infection (Dowd et al., 
2009; Pestka et al., 2007).  IgG class antibodies are typically of low avidity 
during the acute phase of infection and increase in avidity with time (Gaudy-
Graffin et al., 2010; Kanno & Kazuyama, 2002). 
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   HCV genomes appear in the plasma within a few days of infection and peak 
6-10 weeks after infection (Bowen & Walker, 2005).  Viral sequences are 
under selective pressure from the cellular and humoral arms of the immune 
response leading to continuous evolution of the virus.  Transmission dynamics 
during early infection are not well defined; however studies suggest that 
infection is typically established by one founder virus, although in rare cases 
more than one founder virus may seed the infection.  This is followed by a 
genetic bottleneck event characterised by a reduction in viral diversity (Bull et 
al., 2011; Wang et al., 2010).  The rate of sequence evolution during the acute 
phase of infection is limited by strong selective pressures (Bull et al., 2011). 
   In contrast to this description of a single founder virus, the phenomenon of 
mixed acute infections has recently been described.  In a study by Smith et al., 
(2010), 80% of a study cohort were infected by more than 1 viral subtype 
during the acute phase of the disease.  The dominant variant detected at each 
time point changed rapidly in some individuals and highly divergent clades 
within each subtype were also observed.  In addition, the viral load within each 
host was highly dynamic, with changes in viral load of 2 log or greater being 
GHVFULEHGDVµ\R-\R¶YLUDOORDG(Smith et al., 2010). 
   The HCV genome exhibits the greatest sequence diversity in the envelope 
SURWHLQV(DQG(DQGWKH16$SURWHLQ7KH¶non-coding region (NCR) 
and core regions are the most highly conserved regions (Simmonds, 2004).  
6HTXHQFLQJ RI WKH ¶1&5 Ls commonly used for genotyping of viral isolates 
although more recently other regions of the genome such as E1 and NS5B have 
become more popular due to their higher discriminating power (Murphy et al., 
2007).  Studies of viral sequences from sequential serum samples obtained 
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from chronically infected individuals show rates of change across the whole 
genome to be 1.44 x 10-3 nucleotide changes per site per year (Simmonds, 
2004).  The envelope glycoproteins exhibit greater variability; within E1 the 
rate is 7.1 x 10-4 nucleotide changes per site per year (Simmonds, 2004; Smith 
et al., 1997) and HVR1 within E2 also exhibits considerable sequence 
diversity.  The high viral replication rate (1012 virions per day) (Neumann et 
al., 1998), coupled with the error-prone nature of the RNA polymerase, results 
in a highly diverse viral population within chronically infected individuals.   
   Viral load is an important tool for monitoring disease progression and 
response to treatment.  It is typically reported as viral genome copies per ml.  
9LUDOORDGWHVWLQJFDQEHFDUULHGRXWE\DPSOLILFDWLRQRIWKH¶1&5ZKLFKGXH
to its high level of conservation, can be quantified without prior knowledge of 
the viral genotype (Murphy et al., 2007).  Although there is no definitive 
answer as to what is considered a high or low viral load, values greater than 1 x 
106 copies per ml are generally considered to be high (Moreno-Otero, 2005).  
According to the National Institute of Diabetes and Digestive and Kidney 
Diseases (NIDDK), which is part of the 8QLWHG 6WDWHV¶ 1DWLRQDO ,QVWLWXWH RI
Health (NIH), most patients with chronic hepatitis C have viral loads between 
100,000 (105) and 10,000,000 (107) copies per ml (Bell et al., 2010).  
Reduction in viral load is used to measure the efficacy of anti-HCV treatment.  
Any reduction seen in the absence of standard treatment (pegylated IFN-ĮDQG
ribavirin) would indicate spontaneous resolution of the infection. 
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4.1.4 Principles of DNA fingerprinting 
   DNA fingerprinting is a widely used technique in the fields of forensic 
science and paternity testing.  The most commonly used method for DNA 
fingerprinting employs short tandem repeat (STR) markers (Butler, 2006).  
STRs (also known as simple sequence repeats or microsatellites) are 
polymorphic genetic loci containing a repeated nucleotide sequence of between 
2 and 7 nucleotides.  The number of nucleotides per repeat sequence is 
consistent for the majority of repeats within a locus; however the number of 
repeat units at a locus is variable resulting in alleles of many different lengths 
(Edwards et al., 1991; Klintschar et al., 1999).  STRs make up approximately 
3% of the human genome and are thought to arise due to slippage of the DNA 
polymerase during DNA replication (IHGSC, 2001).  Over 1 million STR 
sequences have been identified in the human genome and most are found in the 
non-coding regions of DNA such as introns and intergenic regions (Ellegren, 
2004).  Therefore analysis of STRs does not provide any information about an 
LQGLYLGXDO¶VSUHGLVSRVLWLRQWRGLVHDVHRUDQ\SKHQRW\SLFFKDUDFWHULVWLFVSTRs 
are inherited DNA motifs and when several STRs are analysed simultaneously, 
a pattern which is unique to that individual emerges.  It is this feature that can 
be exploited to match unknown samples to an individual.  Many different 
FRPELQDWLRQV RI 675 ORFL FDQ EH XVHG WR µILQJHUSULQW¶ D VDPSOH  (DUO\
commercially available kits employed just three STR loci; however the 
probability of obtaining a random match with a sample is 1 x 10-3.  That means 
there is a 1 in 1000 chance that a sample will be wrongly matched to a test 
sample.  Currently available commercial DNA fingerprinting kits use anywhere 
up to 16 STR loci with random match probabilities reported at between 1.2 x 
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10-18 and 7.2 x 10-19 (Butler, 2006).  This reduces the chances of an incorrect 
match to 1 in 1 trillion.  Ideally, the STR loci chosen should be located on 
separate chromosomes and therefore segregate independently during meiosis.  
This reduces the likelihood of underestimating or overestimating the frequency 
of a given profile within a population and therefore helps to avoid incorrect 
matches between samples (Butler, 2006). 
 
4.1.5 Analysis of STR loci 
   Polymorphic STR loci are amplified by PCR and the size of the product 
determined.  Traditionally this was done by gel electrophoresis of radiolabelled 
PCR products, however advances in the use of fluorescent dyes and the 
development of capillary electrophoresis has enabled the process to become 
automated and therefore quicker and simpler (Lazaruk et al., 1998).  Each STR 
ORFXVLVDPSOLILHGE\DSDLURISULPHUVRQHRIZKLFKLV ODEHOOHGDW WKH¶HQG
with a fluorescent dye.  The resulting fluorescently labelled products are loaded 
onto a capillary electrophoresis instrument where the negatively charged 
products migrate towards an anode at different speeds on the basis of their 
electrophoretic mobility (Frazier et al., 2000).  As the products migrate past a 
detector the fluorescent dye emits light of a specific wavelength which is 
recorded.  A size standard and allelic ladder are run alongside the samples and 
the information gathered is used to determine the size of the STR loci (Lazaruk 
et al., 1998).  The use of fluorescent dyes with different excitation and 
emission spectra for each primer set enables several different STRs to be 
analysed simultaneously.  The information gathered is presented in an 
electropherogram and provides information about the size of the PCR product, 
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the number of alleles present at a given locus and whether an individual is 
homozygous or heterozygous at that locus. 
   Recent advances have been made in the development of reduced size STR 
lRFL RU µPLQL-675¶ ORFL  7\SLFDOO\ DPSOLILFDWLRQ RI 675 ORFL JHQHUDWHV
amplicons of between 100 and 450 bp.  Mini-STRs are generated from the 
same loci but with PCR primers designed to bind closer to the repeat region of 
the STR.  This generates smaller PCR products and is particularly useful for 
the analysis of damaged or degraded DNA samples (Butler et al., 2003; Chung 
et al., 2004).   
 
4.1.5.1 STR loci used in this study 
   Three STR loci were chosen for this study.  The loci are all widely used in 
commercial DNA fingerprinting applications and have been well studied and 
characterised (Butler, 2006; Butler et al., 2003).  They have also been studied 
within an Egyptian population and shown, individually, to have high 
discriminating power (Ahmed et al., 2001; Klintschar et al., 1999).  The µPLQL-
675¶ YHUVLRQV RI DOO WKUHH ORFL ZHUH DPSOLILHG DQG WKHUHIRUH WKH 675 VL]HV
referred to are the reduced size STRs (Butler et al., 2003). 
 
4.1.5.1.1  THO1 
   The THO1 locus is found within the tyrosine hydroxylase gene (Genbank ref. 
D00269) which is involved in the conversion of tyrosine to dopamine.  It is 
located at position 11p15.5 on chromosome 11.  This STR is a tetranucleotide 
TCAT repeat (Butler, 2006).  The number of possible alleles ranges from 3 to 
14 and the STR size varies from 51 to 98 bp (Butler et al., 2003). 
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4.1.5.1.2 vWA 
   The vWA locus is a polymorphism located at position 12p13.3 on 
chromosome 12 (Genbank ref. M25858).  This particular locus is associated 
with von Willebrand factor, a blood glycoprotein required for clotting.  This 
STR is composed of two tetranucleotide repeats [TCTG][TCTA] (Butler, 
2006).  The allele range for this STR is 10 to 25 with a size range of 88 to 148 
bp (Butler et al., 2003). 
 
4.1.5.1.3 D21S11 
   The D21S11 STR (Genbank ref. AP000433) is a polymorphism located at 
position 21q21.1-q21.2 on chromosome 21.  It is composed of two 
tetranucleotide repeats [TCTA][TCTG] (Butler, 2006).  The number of alleles 
for this STR varies from 24 to 38.2 with a possible size range of 153 to 211 bp 
(Butler et al., 2003).   
 
4.2  Aims of the work presented in this chapter 
   This work was originally designed to analyse the evolution of viral envelope 
sequences under pressure from the antibody response during the acute phase of 
infection in a cohort of patients.  However initial analyses of the viral 
sequences raised questions about the origin of these serum samples.  It was 
therefore deemed necessary to carry out further investigations to confirm that 
sequential samples were taken from the same patient, as reported.  This chapter 
details those investigations; the analysis of the viral sequences and the antibody 
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content of the samples as well as the DNA fingerprinting of patient samples 
and control samples showing. 
 
4.3 Materials and methods 
4.3.1 Serum samples 
   Serum samples were provided by Sanaa Kamal (Ain Shams University, 
Cairo).  Serum was obtained from 34 patients reported to be suffering from an 
acute HCV infection.  Serum was collected at three separate time points during 
the acute phase of infection (providing a total of 102 samples).  Information 
about sampling time for some patients was also provided by Sanaa Kamal and 
is given in Table 4-4 (page 271).  Samples were labelled with three letters e.g. 
AWM, to maintain patient confidentiality followed by a single digit e.g. 
AWM1, AWM2.  These numbers correspond to the order in which samples 
were taken.  Two sample tubes were labelled KJO1, KJO2 and KJO3.  To 
distinguish between the two tubes these were relabelled as KJO1a, KJO1b, 
KJO2a, KJO2b, KJO3a and KJO3b.  Each sample contained approximately 2 
ml of serum which was aliquoted into 1.5 ml screw cap tubes and stored at -
80°C. 
   Control serum samples were kindly provided by Emma Thomson (MRC 
Virus Research Unit, Glasgow).  These were paired serum samples derived 
from two patients with reported mixed acute infection.  Samples 1611 and 
2134 were taken from a single patient, 34, on 27/09/2002 and 21/10/2002 
respectively.  These will be referred to hereafter as samples 34a and 34b 
respectively.  Samples 5645 and 7087 were taken from a single patient, 31, on 
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01/09/2003 and 27/10/2003 respectively.  These will be referred to hereafter as 
samples 31a and 31b respectively.  Both patients were believed to be suffering 
mixed acute infection with genotype 1 and genotype 4 virus (Emma Thomson, 
personal communication).   
 
4.3.2 Isolation and analysis of viral sequences  
4.3.2.1 RNA extraction 
   RNA was extracted from 200 µl of serum using a QIAamp MinElute Virus 
Spin Kit (Qiagen, Crawley, UK) with carrier RNA according to the 
PDQXIDFWXUHU¶VLQVWUXFWLRQV%ULHIO\O4LDJHQSURWHDVH0 µl serum and 
200 µl Buffer AL (containing 28 µg/ml carrier RNA) were mixed by pulse-
vortexing and incubated at 56°C for 15 minutes to allow lysis of proteins and 
inactivation of RNAses to occur.  To the lysate, 250 µl of ethanol absolute (200 
proof) (Sigma Aldrich, Gillingham, UK) was added and incubated at room 
temperature for 5 minutes.  The lysate was loaded onto a QIAamp MinElute 
column and centrifuged at 6000 x g for 1 minute to allow adsorption of the 
nucleic acids onto the silica-gel membrane.  Samples were washed with 500 µl 
Buffer AW1 at 6000 x g for 1 minute, 500 µl Buffer AW2 at 6000 x g for 1 
minute and finally 500 µl ethanol absolute (200 proof) (Sigma Aldrich, 
Gillingham, UK) at 6000 x g for 1 minute to ensure that all contaminants were 
removed.  RNA was eluted from the column in 100 µl AVE Buffer by 
centrifuging at 20,000 x g for 1 minute and stored at -80°C.  Due to the 
presence of carrier RNA in the samples it was not possible to quantify the 
eluted RNA. 
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4.3.2.2 cDNA synthesis with MRORQH\¶VMurine Leukaemia Virus 
(MMLV) RT and random hexamers 
 
   Ten microlitres of RNA, 2.5 µl 5x MMLV RT buffer (Fermentas, St. Leon-
Rot, Germany) and 25 ng of random hexamers (Invitrogen, Paisley, UK) were 
heated to 75°C for 5 minutes and snap cooled on ice.  To this, 25 µl 5x MMLV 
RT Buffer, 30 mM dNTPs (Fermentas, St. Leon-Rot, Germany), 200 units 
MMLV RT (Fermentas, St. Leon-Rot, Germany) and DEPC-treated H2O to a 
final volume of 25 µl were added.  Samples were incubated at room 
temperature for 10 minutes followed by heating to 42°C for 1 hour.  cDNA was 
stored in non-stick 0.6 ml tubes (Alpha Laboratories, Eastleigh, UK) at -20°C. 
 
4.3.2.3 PCR DPSOLILFDWLRQRIWKH¶1&5 
   7KH ¶NCR was amplified from cDNA which had been generated with 
MMLV and random hexamers.  One microlitre of cDNA was used as a 
template in a total reaction volume of 25 µl containing 2.5 mM dNTPs 
(Fermentas, St. Leon-Rot, Germany), 0.3 units HotStar Taq DNA Polymerase 
(Qiagen, Crawley, UK) and 5 pM each of primers NCR FWD and NCR REV.  
The sequence of all primers used for analysis of viral sequences is given in 
Table 4-1.  7KH¶NCR was amplified in a 3-step cycling reaction consisting of 
95°C for 15 minutes, 60 cycles of 95°C for 30s, 60°C for 30s and 72°C for 60s 
followed by 72°C for 2 minutes.  PCR products were detected by agarose gel 
electrophoresis as described in 2.3.1.2.   
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All primers were synthesised commercially by Eurofins MWG Operon, Germany. 
Table 4-1. Primers used for analysis of viral isolates 
 
Target Function of primer Genotype 
specificity 
Primer 
orientation 
Primer name 3ULPHUVHTXHQFH¶-¶ 
¶1&5 PCR, sequencing Universal Sense NCR FWD GCGGAACCGGTGAGTACA 
 PCR, sequencing Universal Antisense NCR REV ACTCGCAAGCACCCTATCAG 
 Real-time qPCR Universal Sense qHCV NCR F GCGGAACCGGTGAGTACA 
 Real-time qPCR Universal Antisense qHCV Sc (fluorophore)CGGCGCGAAAGGCCTTGTGGTACTGCGCCGX 
(quencher+spacer)ACTCGCAAGCACCCTATCAG 
HVR1 Nested PCR 1st round Universal Sense EOS GGACGGGGTAAACTATGCAACAGG 
 Nested PCR 1st round  Antisense E1O_A TCATTGCAGTTCAGGGCAGTCCTGTTGATG 
 Nested PCR 2nd 
round, sequencing 
 Sense EIIS_MOD TGGGATATGATGATGAACTGG 
 Nested PCR 2nd 
round, sequencing 
 Antisense EIIA CTGTTGATGTGCCAGCTGCCA 
E1E2 cDNA synthesis, 
nested PCR 1st round 
Genotype 4 Antisense  OAS4M CACCAGCGGCTGAAGCAGCATTGA 
 Nested PCR 1st round Universal Sense EOS GGACGGGGTAAACTATGCAACAGG 
 Nested PCR 2nd 
round,sequencing 
Genotypes 
1,3,4,5 
Sense 170gt1 CACCATGGGTTGCTCTTTCTCTATC 
 Nested PCR 2nd 
round, sequencing 
Genotype 4 Antisense IAS4.31 GACAGTTATGCCTCGACCTGGGATACCATGAATATC 
 Sequencing   (Internal) 
sense 
EIIS_MOD TGGGATATGATGATGAACTGG 
 cDNA synthesis, 
nested PCR 1st round 
Genotype 1 Antisense OAS1a GGGATGCTGCATTGAGTA 
 Nested PCR 2nd 
round 
Genotype 1 Antisense IASGT1 TTACGCCTCCGCTTGGGATATGAGTAACATCAT 
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4.3.2.4 3XULILFDWLRQRIWKH¶1&5 
   Five microlitres of each PCR positive sample was purified with 10 units 
Exonuclease I (Fermentas, St. Leon-Rot, Germany) and 1 unit µFastAP¶ 
Thermosensitive AP (Fermentas, St. Leon-Rot, Germany) by heating at 37°C 
for 15 minutes.  Enzymes were inactivated by heating to 85°C for 15 minutes.  
Purified PCR product was sequenced with primers NCR FWD and NCR REV 
as described in 2.3.1.10. 
 
4.3.2.5 3K\ORJHQHWLFDQDO\VLVRI¶NCR sequences 
   Sequencing reads were edited using Chromas 2.13 (Technelysium, Brisbane, 
$XVWUDOLDDQGFRQWLJXRXVVHTXHQFHVZHUHPDGHIURPSDLUHG¶1&5VHTXHQFHV
using SeqMan II software (DNASTAR Inc., Madison, USA).  Phylogenetic 
analyses were carried out with MEGA 4 software (Tamura et al., 2007).  
Sequences were aligned and compared to reference genotype sequences 1a 
(Genbank accession number M62321), 1b (M96362, U01214, D10934), 2 
(D16433, D13406), 2b (D10077), 3a (D17763, D28917), 3b (D11443), 4b 
(FJ462435), 4c (FJ462436), 4d (FJ462437, EU392172), 4f (EU392169, 
EU392174), 4g (FJ462432), 4k (EU392173, EU392171, FJ462438), 4l 
(FJ839870), 4m (FJ462433), 4n (FJ462441), 4o (FJ462440), 4p (FJ462431), 4q 
(FJ462434), 4r (FJ462439), 4t (FJ839869), 5 (L29585), 6a (Y12083) and 6b 
(D84262).  The evolutionary relationship was inferred using the Neighbour-
Joining method (Saitou & Nei, 1987) and evolutionary distances were 
computed using the Maximum Composite Likelihood method (Tamura et al., 
2004). 
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4.3.2.6 Nested-PCR amplification of HVR1 
   HVR1 was amplified from cDNA generated with MMLV RT and random 
hexamers in a nested-PCR reaction.  Two microlitres of cDNA or first round 
PCR product was used as template in a total reaction volume of 20 µl 
containing 4 mM dNTPs (Fermentas, St. Leon-Rot, Germany), 1 unit 
LongAmp Taq DNA Polymerase (New England Biolabs, Hitchin, UK) and      
4 pM of each primer.  The first round was carried out with primers EOS and 
E1O_A in a 3-step reaction of 95°C for 30s, 35 cycles of 95°C for 10s, 55°C 
for 30s and 65°C for 1 minute, followed by 65°C for 10 minutes.  The second 
round was carried out with primers EIIS_MOD and EIIA in a 3-step reaction as 
described using 45 cycles of amplification.  PCR products were detected by 
agarose gel electrophoresis as described in 2.3.1.2. 
   
4.3.2.7 Purification and sequencing of HVR1 
   PCR positive samples were purified on a Qiaquick PCR Purification Kit 
(Qiagen, Crawley, UK) as described in section 2.3.1.3.  DNA concentration 
was quantified using a Nanodrop ND1000 Spectrophotometer and the products 
sequenced with primers EIIS_MOD and EIIA as described in 2.3.1.10. 
 
4.3.2.8 cDNA synthesis with Thermoscript RT and gene-specific 
primers 
 
   To generate full-length E1E2 sequences from the viral RNA, cDNA synthesis 
was carried out with Thermoscript RT and a gene-specific primer.  The 
genotype 4-specific primer OAS4M was used to analyse Egyptian study 
samples and control samples.  The genotype 1-specific primer OAS1a was also 
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used to analyse the control samples.  In the first step, 8.5 µl RNA, 10 pM 
primer and 20 mM dNTPs (Invitrogen, Paisley, UK) were heated to 65°C for 5 
minutes to allow primer annealing.  cDNA was synthesised by adding 5x 
Thermoscript RT Buffer (Invitrogen, Paisley, UK), 0.1 M DTT (Invitrogen, 
Paisley, UK), 40 units RNAse OUT (Invitrogen, Paisley, UK), 15 units 
Thermoscript RT (Invitrogen, Paisley, UK) and DEPC-treated H2O to a final 
volume of 20 µl.  The reaction mix was heated to 50°C for 1 hour followed by 
55°C for 1 hour and finally 85°C for 5 minutes.  RNA template was removed 
by addition of 2 units RNAse H (Invitrogen, Paisley, UK) and heated to 37°C 
for 20 minutes.  cDNA was stored in non-stick 0.6 ml tubes (Alpha 
Laboratories, Eastleigh, UK) at -20°C. 
 
4.3.2.9 Nested-PCR amplification of full-length E1E2 
   Two microlitres of cDNA or first round PCR product was used as a template 
in a total reaction volume of 20 µl containing 4 mM dNTPs (Fermentas, St. 
Leon-Rot, Germany), 0.5 unit LongAmp Taq DNA Polymerase (New England 
Biolabs, Hitchin, UK) and 4 pM of each primer.  The first round was carried 
out with primer EOS and either genotype 4-specific primer OAS4M or 
genotype 1-specific primer OAS1a in a 3-step reaction consisting of 95°C for 1 
minute, 35 cycles of 94°C for 15s, 50°C for 30s, and 65°C for 3 minutes 
followed by 65°C for 10 minutes.  The second round was carried out with 
primer 170gt1 and either genotype 4-specific primer IAS4.31 or genotype 1-
specific primer IASGT1 in a 3-step reaction as described using 45 cycles.  PCR 
products were detected by agarose gel electrophoresis as described in 2.3.1.2.   
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4.3.2.10 Purification and sequencing of full-length E1E2 
   PCR positive samples were purified as described in 2.3.1.3.  DNA 
concentration was quantified using a Nanodrop ND1000 Spectrophotometer.  
PCR products were sequenced with primers 170gt1, EIIS_MOD and either 
IAS4.31 (genotype 4) or IASGT1a (genotype 1) as described in 2.3.1.10.  
 
4.3.2.11 Phylogenetic analysis of full-length E1E2 and HVR1 
sequences 
 
   Sequencing reads were edited using Chromas 2.13 software (Technelysium, 
Brisbane, Australia) and contiguous sequences were made from the three E1E2 
sequences and paired HVR1 sequences using SeqMan II software (DNASTAR 
Inc., Madison, USA).  Phylogenetic analyses were carried out with MEGA 4 
(Tamura et al., 2007).  All available HVR1 and E1E2 sequences were 
translated, aligned and trimmed to the same length resulting in a phylogenetic 
analysis based on a 270 bp fragment corresponding to E2 HVR1 and the E1 
and E2 flanking regions.  The evolutionary relationship was inferred using the 
Neighbour-Joining method (Saitou & Nei, 1987) and evolutionary distances 
were computed using the Maximum Composite Likelihood method (Tamura et 
al., 2004).  The same process was repeated with the inclusion of HVR1 
sequences from reference genotype strains 1a (Genbank accession number 
M62321, EU155192), 1b (M96362, U01214, D10934), 2b (AY734982, 
AY734983) 3a (D17763, D28917), 4b (FJ462435), 4c (FJ462436), 4d 
(EU392172, FJ462437), 4f (EU392169, EU392174), 4g, (FJ462432), 4k 
(EU392171, EU392173, FJ462438), 4l (FJ839870), 4m (FJ462433), 4n 
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(FJ462441), 4o (FJ462440), 4p (FJ462431), 4q (FJ462434), 4r (FJ462439), 4t 
(FJ839869), 5 (NC009826), 6a (Y12083), and 6b (D84262). 
 
4.3.3 Quantitative real-WLPH3&5RIWKH¶1&5 
   In order to quantify the viral load of the samples quantitative PCR (qPCR) 
was carried out.  qPCR was carried out with a Scorpion primer, a primer with a 
tail containing a fluorophore/quencher pair and a probe element attached to the 
¶ HQG  $V WKH '1$ VWUDQG LV H[tended, the probe hybridizes to its target 
within the nascent DNA causing a structural change in the primer which results 
in fluorophore unquenching and emission of a fluorescent signal (Whitcombe 
et al., 1999).  The fluorescence levels correlate directly to the amount of 
specific PCR product.  This method has advantages over the use of 
intercalating agents, such as SYBR green, as it is specific to the target gene and 
less likely to produce false-positives (Whitcombe et al., 1999).  One microlitre 
of cDNA, generated as described in section 4.3.2.2, was used as template and 
amplified with 10 pM primer qHCV NCR F and 5 pM of primer qHCV Sc 
(incorporating the Scorpion probe) in a 15 µl reaction containing 0.25 mM 
dNTPs (Fermentas, St. Leon-Rot, Germany) and 0.3 units HotStar Taq DNA 
Polymerase (Qiagen, Crawley, UK).  Real-time PCR was carried out on an 
Mx4000 Multiplex Quantitative PCR System (Agilent Technologies, 
Stockport, UK) with cycling at 95°C for 15 minutes followed by 50 cycles of 
95°C for 30s, 60°C for 30s and 72°C for 30s.  Standard controls containing 
JFH-1 (genotype 2a) cDNA at concentrations ranging from 101 to 107 cDNA 
copies per µl were run in duplicate alongside the samples.  The results were 
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given as cDNA copies per µl of input cDNA.  This was converted to viral load 
(i.e. genome copies per ml of serum) by multiplying by 1250. 
 
4.3.4 STR analysis of RNA-extracted serum samples 
   All STR analyses were carried out on the RNA extracted from patient serum 
samples.  Although the QIAamp MinElute Virus Spin Kit (Qiagen, Crawley, 
UK) is designed to isolate viral nucleic acids from plasma and serum, it will 
isolate any nucleic acids contained within a sample.  Sufficient human DNA 
was present within the RNA samples to be amplified by standard PCR 
techniques.  The sequence of all primers used in STR analysis is listed in Table 
4-2.  
 
Table 4-2. Sequence of primers used for STR fingerprinting of 
serum samples 
Fluorescently labelled primers were synthesised by Applied Biosystems 
(Paisley, UK). Antisense primers were synthesised by Eurofins MWG 
Operon, Germany. 
Target Primer 
orientation  
Primer name Primer sequence 
¶-¶ 
Modifications 
THO1 Sense THO1_fwd CCTGTTCCTCCCT
TATTTCCC 
¶ODEHO9,& 
 Antisense THO1_rev GGGAACACAGACT
CCATGGTG 
 
vWA Sense vWA_fwd AATAATCAGTATG
TGACTTGGATTGA 
¶ODEHO1(' 
 Antisense vWA_rev ATAGGATGGATGG
ATAGATGGA 
 
D21S1
1 
Sense D21S11_fwd ATTCCCCAAGTGA
ATTGC 
¶ODEHO3(7 
 Antisense D21S11_rev GGTAGATAGACTG
GATAGATAGACGA 
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4.3.4.1 PCR amplification of STR loci 
   Each STR was amplified from serum-extracted RNA in a separate reaction.  
Five microlitres of RNA was used as template in a total reaction volume of 
12.5 µl containing 2.5 mM dNTPs (Fermentas, St. Leon-Rot, Germany), 0.3 
units HotStar Taq DNA Polymerase (Qiagen, Crawley, UK) and 2.5 pM each 
of STR-specific primers.  THO1_fwd contains the fluorescent dye VIC at the 
¶HQG9,&KDVDQHPLVVLRQVSHFWUXPRI-554 nm.  vWA_fwd contains the 
IOXRUHVFHQWG\H1('DWWKH¶HQG1('KDVDQHPLVVLRQVSHFWUXPRI-575 
nm.  '6BIZGFRQWDLQVWKHIOXRUHVFHQWG\H3(7DWWKH¶HQG3(7KDVDn 
emission spectrum of 558-595 nm.  A 3-step reaction of 95°C for 15 minutes, 
45 cycles of 94°C for 60s, 57°C for 90s and 72°C for 30s, followed by 60°C 
for 30s was carried out.  THO1 PCR products were diluted 1:5 in MB H20 
(Sigma Aldrich, Gillingham, UK).  vWA and D21S11 PCR products were not 
diluted. 
 
4.3.4.2 Analysis of PCR products on the ABI Prism 3130  
   Due to different levels of amplification of each STR it was necessary to mix 
the PCR products to produce final dilution factors of 1:100 (THO1), 1:20 
(vWA) and 1:1.1 (D21S11).  This was to ensure all PCR products were 
accurately analysed without producing offscale peaks (too much signal) or very 
low peaks (too little signal).  Therefore, 0.5 µl of THO1 PCR product (already 
diluted 1:5), 0.5 µl of vWA PCR product and 9 µl of D21S11 PCR product 
were mixed.  0.5 µl of mixed PCR products was mixed with 12 µl formamide 
containing the Genescan 500 LIZ Size Standard (Applied Biosystems, Paisley, 
UK).  The size standard contains 16 single-stranded DNA fragments ranging in 
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size from 35 to 500 nucleotides each labelled with the fluorescent dye LIZ.  
LIZ has an emission spectrum of 638-655 nm.  Samples were run on the ABI 
Prism 3130 Fluorescent DNA analyser (Perkin-Elmer, Cambridge, UK) and the 
data analysed using Peakscanner 1.0 software (Applied Biosystems, Paisley, 
UK).  Samples were analysed to determine the allele size (or sizes) of each 
STR locus.  Sequential time-point samples from each patient were then 
compared on the basis of STR allele size to determine if they were derived 
from the same patient.  Cluster analysis of STR allele sizes was carried out 
using Genemarker v2.2.0. software (Softgenetics, State College, USA) to 
generate a distance matrix based on the Euclidean distance between single 
samples. 
   
4.3.5 Testing antibody content of serum samples 
4.3.5.1 Total antibody testing 
   Antibody testing was carried out in the NHS Microbiology diagnostic facility 
DW7KH4XHHQ¶V0HGLFDO&HQWUH1RWWLQJKDP on a HCV ADVIA Centaur XP 
Immunoassay System (Siemans, Camberley, UK).  This is a third generation 
assay system with a diagnostic specificity of 99.9% and sensitivity of 100% 
(Denovel et al., 2004).  Samples were scored anti-HCV antibody positive if 
they had an anti-HCV score >11.0. 
 
4.3.5.2 Antibody avidity testing 
   Antibody avidity testing was carried out by Joy Kean (Gartnavel General 
Hospital, Glasgow).  Avidity testing uses ELISA to measure the strength of 
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IgG binding to HCV antigens in the presence or absence of a denaturing 
reagent such as urea.  Results are determined by calculating the ratio of 
absorbance in the presence of urea to absorbance without urea, expressed as a 
percentage.  Results are reported as an Avidity Index (AI) score.  AI values 
greater than 45 indicate high antibody avidity and are associated with 
antibodies produced during the chronic stage of infection (Joy Kean, personal 
communication).  An acute phase control sample and a chronic phase control 
sample were run alongside test samples giving AI values of 9 and 93 
respectively. 
 
4.4 Results 
4.4.1 *HQRW\SLQJYLUDOVHTXHQFHVEDVHGRQWKH¶1&5 
   Initial analyses of the study cohort included genotyping viral isolates from all 
RNA-SRVLWLYH VDPSOHV E\ VHTXHQFLQJ RI WKH ¶1&5 (Figure 4-1).  Although 
genotySLQJ EDVHG RQ WKH ¶1&5 LV QRW DOZD\V DEOH WR GLVFULPLQDWH EHWZHHQ
genotypes 1 and 6 (Murphy et al., 2007), it was expected that the viral isolates 
would be predominantly genotype 4 as this is the most common genotype in 
Egypt (Frank et al., 2000; Ramia & Eid-Fares, 2006).  Therefore sequencing of 
WKH¶1&5VKRXOGEHVXIILFLHQWIRUWKLVVWXG\)LJXUH-1 showed that most of 
the isolates tested clustered with the genotype 4 reference sequences as 
expected.  However several sequences clustered close to both genotype 3 and 
JHQRW\SH  VHTXHQFHV  'XH WR WKH ORZ GLVFULPLQDWRU\ SRZHU RI ¶1&5
sequencing the genotype of these isolates could not be resolved.  There were 
also some discrepancies in the clustering of genotype 2 sequences which were 
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spread throughout the tree.  It has been reported that genotyping based on the 
¶1&5LVOLPLWHGLQLWVDELOLW\WR distinguish some subtypes within genotypes 1, 
2, 3, 4 and 6 (Murphy et al., 2007).  However, subsequent genotyping based on 
HVR1 alongside several reference sequences, clearly showed that the majority 
of viral isolates cluster with genotype 4 reference sequences, consistent with 
the epidemiology of HCV in Egypt.  A small number of sequences clustered 
Figure 4-1. Genot\SLQJ RI YLUDO LVRODWHV RQ WKH EDVLV RI ¶1&5
sequencing. Evolutionary history was inferred using the Neighbour-
Joining method and evolutionary distances computed using the 
Maximum Composite Likelihood method.  The percentage of replicate 
trees in which the associated taxa cluster together in the bootstrap test 
(500 replicates) is given next to the branches.  Genotype reference 
sequences are highlighted with coloured circles: Genotype 1, green; 
Genotype 2, yellow; Genotype 3, purple; Genotype 4, dark blue; 
Genotype 5, light blue; Genotype 6, red. 
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with genotype 1 reference sequences.  This genotype is also found in Egypt 
although it is less common (Ramia & Eid-Fares, 2006) (Figure 4-2).  The 
¶1&5 FRXOG QRW EH VHTXHQFHG IURP VDPSOHV $;- DQG )=* GXH WR WKH
presence of more than one viral sequence resulting in a mixed chromatogram. 
   
It was noted while examining the clustering of samples within Figure 4-1 that 
several of the sequences taken from the same patient clustered with different 
Figure 4-2. Genotyping of viral isolates on the basis of HVR1 
sequencing. Evolutionary history was inferred using the Neighbour-
Joining method and evolutionary distances computed using the 
Maximum Composite Likelihood method. The percentage of replicate 
trees in which the associated taxa cluster together in the bootstrap test 
(500 replicates) is given next to the branches. Genotype reference 
sequences are highlighted with coloured circles: Genotype 1, green; 
Genotype 2, yellow; Genotype 3, purple; Genotype 4, dark blue; 
Genotype 5, light blue; Genotype 6, red. 
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subtypes.  For example samples ASP1 and ASP3 showed homology to 
genotypes 4o and 4d respectively while FPK1 clustered with genotype 4m and 
FPK2 clustered with genotype 4c.  Viral sequences isolated from the same 
patient during the acute phase of infection should show significant sequence 
similarity and therefore cluster together in a phylogenetic tree.  Although 
JHQRW\SLQJRQWKHEDVLVRI¶1&5VHTXHQFHVLVQRWLGHDOWKHODFNRIFOXVWHULQJ
observed for several patients nevertheless raised the possibility that the 
triplicate samples were not derived from the same patient.  This prompted us to 
undertake further analysis of viral isolates using a more informative region of 
the genome.  HVR1 and flanking regions, with their greater sequence 
variability, were chosen to further analyse the relatedness and evolution of viral 
sequences within each patient. 
 
4.4.2 Phylogenetic analysis of patient-derived viral isolates based 
on HVR1 sequencing 
 
   HVR1 within E2 shows significant sequence variability and evolves under 
pressure from the host immune response (Farci et al., 2000; Ray et al., 1999).  
Therefore it has much greater discriminating power in phylogenetic analyses of 
viral isolates.  All viral isolates were aligned on the basis of the HVR1 
sequence and the resulting phylogenetic tree (Figure 4-3) confirmed the 
VXVSLFLRQVUDLVHGE\WKHDOLJQPHQWEDVHGRQWKH¶1&5)LJXUH-1).  Only two 
out of the thirty-four patients tested were found to have viral sequences 
clustering together on the tree.  These were samples HUO1 and HUO2 and 
samples XNZ1 and XNZ3, highlighted in Figure 4-3.  HUO3 and XNZ2 
contained no detectable viral RNA and therefore no sequencing could be 
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Figure 4-3. 
Phylogenetic analysis 
of viral isolates on the 
basis of HVR1 
sequencing. 
Evolutionary history 
was inferred using the 
Neighbour-Joining 
method and 
evolutionary distances 
computed using the 
Maximum Composite 
Likelihood method. 
The percentage of 
replicate trees in 
which the associated 
taxa cluster together 
in the bootstrap test 
(500 replicates) is 
given next to the 
branches.  Patients 
for whom more than 
one isolate was 
sequenced are 
highlighted with 
coloured symbols to 
aid identification of 
patient clusters. 
Those patients for 
whom only one 
sample contained 
nucleic acid are left 
blank. Clusters of 
interest that are 
discussed in the text 
are highlighted with 
an asterisk (*). 
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performed on these samples.  Based on the hypothesis that infection is typically 
established by one founder virus (Bull et al., 2011), epidemiologically linked 
virus strains would be expected to co-cluster within a phylogenetic tree.  
Samples isolated during the acute or window period of infection should cluster 
very closely together.  All other samples however, were scattered randomly 
throughout the tree and did not cluster according to the patient ID.  It was 
possible to pick out some virus clusters which could be derived from the same 
patient; for example, sequences from patients CZR2 and FZG2, AMG3 and 
MHL2, CZR1 and IKW2, ASP3 and FPK2, ASP1 and AWM3, and AXJ1 and 
SAH2, all clustered with 90% or greater bootstrap support.  These are 
highlighted in Figure 4-3.  It is possible therefore that these sample pairs were 
isolated from the same patient.  Despite these putative groups of patient 
samples it was not possible to say with complete confidence that they were 
derived from a single patient.  It was also not possible to determine the order in 
which these samples were taken as there is no reliable information regarding 
sampling time (see section 4.4.4).  Therefore any study of virus evolution 
under the influence of the host immune response would be impossible and 
these samples were deemed to be of no further use to this study. 
   HVR1 could not be sequenced from HDP3, MHL1, SMQ2 and SRP3 either 
due to failure of the PCR amplification or sequencing reactions. 
 
4.4.3 STR fingerprinting serum samples to identify patient 
clusters 
 
   There are two possible explanations for the phylogenetic observations made 
above; the first is that the triplicate samples are not derived from the same 
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patient and therefore are not epidemiologically linked.  Alternatively, several 
of these patients may have developed a mixed acute infection, as suggested by 
Smith et al., (2010).  To distinguish between mixed acute infection and 
µPL[HG-XS¶ RU FRQWDPLQDWHG VDPSOHs the DNA content of the samples was 
analysed.  To provide a positive control for the analysis, mixed acute samples 
from two patients, 31 and 34, were provided by Emma Thomson.   These 
paired samples had previously undergone phylogenetic analysis based on 
HVR1 sequences but had not been subject to DNA fingerprinting analysis.  
STR fingerprinting of three discrete loci was carried out on the RNA 
preparations extracted from all samples and the data analysed using 
Peakscanner 1.0 software.  This displays all STR loci as a peak trace; trace data 
for the positive control 34 alongside data representative of genotype matched 
and unmatched samples are given in Figure 4-4.  Cluster analysis of STR loci 
sizes was subsequently carried out using Genemarker v2.2.0 software to 
generate a Euclidean distance tree of the inferred relationships between virus-
containing samples and is shown in Figure 4-5. 
   Samples derived from the same individual should have identical patterns of 
STR locus size; however this was not the case for the majority of samples and 
samples reportedly from the same patient were found to have very different 
STR loci sizes as shown in Figure 4-4.  Figure 4-5 also shows that the majority 
of samples did not cluster according to patient ID and therefore were not 
epidemiologically linked.  The control samples from patients 31 and 34 
clustered together according to STR analysis, as expected.  HVR1 sequence 
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Figure 4-4. Representative trace files for STR locus analysis. See overpage for the full figure legend. 
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analysis was also carried out and confirmed the status of samples 34a and 34b 
as mixed acute phase samples (Figure 4-5).  When included in the genotyping 
analysis, the samples were found to cluster with genotype 1 and genotype 4 
isolates respectively (Figure 4-2).  HVR1 sequence analysis of samples 31a and 
31b appeared to also show a mixed acute infection (Figure 4-3) although both 
were of genotype 1a strains (Figure 4-2).  This data confirmed the previous 
findings of the viral isolate analysis, proving that the grouped Egyptian 
samples were not derived from a single individual.  The exceptions to these 
findings were patient samples HUO1 and HUO2 and samples XNZ1 and 
XNZ3.  It is interesting to note that these samples were the only ones to contain 
viral isolates which clustered together (Figure 4-3), suggesting that sequencing 
of viral isolates can provide an indication of the reliability and origin of 
samples.  This data also clearly showed that the majority of Egyptian samples 
were not taken from patients suffering a mixed acute infection. 
   Based on the clustering of viral sequences in Figure 4-3 it was possible to 
pick out some putative patient groups (listed in section 4.4.2.).  In some cases 
the STR fingerprinting data and cluster analysis confirmed these patterns.  For 
example, the samples CZR2 and FZG2, CZR1 and IKW2, AMG3 and MHL2, 
and ASP3 and FPK2 clustered based on both viral sequence (Figure 4-3) and 
human genotype (highlighted in Figure 4-5) suggesting that the HCV infection 
in these paired samples was epidemiologically linked.  CZR2 and FZG2 also 
Figure 4-4. Representative trace files for STR locus analysis. Trace 
files generated in Peakscanner 1.0 software for the positive control 
samples, 34a and 34b show identical patterns for sequential samples. 
Paired samples from patient XNZ also possess identical trace patterns 
indicative of matched genotype. Paired samples from patient ASP have 
different trace patterns characteristic of an unmatched genotype. Size 
standards are shown in orange. 
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Figure 4-5. Cluster analysis of 
STR locus sizes. Peak traces 
were analysed using 
Peakscanner 1.0 software to 
determine the size (bp) of the 
allele(s) at each locus within all 
samples. Cluster analysis of STR 
allele sizes was carried out using 
Genemarker v2.2.2 software to 
generate a distance matrix based 
on the Euclidean distance 
between single samples. Only 
samples from which viral RNA 
was extracted are included.  
Patients for whom more than one 
isolate was sequenced are 
highlighted with coloured 
symbols to aid identification of 
patient clusters. Symbols 
correspond to those used in 
Figure 4-3. Clusters of interest 
that are discussed in the text are 
highlighted with an asterisk (*). 
 263 
 
clustered with IDF2, an association that was present in Figure 4-3.  XNZ1 and 
XNX3 clustered within Figure 4-5 replicating the pattern seen in Figure 4-3, as 
did samples HUO1 and HUO 2, as expected for related samples.  Interestingly, 
HUO1 and HUO2 also clustered with PCQ2, although according to HVR1 
sequence analysis this isolate was not related.  Similarly AMG3 and MHL2 
also clustered with VHI3, an association that was not previously observed.  The 
pairing of RRZ2 and RFE3 based on viral sequence similarity (Figure 4-3) was 
partially replicated by DNA fingerprint analysis (Figure 4-5); however the 
cluster was extended to include JZB2 and QAF3 also.  These slight 
discrepancies between viral sequence clustering and human genotype analysis 
are most likely caused by the small number of STR loci analysed.  Commercial 
kits typically use 13 or more loci to provide the statistical power necessary for 
forensic applications.  For the purposes of this study, three loci were sufficient 
to confirm that samples were not related.  However, more loci would be needed 
to accurately match all samples which are epidemiologically linked. 
   The sample pairs JZB3 and SRP1 did not cluster based on human genotype 
despite showing strong viral sequence similarity (86% bootstrap support).  
Therefore these samples would appear not to be derived from the same patient.  
The close viral sequence similarity may be due to a common source of 
infection.  STR locus amplification could not be completed on samples AXJ1 
and SAH2 therefore comparison of this cluster was not possible.  STR locus 
amplification could also not be completed on sample ASP1, preventing 
confirmation of the association with sample AWM3.  Three novel clusters of 
samples were observed in the STR fingerprinting analysis (Figure 4-5).  The 
pairings of DGX2 plus HDP1 and AXJ3 plus SRP1 were not observed in 
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Figure 4-3 and analysis of more STR loci would be needed to confirm any 
association between these samples.  If an association were confirmed, the lack 
of clustering based on viral sequences may represent mixed acute infections.  
The clustering of CLH2 and RRZ1 in Figure 4-5 was partially replicated in 
Figure 4-3, where CLH2 clustered with KJO3a and then formed a larger cluster 
with RRZ1.  Again, further analysis would be needed to confirm the 
relatedness of samples but these may be derived from a single patient. 
   STR locus size could not be determined for all samples.  This may be due to 
degradation of the nucleic acid contained within the sample.  This may be the 
case for samples HUO3 and RFE2 which were negative for both viral RNA 
and human DNA.  Alternatively, the primer binding site may contain a 
mutation which prevents amplification of the target and leads to a phenomenon 
NQRZQDVµDOOHOHGURSRXW¶(Butler, 2006).  This may explain why, in the case of 
sample KJO2a, the vWA locus could not be amplified.  Finally, the presence of 
PCR inhibitors within the sample may have caused the reaction to fail 
producing a negative result as was observed for AXJ1 and SAH2. 
 
4.4.4 Analysis of serum samples for antibody and viral load 
   All Egyptian serum samples were also tested for total antibody content and 
viral load.  Antibody testing was carried out by a commercial third generation 
immunoassay.  Samples with a test score >11.0 were reported as antibody 
positive (++) in Table 4-3.  The remaining samples were non-reactive and 
therefore reported as antibody negative (-).  One sample, HUO3 gave a 
borderline reading and was therefore reported as weakly positive (+).  Viral 
load was tested by an in-house qPCR method based on amplification of the 
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Table 4-3. Antibody and viral load status of serum samples. 
Sample name Antibody status Viral load (copies per ml)  
AMG 1 
AMG 2 
AMG 3 
++ 
++ 
++ 
5.95 x 106 
2.41 x 107 
9.00 x 107 
ASP 1 
ASP 2 
ASP 3 
++ 
- 
++ 
6.44 x 106 
Not detected 
6.49 x 107 
AWM 1 
AWM 2 
AWM 3 
- 
- 
++ 
Not detected 
Not detected 
5.13 x 105 
AXJ 1 
AXJ 2 
AXJ 3 
++ 
++ 
++ 
2.10 x 107 
1.01 x 107 
2.05 x 108 
CLH 1 
CLH 2 
CLH 3 
- 
++ 
++ 
Not detected 
6.20 x 107 
4.46 x 107 
CZR 1 
CZR 2 
CZR 3 
++ 
++ 
++ 
2.38 x 107 
5.21 x 106 
Not detected 
DGX 1 
DGX 2 
DGX 3 
++ 
++ 
++ 
2.71 x 107 
5.03 x 104 
Not detected 
FPK 1 
FPK 2 
FPK 3 
++ 
++ 
- 
6.16 x 106 
7.49 x 106 
Not detected 
FZG 1 
FZG 2 
FZG 3 
++ 
++ 
++ 
1.69 x 107 
1.30 x 106 
7.71 x 106 
HDP 1 
HDP 2 
HDP 3 
++ 
++ 
++ 
2.75 x 106 
4.13 x 107 
5.40 x 106 
HUO 1 
HUO 2 
HUO 3 
++ 
++ 
+ 
1.39 x 107 
6.34 x 106 
Not detected 
IDF 1  
IDF 2 
IDF 3 
Empty tube 
++ 
++ 
Empty tube 
2.83 x 107 
6.46x 106 
IEB 1 
IEB 2 
IEB 3 
- 
- 
- 
Not detected 
Not detected 
Not detected 
IKW 1 
IKW 2 
IKW 3 
++ 
++ 
++ 
5.09 x 106 
2.19 x 107 
1.73 x 107 
JZB 1 
JZB 2 
JZB 3 
- 
++ 
++ 
Not detected 
6.01 x 107 
6.46 x 106 
KJO 1a 
KJO 2a 
KJO 3a 
KJO 1b 
KJO 2b 
KJO 3b 
++ 
++ 
++ 
++ 
++ 
++ 
2.26 x 107 
Not detected 
7.90 x 107 
1.46 x 107 
1.22 x 107 
5.56 x 107 
MHL 1 
MHL 2 
MHL3 
++ 
++ 
++ 
1.45 x 106 
4.28 x 107 
1.35 x 107 
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Sample name Antibody status Viral load (copies per ml) 
MTK 1 
MTK 2 
MTK 3 
++ 
++ 
++ 
3.63 x 106 
Not detected 
Not detected 
MZZ 1 
MZZ 2 
MZZ 3 
++ 
++ 
++ 
3.93 x 106 
4.23 x 106 
Not detected 
NDW 1 
NDW 2 
NDW 3 
++ 
++ 
++ 
Not detected 
Not detected 
Not detected 
OPN 1 
OPN 2 
OPN 3 
++ 
++ 
++ 
Not detected 
Not detected 
Not detected 
PCQ 1 
PCQ 2 
PCQ 3 
++ 
++ 
++ 
Not detected 
1.36 x 107 
Not detected 
QAF 1 
QAF 2 
QAF 3 
++ 
++ 
++ 
Not detected 
Not detected 
2.43 x 107 
RFE 1 
RFE 2 
RFE 3 
++ 
++ 
++ 
Not detected 
Not detected 
1.90 x 107 
RRZ 1 
RRZ 2 
RRZ 3 
++ 
++ 
++ 
2.80 x 107 
4.94 x 107 
Not detected 
SAH 1 
SAH 2 
SAH 3 
++ 
++ 
- 
2.44 x 108 
9.38 x 107 
Not detected 
SMQ 1 
SMQ 2 
SMQ 3 
- 
++ 
- 
Not detected 
8.18 x 107 
Not detected 
SMY 1 
SMY 2 
SMY 3 
- 
++ 
++ 
Not detected 
Not detected 
Not detected 
SRP 1 
SRP 2 
SRP 3 
++ 
++ 
++ 
4.96 x 108 
Not detected 
4.15 x 107 
TWS 1 
TWS 2 
TWS 3 
++ 
++ 
++ 
Not detected 
Not detected 
Not detected 
UHO 1 
UHO 2 
UHO 3 
++ 
++ 
++ 
Not detected 
Not detected 
Not detected 
VHI 1 
VHI 2 
VHI 3 
++ 
++ 
++ 
Not detected 
Not detected 
2.34 x 108 
XNZ 1 
XNZ 2 
XNZ 3 
++ 
- 
++ 
1.38 x 108 
Not detected 
7.80 x 107 
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¶1&5Results, as viral genome copies per ml of serum, were calculated and 
are given in Table 4-3.  A large number of samples contained too little viral 
RNA to be amplified and detected by qPCR (reported as not detected).  The 
lower limit of detection for this method is <1.25 x 105 copies per ml of serum, 
based on the amplification of known size standards.  Failure to amplify viral 
nucleic acid in these samples could also be due to degradation of the sample or 
the presence of PCR inhibitors rather than as a result of low viral load. 
   Examination of the data in Table 4-3 raised a few anomalies.  The large 
number of serum samples which were antibody positive is perhaps surprising 
bearing in mind that these samples were reported to be from the window period 
of infection.  The window phase encompasses the period between exposure to 
the virus and the appearance of antibodies in the serum whereas the acute 
phase also includes the early post-seroconversion period.  Antibody typically 
appears within 7-8 weeks of infection although it can take up to 3 months to 
appear (Pawlotsky, 1999).  When compared to the data available regarding 
sampling time, shown in Table 4-4, it appears that several patients (AMG, 
ASP, CLH, CZR, FPK and HUO) developed antibodies within one month of 
exposure to the virus.  One patient, CZR, had a period of only 13 days between 
exposure to the virus and the detection of antibody.  Sampling time varies from 
2 months to 8 months for those patients for whom data is available.  Therefore 
these samples should fall within the acute phase of disease, however many of 
the samples contain high viral loads which may suggest a chronic stage of 
infection. 
   Four patterns of infection can be seen within the patients tested.  (i) In 
patients CZR, DGX, MTK, MZZ and RRZ viral load became undetectable in 
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Table 4-4. Information regarding sampling time compared to antibody 
status and viral load for selected patient samples. 
Patient Exposure 
Date 
Sample 
no. 
Test 
Date 
Antibody 
status 
Viral load 
AMG 24/05/2008 AMG 1 
AMG 2 
AMG 3 
28/06/08 
Unknown 
Unknown 
++ 
++ 
++ 
5.95 x 106 
2.41 x 107 
9.00 x 107 
ASP 18/04/2008 ASP 1 
ASP 2 
ASP 3 
18/05/08 
20/07/08 
15/09/08 
++ 
- 
++ 
6.44 x 106 
Not detected 
6.49 x 107 
AWM  
 AWM 1 
AWM 2 
AWM 3 
14/01/08 
20/05/08 
25/08/08 
- 
- 
++ 
Not detected 
Not detected 
5.13 x 105 
AXJ 12/2007 AXJ 1 
AXJ 2 
AXJ 3 
07/02/08 
09/06/08 
12/10/08 
++ 
++ 
++ 
2.10 x 107 
1.01 x 107 
2.05 x 108 
CLH 06/06/2008 CLH 1 
CLH 2 
CLH 3 
09/06/08 
10/07/08 
12/08/08 
- 
++ 
++ 
Not detected 
6.20 x 107 
4.46 x 107 
CZR 12/07/2008 
 
resolved  
CZR 1 
CZR 2 
CZR 3 
25/07/08 
31/08/08 
02/10/08 
++ 
++ 
++ 
2.38 x 107 
5.21 x 106 
Not detected 
DGX 18/07/2008 DGX 1 
DGX 2 
DGX 3 
05/09/08 
01/11/08 
15/12/08 
++ 
++ 
++ 
2.71 x 107 
5.03 x 104 
Not detected 
FPK 04/09/2008 FPK 1 
FPK 2 
FPK 3 
10/10/08 
14/11/08 
22/12/08 
++ 
++ 
- 
6.16 x 106 
7.49 x 106 
Not detected 
FZG after 03/2008 FZG 1 
FZG 2 
FZG 3 
12/06/08 
20/07/08 
02/09/08 
++ 
++ 
++ 
1.69 x 107 
1.30 x 106 
7.71 x 106 
HDP 23/03/2008 HDP 1 
HDP 2 
HDP 3 
10/05/08 
12/06/08 
23/07/08 
++ 
++ 
++ 
2.75 x 106 
4.13 x 107 
5.40 x 106 
HUO 14/08/2008 
 
HUO 1 
HUO 2 
HUO 3 
28/09/08 
20/10/08 
29/11/08 
++ 
++ 
+ 
1.39 x 107 
6.34 x 106 
Not detected 
IDF  
 IDF 1 
IDF 2 
IDF 3 
02/08/08 
04/10/08 
03/12/09 
Empty tube 
++ 
++ 
Empty tube 
2.83 x 107 
6.46x 106 
IKW 14/08/2008 IKW 1 
IKW 2 
IKW 3 
02/10/08 
05/11/08 
08/12/08 
++ 
++ 
++ 
5.09 x 106 
2.19 x 107 
1.73 x 107 
 
sample 2 or 3.  As these patients did not receive treatment, this suggests 
spontaneous resolution of infection.  Patients NDW, OPN, TWS, and UHO 
were all antibody positive yet had undetectable viral load throughout the 
sampling period.  These patients may also have spontaneously cleared 
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infection.  (ii) In patients PCQ, QAF, RFE, SRP and VHI one or more samples 
were negative for viral RNA followed by a sample with a detectable viral load.  
This pattern of infection could be caused by reinfection after treatment or after 
spontaneous resolution of an initial infection.  Alternatively, so-FDOOHGµ\R-yo¶
viral load, which was recently described (Smith et al., 2010), could account for 
this pattern.  (iii) Several patients were antibody positive and viral RNA 
positive in all three samples, clearly showing an ongoing infection.  However, 
without accurate sampling times for all samples it is difficult to determine if 
these patients were suffering from an acute infection or if they were chronically 
infected with HCV.  (iv) Three out of the thirty-four patients showed a pattern 
typical of early acute phase infection.  These are samples AWM, CLH, and 
JZB.  They all became antibody positive and viral RNA positive between 
samples 1 and 2 or between samples 2 and 3 suggesting that the crucial 
window period of infection had been captured. 
   Some more unusual patterns of infection were also identified upon closer 
examination of individual patients.  In patients ASP, FPK, SAH, SMQ, XNZ 
and possibly also HUO there was a loss of antibody reactivity from one sample 
to another.  In the case of patients ASP and XNZ, antibody disappeared and 
then reappeared.  This is highly unusual as antibody has been shown to persist 
for several years both in individuals who resolve the infection and in those who 
develop a chronic infection (Dowd et al., 2009; Pestka et al., 2007).  According 
to the sampling data given, patient ASP was tested four times within a period 
of five months.  It is highly unlikely that antibody was truly lost and regained 
within that time-frame.  It is possible that the samples were mixed up and that 
samples 2 and 3 should be reversed, however the loss of antibody so soon after 
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infection is still difficult to explain.  Finally it appears that patient IEB was not 
infected as neither antibody nor viral RNA was detected. 
 
4.4.5 Antibody avidity testing  
   Avidity testing of the antibodies within the Egyptian serum samples was 
carried out by Joy Kean to determine whether these samples were from acutely 
infected patients.  IgG class antibodies produced during the acute phase of 
infection are of low avidity but this increases over time (Gaudy-Graffin et al., 
2010; Kanno & Kazuyama, 2002).  Therefore measuring the avidity of IgG 
gives a good indication of the age of the antibody response and therefore the 
duration of infection.  Almost all of the samples tested were found to contain 
high avidity antibodies with AI values >45 (Table 4-5).  This is characteristic 
of antibodies produced during the chronic stage of infection.  Only two 
samples were found to contain low avidity antibodies below the threshold AI 
value of 45.  These were AMG3 (AI value, 34) and VHI3 (AI value, 35), 
however the previous samples from these two patients contained high avidity 
antibodies making these samples very unreliable as a source of acute phase 
antibodies. 
 
4.5 Discussion 
   Studies of the acute phase of HCV infection are difficult due to the 
asymptomatic nature of the acute phase (Alter, 2007).  Most patients do not 
present any outward signs of disease until the virus has established a chronic 
infection.  Therefore the identification of a cohort of patients suffering from 
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Table 4-5. Avidity of IgG immunoglobulins within patient serum 
samples. AI values >45 indicate high avidity antibodies. 
Sample 
name 
Antibody avidity index 
(AI) 
Sample 
name 
Antibody avidity index 
(AI) 
AMG 1 
AMG 2 
AMG 3 
111 
104 
34 
MHL 1 
MHL 2 
MHL3 
115 
47 
92 
ASP 1 
ASP 2 
ASP 3 
99 
Negative 
102 
MTK 1 
MTK 2 
MTK 3 
113 
103 
114 
AWM 1 
AWM 2 
AWM 3 
Negative 
Negative 
103 
MZZ 1 
MZZ 2 
MZZ 3 
85 
117 
107 
AXJ 1 
AXJ 2 
AXJ 3 
103 
102 
98 
NDW 1 
NDW 2 
NDW 3 
104 
96 
101 
CLH 1 
CLH 2 
CLH 3 
Negative 
99 
94 
OPN 1 
OPN 2 
OPN 3 
77 
104 
114 
CZR 1 
CZR 2 
CZR 3 
107 
85 
101 
PCQ 1 
PCQ 2 
PCQ 3 
117 
108 
109 
DGX 1 
DGX 2 
DGX 3 
96 
98 
97 
QAF 1 
QAF 2 
QAF 3 
106 
103 
100 
FPK 1 
FPK 2 
FPK 3 
84 
87 
Negative 
RFE 1 
RFE 2 
RFE 3 
112 
107 
104 
FZG 1 
FZG 2 
FZG 3 
66 
80 
106 
RRZ 1 
RRZ 2 
RRZ 3 
97 
95 
98 
HDP 1 
HDP 2 
HDP 3 
102 
96 
96 
SAH 1 
SAH 2 
SAH 3 
101 
98 
Negative 
HUO 1 
HUO 2 
HUO 3 
90 
104 
Negative 
SMQ 1 
SMQ 2 
SMQ 3 
Negative 
79 
Negative 
IDF 1  
IDF 2 
IDF 3 
Empty tube 
Not tested 
Not tested 
SMY 1 
SMY 2 
SMY 3 
Negative 
98 
106 
IEB 1 
IEB 2 
IEB 3 
Negative 
Negative 
Negative 
SRP 1 
SRP 2 
SRP 3 
100 
100 
92 
IKW 1 
IKW 2 
IKW 3 
98 
85 
94 
TWS 1 
TWS 2 
TWS 3 
87 
51 
91 
JZB 1 
JZB 2 
JZB 3 
Negative 
105 
106 
UHO 1 
UHO 2 
UHO 3 
87 
92 
84 
KJO 1a 
KJO 2a 
KJO 3a 
KJO 1b 
KJO 2b 
KJO 3b 
110 
108 
111 
107 
116 
105 
VHI 1 
VHI 2 
VHI 3 
89 
83 
35 
XNZ 1 
XNZ 2 
XNZ 3 
99 
Negative 
93 
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acute HCV infection would provide an invaluable tool to study the dynamics of 
the disease.  The panel of acute phase serum samples used in this study were 
obtained from patients with a known exposure to HCV, either through contact 
with an infected partner or exposure within a healthcare setting.  Sampling 
patients of this type is generally easier than in cohorts of intravenous drug 
users who are notoriously unreliable at attending follow-up sessions.  As such, 
this cohort contained 34 separate patients and triplicate time-point samples 
were provided for each patient.  It was hoped that a study of the antibody 
response and virus evolution in this cohort would provide some useful insights 
into acute HCV infection and the role played by the antibody response in 
spontaneous resolution of infection.  Unfortunately, preliminary studies of 
these samples raised serious questions about their provenance. 
   Genotyping analysis of viral isolates was initially carried out on the basis of 
¶1&5 VHTXHQFLQJ  +RZHYHU WKLV ZDV IRXQG WR KDYH LQVXIILFLHQW
discriminatory power to accurately assign viral isolates to a specific genotype.  
This problem was not wholly unexpected as several limitations have been 
LGHQWLILHG ZLWK JHQRW\SLQJ RI WKH ¶1&5  7KLV PHWKRG LV XQDEOH WR HDVLO\
resolve genotype 1 and 6 isolates and to distinguish between some subtypes 
within genotypes 1, 2, 3, 4 and 6 (Murphy et al., 2007), shortcomings which 
were observed in this study (Figure 4-1).  This led us to carry out genotype 
analysis on the basis of HVR1 sequencing and, as expected, most isolates 
clustered with genotype 4 reference sequences (Figure 4-2), the dominant 
genotype within the Egyptian population, while the remainder clustered with 
genotype 1.   
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   Phylogenetic trees generated from viral sequences are very useful tools to 
infer the relatedness of a group of viruses and to reconstruct the epidemiology 
of an outbreak.  This approach has been used to study the origin and 
epidemiology of HIV, influenza, SARS coronavirus and Ebola virus (Pybus & 
Rambaut, 2009) and provide important insights into patterns of virus 
transmission.  The method has also been used to assess transmission events 
between monogamous partners of HCV-infected individuals (de Carvalho-
Mello et al., 2010), characterise the risk factors and HCV transmission 
characteristics within different social networks (Matthews et al., 2011), and to 
identify the single source of HCV outbreaks within haemodialysis units (Lanini 
et al., 2010; Thomson et al., 2011).  In all of these studies epidemiologically 
linked viruses, i.e. those with a common source, show significant sequence 
similarity with high bootstrap values.  These studies differ in the region of the 
virus used for sequencing and there is some disagreement about whether the 
envelope glycoproteins E1 and E2, which evolve under pressure from the 
immune system, provide a more accurate phylogeny than more conserved 
regions of the genome such as NS3 and NS5B (de Carvalho-Mello et al., 
2010).  As this study was concerned with the evolution of the antibody 
response during acute infection, phylogenetic analysis of the envelope 
glycoproteins was deemed most appropriate. 
   Closer analysis of the clustering patterns in Figure 4-1 (and subsequently 
Figure 4-2) had shown that, in several cases, isolates from the same patient 
clustered with different viral subtypes and these unusual patterns were 
subsequently confirmed by phylogenetic analysis of HVR1 (Figure 4-3).  Only 
two patients out of thirty-four were found to have HVR1 sequences from 
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sequential samples that clustered together.  Studies suggest that HCV infection 
is typically established by a single founder virus (Bull et al., 2011; Wang et al., 
2010); as a result of which, viral sequences isolated from a single patient 
during the acute phase of infection show significant similarity and cluster 
closely within a tree.  The highly divergent nature of sequences from the same 
patient therefore suggested multiple different sources of the virus, i.e. these 
viruses had been isolated from different patients.  Other samples were found to 
cluster very closely on the tree and could be considered to have derived from 
the same patient.  An alternative explanation for the divergent nature of the 
sequences is the existence of a mixed acute infection, described recently by 
Smith et al. (2010) in a cohort of acutely infected patients.  By cloning and 
sequencing of HVR1 from samples taken during the first three months post-
infection they reported coinfection with more than one subtype at individual 
time points in 70% of study subjects.  Moreover, these coinfections were 
highly dynamic with multiple switches in the dominant viral variant throughout 
DFXWHLQIHFWLRQ7KH\DOVRGHVFULEHµ\R-\R¶YLUDOORDGYDOXHVLQVHYHUDORIWheir 
study cohort, although this did not correlate with viral subtype switching 
(Smith et al., 2010).  However, this study was not supported by any analysis of 
the human genotype.  Therefore it is not possible to rule out that these mixed, 
highly dynamic acute infections were due to sample contamination or 
mislabelling of samples. 
   In order to distinguish between mixed acute infection and the mislabelling of 
samples within the Egyptian study cohort, STR fingerprinting was carried out.  
This method is widely used in forensic studies and there are several 
commercially available kits.  The principles behind this technology were 
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adapted for use in-house using fluorescently-labelled PCR primers to amplify 
the genes of interest which were then analysed.  Due to the presence of human 
nucleic acids within the RNA samples extracted from serum, no additional 
DNA isolation or purification was required.  Commercial STR fingerprinting 
kits analyse up to 13 STR loci and contain an internal size standard and an 
allelic ladder for each locus.  The internal size standard contains PCR products 
of a known size.  The allelic ladder contains a copy of every known allele of a 
given locus.  This information is then used to determine the size of sample 
peaks and correlates this to a specific allele (Butler, 2006).  As this analysis did 
not use a commercial kit no allelic ladder was available for analysis alongside 
the samples.  A size standard containing 16 DNA fragments 35 to 500 
nucleotides in length was included in all samples.  Therefore the results of STR 
fingerprinting were given as peak size in base pairs only.  As no allelic ladder 
was available it is not possible to convert this information into allele number.  
This does not however prevent full analysis of the samples and the 
identification of those patient samples which do not match.  STR fingerprinting 
analysis (Figure 4-5) did confirm the results of HVR1 sequence analysis 
(Figure 4-3).  It was very clear that most of the samples were isolated from 
different patients and there was very little clustering according to sample name.  
The exceptions to this observation were patients HUO and XNZ which 
clustered by HVR1 sequence and contained identical STR loci (Figure 4-4 and 
4-5).  The inclusion of positive controls from two patients, 31 and 34, that were 
found to cluster according to STR locus size provided further confirmation that 
the Egyptian samples were either mislabelled or contaminated (Figure 4-5).  
These analyses demonstrate that viral isolate sequencing provides a good 
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indicator of the origin of a sample and can be used to identify those samples 
which have a common source.  More sample clusters were identified in Figure 
4-3 which were confirmed to have a common origin by STR analysis (Figure 
4-5).  It is however slightly misleading to say that this relationship has been 
confirmed.  As this study used only three STR loci it lacks the discriminating 
power to provide a positive match between two or more samples.  Three loci 
are sufficient to identify a negative relationship, i.e. two or more samples 
which do not match.  It would be necessary to analyse more STR loci in order 
to accurately identify those samples which are a positive match, derived from 
the same individual.  Even if more STR loci were analysed it would still not be 
possible to determine the chronological order in which samples were taken 
making any study of virus evolution impossible. 
   DNA fingerprinting of these samples confirmed our suspicion that they were 
not epidemiologically linked and ruled out the possibility of mixed acute 
infection.  This highlights a major flaw in the recent paper by Smith et al. 
(2010) which failed to analyse human genotype.  Many of their observations 
such as subtype-VZLWFKLQJ ZLWKLQ VWXG\ VXEMHFWV DQG µ\R-\R¶ YLUDO ORDG
dynamics were also observed in our study samples (Table 4-3 and Figure 4-2).  
Without human genotype analysis it is impossible to confirm the existence of 
these phenomena within acutely infected patients and the speculation that these 
are contaminated or mislabelled samples will continue (Irving & Brown, 2010).  
Mixed acute phase infections do occur, as evidenced by the clustering patterns 
of samples from patients 31 and 34 (Figure 4-5); however we would urge 
careful scrutiny of any unusual data and the validation of all samples used, as 
not all apparently mixed acute infections truly are.   
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   To complete the analysis of this cohort, samples were tested for HCV-
specific antibodies and viral load (Table 4-3).  Only three patients exhibited a 
pattern typical of the window phase of infection, during which time antibodies 
against the virus begin to develop.  Doubts were also raised when it was noted 
that several patients appeared to lose antibody and then regain antibody 
between sampling.  While loss of viral RNA may be caused by spontaneous 
clearance of infection, with or without subsequent reinfection, antibody is not 
so readily lost, particularly not within such a short time-frame.  Loss of 
antibody, or its reduction to undetectable levels, has been reported in patients 
with a resolved acute infection; however this did not occur until, on average, 4 
years after infection was resolved (Alter et al., 1989).  Antibodies have also 
been reported to persist for several years in both chronic and resolved 
infections (Dowd et al., 2009; Pestka et al., 2007).  It therefore seems 
extremely unlikely that six patients should have developed and subsequently 
lost antibodies within a period of a very few months.  Information regarding 
sampling time was provided in an attempt to clear up the confusion (Table 4-
4).  However, this only served to raise more problems as it seemed that several 
patients developed an antibody response and a high viral load within 3 or 4 
weeks of exposure to the virus.  Typically antibody is detectable within 7-8 
weeks but can take up to 3 or 4 months or longer to develop (Alter et al., 1989; 
Pawlotsky, 1999).  Therefore the period of 13 days between exposure to the 
virus and the appearance of antibodies reported for patient CZR is highly 
unusual.  The antibody avidity data (Table 4-5) indicated that the majority of 
samples were from the chronic phase of the disease, providing further proof 
that these samples were not as they were described to be.  Antibody avidity 
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testing has been used to distinguish acute from long-term infection in a number 
of viral infections including rubella virus (Hedman & Rousseau, 1989), 
Varicella-Zoster virus (Junker & Tilley, 1994), EBV (Gray, 1995) and CMV 
(Grangeot-Keros et al., 1997).  It has also been used to discriminate between 
primary HCV infection and the passive transfer of anti-HCV Igs (Ward et al., 
1994) and to identify acutely infected patients (Gaudy-Graffin et al., 2010; 
Kanno & Kazuyama, 2002).  The use of such assays to accurately identify 
acute infection is particularly valuable for HCV due to the largely 
asymptomatic nature of the disease. 
   The data presented in this chapter clearly demonstrates that these samples 
were not isolated during the acute phase of the disease.  It is also obvious that 
the triplicate samples were in fact derived from a number of different 
individuals and that very few clusters of samples could be identified.  Whether 
this discrepancy is as a result of poor sample storage, mislabelling or a wilful 
effort to deceive cannot be known.  It has however prevented any study of the 
antibody response during the acute phase of the disease and its impact on the 
outcome of disease.  This study highlights the importance of establishing the 
provenance and validity of all samples used in studies of viral evolution in 
order to confirm the accuracy of any conclusions made. 
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5 General discussion and conclusions 
   Our current understanding of HCV pathogenesis suggests that a strong 
immune response can protect against chronic infection.  Humoral immunity has 
been shown to protect against primary infection (Feray et al., 1998) and 
reinfection (Osburn et al., 2010), and a broad nAb response during acute 
infection correlates with spontaneous resolution (Dowd et al., 2009; Pestka et 
al., 2007).  The potential for nAbs to prevent infection has made them a 
promising area of research, yet the development of antibody-based vaccines 
requires a better understanding of the protective antibody response.  The 
majority of nAbs identified to date target the envelope glycoproteins, in 
particular E2 and, of these, the most broadly neutralising target the CD81 
binding region which forms a cluster within AR3 (reviewed in (Edwards et al., 
2012).  E2-CD81 interactions are necessary for HCV entry into hepatocytes 
and are clearly an important target for the nAb response, particularly as 
mutational escape would likely incur fitness costs to the virus.  However the 
scarcity of nAbs binding to other viral epitopes has raised questions about the 
diversity of the antibody response to HCV.  Unfortunately, the assays used to 
study the HCV-induced antibody response may have introduced bias towards 
specific regions of E2.  As discussed in section 1.6.2, the early use of Molt-4 
cells (Flint et al., 1999a; Rosa et al., 1996) would have limited the 
identification of antibodies to those blocking CD81 binding sites.  The choice 
of E2 construct, whether it is sE2, E1E2 or expressed on pseudoparticles, also 
has important implications in terms of conformation and antigenicity of the 
glycoprotein (Owsianka et al., 2001).  Most human anti-HCV antibodies target 
conformational epitopes; however, as discussed in section 2.1.1, methods to 
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map antibody binding residues in conformation-sensitive epitopes show several 
limitations.  Therefore a system is needed that can rapidly and easily map 
antibody binding epitopes within any region of the glycoprotein in an unbiased 
manner.  This system would require the expression of the entire glycoprotein 
ectodomain in a conformation that is representative of its native form. 
   To this end, a cell surface display library based on expression of the E2 
ectodomain fused to the influenza A virus HATM domain in D. melanogaster 
S2 cells was developed (Figure 2-14 to 2-17).  Although it was possible to sort 
cells that no longer bound the test MAb but maintained E2 conformation 
(Figure 2-21 and 2-22), the pool of sorted cells was quite small.  It was 
possible however, to enrich for a specific subset of cells by growing and 
expanding the sorted cells for several weeks prior to re-sorting (Figure 2-23).  
Analysis of the sequences isolated from single cells sorted for loss-of-binding 
to MAb AR3A showed that, as expected, some residues within AR3 were 
mutated.  However a number of residues that have not previously been 
implicated in AR3A binding were also mutated (Table 2-4).  Of particular 
interest, two residues L399I and C644R, were observed in the majority of 
sequences (discussed in section 2.5).  This may reflect over representation of 
these substitutions in the library; however further study will be needed to 
investigate what, if any, role these residues have in AR3A binding.   
   Other limitations of the display library were identified which may be 
improved upon.  These are discussed in detail in section 2.5 but it is apparent 
that a larger library will be required to ensure that all possible substitutions at 
all residues are represented.  The efficacy of the library could also be improved 
by increasing the number of cells expressing protein which might be achieved 
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by pre-enriching the library for cells expressing E2.  With these general 
improvements, the D. melanogaster S2 cell library could become a very 
powerful tool to study antibody epitopes within E2.  It is hoped that this system 
will enable the rapid identification of residues involved in MAb recognition, 
regardless of the region targeted by the MAb and without any prior knowledge 
of its function or specificity.  Expression of the entire E2 ectodomain should 
overcome any bias towards a particular region of E2 or a specific receptor 
binding site.  The use of correctly folded glycoprotein and the ability to screen 
all library cells based on protein conformation will facilitate the identification 
of conformation-sensitive MAbs, a process which currently is laborious and 
time-consuming.  Any residues identified by display library screening could be 
investigated further using plate-based binding assays or the HCVpp and 
HCVcc systems to elucidate their importance in MAb binding.   
   Although an E2 cell surface display library expressing the entire ectodomain 
is not biased towards a specific region or epitope within E2, it is limited to 
antibodies targeting this glycoprotein.  E2 appears to be the major target of the 
antibody response and it has been suggested that E1 is less immunogenic 
(Fournillier et al., 2001).  However, to avoid any bias it might be possible to 
generate a display library expressing E1.  This was not attempted due to the 
time constraints of the project.  Expression of E1 has been hampered in the past 
by poor expression and the suggestion that E2 co-expression is required for E1 
to fold correctly (Michalak et al., 1997).  However, an E1-specific human 
antibody isolated with a soluble form of E1 was also shown to react with E1E2 
(Keck et al., 2004b) and broadly nAbs that inhibit infectivity of HCVpp and 
HCVcc also bind soluble forms of E1 (Meunier et al., 2008).  Furthermore, 
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studies with recombinant E1 vaccine candidates demonstrate the induction of 
an E1-specific nAb response (Leroux-Roels et al., 2004; Nevens et al., 2003; 
Verstrepen et al., 2011).  Therefore it appears that an antigenic form of E1 can 
be expressed without E2, although whether the whole protein is correctly 
folded is not clear.  If an E1 display library was successfully generated it could 
be used to screen patient sera, providing important insight into the prevalence 
of E1-specific MAbs, as well as for fine mapping of residues bound by E1-
specific antibodies.  
   Attempts were made to generate a display library bearing E2 from a genotype 
2b strain.  Unfortunately this proved to be unsuccessful and it is not clear 
whether this was due to poor expression or incorrectly folded protein.  The 
genotype 2b E2 construct used has been expressed as recombinant E1E2 and 
on the surface of HCVpp and found to fold correctly (Tarr et al., 2011).  It is 
hoped therefore that this construct can be successfully displayed in the insect 
cell library.  The adaptability of the system to express envelope glycoproteins 
of different genotypes would greatly enhance its utility.  Identifying nAbs with 
broad reactivity is an important consideration as these are most likely to prove 
therapeutically useful.  Testing the breadth of antibody binding with libraries 
bearing E2 of different genotypes would facilitate the identification of residues 
or epitopes that are conserved across genotypes. 
   Ideally, antibody mapping would be done with surface expressed E1E2 to 
recapitulate the native form of the envelope glycoprotein complex.  However, 
this has proven extremely difficult and is hampered by a lack of understanding 
of the functional form of the glycoprotein complex (Vieyres et al., 2010).  
+RZHYHU LIVXFKD OLEUDU\FRXOGEHJHQHUDWHG LWPD\SURYHXVHIXODVD µSXOO-
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GRZQ¶PHWKRGWRLVRODWHVSHFLILFDQWLERGLHVIURPSDWLHQWVHUDRUSRO\FORQDO,J
facilitating the isolation of E1E2-specific MAbs in an unbiased manner.  
Alternatively, experiments with cells expressing E1E2 (or E2) that has been 
engineered to lack specific immunodominant epitopes may enable the isolation 
of rarer antibodies.  This approach was recently used to screen a library of scFv 
fragments for those which bound outside of known neutralising epitopes.  This 
led to the identification of a novel antigenic domain within E2 (Keck et al., 
2012).  By reversing the approach and displaying the glycoprotein on the 
library platform, it may be possible to screen patient sera for nAbs targeting a 
specific epitope.  Antibody isolation in conjunction with epitope mapping 
would help to determine the location of additional neutralising determinants or 
antigenic domains.  Such an approach provides an alternative to cell free assays 
which utilise sE2 to isolate specific antibodies from sera (Sophie Brice, 
personal communication) and may help to determine the prevalence of specific 
antibodies within patient sera.   
   A further problem commonly encountered during studies of the antibody 
response to HCV is the difficulty of obtaining nAbs.  As discussed in section 
3.1.4.1 genetic differences mean that the antibody response in mice does not 
always accurately recapitulate the antibody response seen in humans.  Even in 
mice engineered to express human Ig genes, differences in antigen processing 
may direct the antibody response towards different epitopes.  Isolating nAbs 
directly from humans may yield more useful antibodies; however antibody 
isolation and production methods, such as hybridoma generation, are 
technically challenging and not always successful.  Newer methods, such as the 
immortalisation of B cells, have also met with mixed results (Pinna et al., 
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2009; Traggiai et al., 2004) and the protocol was not successful in our lab (R. 
Urbanowicz, personal communication).  However, combining B cell activation 
methods that stimulate the generation of ASCs with Ig gene isolation and 
sequencing techniques provides a high throughput method to screen the B cell 
repertoire of a given patient.  This method has been widely used in the fields of 
HIV (Pietzsch et al., 2010; Scheid et al., 2011; Wu et al., 2011) and influenza 
(Corti et al., 2011; Grandea et al., 2010) research and, using a combination of 
Ig-specific primers, was successfully adapted to the isolation of Ig genes from 
HCV-infected patients (Table 3-7 to 3-10).  Although single B cell cultures 
were not successfully analysed during the time available, such cultures have 
been successfully stimulated to secrete antibody by other groups and therefore 
it is hoped that, with further troubleshooting (as discussed in section 3.5), 
single cell cultures of ASCs will be generated.  Although isolating paired 
heavy and light chain sequences from cultures of more than one B cell is 
technically possible, it would be very time-consuming and the additional PCR 
steps required would increase the likelihood of introducing experimental 
artefacts into the sequence.  Therefore, in order to develop a robust, high-
throughput method for examining B cell populations it would be extremely 
beneficial to have a reliable protocol for generating single B cell cultures. 
   The IgG gene isolation and sequencing method is intended ultimately as a 
means of MAb production.  Following the isolation of paired heavy and light 
chain genes, these would be cloned into a suitable expression vector and 
expressed in an appropriate host cell.  Such expression vector cloning was 
attempted, however due to incompatibilities between the vector and primer sets 
used this met with only limited success (see section 3.4.6).  The current 
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protocol described in Chapter 3 is time consuming and increases the likelihood 
of introducing artefacts into the IgG gene sequences.  Removing the additional 
amplification steps will also be necessary to streamline the IgG isolation and 
cloning process, making it suitable for routine use in the lab.   
   With the suggested improvements the isolation of MAbs from patient sera 
could be efficiently and quickly achieved.  The B cell isolation and culturing 
technique requires only small volumes of blood and has the potential to 
generate thousands of single B cell cultures from an individual patient.  By pre-
sorting B cells or by screening the antibody-containing supernatant, it would be 
possible to select for antibodies of a certain specificity.  For example, samples 
could be targeted for the presence of fusion-specific nAbs or antibodies with 
cross-genotype reactivity.  IgG genes would only need to be isolated from the 
cultures of interest, thereby reducing the workload and avoiding the 
unnecessary cloning of non-reactive or non-neutralising antibodies.  Paired 
heavy and light chain genes could be cloned from the appropriate cultures into 
the expression vector pDCORIG.  This is a mammalian expression vector that 
has been used by other groups to produce large amounts of antibody 
(Metheringham et al., 2009).  Ideally, after cloning variable Ig genes into the 
vector, it would be transfected into CHO cells, and the antibody secreted into 
the supernatant.  The antibody could then be characterised to determine the 
strength and breadth of neutralisation as well as the epitope targeted by the 
antibody.  To this end, the insect cell display library could be used for epitope 
characterisation, whilst HCVpp and HCVcc assays could be employed to 
determine neutralisation.  Only small amounts of antibody would be needed to 
carry out these preliminary tests.  However, by generating stably transfected 
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cell lines, it would be possible to continually produce antibody allowing for 
more comprehensive characterisation.  As previously suggested, epitope 
mapping with the insect cell library should provide a non-biased way of 
determining antibody specificity, particularly if E1 as well as E2 can be 
displayed in this format.  Generating and maintaining stable mammalian cell 
lines is a fairly straightforward process and, unlike hybridoma generation, there 
is no risk of cell lines reverting to wild-type, provided that the selective agent 
is present.  Each cell line would be transfected with a single plasmid and would 
therefore express MAb.  Secreted antibody would need to be purified from the 
cell culture supernatant but this could be achieved using standard protein 
purification techniques such as affinity chromatography with protein G.  
Production of larger amounts of antibody might be possible by scaling-up the 
CHO cell culture although this can be difficult with adherent cell lines.  
However, CHO cell lines which grow in suspension culture and are more easily 
transfected and selected have been developed (Freestyle CHO-S cells from 
Invitrogen).  Their use would increase the amount of IgG produced and speed-
up the process of MAb generation.  Furthermore these cells are adapted to 
growth in serum-free media, simplifying the purification of antibody from the 
supernatant (Anon, 2007).  Whole antibodies have been successfully expressed 
in the D. melanogaster S2 cell line (Johansson et al., 2007a) which is amenable 
to large-scale culture in spinner flasks and secretes large amounts of protein 
(M. Backx, personal communication).  However, slight differences in 
glycosylation of the resulting antibodies have been reported which may require 
humanisation for optimal antibody activity in vivo (Johansson et al., 2007a).  
No such problems have been reported for antibody produced in CHO cells.  
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The choice of a vector containing human Ig constant domains is another benefit 
of this system.  In therapeutic applications, human antibodies tend to have a 
longer half-life, are less-likely to induce an allergic response than murine 
MAbs or even chimeric MAbs (Hwang & Foote, 2005), and show improved 
effector functions (Li et al., 2006).  Therefore a combination of the IgG gene 
isolation method and the epitope mapping technique may provide a new system 
for the production and characterisation of human MAbs produced during 
natural HCV infection. 
   The isolation of IgG genes may also provide further insight into the 
pathogenesis of HCV by allowing close examination of the gene sequences.  A 
recent study attempted to find correlations between HCV disease outcome and 
the repertoire of germline VH gene segments used (Racanelli et al., 2011).  
Some of their observations were similar to those made in this study (see section 
3.53.5) and it will be interesting to see whether the VH and VL genes 
commonly used in spontaneous resolvers do produce nAb that helps to clear 
the virus.  Studies carried out on HIV and influenza also suggest that antibodies 
targeting a conserved epitope are derived from very few related germline genes 
(Grandea et al., 2010; Scheid et al., 2009; Scheid et al., 2011).  If the same is 
true for HCV, affinity maturation of such germline genes could lead to the 
generation of MAbs with enhanced affinity or broader reactivity.  
Understanding how clonally related antibodies undergo affinity maturation 
may lead to targeted improvements in therapeutic MAbs.  Lymphoproliferative 
disorders, such as mixed cryoglobulinaemia and B-cell non-Hodgkins 
lymphoma, are frequent manifestations of HCV infection (Poynard et al., 
2003) and it has been suggested that HCV induces hypermutation of IgG genes 
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as a means to evade the immune response (Machida et al., 2008).  Studies of 
the IgG gene repertoire in HCV infected individuals may therefore provide 
further insight into the interplay between the virus and the immune system.  It 
will be interesting to see what, if any, impact such immune system impairment 
has on disease outcome.  Resistance to such virus-induced mutation might be a 
hallmark of spontaneous resolvers and identifying the extent to which the virus 
alters the antibody response throughout infection could have important 
implications for therapeutic interventions.   
   A severe impediment to studies of HCV disease dynamics is the difficulty of 
identifying patients during the acute phase.  Therefore, obtaining a cohort of 
patients suffering from acute infection for which sequential serum samples had 
been collected provided a great opportunity to study the evolution of nAb 
responses during acute infection.  Unfortunately it quickly became apparent 
that the samples were not as they appeared and that identifying immune 
correlates of disease outcome would be impossible.  A study of the cohort was 
carried out nonetheless and provided an object lesson in the importance of 
checking the origin and reliability of samples.  Viral isolates from supposedly 
related samples did not cluster together on a phylogenetic tree (Figure 4-3), 
contrary to what was expected for epidemiologically related samples.  The 
development of an in-house DNA fingerprinting technique was critical in 
confirming that the majority of grouped samples were not related and proved 
LQYDOXDEOH LQ GLVWLQJXLVKLQJ VDPSOH µPL[-XS¶ IURP JHQXLQH PL[HG-acute 
infections (Figure 4-5).  This approach could be used to assess the reliability of 
all samples in any future studies requiring blood, serum or PBMCs.  This will 
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improve the reliability of the generated data and the conclusions that are 
subsequently drawn.   
   Neutralising antibodies have the potential to clear infection yet their precise 
role in HCV disease pathogenesis and outcome is incompletely understood.  
Although the majority of human nAbs identified target the E2-CD81 
interaction, several other potential interactions exist for which few, if any, 
nAbs have been isolated.  It is likely that antibodies targeting these interactions 
do exist and their discovery may provide other means of inhibiting virus entry.  
Indeed, the recent description of a novel AR within E2 which elicits a broadly 
neutralising response that does not interfere with CD81 binding (Giang et al., 
2012) supports the notion that additional antibody targets remain to be 
identified.  HCV has proven itself very adept at evading immune clearance and 
lessons learned from HIV research suggest that multiple antibodies targeting 
several distinct but overlapping epitopes will provide the most effective means 
of neutralising infectivity.  Therefore identifying additional neutralising 
epitopes will be important for the development of effective therapeutics.  
Furthermore, the interaction between the virus and the immune response is 
dynamic, and by studying the evolution of the antibody response during acute 
and chronic infection, we may identify important determinants of disease 
outcome.  Such studies will be facilitated by new methods of B cell isolation 
and antibody characterisation, including those developed during this study.  
Understanding the complexity of the relationship between the virus and the 
immune response will require varied approaches.  The techniques described in 
this project will hopefully provide the means to study diverse aspects of the 
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antibody response, techniques which may be used in isolation or combined in a 
novel work model. 
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